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Abstract 
CELF1 is an RNA binding protein with regulatory roles in translation, alternative 
splicing and mRNA degradation. This protein is of particular interest as its 
upregulation is believed to be involved in the pathogenesis of type 1 myotonic 
dystrophy. CELF1 functions by binding to a specific sequence iQ WKH ¶
untranslated region of its target mRNAs. This sequence has been termed the 
³('(1´PRWLIEXW WKHH[DFW UHTXLUHPHQWV IRUELQGLQJRI&(/)ZHUHQRWZHOO
defined. In this study we therefore aimed to determine the sequence requirements 
for an RNA substrate to form a high affinity interaction with CELF1, and 
characterise the structure of the resulting complex. The CELF1 protein is 
composed of three structured RNA recognition motifs separated by flexible 
linkers. Our strategy was to investigate the RNA binding properties of each 
domain in isolation, and then the requirements for tandem binding of the domains 
LQ RUGHU WR EXLOG XS WKH FRPSOHWH ³('(1´ PRWLI FDSDEOH RI IRUPLQJ D KLJK
affinity complex with the wild type protein. 
 
This has been accomplished using NMR spectroscopy to map the chemical shift 
perturbations in each domain on binding to a range of RNA substrates. ITC was 
also used to investigate the binding affinities of each domain, and the 
enhancement of affinity when domains bind in tandem. By these methods we 
have refined the sequence requirements for simultaneous binding of all domains 
of CELF1, and designed RNA substrates which will bind with higher affinity than 
any previously reported. We have also shown the potential involvement of RNA 
secondary structure in forming the CELF1 binding site, and identified two 
possible examples of this in natural mRNA targets. 
 
CELF1 binding triggers deadenylation of its target mRNAs and this is suspected 
to be via a mechanism involving recruitment of poly (A) ribonuclease. These two 
proteins have been shown to interact, but no structural information was available 
to show which domains were interacting, or whether CELF1 was capable of 
ii 
 
forming a ternary complex with both RNA and poly(A) ribonuclease. Since the 
ribonuclease exists as a 146 kDa dimer, the complex of it with CELF1 was an 
ambitious target for NMR. In this study we demonstrate that high resolution 
NMR data can be acquired on this key regulatory complex. Using this we go on 
to confirm the interaction between these two proteins, and that the domains 
involved in binding suggest a ternary complex is possible. 
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1 Introduction 
 
The CELF proteins are a family of RNA binding proteins with regulatory roles in 
translation, alternative splicing and deadenylation. The term CELF stands for 
CUG-BP and ETR-3-like factor, referring to earlier terms for the founder 
members CELF1 and CELF2. Four additional members of this protein family 
have been identified, based primarily on sequence similarity. Some of these 
SURWHLQV KDG SUHYLRXVO\ EHHQ JURXSHG LQWR WKH ³%UXQR-OLNH´ IDPLO\ of proteins, 
named after a homologous protein in Drosophila, which was later determined to 
be equivalent to the CELF family1, 2, 3, 4. CELF proteins are found in most animals 
and plants, but not in yeast or bacteria. The CELF family of proteins is divided 
into two subfamilies: CELF1 - 2 and CELF3 ± 6, with at least one protein from 
each subfamily present in all plants and animals. All six CELF proteins are found 
in humans. The focus of this study is on the CELF1 protein, which is of particular 
interest due to its involvement in type 1 myotonic dystrophy (DM1)5. CELF1 was 
originally identified as a human RNA binding protein by its ability to bind to a 
(CUG)8 RNA substrate6, 7 and hence is referred to in most earlier work as CUG 
binding protein 1 (CUG-BP1).  
 
CELF1 was initially shown to be involved in the alternative splicing of mRNAs 
in the nucleus8, 9, 10. It was however noted to be found in both the nucleus and the 
cytoplasm11 and so was suspected to have additional functions to regulating 
alternative splicing which were dependent on its environment. These additional 
functions were first identified in the Xenopus Laevis homolog of CELF1, which 
was determined to cause rapid deadenylation of certain mRNAs when in the 
cytoplasm. This homolog of the protein was therefore originally named EDEN-
BP (Embryonic Deadenylation Element ± Binding Protein)12. It was later 
demonstrated to bind WR D 8* ULFK VHTXHQFH WHUPHG WKH ³(PEU\RQLF
'HDGHQ\ODWLRQ(OHPHQW´RU('(1PRWLILQWKH¶XQWUDQVODWHGUHJLRQRIP51$V
This triggers deadenylation and translational repression of the mRNA, by a 
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mechanism which is believed to involve the recruitment of poly(A) ribonuclease 
(PARN)13.   
 
1.1.1 Deadenylation 
 
Almost all eukaryotic protein-encoding mRNAs have a poly (A) tail at the 3' end, 
the structure of which is shown in Figure 1.1. When released from the nucleus 
mRNAs have a uniform poly (A) tail length, which is about 250 nucleotides in 
most mammals. Once in the cytoplasm different mRNAs are affected by a range 
of deadenylases and regulatory proteins, resulting in variable length poly (A) 
tails. The length of the poly (A) tail affects the susceptibility of the mRNA to 
degradation, and hence the efficiency with which it is translated. Regulation of 
gene expression is therefore achieved by regulation of the length of these poly 
(A) tails14, 15, 16. 
 
Figure 1.1: Outline of the deadenylation process and its role in mRNA regulation. Top left is shown the 
structure of a section of the poly(A) tail. To the right is shown the structure of a typical mRNA, with a 
PABP bound to the poly(A) tail. If an RNA sequence recognised by CELF1 is present (the Embryonic 
Deadenylation Element or EDEN motif), CELF1 can bind and triggers rapid shortening of the poly(A) tail. 
The mechanism by which CELF1 triggers deadenylation has not been confirmed, but may involve 
recruitment of poly(A) ribonuclease. Shortening of the poly(A) tail reduces the efficiency of the mRNA 
translation, and increases its susceptibility to degradation. 
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The 3' ends of mRNAs are protected from degradation by exonucleases by poly 
(A) binding proteins (PABPs)17. Removal of these (or the 5' cap) is required for 
degradation to occur18, 19. These PABPs have also been determined to promote 
recruitment of the small ribosomal subunit via an interaction with eukaryotic 
translation initiation factor 4F (eIF4F), encouraging translational initiation20. 
Increasing the length of the poly (A) tail that the PABPs can bind to will therefore 
LQFUHDVHWKHHIILFLHQF\RIWKHP51$¶VWUDQVODWLRQ&RQYHUVHO\VKRUWHQLQJRIWKH
poly (A) tail reduces the efficiency of its translation, as well as making the 
mRNA more vulnerable to degradation. 
 
In Xenopus, CELF1 was identified as a translational repressor, which functions 
E\ELQGLQJWRDVSHFLILFPRWLILQWKH¶XQWUDQVODWHd regions of its target mRNAs. 
&(/)¶V WDUJHW51$PRWLIZDVWHUPHGWKH³(PEU\RQLF'HDGHQ\ODWLRQ(OHPHQW´
or EDEN motif12, 21. This binding event triggers rapid deadenylation, and hence 
translational repression and degradation of the bound mRNA. Due to the 
uncertainties in the sequence requirements for CELF1 binding the exact criteria 
for an EDEN motif are not well defined, which prevents easy identification of all 
mRNAs regulated by this protein. While an EDEN motif alone is sufficient for 
GHDGHQ\ODWLRQ WR RFFXU DGGLWLRQDO HOHPHQWV SUHVHQW LQ WKH ¶ 875 have been 
reported to increase the efficiency of the process. Possible auxiliary elements 
include DWULSO\UHSHDWHG$88PRWLILQWKH¶875RIWKHP51$ or a repeating 
AUUUA motif22. 
 
Human and Xenopus CELF1 have a very high degree of sequence conservation. 
They have an 88% sequence identity overall, with an even higher degree of 
conservation within the three structured domains of the protein. The two proteins 
have been demonstrated to be functionally interchangeable, and hence the 
additional role of human CELF1 as a deadenylation factor was identified23. Based 
on this it is presumed that these proteins are recognising the same mRNA 
targets22. Clarifying the nature of the EDEN motif is of particular interest, since 
upregulation of CELF1 has been linked to type 1 myotonic dystrophy, and the 
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phenotype of this disease is believed to be at least partially due to the 
PLVUHJXODWLRQRI&(/)¶VWDrget mRNAs7, 24, 25, 26, 27. 
 
1.2 Structure of the CELF Proteins 
 
All six members of the CELF family of proteins have the same overall domain 
arrangement. The proteins each contain three structured domains, all of which are 
RNA recognition motifs (RRMs). In the CELF proteins RRM1 and 2 are 
generally located relatively close to the N-terminus of the protein, with a short 
flexible linker between them. RRM3 is typically located near the C-terminus of 
the protein, with between 180 and 220 residues of unstructured protein between it 
DQG5507KLVXQVWUXFWXUHGUHJLRQKDVEHHQWHUPHGWKH³GLYHUJHQWGRPDLQ´DV
differences in it are used to divide the CELF family into the two subfamilies. 
 
,WZDVXQFOHDUZKHWKHU WKH³GLYHUJHQWGRPDLQ´ OLQNLQJ550DQG550SOD\V
any direct role in binding to the RNA, or whether it simply allows the RRMs 
sufficient freedom of movement relative to each other to adopt the appropriate 
conformation for binding. Deletion of this linker region in CELF1 has been 
reported to result in a loss of RNA binding in a yeast three-hybrid assay, but the 
construct used not only removed the linker, but also significantly truncated the 
adjacent RRM2 and RRM3 domains28, 29. The resulting disruption to the fold of 
these two structured domains may therefore be responsible for the reported loss of 
binding, rather than the removal of the RRM2 ± RRM3 linker itself. 
 
1.2.1 RNA Recognition Motifs 
 
RNA Recognition Motifs (RRMs) are one of the most abundant classes of protein 
domains in eukaryotes. They are also known as RNA binding domains (RBDs) or 
ribonucleoprotein domains (RNPs). RRMs are also found in prokaryotes but they 
are rarer, and prokaryotic proteins generally do not contain multiple RRMs30. In 
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contrast almost half of those eukaryotic proteins containing an RRM have 
multiple RRM domains, with as many as six in a single protein31. There are 
around 500 human proteins which are currently known to contain at least one 
RRM32. The number of nucleotides that can be recognised by an individual RRM 
varies, with examples known that bind as few as two33, 34, 35, and as many as 
eight36. Multiple RRMs working in combination allow longer RNA sequences to 
be recognised, and can dramatically increase the overall binding affinity into the 
nanomolar range37, 38. 
 
The classic RRM protein fold consists of a four-stranded antiparallel beta-sheet 
packed against two alpha helices. The overall topology is ȕ1 - Į- ȕ2 - ȕ3 - Į2 - 
ȕ4. The first and third strands of the beta sheet contain highly conserved aromatic 
residues, which usually form key parts of the binding surface for the RNA by 
stacking interactions with the RNA bases39, 40. There are some known variations 
on the classic RRM fold, such as the addition of a third alpha helix at the N or C 
terminus of the domain. The N and C-terminal regions of RRMs are generally 
unstructured, but can still play a role in binding the RNA by folding over the 
exposed side of the RNA strand and holding it in place against the beta sheet31, 41, 
42
, 
43
 
Despite their name RRMs are not always restricted to interacting with RNA and 
can also be involved in binding DNA44, and in protein - protein interactions45. In 
some cases this competes with, or completely prevents conventional interactions 
of the RRM with RNA by obstructing the normal binding surface. There are 
however known examples of RRMs which can bind to both proteins and RNA 
simultaneously due to the interactions occurring via different binding surfaces. 
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1.2.2 Structure of CELF1 
 
Human CELF1 has the same basic arrangement of three RRMs as the other CELF 
family members. RRM1 and 2 are located near the N-terminus of the protein, 
separated by approximately 8 residues of relatively unstructured linker. RRM3 is 
near the C-terminus of the protein, separated from RRM2 by around 215 residues, 
which are believed to be completely unstructured. Human CELF1 is a 486 amino 
acid protein with a total mass of 52.1 kDa. The Xenopus Laevis homolog has an 
additional three amino acids in the flexible linker between RRM2 and RRM3, 
increasing the total mass to 52.7 kDa. The exact arrangement of the RRMs is 
shown in Figure 1.2. 
 
 
Figure 1.2: Arrangement of the RRMs in the CELF1 protein sequence. Numbers indicate the approximate 
limits of the structured regions. 
 
In general RRMs have two major conserved regions, which have been termed 
RNP1 (in ȕ-strand 3) and RNP2 in ȕ-strand 146, 47. RNP1 is defined as: K/R ± G ± 
F/Y ± G/A ± F/Y -V/I/L ± X ± F/Y, where X is any amino acid. RNP2 is defined 
as I/V/L ± F/Y ± I/V/L ± X ± N ± L. These RNP1 and 2 motifs are to some extent 
conserved in all three RRMs of CELF1, but there are some notable deviations 
from the normal pattern of residues. 
 
RNP2: I/V/L ± F/Y ± I/V/L ± X ± N ± L 
 
RRM1:  M ± F ± V ± G ± Q ± V 
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RRM2:  L ± F ± I ± G ± M ± I  
RRM3:  L ± F ± I ± Y ± H - L 
 
 
 
RNP1: K/R ± G ± F/Y ± G/A ± F/Y -V/I/L ± X ± F/Y 
 
RRM1: K ± G ± C ± C ± F ± V ± T ± F  
RRM2: R ± G ± C ± A ± F ± V ± T ± F  
RRM3: K ± C ± F ± G ± F ± V ± S ± Y  
 
RRM1 and RRM2 in particular show significant differences in these regions, as 
one of the key conserved aromatic residues is missing. The first aromatic residue 
in RNP1 has been replaced with a cysteine, which is conserved between RRM1 
and RRM2. A phenylalanine residue is however present at this position in RRM3.  
RRM3 also has an additional tyrosine residue in the RNP2 region, as opposed to a 
conserved glycine residue in RRM1 and RRM2. These additional aromatic 
residues permit different potential stacking interactions with the RNA bases, and 
so RRM3 may have distinct differences in interactions with RNA compared to the 
other two domains. One other deviation from the classic RNP regions is the lack 
of a conserved asparigine in RNP2, which is the case for all the three RRMs.  
 
1.2.3 NMR and X-ray Crystallography Data Available for CELF1 
 
Structural data for some domains of CELF1 had already been published prior to 
this study, and additional NMR and x-ray crystallography data appeared during 
its course. In 2004, Jun et al. published NMR assignments and a solution 
structure for the N-terminal region of CELF1, specifically residues 14 - 187 of the 
human CELF1 protein incorporating the whole of RRM1 and RRM248. The 
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structures of these domains are shown in Figure 1.3. In 2009 Tsuda et al. 
published NMR solution structures of an isolated RRM3 construct (residues 377 - 
480), both unbound and in complex with the RNA substrate UGUGUG49. Shown 
in Figure 1.4 are their NMR solution structures for RRM3 in isolation, and in 
complex with the RNA sequence UGUGUG. (PDB ID: 2CPZ and 2RQ4) 
 
 
 
Figure 1.3: Structure of the N-terminal domains of CELF1 by Jun et al. (PDB ID: 2DHS). RRM1 on is on the 
left, RRM2 on the right. The similarities in the fold of each domain can be seen. Given the high level of 
sequence conservation between them it is expected that the structure of the CELF1 domains is the same 
in homologous proteins, such as in Xenopus Laevis. This image was produced using the program 
MOLMOL50. 
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Figure 1.4: Structure of RRM3 of human CELF1, determined by Tsuda et. al. Structures of both the protein 
in isolation (left), and in complex with the RNA sequence UGUGUG (right) are shown. As there is only a 
single residue difference in this domain between human and Xenopus CELF1, it can be assumed that the 
structure and function is conserved between the two protein homologs25. 
 
A notable feature of the RRM3 bound structure was the involvement of an 
unstructured N-terminal extension of the domain in binding RNA. This region 
IROGVEDFNDFURVVWKHȕ-sheet surface, forming additional contacts with the RNA 
strand. Studies of the third domain of the homologous protein in Drosophila 
(usually identified as Bruno-1) had previously indicated a 40 residue N-terminal 
extension was required for RNA binding, which is likely due to a similar 
interaction. No evidence has been presented for any similar extended regions 
being involved in RNA binding by the other two domains. 
 
In 2010 Teplova et al. produced crystal structures of an isolated RRM1 construct 
and a construct of the two N-terminal domains in complex with various U/G rich 
RNA substrates. They were however unable to observe any plausible structures 
for tandem binding of the N-terminal domains onto a single RNA molecule51. 
This was attributed to be a result of crystal packing interactions by the authors, 
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rather than any inherent problem with binding both domains simultaneously to 
the RNA substrates in solution. Teplova et al. also reported attempts to model the 
tandem binding of the two N-terminal domains by analogy to the known 
structures of HuD and PABP. These proteins have similar pairs of RRMs 
separated by comparable flexible linkers of 10 ± 12 residues, but have two 
distinct binding modes. When PABP binds the two RRMs are arranged side by 
siGH DOORZLQJ WKH ȕ-sheets to form a relatively flat surface with the RNA 
substrate bound across it in a linear arrangement. In contrast in HuD the RRMs 
are rotated with respect to each other, introducing a sharp turn into the RNA 
backbone. Plausible models of the N-terminal domains of CELF1 bound to the 
RNA substrate could be constructed for either arrangement due to the flexibility 
of both the linker between the domains, and the spacer between their target sites 
in the RNA sequence. It was concluded that more data was required on the 
tandem binding of the domains to distinguish between these models.  
 
 
The region of the protein between residues 187 and 385 WKH³GLYHUJHQWGRPDLQ´ 
has no NMR or x-ray crystallography data available, but is believed to be 
completely unstructured. There is also no structure incorporating more than two 
of the three CELF1 domains, and so no information as to how RRM3 might work 
together with the N-terminal domains in order to recognise the RNA substrate. 
 
1.3 Target RNA Sequences of CELF1 
 
CELF1 has been shown to interact with three distinct types of RNA sequence: 
UG rich elements28, CUG repeats52 and AU rich elements53, 54. While a (CUG)8 
probe was the first RNA sequence identified to bind to CELF1, UG rich 
sequences, in particular those containing UGU trinucleotides, were later found to 
bind with a much higher affinity29, 55. Isothermal titration calorimetry conducted 
by Tsuda et al. on RRM3 in isolation showed a strong preference for UG repeats 
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over CUG or AU repeats, the latter two showing no significant interaction49. The 
reported interactions of CELF1 with CUG and AU repeats must therefore involve 
one or both of the N-terminal domains of the protein. The comparison of the 
residues in the RNA binding surfaces of each RRM of CELF1 showed that 
RRM3 is the most distinct of the three domains, with two additional aromatic 
residues. It would therefore not be surprising if its preferred target sequences 
were also distinct.  
 
Some natural mRNA sequences have been empirically determined to be targets of 
CELF1 by observation of binding to the protein, and subsequent deadenylation 
and translational repression of the mRNA in a reporter assay. In 2006 Moraes et 
al. reported that sections of the RNAs TNFĮ DQG F-fos were capable both of 
binding to CELF1, and inducing rapid shortening of an attached poly(A) tail 
suggesting that these sequences contain functional EDEN motifs56. These 
sequences are however 250 bases in length, and the size of the RNA binding 
surfaces of CELF1 means that only a small section of these sequences can 
possibly be being recognised. Both RNAs contain multiple UGUX sites, with 
eight LQ 71)Į DQG QLQH LQ F-fos. This is higher than would be expected for a 
randomly generated RNA sequence, which would average 2.9 of these sites in 
250 bases. The authors tentatively suggested the section near the start of the c-fos 
sequence: UGUUCAUUGUAAUGUU as a possible binding site for CELF1 as it 
contains three of these UGUX sites in close proximity, one for each RRM. 
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Figure 1.5: RNA sequences of known CELF1 targets c-fos, c-ŵŽƐ ĂŶĚ dE&ɲ ? ? h'h ?h ?' ? ƐŝƚĞƐ ĂƌĞ
highlighted, as are A/U rich regions which have been reported to increase deadenylation efficiency. 
Sequences reproduced from Moraes et al. 2006.56 
 
,Q71)ĮE\FRPSDULVRQWKH8*ULFKUHJLRQVare scattered and the shortest section 
incorporating three UGUX sites is more than 40 nucleotides in length. It is 
therefore unclear how the three RRMs of CELF1 are recognising this sequence. A 
possibility considered was that some secondary structure is present in this 
sequence which can bring distant UGU sites into close proximity allowing a 
single CELF1 protein to bind to them. 
 
In 2008 Graindorge et al. carried out an analysis of mRNAs which were co-
purified with CELF1 from Xenopus cells. More than 150 associated RNAs were 
identified, and a UGUX repeat was found to be the most highly conserved 
feature. The sequence UGUUUGUUUGUUUGU (which was termed EDEN15) 
was identified as a consensus sequence. The fourth UGU site and the nucleotides 
separating the UGU sites were somewhat less conserved than the rest of the 
13 
 
sequence57. Also in 2008 Vlasova et al. identified the consensus sequence 
UGUUUGUUUGU as a possible CELF1 binding site, which was commonly 
present in short lived mRNAs58, 59. In 2010 Rattenbacher et al. reported further 
studies of human CELF1 mRNA targets, producing a consensus sequence of 
UGUGUGUGUGU, with some flexibility for G -> U substitution between UGU 
sites60. These three sequences are all consistent with CELF1 targeting a repeating 
UGU motif, with the nucleotides separating the UGU sites being of lesser 
importance. The 11 nucleotide sequence UGUUUGUUUGU has therefore been 
proposed as a functional EDEN motif, and has been termed the ³*XDQLQH5LFK
(OHPHQW´*5(57-58. 
 
A limitation of these analyses is that they only demonstrated that the GRE and 
similar sequences were being bound by at least some of the domains of CELF1, 
not that they were sufficient to trigger deadenylation and hence translational 
repression when present in an mRNA. Both Vlasova et al. and Rattenbacher et al. 
demonstrated that certain RNA sequences containing the GRE trigger 
deadenylation, and so represent functional EDEN motifs. However the GRE was 
only a small part of these sequences which in all cases were at least 50 
nucleotides in length, and contained additional UGU sites outside of the GRE.  
 
Figure 1.6: These are the RNA sequences which were shown to trigger deadenylation in these two 
studies, and so must contain functional EDEN motifs. All of them contain a GRE and/or an extended UG 
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repeating region. Mutation of the central G in all UGU trinucleotides to C was demonstrated to render 
the EDEN motif non-functional for all of the sequences except PPIC-GU, where these mutations were not 
conducted. 
 
In Figure 1.6 are shown the complete sequences which were demonstrated to 
contain functional EDEN motifs in these two studies. While each does contain 
either the GRE or a lengthy UG repeat, there are a minimum of six possible UGU 
sites in each sequence. There is also a wide range of possible spacing between 
UGU sites, and no indication which sites are being occupied by the three domains 
of CELF1. There was therefore insufficient evidence to conclude that the GRE 
alone was sufficient for binding of all three domains of CELF1, or to serve as a 
functional EDEN motif capable of triggering deadenylation. An extended version 
of the c-jun sequence had previously been shown to be a functional EDEN motif 
in Xenopus22.  
 
During the course of this study Teplova et al. reported crystal structures showing 
that both RRM1 and RRM2 were capable of recognising the RNA sequence 
UGUU. If the EDEN11 GRE sequence is capable of binding all three domains of 
CELF1 simultaneously, then at least one of the three domains would have to be 
binding to a UGU site rather than a UGUU site. Their model of the tandem 
interaction of the N-terminal domains also highlighted the importance of the 
spacing between the binding sites of each domain. Depending on whether a 
domain was recognising a UGU or a UGU(U/G) site, it would have only a single 
nucleotide, or no spacer at all between it and the neighbouring binding site on the 
GRE substrate. These short or non-existent spacers between the binding sites 
seemed likely to result in steric clashes between the RRMs. To predict whether 
any given sequence can bind CELF1 it was therefore important to clarify not only 
the minimum site required for each domain to bind, but also the spacing between 
the sites that would permit the domains to bind in tandem. 
Proposed EDEN Motif RNA Sequence 
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c-fos ARE56 UGUUCAUUGUAAUGUU 
EDEN1557 UGUUUGUUUGUUUGU 
EDEN11 GRE58 UGUUUGUUUGU 
UG Repeat60 UGUGUGUGUGU 
 
Table 1-1: This table shows short RNA sequences which have been proposed as EDEN motifs. The 
underlined nucleotides are suggested to be critical to binding, with the nucleotides separating them 
being less conserved. While longer sequences containing these motifs have been demonstrated to trigger 
deadenylation, it has not been shown that any of these alone are sufficient to function as an EDEN motif. 
They may therefore represent only part of the minimum EDEN motif. While all have been demonstrated 
to bind CELF1, no structural data has been published to show whether this is involving simultaneous 
binding of all three RRMs, or only a subset of them. 
 
1.4 Link between CELF1 and Myotonic Dystrophy 
 
Myotonic dystrophy type 1 (DM1), also known as Steinert's disease, is the most 
common form of muscular dystrophy, affecting around 1 in 8000 people. The 
major symptoms are progressive muscle atrophy, myotonia (an inability to relax a 
contracted muscle) and cardiac conduction defects61. At a molecular level 
misregulation of alternative splicing of some mRNAs has been observed in cases 
of DM1. Incorrect splicing patterns have been found in more than 20 different 
mRNAs in DM1 tissues, mostly in skeletal muscle and the brain. These include 
the mRNAs for the insulin receptor, the tau protein and the CLC-1 muscle 
chloride channel. Not all of these mis-spliced mRNAs have been correlated with 
the symptoms of DM1, though the mis-splicing of the CLC-1 mRNA is 
associated with myotonia. In CLC-1 exon 7a is inappropriately incorporated, 
which results in a truncated and non-functional form of the CLC protein62, 63. 
Overexpression of CELF1 in mouse models reproduces these splicing defects, as 
well as the other features of the DM1 phenotype64, 65, 66. Correction of the CLC-1 
splicing defect in a mouse model with a myotonic phenotype restored normal 
chloride transport and hence normal function67. 
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DM1 is an inherited disorder, caused by an expanded region of CUG repeats in 
the 3' UTR of the dystrophia-myotonica protein kinase gene (DMPK) of 
chromosome 1968, 69, 70, 71, 72, 73. Healthy individuals have been observed to have 
up to 38 repeats of CUG at this position. Symptoms of DM1 have been observed 
in individuals with as few as 50 repeats, and cases with more than 4000 CUG 
repeats are known. There is a strong correlation between the number of repeats 
and the severity of the DM1 symptoms74, 75. The age of onset of DM1 is also 
strongly correlated to the number of repeats76. The most severe and early onset 
form of the disease is associated with a minimum of 1500 repeats. The number of 
these repeats is unstable, and can increase through generations77. Type 2 
myotonic dystrophy (DM2) has similar symptoms to DM1, but is caused by an 
expanded CCUG repeating motif in the unrelated ZNF9 gene78, 79. Between 100 
and 11000 CCUG repeats have been observed in DM2 cases.  
 
In both DM1 and DM2 these expanded RNAs form aggregates in the nucleus, and 
it has been concluded that the symptoms of the disease are a result of the presence 
of these mutant RNAs, rather than effects directly related to the DMPK and ZNF9 
genes80, 81. 
 
Antisense transcripts, consisting of a CAG repeating sequence may also be 
expressed in DM1 cells. Expression of long CAG repeating RNAs has been 
shown to induce toxicity in animal models82, 83. Both the sense and antisense 
transcripts also have the potential to undergo non-ATG initiated transcription, 
resulting in the production of long chains of a single amino acid type 
(polyglutamine and polyleucine)84. These would be expected to aggregate, giving 
another possible source of cellular toxicity85, 86. Polyglutamine aggregates have 
been observed in DM1 tissues, so may play some role in the disease pathogenesis. 
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The expanded RNAs are not exported from the nucleus to the cytoplasm, instead 
aggregating into insoluble foci. Electron microscopy and crystallography have 
shown that the extended CUG repeats of DM1 form stable hairpin structures. 
These are composed of normal Watson-Crick base pairing between C and G bases 
separated by mismatched U-U pairs87, 88. While CELF1 is known to bind at least 
with a low affinity to long CUG repeating sequences, it has not been detected in 
these foci. The RNA splicing protein muscle blind-like (MBNL1) has been found 
to bind to the double stranded sections of these RNAs, and is sequestered into the 
foci89, 90. This has lead to the hypothesis that CELF1 is not involved in binding to 
these CUG repeat RNAs in vivo at all and so is not directly involved in DM1 
pathogenesis, but this is inconsistent with the observed effects of CELF1 
upregulation in mouse models. It has however been found that very short CUG 
RNAs do not form foci but still result in the DM1 phenotype, suggesting the foci 
are a symptom rather than a direct cause of DM1. The possibility that the foci 
only contain a fraction of the CUG RNAs has been raised to explain this 
observation91. If this is the case then direct binding of CELF1 to extended CUG 
RNAs may be occurring, and playing a role in DM1 pathogenesis. 
 
This theory is supported by size exclusion chromatography of CELF1 extracts 
from DM1 cells, which give an apparent molecular weight for the protein in 
excess of 150 kDa. This is in contrast to the protein from wild type cells with a 
mass of just over 50 kDa, and was found to be sensitive to the presence of 
RNases indicating this shift is due to binding to a long RNA sequence91. Almost 
all of the CELF1 protein in DM1 cells was found to be in the form of this RNA 
complex. CELF1 has been shown to be incapable of binding to double stranded 
RNA in vitro. Electron microscopy of CUG RNA hairpins showed CELF1 would 
only bind to single stranded sections at the ends of the hairpin, not to the double 
stranded stem92. It can be hypothesized that binding to MBNL1 encourages 
formation of double stranded RNA, displacing CELF1. This would account for 
the complete absence of CELF1 in the insoluble foci, despite it being almost 
saturated by soluble non-focus CUG RNA. 
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CELF1 and MBNL1 appear to be antagonistic proteins. Sequestering of MBNL1 
in the insoluble foci effectively results in increased CELF1 activity. The half-life 
of CELF1 is normally quite short (estimated at 3 hours in vivo), but is likely to be 
increased by up to a factor of five by binding to the longer lived single stranded 
CUG RNA93. It has been suggested that CELF1 upregulation in DM1 is due to 
the protein being hyperphosphorylated by protein kinase C (PKC) and hence 
stabilized94. The mechanism of this PKC activation is unknown, and it is possible 
that PKC upregulation is an effect of CELF1 upregulation rather than a cause.  
 
A recent paper by Masuda et al. (2012) suggests a more direct mechanism for 
CELF1 upregulation in DM1 cells. In cross-linked immunoprecipitation assays 
with CELF1 and MBNL1, they note that the CELF1 mRNA appears to have an 
0%1/WDUJHWVLWHLQLWV¶XQWUDQVODWHGUHJLRQ8757KH\DOVRQRWHGDSRVVLEOH
&(/)WDUJHWRU('(1PRWLILQWKH¶875RIWKH0%1/P51$6LQFHERWK
of these proteins ultimately trigger the degradation, and hence repression of their 
target mRNAs, this implies that CELF1 and MBNL1 directly regulate each other. 
When MBNL1 is sequestered by the expanded CUG repeat RNA in DM1 cells, 
this will reduce its repression of its target mRNAs, including CELF1. CELF1 will 
therefore be upregulated, even without any extension of its half life via 
phosphorylation, or binding to soluble CUG RNAs. Hyperphosphorylation by 
PKC may be exacerbating the condition by stabilizing the already elevated levels 
of CELF1, but this may not be the direct cause it was originally thought to be. 
This has implications for the treatment of DM1. Potential therapies for DM1 have 
so far focused on disruption of the MBNL1/CUG repeat RNA interaction95, 96, 97. 
This mutual regulation suggests that if CELF1 could be sequestered or otherwise 
inactivated, it should not only restore normal splicing patterns, but also 
upregulate MBNL1 directly. CELF1 therefore represents a potential drug target 
for treatment of DM1. 
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1.5 MBNL1 
 
Muscle Blind-Like 1 (MBNL1) is an RNA binding protein known to regulate 
alternative splicing of mRNA. It has recently been reported to also be involved in 
translational repression, similar to CELF1. The interplay of these two regulatory 
proteins, particularly in the context of type 1 myotonic dystrophy is of interest. 
The MBNL1 protein has 388 amino acid residues, and a total mass of 41.8 kDa. It 
is composed of four small CCCH - type zinc finger domains, arranged in pairs. 
Domains 1 and 2 are located near the N-terminus, while 3 and 4 are roughly in 
the middle of the protein chain. X-ray crystal structures of all four domains are 
available (Teplova et al. 2008), and the rest of the protein is believed to have no 
significant secondary structure98. 
 
These four zinc finger motifs recognize a YGCY motif, where Y is either of the 
pyrimidine bases99, 100. Immunoprecipitation assays by Masuda et al. identified a 
somewhat different MBNL1 target motif of CU(G/C)C, consistent with earlier 
reports101. The extended CUG RNA sequences in DM1 satisfy both sets of 
criteria, and have been shown to sequester MBNL1 along the double stranded 
sections of the resulting CUG hairpins. Both MBNL1 and CELF1 are regulators 
of alternative splicing, but analysis of the distribution of their target motifs 
around introns and exons shows distinct patterns for the two proteins. EDEN 
motifs were found to be concentrated immediately before and after alternative 
exons. MBNL1 motifs in contrast are less common in these regions, and more 
enriched in the exon regions themselves102.  
 
1.6 Dimerisation of CELF1 
 
Xenopus CELF1 has been reported to undergo dimerisation in a yeast two-hybrid 
assay, and it has been suggested that this might have a role in recognition of 
RNA54, 103. No evidence of dimerisation has been reported in the literature for 
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human CELF1. It is not clear if the yeast two-hybrid observation is due to the 
formation of a true dimer, or if it could be the result of two CELF1 proteins 
binding onto a single RNA molecule of the RNA substrate. 
 
1.7 Phosphorylation of CELF1 
 
Shortly after its discovery CELF1 was shown to be a phosphoprotein11, 104. 
Protein kinase C (PKC), as mentioned previously, can stabilise CELF1 by 
hyperphosphorylating the protein in DM1 cells. However the protein is also 
predicted to have phosphorylation sites for several other phosphatases105. It has 
been suggested that phosphorylation of CELF1 may therefore play an important 
role in regulating its RNA binding preferences, and interactions with other 
proteins106, 107, 108. Phosphorylation has been demonstrated to occur at Ser28 and 
Ser302, with some reported effects on the RNA binding properties of CELF1106, 
109
. ,WKDVEHHQSURSRVHGWKDWSKRVSKRU\ODWLRQDW6HUPD\VHUYHDVD³VZLWFK´
DOWHULQJ&(/)¶Vpreferred target from the U/G rich sequences so far identified to 
a C/G rich sequence. A specific example is a reported increase binding affinity to 
the cyclin D1 mRNA sequence shown below when the phosphomimetic mutation 
S28D is made to CELF1109. 
 
Cyclin D1: 
5'-CCCAGCCAGGACCCACAGCCCUCCCCAGCUGCCCAGGAAGAGCCCCAGCC-3' 
 
This sequence is very distinct from any other CELF1 consensus sequence in the 
literature, as it is G/C rich and with very few uracils. If this concept of a Ser28 
VZLWFK LV FRUUHFW LW LV SRVVLEOH WKDW WKH ³('(1 PRWLI´ PD\ DFWXDOO\ YDU\
depending on the phosphorylation state of CELF1. 
 
1.8 Interactions of CELF1 with Poly (A) Ribonuclease 
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CELF1 has been reported to interact with poly(A) ribonuclease (PARN), also 
known as DAN (deadenylating nuclease)56. This interaction was observed even in 
the absence of RNA, suggesting the two proteins bind directly to each other. 
Since the function of PARN is to shorten the poly(A) tail of mRNAs, it presents a 
possible mechanism for how CELF1 triggers deadenylation of its mRNAs. If 
CELF1 can interact with both PARN and its mRNA targets simultaneously, it can 
therefore recruit the deadenylase to the mRNA. PARN has been successfully 
purified110, and the structures of all of its domains are known from x-ray 
crystallography111, 112. So far no structural data has been reported to indicate 
which regions of the proteins are involved in the interaction with CELF1. NMR 
data has previously been collected on an isolated construct of the RRM (residues 
430 ± 516), but not on any larger sections of the protein. 
 
1.9 Aims and Objectives 
The primary aim of this study was to determine the sequence requirements for 
high affinity CELF1 binding. While a few potential high affinity CELF1 targets 
had been identified (e.g. the GRE and EDEN15 consensus sequences), the criteria 
for an ³('(1PRWLI´were still not well defined. It was also unknown what role 
each domain of CELF1 played in recognising RNA. Our aims were therefore: 
 
1) Express and purify constructs of each domain of CELF1 in isolation. 
Using these, determine the minimum RNA sequence requirements for 
each domain to bind. NMR and ITC can be used to investigate whether 
each domain requires a UGU(U/G) site, or if the shorter UGU site is 
sufficient. Also we aimed to investigate which domains are involved in 
the reported interactions of CELF1 with CUG repeats and AREs. 
2) Using a construct containing the two N-terminal domains of CELF1, 
determine the spacing required between UGU or UGU(U/G) sites in a 
sequence for tandem binding of the two domains onto a single RNA 
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molecule. Confirm by ITC that this tandem interaction results in an 
enhanced binding affinity compared to the isolated RRMs. Investigate 
whether a similar enhancement in binding affinity is seen for tandem 
interactions with CUG repeats and AREs. We also aimed to check for any 
involvement of N- and C-terminal extensions of RRM1 and RRM2 in 
RNA binding, similar to that seen for RRM3.  
3) Express and purify a construct containing all three RRMs of CELF1, 
ideally the full length wild type protein. NMR titrations can then be used 
to determine whether all three RRMs are capable of binding onto the 
EDEN15 and GRE sequences, and so whether these represent complete 
and functional EDEN motifs. If these sequences are not capable of 
simultaneous interaction with all three domains, we aimed to design 
sequences that can form a high affinity complex. By investigating the 
minimum sequence that will still bind all three RRMs, we can determine 
the criteria for a functional EDEN motif. We also aimed to determine by 
ITC whether binding affinity is enhanced for simultaneous binding of all 
three domains. 
4) Using the criteria determined for the EDEN motif, rationalise those 
sequences already reported to be functional EDEN motifs, and show 
which regions of these long sequences are actually recognised by CELF1.  
5) Characterise the structure of CELF1 in complex with a high affinity 
EDEN motif, ideally using a combination of NMR and x-ray 
crystallography. 
6) Investigate whether phosphorylation at Ser LV VHUYLQJ DV D ³VZLWFK´
altering the RNA binding preferences of CELF1. Using NMR and ITC on 
a phosphomimetic mutant (S28D) we will determine if phosphorylation 
does change the target from UG rich sequences to CG rich sequences as 
suggested. 
7) Investigate the reported interaction between poly(A) ribonuclease and 
CELF1. To this end we aimed to express and purify full length wild type 
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PARN, and conduct preliminary NMR studies of the protein in isolation, 
and in the presence of wild type CELF1. PARN forms a homodimer with 
a mass of 146 kDa, and so a complex with CELF1 could be as large as 
200 kDa. This system is therefore a challenging target for NMR, and our 
first aim was to determine whether high resolution NMR data could be 
collected on this key regulatory complex. If it proved possible to acquire 
high resolution NMR data, we aimed to observe chemical shift 
perturbations from interaction of the proteins, and so determine which 
domains of both the CELF1 and PARN proteins are involved in their 
interaction. 
 
2 Biophysical Techniques 
 
2.1 Protein NMR 
 
NMR spectroscopy is an established technique for both structural determination 
of proteins, and observing their interactions with other molecules. It has a major 
advantage over techniques such as ITC and mass spectrometry in that it can 
provide information on a residue by residue basis, rather than just the overall 
properties of the protein. NMR can also provide detailed structural data of 
proteins in biologically relevant aqueous solutions, without the need for 
crystallization. This allows dynamic aspects of protein systems to be investigated, 
which would not necessarily be evident from crystal structures113, 114. Over 8000 
structures derived from NMR data are present in the protein data bank, 
representing a significant fraction of all protein structures so far solved. Large 
proteins (with masses of greater than ~35 kDa) have historically been challenging 
for NMR, but the development of techniques such as TROSY, selective isotopic 
labelling of amino acid types, and improvements in spectrometer field strength 
have greatly increased the size of the systems that can be investigated by this 
technique115, 116. Proteins of several hundred amino acids have been successfully 
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assigned, and high resolution spectra have been collected for proteins in 
complexes in excess of 800 kDa in mass117, 118. 
 
In protein NMR the 1H-15N HSQC, which correlates 1H and 15N chemical shifts, 
is a particularly useful experiment since it shows a single peak for each residue in 
the protein119. Each amino acid gives a single peak from the backbone NH, with 
the exception of proline where the nitrogen has no hydrogen bonded to it. Some 
additional peaks are also produced by NH and NH2 groups in the side chains of 
amino acids (specifically tryptophan, arginine, asparigine, glutamine and lysine). 
The 1H-15N HSQC FDQWKHUHIRUHVHUYHDVD³ILQJHUSULQW´IRUWKHSURWHLQZLWKHDFK
peak providing information on the environment of each residue. If the 
environment of a residue changes, for example when a ligand binds to the protein 
or if the protein conformation is altered, then the chemical shifts will change and 
the peak for the residue will move in the 1H-15N HSQC. 
 
2.1.1 Transverse Relaxation Optimized Spectroscopy (TROSY) 
 
The size of the proteins and other macromolecules that could be studied by NMR 
was initially quite limited. Prior to the development of the TROSY technique by 
Pervushin et al. in 1997 very few solution NMR structures for proteins larger than 
20 kDa were produced120. NMR of larger proteins has two inherent problems. 
Firstly larger proteins inevitably result in more signals on any given spectrum, 
leading to spectral crowding and overlapping peaks. Secondly larger proteins 
have lower transverse relaxation times (T2). The rapid loss of magnetization 
therefore results in very low intensity signals for large proteins. 
 
In the case of amide protons there are two major relaxation mechanisms: the 
chemical shift anisotropy of the protons (CSA), and dipole-dipole interactions 
between the proton and nitrogen spins (DD). CSA relaxation is proportional to 
B02, while DD relaxation is independent of magnetic field strength. At high 
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magnetic fields, such as in the 600 and 800 MHz spectrometers used in this study, 
these effects are of comparable magnitude. In a 1H-15N HSQC spectrum with no 
decoupling a peak from an amide proton is split into four by coupling between the 
1H and 15N nuclei, as shown in Error! Reference source not found., with 
each of the four components having different relaxation rates and linewidths. 
These differences are the result of constructive and destructive interference 
between the CSA and DD relaxation mechanisms. The normal decoupling process 
for an HSQC collapses these four components into a single peak, averaging the 
relaxation rates. The TROSY experiment instead selects for the component (DD-
CSA), which has the slowest relaxation rate and hence the narrowest linewidth121, 
122, 123
, 
115
 
 
The TROSY experiment has only 50% of the inherent sensitivity of the HSQC 
since the signal from the faster relaxing components is discarded. However in 
proteins larger than ~20 kDa, this is more than compensated for by the narrower 
line widths. The effect is dependent on the field strength (as CSA relaxation is 
proportional to Bo2), with optimal results for 15N amide groups at 1 GHz. Use of 
this technique has allowed NMR studies of much larger proteins and complexes 
than was previously possible115. 
 
 
 
 
2.1.2 NMR Assignment of Proteins 
 
In order to extract most of the useful information from an NMR spectrum such as 
a 1H-15N HSQC it is necessary to know which peak corresponds to which residue 
in the protein. Without this only the general properties of the whole protein such 
as its size and whether it is folded into a rigid structure can be determined. 
Matching each peak to a specific residue LVNQRZQDV³DVVLJQLQJ´WKHVSHFWUXP
and there are a number of possible methods for accomplishing this. 
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The simplest method is to use 2D homonuclear experiments, specifically the Total 
Correlation Spectroscopy (TOCSY) and Nuclear Overhauser Effect Spectroscopy 
(NOESY) experiments. The TOCSY experiment shows correlations from 
magnetisation transfer through bonds by scalar coupling of spins. The NOESY 
experiment shows through-space magnetisation transfer rather than directly 
through bonds. By observing cross-peaks between the backbone NH of a residue 
and its neighbouring resLGXHVLWLVSRVVLEOHWR³ZDON´DORQJWKHSURWHLQEDFNERQH
Different amino acids give different patterns of side chain proton peaks, and once 
the type of each amino acid in a chain is known, it is then possible to match the 
chain to a specific section of the protein sequence124.  
 
This method has the advantage that it does not require any expensive isotopic 
labelling of the protein, but it is generally unsuitable for large proteins (larger 
than ~10 - 15 kDa) as signals from each residue are only separated by their proton 
chemical shift. As the size of the protein increases the odds of it containing 
multiple residues with the same proton chemical shift also increases. Overlapped 
signals can make connectivities extremely difficult to determine, and this problem 
is exacerbated by the tendency to broader linewidths for larger proteins. With 15N 
labelled protein the signals can be separated by their 15N chemical shift as well as 
the proton shift in 3D experiments such as the HSQC-NOESY and HSQC-
TOCSY. This reduces the issue of overlapping signals to some extent125, 126. 
 
To assign larger proteins a different strategy using 3D heteronuclear NMR 
experiments is preferred, in which peaks are separated in the carbon and nitrogen 
dimensions as well as the proton dimension, reducing spectral crowding and 
overlap even further127. These experiments require the protein to be isotopically 
labelled with both 13C and 15N. The more abundant 12C is not detectable by NMR 
as it has a spin of zero. 14N is detectable by NMR as it has a net spin of 1, but 
quadrupolar interactions result in extreme broadening of its signals in large 
molecules making it impractical to acquire high resolution data. The 13C and 15N 
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nuclei both have spins of ½ and so are suitable for high resolution NMR studies. 
The natural abundance of these isotopes is low (1.11% for 13C and 0.37% for 
15N), and their sensitivity is lower than for 1H, so it is necessary to produce 
proteins enriched with these isotopes. This is usually accomplished by 
recombinant expression in a medium where only suitably labelled carbon and 
nitrogen sources are present128.  
 
Once isotopically labelled material is available 3D heteronuclear experiments 
such as the HNCACB129, HNCO130, HNCA131, HN(CA)CO132 and 
HN(CO)CACB130, 133 can be carried out. The name of each experiment refers to 
which of the nearby carbon nuclei are correlated to each backbone amide group. 
The exact magnetization transfer pathways and how the experiments can be used 
to assign the 1H-15N HSQC spectrum of a protein are explained in the following 
sections. TROSY versions of all of these 3D heteronuclear experiments exist, and 
allow high quality spectra to be collected for large proteins134, 135. All of the 
protein assignments in this study were determined using this strategy of 3D 
heteronuclear NMR experiments on proteins labelled with both 13C and 15N. 
 
2.1.3 Protein Backbone Assignment Using 3D Heteronuclear NMR 
Experiments 
 
In the HNCACB experiment magnetization is transferred from the NH proton to 
the 151 DQG WKHQ WR WKH &Į DQG &ȕ RI ERWK WKH i and i-1 residues. It is then 
transferred back to the 15N and the NH proton in order to be detected, as shown in 
Figure 2.1129. The spectrum therefore usually shows four peaks correlated to each 
1+7KH&ĮDQG&ȕRI WKHVDPHUHVLGXHDV WKH1+UHVLGXH LXVXDOO\UHVXOW LQ
high intensity peaks, and are of RSSRVLWHSKDVHV7KHUHDUHDOVRSHDNVIRUWKH&Į
DQG &ȕ RI WKH SUHFHGLQJ UHVLGXH (residue i-1) which are generally of weaker 
intensity and may not be visible in experiments with a poor signal to noise ratio. 
An alternative experiment exists (CBCANH) in which the magnetization is 
WUDQVIHUUHGIURPWKH+ĮDQG+ȕRIERWKWKH i and i-1 residues to the corresponding 
&ĮDQG&ȕDQG WKHQ WR WKH1+136. The same set of peaks is observed as in the 
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HNCACB experiment, but the sensitivity is generally inferior for proteins with 
short T2 relaxation times127.  
 
Figure 2.1: Magnetisation transfer during an HNCACB experiment. Atoms highlighted in red indicate 
those observed in the spectrum. On the right is shown an example of the resulting pattern of peaks seen 
in this experiment for each atom ŝŶ ƚŚĞĂŵŝŶŽĂĐŝĚ ?dŚĞƐŝŐŶĂůƐ ĨƌŽŵƚŚĞɲĂŶĚɴ ŽĨ ƌĞƐŝĚƵĞ i-1 are 
generally less intense than those from residue i due to the lower efficiency of the transfer from the 
nitrogen to the Cɲ. 
 
The HNCACB experiment can be paired with the HN(CO)CACB experiment, in 
which the magnetization is transferred to the carbonyl before being transferred to 
WKH&Įsee Figure 2.2).  This results in a spectrum ZKLFKVKRZVRQO\WKH&ĮDQG
&ȕRIWKHSUHFHGLQJUHVLGXH (i-1) to that containing the NH133. Overlaying these 
spectra removes any ambiguity in the HNCACB experiment as to which peaks 
correspond to the i and i-1 residues. The only exception to these patterns is if 
either the i or i-1 residue is a glycine, in which case there will EHQR&ȕVLJQDOIRU
that residue. 
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Figure 2.2: Transfer of magnetization in the HN(CO)CACB experiment. Atoms in red are observed in the 
spectrum. Atoms in blue have magnetization transferred through them, but are not observed in the 
spectrum. 
 
Locating a different residue ZKLFK KDV &Į DQG &ȕ FKHPLFDO VKLIWV LQ WKH
HNCACB spectrum matching those seen in the HN(CO)CACB spectrum for the 
first residue allows it to be assigned as the preceding residue in the protein chain. 
In this manner the correlations can be tracked from residue i to i-1 along the 
backbone of the protein. Alternatively the protein backbone can be traced in the 
opposite direction (from residue i to i+1E\LGHQWLI\LQJWKH&ĮDQG&ȕVKLIWVRI
residue i IURPWKH+1&$&%VSHFWUXPDQGPDWFKLQJWKRVHWR&ĮDQG&ȕVKLIWVLQ
the HN(CO)CACB spectrum for a different residue, which can then be confirmed 
as residue i+1 in the chain. An example of this assignment method is shown in 
Figure 2.3.  
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Figure 2.3: An example of assignment of the protein backbone using the HNCACB and HN(CO)CACB 3D 
experiments. From left to right are shown four strips through the 3D spectra at the 1H and 15N chemical 
shifts of four peaks in the 1H-15N HSQC. &ŽƌĞĂĐŚƌĞƐŝĚƵĞƚŚĞƉĞĂŬ ĨŽƌ ƚŚĞɲŽĨ ƚŚĞĐƵƌƌĞŶƚ ƌĞƐŝĚƵĞ ŝƐ
ƐŚŽǁŶŝŶƉŝŶŬ ?ǁŚŝůĞƚŚĞƉĞĂŬĨŽƌƚŚĞɲŽĨƚŚĞƉƌĞĐĞĚŝŶŐƌĞƐŝĚƵĞŝƐƐŚŽǁŶŝŶŵĂƌŽŽŶ ?^ŝŵŝůĂƌůǇɴŽĨƚŚĞ
ĐƵƌƌĞŶƚƌĞƐŝĚƵĞŝƐƐŚŽǁŶŝŶůŝŐŚƚŐƌĞĞŶ ?ǁŚŝůĞƚŚĞɴŽĨƚŚĞƉƌĞĐĞĚŝŶŐƌĞƐŝĚƵĞŝƐƐŚŽǁŶ in dark green. The 
arrows show matching 13C chemical shifts for peaks in the HNCACB spectrum of residue i and peaks in the 
HN(CO)CACB spectrum of residue i+1. For example, correlated to the amide proton of Lys59 are two 
peaks unique to the HNCACB spectrum, from ƚŚĞ ɲ ĂŶĚ ɴ ŽĨ >ǇƐ ? ? ? dŚĞŝƌ13C chemical shifts match 
those of two peaks correlated to the amide proton of Gly60 in the HN(CO)CACB spectrum, which are 
known to be ĨƌŽŵƚŚĞɲĂŶĚɴŽĨƚŚĞƉƌĞĐĞĚŝŶŐƌĞƐŝĚƵĞƚŽ'ůǇ ? ?. This therefore confirms that Lys59 is 
the preceding residue to Gly60. 'ůǇ ? ?ŚĂƐŽŶůǇĂɲƐŝŐŶĂů ?ǁŝƚŚĂ13C chemical shift that matches a signal 
in the HN(CO)CACB spectrum that is correlated to the amide proton of Cys61, again showing these 
residues are connected. Similarly matching Cɲ ĂŶĚ ɴ chemical shifts are highlighted for Cys61 and 
Cys62. This example shows data from residues 59  ? 62 of the RRM1 construct of CELF1. 
 
The HNCO and HN(CA)CO spectra also allow backbone connectivities to be 
determined by a similar method, and so can be used to corroborate the 
assignments made based on the HNCACB and HN(CO)CACB pair of 
experiments. In the HNCO experiment the magnetization is passed from the 
proton to 15N, and then to the directly bonded carbonyl. This experiment therefore 
shows only a single peak, which is from the carbonyl of the i-1 residue (see 
Figure 2.4)133.  
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Figure 2.4: Magnetization transfer in the HNCO experiment. The short pathway results in this experiment 
having the highest sensitivity of this set. 
 
In the HN(CA)CO experiment the magnetization is passed from 15N to both the i 
and i-1 &Į LQVWHDG DQG IURP WKHUH RQWR WKH GLUHFWO\ ERQGHG FDUERQ\OV 7KH
spectrum therefore has two peaks, one from the carbonyl of residue i, and one 
from i-1 (see Figure 2.5)132.  
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Figure 2.5: Magnetization transfer pathway in the HN(CA)CO experiment. While the magnetization is 
ƚƌĂŶƐĨĞƌƌĞĚǀŝĂƚŚĞɲ ?ŽŶůǇƚŚĞĐĂƌďŽŶǇůƐĂƌĞŽďƐĞƌǀĞĚŝŶƚŚĞƐƉĞĐƚƌƵŵ ?dŚĞƚƌĂŶƐĨĞƌĨƌŽŵƚŚĞŶŝƚƌŽŐĞŶ
ƚŽ ƚŚĞ ĚŝƌĞĐƚůǇ ďŽŶĚĞĚ ɲ ŝŶ ƌĞƐŝĚƵĞ i is generally more efficient than to the i-1 ɲ ? ƐŽ ƚŚĞ ƌĞƐŝĚƵĞ /
carbonyl usually gives a more intense signal. 
 
The carbonyl chemical shifts cannot be used to identify the residue type since no 
amino acids have particularly distinctive shifts, but can help resolve situations 
where multiple residues have YHU\VLPLODU&ĮDQG&ȕVKLIWV An example of this is 
shown in Figure 2.6. 
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Figure 2.6: An example of using the HNCO and HN(CA)CO spectra for backbone assignment. As the 
HN(CA)CO spectrum shows peaks for both the i and i-1 residue, while the HNCO spectrum only shows the 
i-1, it is again possible to find matching 13C chemical shifts and track the connectivity along the protein 
backbone. A strip through the 3D spectra is shown for each residue at the 1H and 15N chemical shifts 
corresponding to their signal in the 1H-15N HSQC. Phe43 shows a single peak correlated to the amide 
proton in the HNCO spectrum, and two in the HN(CA)CO spectrum. The peak that only appears in the 
HN(CA)CO spectrum is from the carbonyl of Phe43. The peak appearing on both spectra is from the 
carbonyl of the preceding residue. An arrow indicates the matching 13C chemical shifts of the Phe43 
carbonyl and the peaks known to be from the carbonyl of the previous residue to Gly44.  This confirms 
the residues are connected, and similarly matching chemical shifts are highlighted for Gly44, Asn45 and 
Val46. This example shows data from residues 43  ? 46 of the RRM3 construct of CELF1. 
 
Since they have no amide proton and so are not visible in the 1H-15N HSQC, 
prolines in the sequence create breaks in the chain of connected residues. Weak or 
missing signals from other residues in the 1H-15N HSQC will also cause breaks, 
so normally the connectivity cannot be tracked all the way from the C-terminus to 
N-terminus. Instead a series of shorter sections are assigned and combined to give 
the complete assignment of the protein. 
 
This method has so far produced a set of short chains of connected residues, but 
as yet the position of each chain in the protein sequence, and hence the exact 
assignment of each NH signal in the 1H-15N HSQC has not been determined. To 
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unambiguously assign a signal to a specific residue requires examination of the 
H[DFW&ĮDQG&ȕFKHPLFDOVKLIWVVHHQLQWKHHNCACB spectrum. Certain amino 
acid residues have distinctive shifts which allow the amino acid type for a 
specific residue to be determined. For example, glycine is unique in that it has no 
&ȕDQGVRKDVfewer peaks than other residues in the HNCACB VSHFWUXP7KH&Į
also has a distinctive shift of 45 ± 2 ppm allowing glycine residues to be 
immediately recognised (such as Gly60 in Figure 2.3). Other distinctive residue 
types DUHDODQLQHZKLFKKDVDXQLTXHO\ORZ&ȕ chemical shift of 18 ± 3 ppm) as 
ZHOO DV VHULQH DQG WKUHRQLQH ZKLFK DUH WKH RQO\ UHVLGXHV ZLWK ODUJHU &ȕ VKLIWV
WKDQ&ĮVKLIWV 
 
Unique patterns of these distinctive residues can then be identified in the 
sequential chains so far produced, and matched to the sequence of the protein. For 
example, the t187 construct of CELF1 contains the sequence TFTT from residues 
154 - 157. This is the only instance of two adjacent threonine residues in the 
protein sequence. When two residues adjacent in the chain were determined to be 
WKUHRQLQHVE\WKHLUXQXVXDO&ȕVKLIWVWKH\FRXOGWKHUHIRUHEHVSHFLILFDOO\DVVLJQHG
DV7KUDQG7KU7KLV³ORFNHGLQ´WKLVSDUWLFXODr chain section allowing all 
the other residues in it to be assigned as well. The assignment could then be 
confirmed by the presence of another threonine two residues before Thr156, and 
E\ FKHFNLQJ WKH RWKHU UHVLGXHV LQ WKH FKDLQ KDG SODXVLEOH &Į DQG &ȕ VKifts for 
their assigned amino acid type. These were verified using the reference chemical 
shifts in CCPNMR Analysis version 2.0.137  
 
The assignment could be extended out from these known residues, but not beyond 
the proline residues at positions 143 and 180 which have no NH signal, and hence 
no known chemical shift information. Other distinctive residues, such as the 
adjacent alanine residues at positions 71 and 72 were therefore necessary to build 
up the full assignment of the protein. Use of this strategy can provide assignments 
for the HN, NH, CO, HĮ, CĮ and Cȕ (if present) atoms of each amino acid in the 
protein. Assignment of any additional side chain atoms can be assisted by 3D 
experiments such as the HCCH-TOCSY if required138. 
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2.2 NMR Titrations 
 
The exact chemical shifts observed for an amide group in the protein are sensitive 
to the surrounding environment. If that environment changes, for example when a 
ligand binds to the surface of the protein, then the chemical shifts of nearby 
residues will change significantly. Movement of peaks in the NMR spectra 
therefore can be used to confirm whether a given ligand does or does not bind to 
the protein. From the 1H-15N HSQC information can also be collected on a per-
residue basis, identifying which residues are most disrupted upon binding to the 
ligand. This method can be used to map the binding surfaces of the protein139. 
Depending whether the exchange between free and bound forms is fast or slow on 
the NMR timescale, two different effects may be seen. If the rate constant k is 
JUHDWHUWKDQWKHIUHTXHQF\GLIIHUHQFHEHWZHHQWKHH[FKDQJLQJVLWHVįȞWKHQWKH
process is said to be in fast exchange. In fast exchange the peak for each 
backbone NH appears with chemical shifts that are a population weighted average 
of the shifts for the bound and unbound states. These peaks therefore move 
gradually over the course of the titration as shown in Figure 2.7.  
 
Figure 2.7: Example of a titration with signals in fast exchange. The peaks gradually move over the course 
of the titration allowing their assignments to be tracked from point to point. Data is from a titration of a 
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construct of RRM1 of CELF1 with the RNA substrate UGUUUGU, and shows a region of the 1H-15N HSQC 
containing three peaks. Gly60 and Cys62 are in fast exchange. Gly21 is in intermediate exchange with 
very weak signals for some of the intermediate points. 
 
An alternative is slow exchange, ZKHUH N  įȞ in which case the intensity of 
affected peaks from the unbound protein will decrease over the course of the 
titration, and a new set of peaks from these residues in the bound protein will 
appear. An example of this is shown in Figure 2.8. A disadvantage of titrations in 
slow exchange is that the assignments cannot simply be tracked from the free 
form to the bound form throughout the titration. In crowded regions of the 
spectrum it is often unclear which residues new peaks from the bound form 
correspond to without collecting additional 3D heteronuclear data and reassigning 
them. While it can be stated that the residues for which the peaks from the free 
form are lost on titration are involved in the binding, this cannot be quantified 
without assignment of the bound form. An intermediate situation where k is 
FRPSDUDEOHWRįȞFDQRFFXU LQZKLFKFDVHWKHSHDNZLOOERWKORVHLQWHQVLW\DQG
move, as can be seen for Gly21 in Figure 2.7. 
 
Figure 2.8: An example of an NMR titration with some residues in slow exchange. In blue is shown the 
spectrum of the unbound protein. In red is the spectrum when the titration with RNA is at saturation 
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point. In green is the spectrum at a 0.5:1 RNA to protein ratio (the midpoint of the titration. The peaks 
from Gly113, Gly149 and Gly448 do not move gradually as in fast exchange, but instead disappear 
over the course of the titration. New peaks from the bound form appear, as can be seen for Gly448. It 
is possible to see both the free and bound peaks for this residue at the midpoint. Some of the less 
affected residues in this titration are still in fast exchange, such as Gly400. Data is from a titration of 
the RRM23 construct of CELF1 with UGUUUGU, collected on an 800 MHz Bruker Avance III 
spectrometer. 
 
It is possible to have a mixture of residues in fast exchange and slow exchange in 
a single tLWUDWLRQDVįȞEHWZHHQWKHUHVRQDQFHVRIWKHIUHHDQGERXQGIRUPVZLOO
be different for each affected residue. The effects on each residue can be 
quantified as the ³chemical shift perturbation´ (CSP) to highlight the most 
affected regions of the protein. Since the 15N chemical shifts have a larger 
dispersion than the 1H chemical shifts it is necessary to apply a scaling factor to 
them. Without this scaling the overall CSP value will be almost entirely 
dependent on the 15N component. The chemical shift perturbation is calculated as: 
 ൌ ൭ቆ ?ɁH? ? ? ቇ ൅   ?ɁH?൱H?ǤH? 
 
In this study 15N labelled protein was titrated with RNA to identify the affinity 
and binding sites of different RNA substrates for each RRM. A 1H-15N 
HSQC/TROSY spectrum was collected at each titration point so that binding 
curves could be produced and the saturation point of each titration identified.  
 
2.3 Isothermal Titration Calorimetry (ITC) 
 
Isothermal titration calorimetry is a powerful technique for directly measuring the 
affinity of interactions between biomacromolecules140. It can be used to 
investigate protein-protein interactions141, protein-nucleic acid interactions142, 143, 
and interactions between proteins and small molecules144. In this study ITC was 
carried out using a VP-ITC microcalorimeter containing two cells, as shown in 
Figure 2.9. One is a sealed reference cell containing water, while the other is the 
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sample cell containing 1.424 ml of a dilute solution of one of the two molecules 
to be studied (usually a protein). 300 µl of the second molecule (such as a small 
ligand molecule or another protein) is injected into the sample cell from the 
syringe in small aliquots (typically 5 or 10 µl), stirring constantly to ensure 
mixing of the solutions. The syringe concentration is generally a minimum of 10 
times the cell concentration to ensure the titration reaches saturation point. The 
experiment can also be run reversed with the protein in the syringe and ligand in 
the cell which may be necessary if one of the components has a limited solubility.  
 
Processes such as binding or dissociation result in release or uptake of heat from 
the sample cell. This is compensated by a highly sensitive thermostat which 
maintains the reference and sample cells at the same constant temperature. The 
difference in power required to maintain the sample cell at the same temperature 
as the reference cell is directly dependent on the enthalpy change of the reaction. 
By plotting the enthalpy change for each injection against the molar ratio of the 
two components, and fitting a suitable model to the resulting curve, the 
stoichiometry (n), Kd¨+DQG¨6IRUWKHLQWHUDFWLRQ can be determined. 
 
 
Figure 2.9: Left is a diagram showing the basic layout of an isothermal titration calorimeter. On the right 
is shown an example of a typical ITC trace for a 1:1 binding interaction with the relationships to the 
parameters n, Kd and ȴH for the process highlighted. 
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Also in Figure 2.9 is shown an example of raw ITC data for a simple 1:1 binding 
case. This particular example shows an exothermic reaction, so each injection 
results in a release of heat, and hence a brief reduction in the power required to 
maintain the sample cell at a constant temperature. This appears as a negative 
peak on the ITC trace. As more of the ligand is injected the protein in the cell will 
approach saturation. Fewer protein molecules are unoccupied and free to bind 
ligands and release heat with each injection, so the magnitude of the peaks 
declines to zero. Eventually the protein is completely saturated, no further 
interaction can occur, and so no significant change is seen from further ligand 
injections. Integration of each peak with respect to time gives the area under it 
ZKLFKLVHTXDOWRQ¨+ for the injection, and can be plotted against the molar ratio 
of the two components. 
 
For a simple 1:1 binding case, the enthalpy of the reaction is the difference 
between the magnitudes of the initial and final injections. Ideally the final 
injections will result in no significant enthalpy change, though buffer mismatches 
can result in the baseline of the trace reaching a plateau above or below zero. The 
stoichiometry of the reaction is the ligand/protein ratio at the inflection point of 
the curve, and the gradient of the curve at that point is equal to 1/Kd. In the event 
of a buffer mismatch the experiment can be repeated without the protein in the 
cell to produce a ligand into buffer trace which can be subtracted from the main 
titration trace as a baseline correction145. 
 
In a reaction at equilibrium the rate of formation of the complex is defined as k1 
and the rate of dissociation of the complex is defined as k
-1. The dissociation 
constant Kd is a useful measure of the affinity of an interaction, and can be 
calculated as: 
 
Kd = k-1/k1 
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ITC can accurately determine Kd values between several hundred micromolar and 
10 nanomolar146, 147. For higher affinity binding the curve becomes a step 
function, with very few points defining the shape around the inflection point. This 
prevents accurate determination of the gradient at the inflection point, and hence 
Kd. Reducing the concentration of both protein and ligand will result in a 
shallower curve, but this also reduces the absolute magnitude of each peak and 
hence the signal to noise ratio for the experiment. This renders ITC unsuitable for 
direct measurement of Kd values less than ~10 nM. In some cases it is possible to 
calculate Kd values for very high affinity ligands from competition experiments 
with lower affinity ligands. Very low affinity binding cannot be measured because 
the concentration of the ligand would have to be impractically high in order for 
the titration to reach saturation point. ITC has the disadvantage of requiring a 
relatively large amount of material compared to techniques such as surface 
plasmon resonance (SPR). For the titrations in this study concentrations of 125 ± 
250 µM were required for the component in the syringe. From the Kd values, the 
bLQGLQJ VWRLFKLRPHWU\ Q DQG¨+ LW LV SRVVLEOH WR FDOFXODWH ¨*DQG¨6 for the 
interaction using the equations: 
 
¨G = -RTlnKa (where Ka = 1/Kd) 
¨* ¨+- 7¨6 
 
Where R = 8.314 JK-1mol-1 (the gas constant) and T is the temperature in 
kelvin148. 
 
The software package Origin 7.0 was used to fit binding curves to the ITC data 
collected throughout this study. Since the volume of solution in the cell changes 
over the course of the titration the concentration of the macromolecule in the cell 
is not a constant. The model adjusts for this change in concentration at each point 
in the titration using the equation: 
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ܯH?ൌ ܯH?H?ቀ ? െ ?ܸ ? Hܸ?ቁቀ ? ൅ ?ܸ ? Hܸ?ቁ 
 
Where Mt is the current concentration of macromolecule in the cell, Mt0 is the 
initial concentration macromolecule in the cell, Vo is the initial cell volume and 
ǻ9LVWKHYROXPHDGGHGIURPWKHV\ULQJH. Similarly the adjusted concentration of 
the ligand at each point (Xt) can be calculated from hypothetical concentration of 
the ligand if there was no volume change (Xt0) using the equation: 
 ܺH?ൌ ܺH?H?ሺ ? െ ?ܸ ? Hܸ?ሻ 
 
These adjusted values are then used in Origin's binding model for a simple 1:1 
interaction to calculate the total heat content of the solution (Q) at each point as 
follows: 
 
Ka = Binding constant 
n = Number of binding sites on each macromolecule in the cell. 
Vo = Cell volume 
ǻ+ PROar enthalpy change for ligand binding 
 
ܳ ൌ ቀH?H?೟ H?H?బH? ቁ ቆ ? ൅ ቀH?೟H?H?೟ቁ ൅ ቀ H?H?H?ೌH?೟ቁ െ ൬ቀ ? ൅ H?೟H?H?೟ ൅ H?H?H?ೌH?೟ቁH?െ H?H?೟H?H?೟൰ቇH?ǤH?  
 
From this equation the model can calculate Q at each point in the experiment for 
specified values of n, Ka DQGǻ+7KHH[SHULPHQWDOGDWD however is measuring 
the change in Q for each injection. The heat released by the ith injection is: 
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 ? Hܳ?ൌ  ܳH?൅ ൬݀ Hܸ?Hܸ?൰ ൬ܳH?൅ ܳH?H?H? ? ൰ െ ܳH?H?H? 
 
Where Vi is the volume of the ith injection. From an initial estimate of the values 
RIQǻ+DQG.a an iterative fitting process using a non-linear regression method 
is then conducted to determine the closest fitting values to the experimental 
data144. 
 
2.4 Small Angle X-ray Scattering 
 
Small angle X-ray scattering (SAXS) is a technique which can be used for 
studying the general structure of biomacromolecules in solution. It does not allow 
high resolution structures to be produced but it can be used to construct a low 
resolution 3D model showing the average size and shape of the particles. SAXS 
has a resolution range of approximately 10 ± 250 Å149. This is usually not 
sufficient to resolve secondary structure elements, but it can determine the 
relative orientation of large structured domains. This technique can also provide 
the radius of gyration of the protein or complex from a Guinier plot, and general 
information about its overall flexibility from a Kratky plot150. 
 
In a SAXS experiment a monochromatic beam of x-rays is directed through the 
sample. These x-rays are scattered by the particles in the sample, typically 
through a very small angle. A large fraction of the x-rays are not scattered, and 
simply pass straight through the sample to the detector, so a tightly focused (or 
collimated) x-ray beam is required. Since the buffer will also cause some 
scattering, it is usual to repeat the experiment with a blank sample containing 
only the buffer solution. This scattering curve can then be subtracted from the 
curve for the real sample, leaving only the SAXS profile of the macromolecules 
in the solution. As the properties measured are averaged over all the particles in 
the sample SAXS requires the sample to be monodisperse (i.e. it must be ensured 
that all of the scattering particles are identical, and non-interacting). The presence 
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of aggregates, or different size oligomers in the sample is particularly problematic 
as the scattering intensity of a particle varies with the square of its molecular 
weight. A small population of high molecular weight aggregates, which would be 
tolerated by NMR techniques due to line broadening rendering them 
unobservable, can make SAXS data impossible to interpret.  
 
 
Figure 2.10: Basic scheme for a SAXS experiment. Below is shown an example of a 1D scattering curve. 
 
A 1D SAXS trace shows a plot of intensity against s ʌVLQșȜZKHUHș LV WKH
VFDWWHULQJ DQJOH DQG Ȝ LV WKH ZDYHOHQJWK )RU PRQRGLVSHUVH SDUWLFOHV WKLV
approximates to a Gaussian curve for small values of s. Therefore ln(I) = ln(I0) ±
Ks2 (where K is a constant). A Guinier plot of ln(I) against s2 therefore should be 
linear near the origin, and this can be used as a check that a sample is 
monodisperse. The gradient of the line in the Guinier plot (K) is approximately 
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equal to -Rg2/3, where Rg is the radius of gyration of the protein. Collecting this 
information at multiple concentrations can detect any aggregation of the protein, 
since the apparent radius of gyration would then vary depending on the 
concentration150. 
 
A Kratky plot of Is2 plotted against s provides qualitative information about the 
overall structure and flexibility of a particle in solution151. In general a Kratky 
plot for a rigid globular protein takes the form of a Gaussian curve. An unfolded 
protein typically shows a plateau for high values of s, without a clearly defined 
peak. A protein with multiple structured domains separated by flexible linkers 
generally shows a mixture of these schemes, potentially with multiple peaks152. 
 
A major advantage of SAXS is that it operates on solution samples, and does not 
require crystallization of the protein. Difficulties producing crystals of sufficient 
quality for diffraction studies can be a major barrier to x-ray crystallography. 
CELF1 constructs containing all three RRMs have failed to produce diffraction 
quality crystals, hence the use of solution techniques such as NMR and SAXS to 
examine the structure of the larger complexes. SAXS also has the advantage that 
it can provide structural information on very large protein complexes, where 
NMR becomes impractical due to signal broadening from rapid relaxation, and 
signal overlap. Sample preparation is straightforward, and does not require 
isotopic labelling or large quantities of material. 
 
A limitation of SAXS is that the scattering curves produced are one-dimensional. 
This can result in ambiguities when producing a 3D model of the particle, as there 
may be many models consistent with the 1D SAXS data. For example, SAXS is 
not capable of determining chirality. Enantiomers appear identical as only 
information on the distances between scattering centres is measured. The SAXS 
model of a particle inevitably is of a low resolution, typically 10 Å or larger, so 
this technique is generally used to complement other techniques such as NMR 
and X-ray crystallography153.  
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2.5 Mass Spectrometry 
 
In mass spectrometry a sample is ionised, and the resulting measurements are 
therefore for a sample in the gas phase. There are several possible methods for 
ionising a sample, the most commonly used being electrospray ionisation (ESI) 
and matrix-assisted laser desorption/ionisation (MALDI)154. For all experiments 
in this study, ESI was the ionisation method used.  
 
In electrospray ionisation the sample is pumped through an extremely narrow 
capillary, across the tip of which a high voltage is applied. An additional 
nebulising gas (nitrogen) flows around the outside of the capillary and into the 
mass spectrometer. This results in the formation of extremely small charged 
droplets, which decrease in size as the volatile solvent evaporates. As these 
droplets shrink they release sample ions, which pass through an intermediate 
vacuum region before entering the high vacuum of the mass analyser. The mass to 
charge ratio (m/z) of the ions determines their velocity, and hence the time 
required to reach the detector. In time of flight mass spectrometry this is used to 
calculate the m/z of the sample ions155. ESI results in sample ions with a range of 
charge states (ions with equal mass, but different charges which appear as discreet 
peaks in the mass spectrum). This is in contrast with MALDI which generally 
results in only a single charge state for each species156, 157. 
 
The number of populated charge states, and the overall average charge provide 
some indication of how folded a protein is. This is because they are dependent on 
the solvent exposed surface area of the protein during the early stages of 
desolvation. This will be larger for an unfolded protein than for a structured 
protein of the same mass. Unfolded proteins therefore show a wider range of 
different charge states, and a higher average charge than structured proteins158, 159. 
 
Mass spectrometry measures the mass to charge ratio (m/z) of the ions produced 
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and so the mass of a protein. This makes it a rapid method to confirm the identity 
of a protein. This technique has the advantage that it can be used on very low 
sample concentrations (< 1 µM), and so requires very little material. It can also be 
used to investigate much larger protein complexes than techniques such as NMR, 
capable of observing complexes in the MDa range160. Mass spectrometry data can 
usually be collected in a matter of minutes, making it considerably faster than ITC 
or multidimensional NMR. Binding stoichiometries can be determined simply 
based on the mass of the bound complex, if it remains intact in the gas phase. 
 
A major limitation of ESI-MS is the need to remove NaCl and similar salts from 
the sample. Even in very small quantities, these lead to the formation of sodium 
adducts. Proteins with different numbers of attached sodium ions have slightly 
different masses, resulting in poorly defined broad signals from which it may not 
be possible to calculate an accurate mass for the protein itself. A similar problem 
is encountered for ESI-MS of nucleic acids. 
 
Since it measures the mass to charge ratio rather than simply the mass of an ion, 
mass spectrometry can have problems distinguishing between protein oligomers 
and monomers. While a protein dimer has twice the mass of the monomer, it will 
also tend to have twice the charge resulting in the same overall m/z value. For 
ionisation methods such as ESI that generate a range of charge states it is however 
possible to determine the presence of dimers. The dimeric species will result in an 
extra set of peaks between those of the monomeric species with m/z values 
implying half-integer values of z. These are the odd numbered charge states of the 
dimeric species. An example of this in ESI-MS is shown in Figure 2.11. 
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Figure 2.11: An example of an ESI mass spectrum of a mixture of a protein monomer and dimer. A range 
of charge states from 4+ to 8+ is seen for the monomeric form. There is an additional peak with an 
apparent +5.5 charge state, which is the 11+ charge state from a small population of the dimeric form. 
The even numbered charge states of the dimer would give peaks with the same m/z values as the 
monomeric species. This data is from an isolated RRM1 construct of CELF1. 
 
There is a potential issue with ESI-MS that interactions in the gas phase may not 
be representative of the protein's behaviour in solution, particularly for non-
covalently bound complexes. For example, binding that relies on hydrophobic 
interactions may be lost on entering the gas phase due to the lack of solvent 
molecules161. Clusters of proteins may also form in the gas phase which do not 
form in solution161-162. 
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3 Materials and Methods 
 
3.1 Protein Sequences 
 
The genes for Xenopus Laevis CELF1 and Xenopus Laevis poly (A) ribonuclease 
had been previously cloned into the pET28 and pET33 plasmids respectively by 
Dr Emilie Malaurie, who also produced the t187 and t242 constructs of CELF1 
cloned into the pET28b vector (shown in Figure 3.1).  
 
Figure 3.1: Plasmid map of the pET-28b vector.  
 
All other constructs used in these studies were derived from these plasmids. The 
protein sequences are as follows: 
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Wild Type CELF1 (Xenopus Laevis) 
 
MNGTMDHPDHPDPDSIKMFVGQVPRSWSEKELRELFEQYGAVYEINVLRDRSQNPPQSK
GCCFITFYTRKAALEAQNALHNMKVLPGMHHPIQMKPADSEKNNAVEDRKLFIGMVSKN
CNENDIRAMFSPFGQIEECRILRGPDGMSRGCAFVTFTTRSMAQMAIKSMHQAQTMEGC
SSPIVVKFADTQKDKEQKRMTQQLQQQMQQLNAASMWGNLTGLNSLAPQYLALLQQTA
SSGNLNSLSGLHPMGAEYGTGMTSGLNAIQLQNLAALAAAASAAQNTPSAGAALTSSSSPL
SILTSSGSSPSSNNSSINTMASLGALQTLAGATAGLNVNSLAGMAAFNGGLGSSLSNGTGST
MEALSQAYSGIQQYAAAALPSLYNQSLLSQQGLGAAGSQKEGPEGANLFIYHLPQEFGDQD
LLQMFMPFGNVVSSKVFIDKQTNLSKCFGFVSYDNPVSAQAAIQSMNGFQIGMKRLKVQL
KRSKNDSKPY 
 
Poly (A) Ribonuclease (Xenopus Laevis) 
 
MEITRSNFKDTLPKVYKAIEEADFLAIDGEFSGISDGPSVSTLTNGFDTPEERYTKLKKHSMEF
LLFQFGLCTFNYDNTEAKYLMKSFNFYIFPKPFNRNSPDKKFVCQSSSIDFLANQGFDFNKV
FRNGIPYLNQEEERVLRDQYEDRRSQSNGASTMSYISPNSSKTPVSIPDEQKGFIDKVVERV
EDFLKNEQKSMNVEPCTGYQRKLIYQTLNWKYPRGIHVETVESEKKERYIVISKVDEEERKR
MEQQKQAKEREELDDAVGFSRIIQAISSSGKLVVGHNMLLDVMHTIHQFFCQLPDELNEFK
EVTNCVFPRVLDTKLMASTNPFKEIIYNTSLAELEKRLKEAPFKPPKVDSAEGFQSYNTASEQ
LHEAGYDAYITGLCFISMANYLGSFLSPPKDYVSCRSKIVRPFFNKLFLMRIMDIPYLNLEGPD
LQPKRDNVLHVTFPKEWKTSDLYQLFSAFGNIQVSWIDDTSAFVSLSQPEQVQIAVNTSKYA
ESYRIQTYAEYIEKKNDESQTKRKWAEDGWKDLERKRLKTQYNSYIPQNPVFYGNCFAPSFA
VKRSMSPIQEEAASDDTEEVHTHENDPSNPGATEQGKKPKNHKRQKIDSAPPETSDGGSS
VLFEVPDTW 
 
All constructs were fused to an N-terminal histidine tag (consisting of six 
histidine residues in a row), with a thrombin cleavage site between the tag and the 
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protein allowing its removal where necessary. Removal of the tag with thrombin 
leaves an additional six amino acids (GSHMAS) attached to the N-terminus of 
the protein. This allowed the proteins to be purified by metal affinity 
chromatography. 
 
3.2 Sterilization 
 
All glassware, pipette tips, media and buffers were sterilized by autoclaving for 
15 minutes at 121°C (using a Phillip Harris Status Autoclave). Universals, petri 
dishes and other disposables were supplied in sterile condition by the 
manufacturers. Any reagents that could not be autoclaved due to heat sensitivity 
(e.g. kanamycin, IPTG) were sterilized by filtering through a 0.22 µm sterile filter 
immediately before use. 
 
Workspaces were cleaned using 100% ethanol before growths or other cell work 
was conducted. All sterile work was carried out by a Bunsen burner flame. 
Glassware used in growths and other cell work was sterilised with Trigene for 20 
minutes, or by autoclaving in the case of the 2 L flasks. Disposable materials 
were autoclaved prior to incineration. 
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3.3 Buffers 
 
The following table shows the buffers which were used for cell lysis, purification 
and NMR experiments for each protein construct. 
Buffer Composition Constructs 
Lysis buffer A 25 mM potassium phosphate, 
50 mM NaCl, pH 7.0 
RRM1, RRM2, RRM3, 
t187, t242 
Lysis buffer B 25 mM potassium phosphate, 
200 mM NaCl, pH 7.0 
RRM123, RRM23 
Lysis Buffer C 25 mM potassium phosphate, 
50 mM NaCl, 4 M Urea, pH 
7.0 
Wild Type CELF1 
Lysis Buffer D  20 mM potassium phosphate, 
500 mM NaCl, 10% v/v 
glycerol, 5 mM imidazole, pH 
7.9. 
Wild Type Poly (A) 
Ribonuclease 
Anion Exchange A 25 mM potassium phosphate, 
50 mM NaCl, 10% v/v 
glycerol, 200 µM EDTA, pH 
7.0 
Wild Type Poly (A) 
Ribonuclease 
Anion Exchange B 25 mM potassium phosphate, 
2 M NaCl, 10% v/v glycerol, 
200 µM EDTA, pH 7.0 
Wild Type Poly (A) 
Ribonuclease 
NMR Buffer A 25 mM potassium phosphate, 
50 mM NaCl, 10% v/v D2O, 
pH 7.0 
RRM1, RRM2, RRM3, 
t187, t242 
NMR Buffer B 25 mM potassium phosphate, 
200 mM NaCl, 10% v/v D2O, 
pH 7.0 
RRM123, RRM23 
NMR Buffer C 25 mM potassium phosphate, 
50 mM NaCl, 200 mM Urea 
10% v/v D2O, pH 7.0 
Wild Type CELF1, Wild 
Type Poly (A) 
Ribonuclease 
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3.4 Overnight Cultures 
  
15 ml of overnight cultures were grown in autoclaved Luria-Bertani broth 
(Sigma. 10 g/L tryptone, 5 g/L yeast extract, 10 g/l NaCl). E. Coli. XL1-Blue and 
BL21 (DE3) strains were used throughout. All constructs used in this study were 
in either a pET28 or pET33 vector both of which incorporate kanamycin 
resistance. 30 µg/ml kanamycin was therefore used as an antibiotic control. 
&XOWXUHVZHUHJURZQIRUaKRXUVDWÛ&DQGDQDJLWDWLRQUDWHRIUSP 
 
3.4.1 Glycerol Stocks 
 
Glycerol stocks were produced from overnight cultures by mixing 0.4 ml of cell 
culture in LB with 0.4 ml of autoclaved 30% (v/v) glycerol in sterile eppendorfs. 
All glycerol stocks were stored at -80°C. 
 
3.5 Overexpression 
 
1 L baffled flasks of LB were each inoculated using one 15 ml overnight culture, 
containing 30 µg/ml of kanamycin as antibiotic control. These 1 L cultures were 
incubated at 37°C, with an agitation rate of 180 rpm, until the OD at 595 nm was 
in the range 0.6 - 0.8. At this point 1 ml of 1 M IPTG was added to each flask to 
induce protein overexpression in E. Coli BL21 (DE3). The flasks were then 
incubated overnight (~16 hours) at 30°C, 180 rpm, unless otherwise specified. 
Cells were harvested by centrifugation at 3000 g for 15 minutes. The supernatant 
was then discarded and the pelleted cells stored at -20°C. 
 
3.6 Sonication 
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For all constructs except CELF1 Wild Type and PARN deadenylase, a cell pellet 
from 1 litre of cell culture was resuspended in 10 ml of lysis buffer (50 mM 
NaCl, 25 mM phosphate, pH 7.0) from here referred to as buffer A. One EDTA-
free protease inhibitor tablet (manufactured by Roche) was added to prevent 
protein degradation.  The suspension was then sonicated at 10 microns for 10 
minutes with 30 second breaks on ice every 30 seconds. Cell debris was pelleted 
by centrifugation at 35000 g for 30 minutes. The supernatant was then loaded 
onto an IMAC column. 
 
For the purification of CELF1 wild type, cell lysis was carried out in 4 M urea, 
200 mM NaCl, 25 mM phosphate, pH 7.0 buffer. Under these conditions the 
fragmentation of the linker between RRM2 and 3 was substantially reduced. The 
purification of poly (A) ribonuclease used a different lysis buffer (20 mM 
potassium phosphate, 500 mM NaCl, 10% v/v glycerol, 5 mM imidazole, pH 7.9) 
which was based on the 2006 paper by Nilsson et al. 
 
3.7 Metal Affinity Chromatography 
 
The attachment of a six histidine tag to the protein allows it to undergo a high 
affinity interaction with metal ions such as Ni2+ and Co2+. The His-Pur affinity 
column (Pierce, Thermo Scientific) uses Co2+ ions attached to the surface of glass 
beads in a resin. The His-tagged proteins in the cell lysate can therefore be 
selectively bound to this solid column matrix. After washing to remove non-
specifically binding proteins the His-tagged protein can be eluted, usually by 
addition of a high concentration of imidazole to compete for the metal binding 
sites. The protein can also be eluted by reduction of the pH to less than 6.0, but 
acidic conditions may not be tolerated by some proteins. 
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A His-tag binding cobalt column was prepared by addition of 1 ml of His-Pur 
resin to a Talon PD10 column (GE Life Sciences), washing with 20 column 
volumes of water and finally 20 column volumes of buffer A. The supernatant 
from the sonication step was then added to this column, which was capped and 
tumbled at 4°C for 2 hours to allow binding of the protein to the beads. After two 
hours the supernatant was drained off the column under gravity, leaving the His-
tagged protein bound to the cobalt resin.  
 
For the t187, t242, RRM1, RRM2 and RRM3 constructs, the IMAC column stage 
of the purification was conducted as follows. After the supernatant was drained 
from the cobalt column, the beads were washed with 25 ml of a high salt buffer 
(25 mM phosphate, 2 M NaCl, pH 7.0) to remove any RNA or DNA bound to the 
protein. This was followed by a 25 ml low imidazole wash to remove non-
specifically binding proteins (25mM phosphate, 100 mM NaCl, 10 mM 
imidazole, pH 7.0). The protein was finally eluted from the column using 750 
mM imidazole, 25 mM phosphate, 100 mM NaCl pH 7.0 elution buffer. This was 
collected in 2 ml fractions which were tested for protein content by SDS-PAGE. 
The proteins were normally eluted in the first 6 ml of elution buffer. Protein 
containing fractions were then recombined for the thrombin cleave step. The 
RRM123 construct was purified by the same protocol except that the His-tag was 
not removed from the protein, which was immediately gel-filtered. 
 
For CELF1 wild type, centrifugation to remove cell debris and binding to the 
IMAC column was carried out as for the other constructs. After allowing time for 
protein to bind to the column a high salt wash (25 ml 2 M NaCl, 2 M urea, 25 
mM phosphate) was applied, followed by a dilute imidazole wash (25 ml of 200 
mM NaCl, 2 M urea, 25 mM phosphate, 1 mM imidazole). The protein was 
eluted in 0.5 M Imidazole, 2 M NaCl, 1 M urea, 25 mM phosphate and collected 
in 2 ml aliquots. The thrombin cleave step was omitted, so EDTA was added to 
the elution fractions to a concentration of 5 mM, and the eluted protein was 
immediately gel filtered using the protocol in section 3.9. 
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3.8 His-Tag Removal by Thrombin Cleave 
 
All proteins constructs incorporated a thrombin cleave site (LVPRGS) between 
the 6-His-tag and the protein. Elution fractions from the IMAC column were 
transferred to a centrifugal concentrator (3 kDa molecular weight cutoff), and 
diluted up to 20 ml with buffer A. This was then spun at 4000 g until the volume 
had been reduced by 50%, at which point it was again diluted to 20 ml with 
buffer A. This was repeated until the imidazole concentration of the solution was 
reduced to less than 0.1 M, as a higher concentration could interfere with the 
thrombin cleave step. The protein solution was then transferred to a universal, and 
5 units of thrombin were added. The universal was agitated overnight at room 
temperature to cleave the His-tag from the protein. Mass spectrometry was used 
to confirm the tag had been successfully removed. Due to solubility and stability 
issues the His-tag was not removed from RRM123, wild type CELF1 or poly(A) 
ribonuclease. In the purification protocol for these proteins the elution fractions 
from the IMAC were immediately loaded onto a gel filtration column.  
 
3.9 Gel Filtration 
 
Gel filtration separates out any impurities left after the metal affinity 
chromatography stage based on their different molecular masses and also the 
overall shape of the proteins. It also serves to buffer exchange the protein from 
the high imidazole elution buffer to an imidazole-free phosphate buffer. Initial 
purifications of t187 and all purifications of t242, RRM123, CELF1 wild type 
and PARN deadenylase were carried out using a Superdex 200 gel filtration 
column (GE Life Sciences). RRM1, RRM2, RRM3 and later purifications of t187 
were gel filtered using a Superdex 75 column due to the lower mass of these 
constructs.  
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Gel filtration columns were pre-equilibrated with 400 ml of 30 mM potassium 
phosphate, 100 mM NaCl, pH 7.0 buffer. Protein solutions were centrifuged at 
4000 g for 10 minutes, or filtered through a 0.2 µm filter prior to loading onto the 
column in order to remove any insoluble material. Gel filtration columns were 
run at 3 ml/min unless otherwise specified. 10 ml fractions were collected, and 
those containing protein were identified by 280 nm absorbance except in the case 
of RRM2. Since the RRM2 construct contains no tryptophan or tyrosine it has no 
significant 280 nm absorbance, so it was necessary to locate the protein by SDS-
PAGE. RRM3 also showed limited absorbance at 280 nm due to the absence of 
tryptophan in the construct. Normal elution fractions for all constructs are shown 
in the table below. 
 
Protein 
Construct 
Gel Filtration 
Column 
Elution Fractions 
T187 Superdex 200 260 - 270 ml 
Superdex 75 180 - 200 ml 
T242 Superdex 200 240 - 260 ml 
RRM1 Superdex 75 210 - 220 ml 
RRM2 Superdex 75 230 - 250 ml 
RRM23 Superdex 75 190 ± 210 ml 
RRM123 Superdex 200 220 ± 240 ml 
 
Those gel filtration fractions containing protein were frozen with liquid nitrogen 
and lyophilised. 
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3.10 Desalting 
 
Lyophilised protein from the gel filtration step was redissolved in MilliQ water 
and centrifuged at 4000 g for 10 minutes to remove any insoluble material before 
loading onto 5x5 ml HiTrap desalting column (Amersham Biosciences). The 
column was pre-equilibrated with degassed and filtered MilliQ water. The salt 
content of the elution fractions was monitored based on conductivity, while 
protein content was monitored based on 280 nm absorbance. Liquid nitrogen was 
used to freeze the relevant desalted fractions for lyophilisation. 
 
3.11 Storage and Stability 
 
Lyophilised protein was stored at -20°C. Protein solutions requiring long-term 
storage were kept at -80°C. RNA and DNA solutions were stored dissolved in 
nuclease-free water at -20°C. 
 
3.12 Production of Isotopically Labelled Protein 
 
For the production of 15N labelled protein the growth was carried out in minimal 
media rather than LB. M9 Minimal media was prepared by dissolving 6 g 
dipotassium hydrogen phosphate, 3 g sodium dihydrogen phosphate, 0.5 g of 
NaCl, 0.3 g anhydrous magnesium sulphate and 0.015 g calcium chloride in 1 L 
of water. The media was then autoclaved to sterilise it. 1 g of 15N labelled 
ammonium chloride and 4 g of glucose were dissolved in 40 ml of MilliQ water 
and added to the media using a 0.2 µm syringe filter to sterilise the solution. 
These were the only nitrogen and carbon sources in the media. In addition 10 mg 
of biotin and 10 mg of thiamine were added.  
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Four 15 ml overnight cultures were prepared for each 1 litre flask. Prior 
innoculating the M9 minimal media the cells were harvested by centrifugation at 
1000 g for 10 minutes. The cells were then resuspended in 15 ml of M9 minimal 
media and incubated at 37°C 200 rpm for 30 minutes. The cells were then added 
to the 1 litre flasks, which were incubated at 37°, 180 rpm until the OD at 595 nm 
reached 0.6 ± 0.8. Protein expression was then induced by addition of 1 ml of 1 M 
IPTG per litre. The remainder of the expression and purification protocol was 
identical to that for LB growths. 
 
To produce samples with both 15N and 13C labelling, the 4 g of glucose was 
replaced with 2 g of 13C labelled glucose. The growths normally required an 
additional 2 hours before induction (until an O.D. of approximately 0.6 was 
reached) to compensate for the lower glucose concentration.  
 
3.13 Test Growths 
 
10 ml growths were used as a small scale test for successful induction of protein 
expression and solubility. 10 ml of LB in a universal was inoculated with BL21 
(DE3) cells containing the relevant protein construct. The appropriate antibiotic 
control (normally kanamycin at 30 µg/ml) was added to these. These test growths 
were incubated at 37ºC. When the O.D. of the growths reached 0.6 a 1 ml SDS-
PAGE gel sample was taken, and the growths were induced with 10 µl 1 M IPTG. 
Test inductions were carried out at multiple temperatures (e.g. 37°C, 30°C and 
25°C) to determine the optimum conditions for overexpression of soluble protein. 
1 ml SDS-PAGE samples were then taken at intervals so the levels of protein in 
the soluble and total fractions could be monitored. 
 
These SDS-PAGE samples were prepared by resuspending the cells in 300 µl of 
buffer A and sonicating them for 10 seconds, followed by a 10 second break on 
ice, followed by a final 10 seconds of sonication. 20 µl gel samples were taken 
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from this total fraction, and the remainder was centrifuged at 13,000 g for 10 
minutes to pellet all insoluble proteins. 20 µl of the supernatant was then taken 
from the soluble protein fraction. SDS-PAGE was carried out as specified in 
section 3.14 to determine the most suitable temperature and duration to maximise 
the yield of soluble protein. 
 
3.14 SDS-PAGE Gels 
 
Approximate quantities and molecular weights of proteins in samples at various 
stages in the purification were determined using a Min-Protean®3 SDS-PAGE 
system (BioRad). 15% polyacrylamide gels were used for the t242, t187 and 
isolated RRM constructs. 20% gels were used for RRM123, wild type CELF1 
and PARN deadenylase. The 15% resolving layer was prepared from 1.7 ml 30% 
protogel, 0.85 ml 1.5 M Tris.HCl pH 8.8, 0.034 ml 10% m/v sodium dodecyl 
sulphate (SDS), 0.816 ml MilliQ water. Immediately before pouring 40 µl of 100 
mg/ml ammonium persulfate and 10µl TEMED were added to start the 
polymerisation reaction. The stacking gel was prepared from 0.266 ml 30% 
protogel, 0.5 ml 0.5 M Tris.HCl pH 6.8, 0.02 ml 10% SDS, 1.21 ml MilliQ water. 
30 µl of 100 mg/ml ammonium persulfate and 10 µl TEMED were added 
immediately prior to pouring the gel. The stacking layer was added over the 
resolving layer once it had set and was cast around a Teflon comb to form ten 
sample wells, each with a volume of approximately 12 µl. 
 
Samples were prepared by adding 0.5 sample volumes of loading buffer (100 mM 
Tris, pH 6.8, 4% SDS (w/v), 0.2% bromophenol blue (w/v), 20% glycerol (v/v), 
200 mM DTT), and heating for 5 minutes at 90ºC. 10 µl of sample was then 
loaded into the sample wells. 5 µl of low molecular weight markers (either Sigma 
Low Range Markers or Novex Prestained Protein Standard (Invitrogen)) were run 
in one lane of each gel as a reference. The mass of each protein in the reference 
markers is listed in the table below. 
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Sigma Low Molecular Weight Markers: 
Protein Mass (kDa) 
Albumin 66 
Ovalbumin 45 
Glyceraldehyde-3-Phosphate Dehydrogenase 36 
Carbonic Anhydrase 29 
Trypsinogen 24 
Trypsin Inhibitor 20 
Į-lactalbumin 14.2 
Apoprotinin 6.5 
 
A Biorad SDS-PAGE kit was used to run the gel in SDS buffer (25 mM Tris, 
0.25 M glycine, 0.1% v/v SDS). Gels were run at 180 V for approximately 1 
hour. Coomassie Brilliant Blue protein stain was used to stain gels (0.25% w/v 
Brilliant Blue R-250 (Fisher) 45% v/v methanol, 10% v/v glacial acetic acid) for 
1 hour. Destaining was carried out with a mix of 10% v/v glacial acetic acid and 
25% v/v methanol, over the course of at least 24 hours. Images of the gels were 
collected using a Syngene gel documentation system. 
 
3.15 Molecular Biology 
 
3.15.1 Plasmids 
 
Both the pET28 and pET33 vectors (Novagen) are based on the system developed 
by Studier et al163, 164, 165. This encodes a T7 promoter sequence upstream of a 
multiple cloning site (MCS) into which the gene to be expressed can be cloned. 
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This T7 promoter is specific to the bacteriophage T7 RNA polymerase, which is 
not found elsewhere in prokaryotes. The plasmid also encodes the lac repressor 
protein, a lac operator and an antibiotic resistance gene (in both of these vectors 
this is kanamycin resistance). Expression of the gene of interest can only occur if 
the T7 RNA polymerase is present, and the lac operator is not being repressed. 
 
The strain of host cells used throughout was BL21 (DE3), which incorporate the 
gene for T7 RNA polymerase, again after a lac operator. The lac operators 
therefore repress both the expression of the T7 RNA polymerase in the bacterial 
chromosome and the expression of the gene of interest in the pET vector. The lac 
operator is only represses these genes in the absence of allolactose (a metabolite 
of allolactose). Expression of the proteins is induced by the addition of isopropyl-
thio-ȕ-D-galactoside (IPTG), which mimics allolactose and so activates both of 
the genes repressed by lac operators. Once the T7 polymerase is present the 
protein of interest is then rapidly expressed. 
 
In both of these vectors the protein of interest is expressed as a fusion with an N-
terminal 6-His-tag. This tag is separated from the protein by a thrombin cleavable 
site (LVPRGS) allowing it to be removed if necessary. The tag allows the protein 
to be purified by immobilised metal ion affinity chromatography (IMAC), as 
explained in section 3.7. 
 
3.15.2 Site Directed Mutagenesis 
 
The required primers were produced by the School of Biomedical sciences, 
University of Nottingham. A QuikChange site directed mutagenesis (Stratagene) 
was used for the process. The forward and reverse primers were designed to meet 
the kit's specification, which was a 25 ± 45 bases in length for each primer, a 
minimum of 40% G/C content, a melting temperature of at least 78ºC and for the 
primer to terminate with at least one G or C base. For the reaction the following 
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reagents were combined in a sterile 0.2 ml thin walled PCR tube (Starlab): 
 
37.5 µl Sterile MilliQ water 
5 µl 10x reaction buffer (20 mM Tris.HCl pH 8.8, 10 mM KCl, 10 mM NH4SO4, 
2 mM MgSO4, 0.1% Triton X-100, 0.1 mg/ml bovine serum albumen).  
2.5 µl DMSO 
1 µl template DNA (approximately 50 ng/µl) 
1 µl Forward primer (125 ng/µl) 
1 µl Reverse primer (125 ng/µl) 
1µl dNTPs (10 mM for each nucleotide) 
1 µl (3 units) Pfu Turbo DNA polymerase (added last). 
 
The PCR tube was then transferred to the PCR thermocycler block and run for 18 
cycles of 30 seconds at 95ºC, 30 seconds at 55ºC, 30 seconds at 68ºC. The 95°C 
step denatures the template DNA, separating the two strands. The 55°C step 
allows the primers to anneal to their complementary sections in the template 
DNA. To optimise the reaction the annealing temperature sometimes required 
adjusting in the 50 ± 60°C range. The 72°C step is a suitable temperature for the 
DNA polymerase to extend the primers. 
 
The remaining parental template DNA was digested with 1 µl (10 units) DpnI 
endonuclease (New England Biolabs) at 37ºC for 1 hour. DpnI selectively cleaves 
methylated DNA. This step is necessary as this DNA will not contain the point 
mutation, but will still provide antibiotic resistance when transformed into cells. 
In all cases the template DNA was extracted from XL1 Blue E. Coli cells and was 
therefore methylated. DNA generated by the PCR is not methylated, and so is not 
digested by the DpnI. The PCR product was transformed into XL1 Blues using 
the protocol in section 3.15.9. 
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3.15.3 Cloning 
 
Template DNA containing the gene to be cloned was extracted from XL1 Blues 
using a Qiagen Spin Miniprep kit. The primers for production of the isolated 
RRM2 construct were designed so that the forward primers contained the HindIII 
UHVWULFWLRQVLWHDWWKH¶HQGRIWKHJHQH, while the reverse primers contained the 
1KH, UHVWULFWLRQ VLWH DW WKH ¶ HQG RI WKH JHQH $ PCR of the insert was then 
carried out by combining 1 µl of template DNA, 1 µl forward primer, 1 µl reverse 
primer, 1 µl dNTPs, 5 µl reaction buffer (New England Biolabs buffer B as the ) 
and 40 µl sterile MilliQ water were mixed in a 0.2 ml thin walled PCR tube. 1 µl 
of TAQ polymerase was then added, and the tube transferred to a PCR machine. 
This was heated to 95ºC for 2 minutes to denature the DNA, and then underwent 
30 cycles of 30 seconds at 95ºC, 30 seconds at 60ºC and 30 seconds at 72ºC to 
amplify the insert. 
 
The PCR product was digested with 1 µl Dpn1 for 1 hour at 37ºC.  A PCR 
purification kit (Qiagen) ZDVXVHGDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVWo 
purify the insert, which was then purified further by running on a 1% w/v agarose 
gel. The section of the gel containing the insert DNA was then excised from the 
agarose gel using a sterile scalpel, and the DNA extracted using a Qiagen gel 
extraction kit. The vector DNA was prepared by growing a 15 ml overnight cell 
culture of XL1 Blues containing a ³EODQN´ pET28b plasmid with no gene present 
in the multiple cloning site. This plasmid DNA was extracted using a Qiagen 
Miniprep Spin kit. 
 
3.15.4 Restriction Digest 
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For the restriction digest two sterile 0.2 ml thin-walled PCR tubes were used, one 
to prepare the insert and the other for the vector. The following reagents were 
combined: 
 
Insert: 
37.5 µl Insert DNA 
5 µl 10x Reaction Buffer B 
2.5 µl Sterile MilliQ water 
1 µl 50x BSA 
2 µl HindIII restriction enzyme 
2 µl NheI restriction enzyme 
 
Vector: 
32 µl blank pET28 vector DNA 
4 µl 10x reaction buffer B 
1 µl 50x BSA 
2 µl HindIII restriction enzyme 
2 µl NheI restriction enzyme    
 
These PCR tubes were then incubated at 37ºC for 3 hours, after which the 
enzymes were inactivated by heating to 65ºC for 15 minutes. The vector was then 
treated with antarctic phosphatise, in the reaction mixture shown below. During 
this process the insert was stored on ice. 
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40 µl Vector DNA 
5 µl 10x antarctic phosphatase buffer 
4 µl Sterile MilliQ water 
1 µl Antarctic phosphatase  
 
The reaction mixture was heated to 37ºC for 10 minutes, and then to 65ºC for 15 
minutes to heat inactivate the enzyme. This left the insert and vector with 
complementary ends which could be ligated together. The insert and vector were 
both visualised and purified on a 1% w/v agarose gel. A deeper gel than usual (42 
ml instead of the normal 30 ml) was used to accommodate the larger volume of 
DNA. The DNA was extracted from the gel using a Qiagen gel extraction kit 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV 
 
3.15.5 Ligation 
 
A 4:1 ratio of insert to vector DNA was combined in a 0.2 ml thin walled PCR 
tube, with 2 µl of 10x ligation buffer (New England Biolabs) and 1 µl T4 ligase 
(Promega, 3 units). The total reaction volume was 18 µl. Ligation was carried out 
at 16ºC overnight (~16 hours). After this the reaction mixture was heated to 65ºC 
for 10 minutes to inactivate the ligase. The ligated product was then transformed 
into XL1-Blue cells (using the protocol in section 3.15.9, except that an increased 
volume of 5 µl of DNA was added to 100 µl of competent cells), and plated onto 
agar. Tetracyclin and kanamycin were used as antibiotic selections. 
 
3.15.6 Production of Deletion Constructs 
 
The RRM3, RRM23 and RRM123 constructs were produced by deletion of 
unwanted sections of the CELF1 wild type construct. This used a single step PCR 
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process, as outlined by Qi et al. and Liu et al.166, 167. The following reagents were 
combined in a 0.2 ml thin-walled PCR tube. 
 
37.5 µl sterile MilliQ water. 
5 µl 10x Reaction Buffer 
2.5 µl DMSO 
1 µl dNTPs 
1 µl Template DNA (in this case full length CELF1 wild type) 
1 µl Forward Primer 
1 µl Reverse Primer 
1 µl (3 Units) Pfu Phusion DNA Polymerase (Promega) 
 
The thermocycler program used was as follows: 
1 Cycle: 
5 minutes at 95°C (Initial denaturation of the DNA) 
18 Cycles: 
1 minute at 95°C (Denaturation) 
2 minutes at 68°C (Annealing of the non-overlapping sections of the primers) 
12 minutes at 72°C (Extension step, lasting 1 minute per 500 bases in the DNA 
template) 
1 Cycle: 
2 minutes at 60°C (Annealing of the complimentary sections of the primers) 
30 minutes at 72°C (Final elongation step) 
 
1 µl DpnI was then added, and the reaction mixture was incubated at 37°C for 2 
hours to break down any remaining methylated template DNA. The PCR product 
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was then visualised by agarose gel to confirm amplification. As all PCRs using 
this method deleted several hundred bases from the construct, the size difference 
between the PCR product and template on the agarose gel provided an indicator 
of whether the deletion was successful. The PCR product was then transformed 
into XL1 Blue cells using the protocol in section 3.15.9. If the reaction was 
successful the cells had resistance to the antibiotic, and formed colonies on the 
LB agar plate. 
 
3.15.7 Sequencing 
 
PCR products and cloned plasmids were sequenced using the Sanger method168 
by the School of Biomedical Sciences, Queens Medical Centre, Nottingham. 5 µl 
DNA samples with concentrations of approximately 100 ng/µl were supplied, 
with 5 µl of forward and reverse primers where appropriate. The T7 promoter 
primer (TAA TAC GAC TCA CTA TAG GG) was used for sequencing all 
constructs in the pET28 vector. The program Chromas 2.21 (Technelyesium) was 
used to view sequencing results. 
 
3.15.8 Production of Calcium Competent Cells 
 
15 ml of LB containing 12.5 µg/ml of tetracycline was inoculated with XL1 
blues, and incubated at 37ºC for 16 hours. After 16 hours 200 µl of this culture 
was transferred to a second universal of 10 ml LB with 12.5µg/ml of tetracycline. 
This was again incubated at 37ºC until the OD reached approximately 0.3. The 
cells were then centrifuged at 1000 g for 15 minutes, and the supernatant 
discarded. 4 ml of sterile, chilled 50 mM CaCl2 was then used to resuspend the 
cells, after which they were stored on ice for a minimum of 2 hours.  
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3.15.9 Transformation 
 
After at least 2 hours on ice the cells were centrifuged at 1000 g for 15 minutes, 
and resuspended in 800 µl of chilled, sterile 50 mM CaCl2 before being returned 
to the ice bath for another 30 minutes. These calcium competent cells were 
divided into 100 µl aliquots.  For transformations using the product of a PCR, 5 
µl of DNA was added to an aliquot of calcium competent cells. For 
transformations into BL21 (DE3) cells 1 µl of DNA was used. The cells were 
heat-shocked by transferring them to a water bath at 42ºC for 30 seconds, after 
which they were placed back on ice for 2 minutes. 400 µl of LB was then added 
to each aliquot, and these were incubated at 37ºC for 30 minutes. The cells were 
then spread onto agar plates with appropriate antibiotic selections, which were 
then sealed with Nesco film and incubated overnight at 37ºC. A negative control 
plate was produced using an aliquot of cells with no added plasmid DNA, to 
confirm the antibiotic control was effective. 
 
The following day colonies were picked and 10 ml overnight cultures inoculated 
with them. Glycerol stocks were prepared from these overnights, and DNA was 
extracted from the remainder of the cell culture using a QIAprep miniprep kit 
(Qiagen) according to the PDQXIDFWXUHU¶V instructions. 
 
3.15.10 Agar Plates 
 
Agar plates were prepared by dissolving LB-agar (Sigma, 15 g/l agar, 10 g/l 
tryptone, 5 g/l yeast extract, 10 g/l NaCl) in MilliQ water at 40 g/l. After 
autoclaving, the agar was melted in a microwave and allowed to cool to 
approximately 40°C. Any required controls (kanamycin and/or tetracycline) were 
sterile filtered through a 0.22 µm filter before addition to the agar. The agar was 
then plated onto sterile petri dishes and stored at 4°C. Before use the plates were 
transferred to a 37°C incubator for 30 minutes to remove any excess moisture. 
70 
 
 
3.15.11 Agarose Gels 
 
1% w/v DNA gels were prepared by dissolving 0.3 g of agarose in 30 ml Tris 
Acetate EDTA (TAE) buffer (40 mM Tris-acetate pH 5.0, 1 mM EDTA), and 
then heating the resulting mixture in a microwave until the agarose had melted. 
The solution was allowed to cool for 5 minutes, after which 1 µl of ethidium 
bromide was added. The gel was then cast in a 7 x 10 cm gel tray (Mini Sub GT 
Cell ± Biorad), around a comb to create eight 20 µl sample wells. After the gel 
had set, it was immersed in TAE buffer (40 mM Tris.HCl, 1 mM EDTA, 20 mM 
acetic acid).  DNA samples were prepared by adding 2 µl of 6x DNA loading 
buffer (Novagen, bromophenol blue) to 10 µl of sample. 2-log DNA ladder 
markers (New England Biolabs) were used as a reference, prepared from 1 µl 
supplied marker stock, 1 µl 6x loading dye and 4 µl MilliQ water. A potential of 
70 V was applied across the gel until the bands had migrated sufficiently to 
resolve the different masses. UV light was used to visualize the DNA bands, and 
gels were imaged using a Syngene gel documentation system. 
 
When used for purification rather than visualisation of PCR products a deeper gel 
was prepared to accommodate the greater volume of sample. 0.42 g of agarose 
was dissolved in 42 ml of TAE buffer to prepare a 1% gel. DNA samples were 
loaded into adjacent lanes, so they could be excised in a single piece of the 
agarose gel. 
 
3.16 NMR Acquisition 
 
All NMR experiments were run on a 600 MHz Bruker Avance spectrometer with 
a TXI probe or an 800 MHz Bruker Avance III spectrometer with a QCI probe. 
Data processing was carried out using Topspin 2.3 and later 3.0. Standard Bruker 
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pulse sequences were used throughout. Spectra were referenced internally to 
trimethylsilylpropionate (TSP) at 0.00 ppm in the 1H dimension. 
 
3.16.1 Data Analysis 
 
An exponential window function with 2 Hz line broadening was applied to all 1D 
proton spectra. For 2D spectra zero-filling of up to 2048 points was applied to the 
direct and indirect dimensions for data acquired on the 600 MHz spectrometer. 
Zero-filling of up to 4096 points was applied to data from the 800 MHz 
spectrometer. A sine-squared apodization function and polynomial baseline 
correction was applied to both dimensions. CCPNMR versions 1.1.15 and 2.1.2 
were used for data analysis.  
 
3.16.2 Sample Preparation 
 
The composition of NMR buffer was 25 mM phosphate, 50 mM NaCl, 10% (v/v) 
D2O, pH 7.0 unless otherwise specified. The buffers were prepared using RNase 
free water throughout. Lyophilised protein samples were dissolved in 600 µl of 
buffer, centrifuged at 13,000 g for 1 minute to remove any insoluble material, and 
then transferred to NMR tubes. Protein concentrations were between 400 µM and 
1 mM for experiments using the 600 MHz spectrometer and 20 µM ± 400 µM for 
those at 800 MHz. All RNA substrates were supplied by Dharmacon in a 2' 
protected form. Prior to the experiments the RNA was deprotected according to 
the supplier's instructions and dissolved in RNase free water to a concentration of 
5 mM.  
 
3.16.3 1D experiments 
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Standard Bruker pulse sequences were used in recording all 1D experiments. 
Appropriate decoupling was applied when necessary for isotopically labelled 
samples. Water suppression was applied using excitation sculpting169 and 
WATERGATE pulse sequences170. The transmitter frequency was set to the 
water frequency (~4.7 ppm, 2823 Hz for the 600 MHz spectrometer, 3765 Hz for 
the 800 MHz spectrometer).  
 
3.16.4 HSQC Experiments 
 
15N and 13C Heteronuclear single quantum coherence spectra (HSQCs) were 
recorded for the smallest construct (RRM2). For larger constructs 15N transverse 
relaxation optimised spectroscopy (TROSY) was used to compensate for loss of 
signal from rapid relaxation. RNA titrations used a protein concentration of 400 
µM when recorded with the 600 MHz spectrometer, and 250 µM with the 800 
MHz spectrometer, except where otherwise specified. RNA was titrated into the 
sample until saturation point was reached (determined by no further changes 
being observed in the 1H-15N HSQC/TROSY of the protein over multiple titration 
points).  
 
3.16.5 3D Experiments 
 
In order to assign the NH, +1&
&ĮDQG&ȕRIHDFKUHVLGXHDVHULHVRIVWDQGDUG
3D Bruker experiments were used. These included HNCO130, HN(CA)CO132, 
HNCA131, HNCACB129, HN(CO)CACB130, 133 and HCCH-TOCSY138.  These 
experiments were conducted on the RRM1, RRM2, RRM3 and t187 constructs, 
and also the S28D mutant of RRM1. 
 
t187 
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Experiment Scans 1H 15N 13C Spectral 
Widths (ppm) 
(1H, 15N, 13C) 
AQ Times 
(s) 
(1H, 15N, 13C) 
1H-15N HSQC 64 2048 64 - F2: 16.02  
F1: 32.00 
F2: 0.10650, 
F1: 0.01644 
HNCO 32 2048 64 98 F3: 11.97  
F2: 32.00  
F1: 25.00 
F3: 0.14254, 
F2: 0.01644, 
F1: 0.01299 
HN(CA)CO 256 2048 32 48 F3: 11.97 
F2: 32.00  
F1: 25.00 
F3: 0.14254, 
F2: 0.00822, 
F1: 0.00636 
HNCACB 72 2048 40 64 F3: 11.97  
F2: 32.00 
F1: 74.96 
F3: 0.14254, 
F2: 0.01028, 
F1: 0.00250 
HN(CO)CACB 48 2048 32 128 F3: 11.97  
F2: 32.00 
F1: 74.96 
F3: 0.14254, 
F2: 0.00822, 
F1: 0.00565 
HCCH-
TOCSY 
32 2048 64 64 F3: 11.97 
F2: 74.96 
F1: 12.00 
F3: 0.14254, 
F2: 0.00283, 
F1: 0.00444 
 
RRM1 
Experiment Scans 1H 15N 13C Spectral 
Widths (ppm) 
(1H, 15N, 13C) 
AQ Times 
(s) 
(1H, 15N, 13C) 
1H-15N HSQC 64 2048 64 - F2: 16.02  
F1: 32.00 
F2: 0.10650, 
F1: 0.01644 
HNCO 32 2048 64 98 F3: 14.98  
F2: 32.00 
F3: 0.11387, 
F2: 0.01644, 
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F1: 25.00 F1: 0.01259 
HN(CA)CO 32 2048 64 98 F3: 14.98 
F2: 32.00 
F1: 25.00 
F3: 0.11387, 
F2: 0.01644, 
F1: 0.01299 
HNCACB 72 2048 40 64 F3: 14.98 
F2: 32.00 
F1: 85.02 
F3: 0.11387, 
F2: 0.01028, 
F1: 0.00250 
HN(CO)CACB 48 2048 32 128 F3: 14.98  
F2: 32.00 
F1: 85.02 
F3: 0.11387, 
F2: 0.00822, 
F1: 0.00472 
HCCH-
TOCSY 
32 2048 64 64 F3: 11.97 
F2: 74.96 
F1: 12.00 
F3: 0.14254, 
F2: 0.00283, 
F1: 0.00444 
 
RRM2 
Experiment Scans 1H 15N 13C Spectral 
Widths (ppm) 
(1H, 15N, 13C) 
AQ Times 
(s) 
(1H, 15N, 13C) 
1H-15N HSQC 64 2048 64 - F2: 16.02 
F1: 32.00 
F2: 0.10650, 
F1: 0.01644 
HNCO 32 2048 64 80 F3: 14.98  
F2: 32.00 
F1: 25.00 
F3: 0.14254, 
F2: 0.01644, 
F1: 0.01060 
HN(CA)CO 64 2048 32 80 F3: 14.98  
F2: 32.00 
F1: 25.00 
F3: 0.14254, 
F2: 0.00822, 
F1: 0.00808 
HNCACB 48 2048 40 128 F3: 14.98 
F2: 32.00 
F1: 84.96 
F3: 0.11387, 
F2: 0.01028, 
F1: 0.00499 
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HN(CO)CACB 48 2048 32 128 F3: 14.98 
F2: 32.00 
F1: 84.96 
F3: 0.11387, 
F2: 0.01028, 
F1: 0.00499 
HCCH-
TOCSY 
40 2048 48 64 F3: 11.97 
F2: 74.96 
F1: 12.00 
F3: 0.14254, 
F2: 0.00212, 
F1: 0.00444 
 
RRM3 
Experiment Scans 1H 15N 13C Spectral 
Widths (ppm) 
(1H, 15N, 13C) 
AQ Times 
(s) 
(1H, 15N, 13C) 
1H-15N HSQC 64 2048 64 - F2: 16.02  
F1: 32.00 
F2: 0.10650, 
F1: 0.01644 
HNCO 32 2048 64 80 F3: 14.03  
F2: 32.00  
F1: 25.00 
F3: 0.12165, 
F2: 0.01644,  
F1: 0.01060 
HN(CA)CO 32 2048 64 80 F3: 14.03  
F2: 32.00  
F1: 25.00 
F3: 0.12165, 
F2: 0.01644,  
F1: 0.01060 
HNCACB 40 2048 64 128 F3: 15.02 
F2: 32.00 
F1: 90.00 
F3: 0.11360, 
F2: 0.01644, 
F1: 0.00471 
HN(CO)CACB 32 2048 44 128 F3: 17.96 
F2: 35.23 
F1: 75.02 
F3: 0.09503, 
F2: 0.01120,  
F1: 0.00499 
 
Assignment of the structured regions of RRM123 and wild type CELF1 were 
carried out by comparison with the assignments of the isolated RRMs. With the 
exception of residues immediately adjacent to the cut sites of these constructs, 
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there were minimal differences in the chemical shifts, allowing assignments to be 
directly transferred.  
 
3.16.6 15N Heteronuclear NOE 
 
Pulse sequences consisting of standard 1H-15N HSQCs with and without proton 
saturation during the relaxation period prior to the initial 15N pulse were used to 
measure the heteronuclear NOE. The experiments were run as interleaved 1H-15N 
HSQCs which were subsequently split into a pair of 1H-15N HSQCs, one with 
proton saturation and one without. The heteronuclear NOE for each residue was 
calculated as intensity (with proton saturation)/ intensity (equilibrium). 15N 
heteronuclear NOE data was collected at the start and end points of RNA 
titrations to compare flexibility in the free and bound states. 
 
3.16.7 Paramagnetic Relaxation Enhancement 
 
Dipolar interactions with unpaired electrons enhance the relaxation rate of 
surrounding nuclear spins. The magnitude of the relaxation enhancement is 
related to the distance from the paramagnetic centre. PRE can therefore be used to 
obtain additional distance restraints between the paramagnetic centre and the 
surrounding nuclei171. 1H nuclei are the most sensitive to paramagnetic relaxation 
enhancement (PRE), with 13C and 15N showing only 1/16 and 1/100 of the effect 
respectively. 
 
There are various methods for incorporating an unpaired electron spin into 
proteins and other macromolecules. One common method is the introduction of 
lanthanide 3+ ions coordinated to the protein, normally by substituting for a 
naturally occurring metal ion such as Mg2+. Another method is to couple a small 
stable radical group, such as a nitroxide, to the protein. This is generally carried 
out by attaching it to a free thiol group in the protein. If no suitable cysteines are 
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naturally present in the protein, this requires site directed mutagenesis to add one 
in a suitable location. Proteins with multiple cysteines present may require all but 
one mutating to a similar residue (e.g. alanine or serine) in order for the 
paramagnetic tag to be attached to one specific site in the protein, which can 
present a problem if they are involved in interactions of interest172. 
 
Similar methods can be used to attach a paramagnetic group to RNA or DNA. In 
RNA 4-thiouridine can be incorporated into specific positions in the sequence 
which allows MTSL to be attached in a similar reaction to that with cysteines in 
proteins. RNAs containing 4-thiouridines at specific positions are commercially 
available, and were purchased from Dharmacon. 
 
CELF1 has seven endogenous cysteine residues at positions 61, 62, 119, 137, 
150, 172 and 446. Of these 61, 62 and 150 are part of the RNA binding patch, and 
have substantially perturbed chemical shifts on binding. Attaching a large 
paramagnetic tag to any of these residues would likely disrupt RNA binding. 
Selectively attaching a paramagnetic tag to the t187 construct would require 
mutating five cysteines to other residues. RRM3 is the easiest construct to attach 
the tag to, since it has only a single cysteine residue, and it is not located in the 
RNA binding patch. 
 
After completion of PRE titrations the paramagnetic tag was reduced by addition 
of a 5 molar excess of sodium L-ascorbate to the NMR sample. 16 hours was 
sufficient for full reduction of the tag attached to a cysteine in RRM3. The tag 
attached to 4-thiouridine RNA however was only partially reduced after this time. 
A final 1H-15N HSQC was then collected on the reduced sample to confirm the 
magnitudes of the PRE effects. 
 
3.17 X-ray Crystallography 
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Crystallization trials of the RRM1 construct unbound and in the presence of the 
CUGCUG RNA substrate were conducted using Qiagen crystallization screening 
suites. An identical set of trials were also conducted for the S28D mutant of 
RRM1. Trials were also run for the RRM123 construct unbound, and in the 
presence of the EDEN2U/4U RNA. In all cases these consisted of 96-well 
Intelliplate sitting drop vapour diffusion plates, which were loaded using a Matrix 
Hydra II micro-dispensing system. No diffraction quality crystals were produced 
in any of these trials. 
 
3.18 Size Exclusion Chromatography 
 
An analytical Superdex GF200 column (GE Life Sciences) was used for size 
exclusion chromatography. Since this technique was only used in order to 
compare the bound complex to the free protein a size calibration curve with 
known protein standards was not collected. Samples were dissolved in 1 ml of 50 
mM potassium phosphate, 200 mM NaCl, pH 7.0 buffer and injected on the 
column. The elution volume of the protein and RNA was detected by the change 
in absorbance at 280 nm. 
 
3.19 SAXS 
 
SAXS samples were prepared by dissolving lyophilised protein in 30 mM 
potassium phosphate, 100 mM NaCl, pH 7.0 buffer. RNA was added from a 5 
mM stock to a 1:1 ratio to produce the samples of the complex. The samples of 
the protein-RNA complex were then loaded onto a Superdex 200 gel filtration 
column in order to separate the complex from any remaining unbound protein or 
RNA. This step was essential in order to ensure the SAXS sample was 
monodisperse. The sample was then transferred to a 3000 MWCO centrifugal 
concentrator and concentrated to 5 mg/ml. The sample concentration was checked 
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by the 280 nm absorbance using a Nanodrop ND-100 spectrophotometer. Once at 
a concentration of 5 mg/ml samples were frozen using liquid nitrogen and stored 
at -80°C. A range of concentrations for SAXS data collection was produced by 
dilution of this concentrated stock. 
 
3.20 ITC 
 
Isothermal titration calorimetry (ITC) was carried out using a VP-ITC high 
sensitivity microcalorimeter (manufactured by MicroCal Inc, GE Healthcare). 
The instrument was controlled using VPViewer2000 version 1.4.27 (MicroCal). 
The ITC cell was cleaned by addition of Decon90 to the cell for 10 minutes, 
followed by washing through a minimum of 500 ml of MilliQ water. The syringe 
was also cleaned by washing through 500 ml of MilliQ water. A titration of water 
into water was carried out prior to each experiment to confirm the machine was 
free of contamination and that the baseline was stable. All solutions were 
degassed for 10 minutes in a Thermovac (MicroCal) before loading. For reverse 
titrations the cell was filled with 1.4 ml of 25 µM RNA dissolved in RNase free 
water. 300 µl of 250 µM protein, also dissolved in RNase free water, was loaded 
into the syringe. In experiments involving the RRM123 construct the cell 
concentration was reduced to 12.5 µM, and the syringe concentration to 125 µM. 
All titrations were carried out at 25°C. After an equilibration period of 20 
minutes, 30 injections of 10 µl were added at 600 second intervals. A constant 
stirring speed of 300 rpm was applied throughout the titration to rapidly mix the 
contents of the cell. 
 
A reference power of 5 µcals-1 was used except where otherwise specified. Fitting 
of the resulting data was carried out using the Origin 7.0 fitting program, 
assuming a single site bLQGLQJ PRGHO IURP ZKLFK ǻ+ ǻ6 .d and the 
stoichiometry for the interaction could be determined. For traces where a one site 
model was not appropriate, such as those showing multiple binding events, a fit to 
a multi-site binding model was attempted instead. Baseline correction was 
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necessary for some datasets. 
 
3.21 Mass Spectrometry 
 
All ESI mass spectra were collected on a Waters SYNAPT instrument with a 
quadruple time-of-flight mass analyzer calibrated using horse heart myoglobin. 
Data acquisition and analysis was carried out using Masslynx (Waters) software. 
All proteins required an additional desalting step to reduce salt to levels suitable 
for ESI mass spectrometry. This second desalt was carried out into 50mM 
ammonium acetate, in which the HiTrap desalting column had been pre-
equilibrated. All proteins were run as native rather than denatured samples so that 
binding activity could be observed. Sample was injected at 5 µl/minute using a 
Harvard Apparatus automatic syringe pump and a 100 µl Hamilton syringe. The 
capillary voltage was 2.80 kV. The sample cone voltage was 30 V. Unbound 
protein samples were run in positive ion mode, bound protein/RNA complexes 
were run in both positive and negative ion mode. Data acquisition was carried out 
over 3 minutes at 1 scan/second and combined. Data was acquired over an m/z 
range of 500 ± 5000. 
 
3.22 Molecular Modelling  
 
All hydrogen atoms for both the protein and RNA were introduced to the PDB 
files, using XLEAP. Na+ ions were also introduced to give an overall neutral 
charge (all protein/RNA systems modelled otherwise had an overall negative 
charge due to the RNA phosphate backbone). TIP3P water was used as an explicit 
solvent, and was added in a truncated octahedron geometry to a distance of 9 Å 
around the protein. Energy minimisation was carried out using the SANDER 
modules of the AMBER program. Energy minimisation was conducted in three 
stages. The first step minimised the water molecules only, by applying a restraint 
mask with a force constant of 200 to all other atoms in the system. The second 
stage minimised the water and Na+ ions added to achieve an overall neutral 
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charge for the system, by restricting the restraint mask to the atoms of the protein 
and RNA only. The third step minimised the entire system, with no restraint 
mask. Each step included an initial minimisation by the steepest descent method, 
lasting for 50 cycles, followed by conjugate gradient minimisation for up to a 
maximum of 5000 cycles. Molecular dynamics simulations consisted of an initial 
10 ps step at 100 K, followed by a temperature ramp to 300 K over a further 10 ps 
with a restraint mask of weight 200 applied to the protein and nucleic acid. The 
force constant of the restraint mask was then reduced to zero in seven stages (100, 
50, 25, 10, 5, 2, 1) of 10 ps each. The final step of the molecular dynamics 
simulation was at 300 K with no restraint mask, and allowed to run for a 
minimum of 1 ns. The resulting models were viewed using Pymol.  
 
Three crystal structures were used as starting points for constructing models: the 
structure of RRM3 in complex with the RNA sequence UGUGUG by Tsuda et al. 
(PDB ID: 2RQC), the structure of two RRM1 proteins in complex with the 
sequence GUUGUUUUGUUU by Teplova et al. (PDB ID: 3NNH), and the 
structure of the two N-terminal RRMs with RRM2 bound to the RNA sequence 
GUUGUUUUGUUU, also by Teplova et al. (PDB ID: 3NMR).  
 
The first model to be constructed was of the two N-terminal domains (the t187 
construct) in complex with the RNA sequence UGUUUUGU. The RNA in the 
structure of bound RRM1 (3NNH) was truncated to the sequence UUGU, leaving 
a single RRM1 protein bound to a UGU site. The second RRM1 protein was 
removed. The residues of the remaining RRM1 protein were then superimposed 
onto the RRM1 section of the protein in structure 3NMR, minimising RMSD for 
the protein. Replacing the atom coordinates of the RRM1 section of the protein in 
structure 3NMR with those from the superimposed RRM1 from structure 3NNH 
combined the two structures, resulting in a single protein of residues 14 - 187 of 
CELF1, with a fragment of RNA containing a UGU(U) site bound to each 
domain. Residues 1 ± 13 are not included in any crystal structure, and since they 
were not believed to be involved in RNA binding they were omitted. The RNA 
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molecule bound to RRM2 in this structure was truncated to the core UGUU 
sequence in contact with the protein.  
 
The RNA fragments UGUU (bound to RRM2) and UUGU (bound to RRM1) 
were then connected to form the RNA UGUUUUGU. Due to the orientation of 
the two domains in the original 3NMR structure this required the introduction of 
an implausibly long bond connecting the two RNA fragments in this initial 
structure. The energy minimisation step detailed earlier allowed the protein 
domains and RNA to shift until this bond had relaxed to a normal length. 
Molecular dynamics simulations were then conducted from this starting point, 
using the temperature ramps specified earlier. 
 
This structure served as the N-terminal fragment for later models containing all 
three RRMs of the protein. Since no structural data exists for the RRM2 ± RRM3 
linker region a section of the RRM123 protein consisting of residues 186 - 216 
was constructed in the program XLEAP, and then energy minimised in AMBER. 
This linker was then attached to the N-terminal fragment by superimposing 
residues 186 and 187 of the linker onto their counterparts in RRM2 of the N-
terminal fragment (minimising RMSD). The C-terminal fragment was similarly 
attached by superimposing residues 215 and 216 of the RRM3 structure onto the 
corresponding residues in the RRM2 - RRM3 linker. Combining the atom 
coordinates from the PDB files resulted in a complete RRM123 protein with two 
separate RNA fragments, UGUUUUGU bound to the N-terminal domains and 
UGUGUG to RRM3. This model was energy minimised, and underwent 
molecular dynamics simulations in AMBER for 1 ns at 300 K.  
 
To produce the complex with the EDEN-2U/4U RNA the fragment bound to 
RRM3 was truncated to the UGU site. A section of RNA consisting of the 
sequence UUUUUU was constructed in XLEAP, energy minimised in AMBER, 
DQGDWWDFKHGWRWKH550IUDJPHQWE\VXSHUSRVLWLRQRIWKH¶XUDFLOZLWKWKH¶
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XUDFLORIWKLV8*8VLWH7KH¶XUDFLORIWKLV51$VSDFHUZDVWKHQVXSHULPSRVHG
RQWR WKH ¶ 8 RI WKH 1-terminal bound UGUUUUGU fragment, which 
necessitated the introduction of implausibly long bonds into the RNA backbone 
to make this connection. This structure, corresponding to RRM123 in complex 
with EDEN-2U/4U with the domains arranged in the order 2 ± 1 ± 3, was energy 
minimised over five steps, with a restraint mask applied to the protein and RNA. 
The force constant of this restraint mask was reduced (from 200 to 100, 50, 10 
and 1) allowing all bonds to relax slowly to normal lengths. The structure was 
then subjected to molecular dynamics simulations in AMBER for 2 ns. A model 
of the same complex, but with the RRMs in the order 3 ± 2 ± 1 was also 
constructed by the same method. 
 
Models of RRM123 in complex with the EDEN-2U/HL RNA sequence were also 
constructed. The RNA hairpin (consisting of the sequence 
UCCCGAGGACGGGU folded to form hydrogen bonds between the bases in 
LWDOLFVZDVFRQVWUXFWHGLQ;/($3DQGHQHUJ\PLQLPLVHG7KH¶DQG¶XUDFLOV
were then superimposed onto U9 and U12 respectively of EDEN-2U/4U in the 
complex of this RNA sequence with RRM123. U10 and U11 of the EDEN-
2U/4U sequence were then deleting, leaving an overall RNA sequence matching 
EDEN-2U/HL. The model then underwent energy minimisation and a 2 ns 
molecular dynamics simulation.  
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4 RNA Interactions of the Isolated RRMs of CELF1  
 
Our initial aim was to produce constructs of each of the three RRMs of CELF1 in 
isolation, and assign their NMR spectra. The smaller size of these constructs 
made them more amenable to some biophysical techniques, in particular NMR. 
They were also far less prone to degradation than the full length CELF1 protein, 
and were considerably more soluble in buffers with low salt concentrations. 
Knowing the minimum RNA sites for binding of each RRM made it easier to 
design sequences to bind the full length protein, and understand the role of each 
RRM in recognising the EDEN motif. 
  
Consensus sequences for CELF1 from the literature provided a starting point.  
UGUUUGUUUGU (the EDEN11 GRE) and UGUUUGUUUGUUUGUU (the 
EDEN15 GRE) have been suggested as possible targets for wild type CELF1. 
Long UG repeating sequences had also been suggested as possible targets.  From 
this it has been hypothesised that each domain is recognising a UGU, UGUU or 
UGUG site. We therefore aimed to determine the minimum site required for 
binding of each of the three domains of CELF1. 
 
CELF1 was originally noted to bind to a long repeating CUG RNA, hence its 
original name of CUG-BP1, before it was discovered to bind UG rich sequences 
such as the GRE with a higher affinity. Even though CUG sequences were known 
to be relatively low affinity substrates they were still of interest due to the 
possibility of them binding to CELF1 in DM1 cells. We therefore also aimed to 
identify the binding sites on the protein for CUG sequences to determine if they 
overlapped with the sites for UG rich sequences and so whether there would be 
competition between these RNAs.  
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4.1.1 Purification of RRM1  
 
The RRM1 construct was produced by making a single point mutation in a 
plasmid of CELF1 in the pET28b(+) vector, which was supplied by Dr Emilie 
Malaurie (University of Nottingham). This altered the codon for Asn102 to a stop 
codon, truncating the protein and leaving only residues 1 - 101 attached to the N-
terminal 6-His tag. The stop codon was placed at this position as it was in a 
flexible section of the linker between RRM1 and RRM2, and four residues after 
the C-terminus of the structured RRM1 domain. DNA sequencing confirmed that 
the point mutation was successful. 
 
The plasmid DNA was transformed into BL21 (DE3) cells for expression. RRM1 
was found to be soluble in lysis buffer A, with the vast majority of the protein 
remaining in the soluble fraction after a 16 hour induction at 30°C. These cells 
were lysed by sonication and the protein was allowed two hours to bind to an 
IMAC cobalt resin column. Washing and elution steps were carried out according 
to the protocol in section 3.7. After a thrombin cleave step to remove the N-
terminal 6-His tag, the protein was gel filtered using a Superdex GF75 column to 
remove trace impurities. Finally the protein was desalted, frozen with liquid N2 
and lyophilised to produce pure protein. The mass and purity of the protein at 
each stage was checked using SDS-PAGE, an example of which is shown in 
Figure 4.1. The overall yield was approximately 25 mg/l of RRM1 for growths in 
LB, and 14 mg/l for M9 minimal media. 
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Figure 4.1: SDS-PAGE of samples from the IMAC column stage of the RRM1 purification. Standard 
molecular weight markers (Sigma) are shown in lane 1. Lane 2 contains a diluted sample of the cell lysate 
drained from the IMAC column after the His-tagged proteins had been allowed to bind. Lanes 3 and 4 
contain samples from the two wash steps, both of which eluted significant quantities of RRM1 as well as 
non-specifically binding proteins. To reduce this loss of protein the NaCl concentration in the high salt 
wash was reduced to 1 M and the imidazole concentration in the low imidazole wash was reduced to 1 
mM in later purifications.  Lanes 5  ? 9 contain samples from the high imidazole elution fractions. These 
five fractions were retained for gel filtration to remove the impurities visible on the gel (particularly in 
fractions 1  ? 3). 
 
Once the unlabelled material was confirmed to be intact and correctly folded 
based on the dispersion of peaks in the 1D proton NMR spectrum, 15N labelled, 
and doubly labelled (15N and 13C) RRM1 was produced so the 1H-15N HSQC of 
the protein could be collected and assigned. 
 
4.1.2 NMR Assignment of RRM1 
 
The RRM1 construct has 101 residues, of which 9 are prolines which have no 
backbone amide protons and hence no signals in the 1H-15N HSQC. There are six 
additional residues (GSHMAS) remaining at the N-terminus from the 6-His-tag 
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after thrombin cleavage. A very poor signal to noise ratio was observed in the 1H-
15N HSQC for residues in this region of the protein, and in most cases no 
corresponding signals in the 3D spectra could be located. This can be attributed to 
the N-terminus of the protein being sufficiently dynamic to adopt a range of 
conformers in solution, each with slightly different chemical shifts for these 
residues, broadening the peaks. Example data from the HNCACB and 
HN(CO)CACB spectra used for assignment is shown below. 
 
 
Figure 4.2: This figure shows strips through the three dimensional HNCACB and HNCOCACB data for 
residues 59  ? 66 of the RRM1 construct. Peaks in the HN(CO)CACB spectra are shown in green. Peaks 
ĨƌŽŵƚŚĞ,EƐƉĞĐƚƌĂĂƌĞƐŚŽǁŶŝŶůŝŐŚƚĂŶĚĚĂƌŬďůƵĞ ?EĞŐĂƚŝǀĞƉŚĂƐĞƉĞĂŬƐ ?ĐŽƌƌĞƐƉŽŶĚŝŶŐƚŽɴƐ
 ?ĂŶĚ ɲƐ ŽĨ ŐůǇĐŝŶĞƐ ? ĂƌĞ ŝŶ ĚĂƌŬ ďůƵĞ ? WŽƐŝƚŝǀĞ ƉŚĂƐĞ ƉĞĂŬƐ ? ĐŽƌƌĞƐƉŽŶĚŝŶŐ ƚŽ ƚŚĞ ɲƐ ŽĨ Ăůů ƌĞƐŝĚƵĞƐ
except glycines are shown in light blue. In each strip the peaks are labelled, showing the matching 
chemical shifts between residue i and residue i-1 ?dŚĞďůĂĐŬůŝŶĞƐƐŚŽǁƚŚĞ “ďĂĐŬďŽŶĞǁĂůŬ ?ƚŚƌŽƵŐŚƚŚŝƐ
section of the protein. 
 
Of the 92 non-proline residues in RRM1 itself, 90 were assigned to peaks in the 
1H-15N HSQC. Assignments are missing for Met1 and Asp12, as well as the 
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remaining residues from the 6-His tag. Asp12 is situated between prolines 11 and 
13, preventing the normal 3D heteronuclear assignment strategy from being used. 
The assignment of RRM1 is shown in Figure 4.3. 
 
Figure 4.3: Assignment of the 1H-15N HSQC of RRM1 (residues 1 - 101). There are some additional peaks 
from side chain NH2 groups visible in the upper right region of the spectrum, which have not been 
assigned. Chemical shifts for all assigned residues are tabulated in the appendix. 
 
Figure 4: Histogram comparing the chemical shifts in Jun et al. ?Ɛ ĂǀĂŝůĂďůĞ ĂƐƐŝŐŶŵĞŶƚƐ ǁŝƚŚ ŽƵƌ
assignments. Difference is calculated using the same method as for chemical shift perturbations, as 
outlined in section 2.2. Our data is for Xenopus CELF1, while Jun et al. ?Ɛdata is for human CELF1.  
Residues which are not conserved between these homologs are highlighted with black arrows. Gaps 
indicate residues for which assignments are not available in one or both of the datasets. 
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There is generally good agreement between our assignments and those of Jun et 
al. The largest discrepancies are for residues 15, 16, 26 and 31 which are all 
either not conserved between these constructs, or directly adjacent to a non-
conserved residue. Lys101 also shows a large difference, but this is to be 
expected as it is the C-terminal residue in this construct, as opposed to being in 
the middle of Jun et al.¶VFRQVWUXFW 
 
4.1.3 Purification of RRM2 
 
The RRM2 construct was produced by PCR amplification of the DNA for 
residues 108 - 187 of Xenopus CELF1 using the primers specified in section 11.1. 
This insert was then cloned into the Xho I/Hind III sites of the multiple cloning 
site of the pET28b(+) vector (Novagen) and transformed into E. Coli XL1 Blue 
cells. As with RRM1 the construct is expressed with an N-terminal 6-His-tag, 
cleavable with thrombin, to allow purification using IMAC. After sequencing had 
confirmed the sequence of the RRM2 construct was correct, the plasmid DNA 
was transformed into E. Coli BL21 (DE3) cells for expression of the protein. Test 
growths and inductions confirmed RRM2 was successfully overexpressed, and 
remained in the soluble fraction after a 16 hour induction at 30°C.  
 
Large scale expression and purification of RRM2 was carried out using the same 
protocols as for RRM1. Since the RRM2 construct contains no tryptophan or 
tyrosine residues it has almost no absorbance at 280 nm. Protein containing 
fractions at the gel filtration and desalting steps therefore had to be identified by 
SDS-PAGE. 15N and 13C/15N isotopically labelled protein was produced for NMR 
assignment and characterisation. 
90 
 
 
Figure 4.5: SDS-PAGE of washes and elution fractions from the IMAC column stage of the RRM2 
purification. Significant quantities of protein were eluted by the 10 mM imidazole wash, which was 
reduced to 1 mM for the later purifications. The expected mass of the protein, allowing for the 6-His tag, 
was 9.6 kDa. The presence of multiple faint bands above the main RRM2 band suggests impurities bound 
to the protein. 
 
Figure 4.6: SDS-PAGE of elution fractions from the gel filtration stage of the purification, using a Superdex 
GF75 column. A single clean band is now visible, confirming the impurities from the IMAC column stage 
were removed. 
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The overall yields for this protein were lower than for RRM1 at approximately 12 
mg/l from LB growths, and 8 mg/l from M9 minimal media. Due to the lack of 
absorbance at 280 nm protein concentrations when preparing samples were based 
on the mass of the lyophilised protein, as measured on a balance accurate to 0.1 
mg. 
 
4.1.4 NMR Assignment of RRM2 
 
The TROSY technique was not used for NMR data collection on RRM2 since its 
small size (9.6 kDa) results in minimal loss of signal intensity from relaxation, 
and a conventional HSQC has twice the inherent sensitivity. Doubly labelled 
RRM2 was prepared, and 3D NMR data collected for assignment purposes. 
HN(CA)CO, HNCO, CBCANH and CBCA(CO)NH spectra were acquired on a 1 
mM sample of 13C and 15N labelled RRM2. HCCH TOCSY data was also 
acquired for the purpose of side chain assignment.  
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Figure 4.7: This figure shows strips through the three dimensional HNCACB and HNCOCACB data for 
residues 147  ? 154 of the RRM2 construct. Peaks in the HN(CO)CACB spectra are shown in green. Peaks 
ĨƌŽŵƚŚĞ,EƐƉĞĐƚƌĂĂƌĞƐŚŽǁŶŝŶůŝŐŚƚĂŶĚĚĂƌŬďůƵĞ ?EĞŐĂƚŝǀĞƉŚĂƐĞƉĞĂŬƐ ?ĐŽƌƌĞƐƉŽŶĚŝŶŐƚŽɴƐ
 ?ĂŶĚ ɲƐ ŽĨ ŐůǇĐŝŶĞƐ ? ĂƌĞ ŝŶ ĚĂƌŬ ďůƵĞ ? WŽƐŝƚŝǀĞ ƉŚĂƐĞ ƉĞĂŬƐ ? ĐŽƌƌĞƐƉŽŶĚŝŶŐ ƚŽ ƚŚĞ ɲƐ ŽĨ Ăůů ƌĞƐŝĚƵĞƐ
except glycines are shown in light blue. In each strip the peaks are labelled, showing the matching 
chemical shifts between residue i and residue i-1 ?dŚĞďůĂĐŬůŝŶĞƐƐŚŽǁƚŚĞ “ďĂĐŬďŽŶĞǁĂůŬ ?ƚŚƌŽƵŐŚƚŚŝƐ
section of the protein. 
 
Based on the 3D heteronuclear data 98% percent of the backbone amide signals 
were assigned. Assignments were determined for all non-proline residues except 
Ser178. As with RRM1 there are additional signals from the remainder of the 6-
His tag left after the thrombin cleave, which were not assigned. The assignment 
of RRM2 is shown in Figure 4.8. 
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Figure 4.8: Assignment of the 15N TROSY spectrum of RRM2 (residues 108  ? 187 of CELF1). No assignment 
is available for Ser178. Additional peaks from side chain NH2 groups are visible in the upper right region 
of the spectrum, which have not been assigned. 
 
The assignments for most residues in RRM2 of human CELF1 were deposited in 
the BMRB by Jun et al. (Entry 6121)48. A comparison of this data with our 
assignments is shown in Figure 4.9.  
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Figure 4.9: Histogram comparing the chemical shifts in Jun et al. ?Ɛ ĂǀĂŝůĂďůĞ ĂƐƐŝŐŶŵĞŶƚƐ ǁŝƚŚ ŽƵƌ
assignments. Difference is calculated using the same method as for chemical shift perturbations, as 
outlined in section 2.2. Our data is for Xenopus CELF1, while Jun et al. ?Ɛdata is for human CELF1.  
Residues which are not conserved between these homologs are highlighted with black arrows. Gaps 
indicate residues for which assignments are not available in one or both of the datasets (e.g. Val183, 
which is missing from Jun et al. ?ƐĂƐƐŝŐŶŵĞŶƚƐ ? ? 
 
While some significant differences are seen, they correspond to residues which 
differ between the two constructs, and those in close proximity to them. In those 
sections of the protein which are well conserved there is good agreement our 
assignments and those of Jun et al.  
 
4.1.5 Purification of RRM3 
 
The RRM3 construct was produced from the wild type CELF1 plasmid DNA 
using a single step PCR method which deleted the DNA codons for residues 1 - 
384, as outlined in section 3.15.6. This left an N-terminal 6-His tag attached to 
RRM3. A sufficiently long N-terminal extension was present in the construct that 
its involvement in RNA binding subsequently discovered by Tsuda et al. should 
still be possible. Protein expression and purification was carried out using the 
same methods as for RRM1 and RRM2. The RRM3 construct does not contain a 
tryptophan residue, so the 280 nm absorbance is relatively low, but there are 
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tyrosines present in this RRM. Protein containing fractions from the gel filtration 
stage could therefore still be identified by 280 nm absorbance, unlike RRM2. 
 
The expression and purification used the same protocols as for the RRM1 
construct. Analysis by SDS-PAGE, which is shown in Figure 4.10, confirmed that 
RRM3 was expressed intact. 
 
Figure 4.10: SDS-PAGE of samples from the IMAC column stage of the RRM3 purification. In lane 1 are 
reference markers (Novagen). Lane 2 is a diluted sample of the runoff from the IMAC column. Lanes 3 
and 4 show proteins eluted in the two wash steps. Lanes 6  ? 10 show the first five of the 0.75 M 
imidazole elution fractions. RRM3 was found to be relatively pure even at this stage, but was gel filtered 
through a Superdex 75 column to remove any trace impurities. 
 
4.1.6 NMR Assignment of RRM3 
 
A 15N TROSY spectrum was collected, as well as HNCACB, HN(CO)CACB, 
HNCO and HN(CA)CO 3D heteronuclear experiments in order to assignment the 
protein backbone. The assignment for this domain is shown in Figure 4.12. The 
flexible residues at the N-terminus resulted in very weak signals in the NMR 
spectra, hindering assignment of this region. 90% assignment of the backbone of 
the structured domain was achieved. 
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Figure 4.11: This figure shows strips through the three dimensional HNCACB and HNCOCACB data for 
residues 437  ? 444 of the RRM1 construct. Peaks in the HN(CO)CACB spectra are shown in orange and 
ŐƌĞĞŶ ?KƌĂŶŐĞƉĞĂŬƐĐŽƌƌĞƐƉŽŶĚƚŽɲƐŝŶƚŚĞƉƌĞĐĞĚŝŶŐƌĞƐŝĚƵĞ ?ǁŚŝůĞŐƌĞĞŶƉĞĂŬƐĐŽƌƌĞƐƉŽŶĚƚŽɴƐ ?
Peaks from the HNCACB spectra are shown in light and dark blue. Negative phase peaks, corresponding 
ƚŽɴƐĂƌĞŝŶĚĂƌŬďůƵĞ ?WŽƐŝƚŝǀĞƉŚĂƐĞƉĞĂŬƐ ?ĐŽƌƌĞƐƉŽŶĚŝŶŐƚŽƚŚĞɲƐĂƌĞƐŚŽǁŶŝŶůŝŐŚƚďůƵĞ ?/ŶĞĂĐŚ
strip the peaks are labelled, showing the matching chemical shifts between residue i and residue i-1. The 
ďůĂĐŬůŝŶĞƐƐŚŽǁƚŚĞ “ďĂĐŬďŽŶĞǁĂůŬ ?ƚŚƌŽƵŐŚƚŚŝƐƐĞĐƚŝŽŶŽĨƚŚĞƉƌŽƚĞŝŶ ? 
 
Assignments are missing for five residues in the flexible N-terminal extension, 
Gly395 and for residues 481 - 484 at the C-terminus. 
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Figure 4.12: Assignment of the RRM3 1H-15N HSQC spectrum. The numbering scheme refers to the residue 
number in full length CELF1. There are a number of peaks which could not be assigned due to poor signal 
to noise in the 3D spectra, and the limited peak dispersion in some regions of the 1H-15N HSQC. 
 
Chemical shift data was subsequently deposited by Tsuda et al. in the BMRB 
(Entry 11408)49. A histogram showing the differences between these assignments 
and ours is shown in Figure 4.13.  
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Figure 4.13: Histogram comparing the chemical shifts in Tsuda et al. ?Ɛavailable assignments with our 
assignments. Difference is calculated using the same method as for chemical shift perturbations, as 
outlined in section 2.2. The constructs used were not identical, and residues which differ between them 
have been highlighted with black arrows. 
 
A good agreement is seen between our assignments and those of Tsuda et al. with 
the exception of residue 433, which is not conserved, and the terminal residues 
(due to the constructs being of different lengths, and the incorporation of non wild 
type residues at the C-terminus of Tsuda et al.¶VFRQVWUXFW 
 
4.2 Interaction of CELF1 RRMs with Guanine-Rich Elements 
 
With the vast majority of the residues in each RRM assigned it was possible to 
determine by NMR whether any given RNA sequence was binding to an RRM, 
and the areas of the protein involved in the binding interaction. The highest 
affinity RNA substrates reported in the literature were the Guanine Rich Elements 
(GREs), consisting of a repeating UGUU pattern of nucleotides. Three or 
possibly four repeats of this pattern were suggested to be sufficient to bind all 
three RRMs of CELF1 (the EDEN11 and EDEN15 GREs). This seemed to imply 
each RRM could be recognising a UGUU site. The RRM fold has however been 
known to recognise anywhere from 2 ± 8 nucleotides, so potentially a single 
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RRM could be recognising additional nucleotides on either side of the UGUU 
repeat. One of the RRMs recognising more than one UGUU repeat would also be 
a possible explanation for the fourth conserved UGU site in the EDEN15 
consensus sequence reported by Graindorge et al. (2008). High affinity 
interactions have also been reported between CELF1 and UGUG repeats. This 
could imply that the fourth nucleotide is not involved in binding, and the RRMs 
are recognising UGU sites rather than UGUU sites. Alternatively the fourth 
nucleotide could be involved in binding, but the protein is tolerant of either U or 
G at that position. 
 
In order to distinguish between these possibilities the RNA sequences 
UGUUUGU (termed EDEN7) and UGU (EDEN3) were selected for 
investigation. If an RRM is recognising more than one UGUU repeat or a four 
nucleotide UGU(U/G) site it would be expected either to not bind to the short 
UGU substrate, or to show a much smaller binding patch on the surface of the 
protein compared to the EDEN7 substrate. If however an RRM was recognising 
just a three nucleotide UGU site, it should show the same binding patch on the 
protein for both of these RNA substrates. 
 
4.2.1 Interactions of RRM1 with Guanine-Rich Elements 
 
15N labelled RRM1 was titrated with the RNA substrate EDEN7 (UGUUUGU). 
Significant chemical shift perturbations (CSPs) were seen for several residues, 
confirming that RRM1 does bind to the EDEN7 sequence. Most residues were in 
fast exchange, and so their assignments could simply be tracked from point to 
point throughout the titration. In Figure 4.14 are shown overlaid spectra of the 
unbound protein and the protein bound to RNA. Highlighted are the peaks for 
some of the residues which show the greatest perturbation throughout the 
titration. 
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Figure 4.14: Overlaid 15N TROSY spectra for the titration of RRM1 with the RNA substrate EDEN7 
(UGUUUGU) The spectrum of the unbound protein is shown in blue, and the fully bound protein in red. 
Intermediate titration points are shown as a spectrum. Insets are expanded views of some of the most 
affected peaks. Most of the affected residues are in fast exchange, such as Phe19, Gly21, Cys61, Cys62 
and Leu85. There are some residues that are in intermediate exchange such as Gln22, for which the peak 
from the free form is highlighted, but the bound peak is lost due to broadening. There are also residues in 
slow exchange such as Gln93, where both the peak is visible in both the free and fully bound forms, but 
not the intervening titration points. This prevents the peak being tracked through the titration, which can 
present problems in determining the assignment of the bound form. 
 
While most residues are in fast exchange there are a few, such as Gln22 which are 
in intermediate exchange, and so broaden out and are lost in the early stages of 
the titration. Additional peaks also grow in during the later stages of the titration 
from the bound forms of residues in slow exchange, but the assignment of these 
new peaks is in some cases ambiguous due to overlap. It can be stated these 
residues are definitely involved in binding the RNA, but the chemical shift 
perturbation cannot be quantified unless the corresponding peak from the bound 
form can be located. In cases of slow exchange where bound assignments are 
unclear a minimum CSP can be stated based on the closest unassigned peak in the 
bound spectrum. This is not possible in some intermediate exchange situations as 
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the peak from the bound form may be too broad to observe. Residues in more 
dynamic regions of the protein are more likely to fall into this category as they 
tended to give weak, broad peaks even in the spectrum of the unbound protein. 
 
The nitrogen chemical shift has a greater dispersion than the proton chemical 
shift. When combining the changes in the proton and nitrogen chemical shifts into 
a single chemical shift perturbation value (CSP), they must therefore be weighted 
so that changes in the proton dimension are not obscured. CSP values were 
calculated throughout using the formula below. 
 ൌ ൭ቆ ?ɁH? ? ? ቇ ൅   ?ɁH?൱H?ǤH? 
:KHUHǻį1LVWKHGLIIHUHQFHLQFKHPLFDOVKLIWLQWKHQLWURJHQGLPHQVLRQEHWZHHQ
the saturation point and the zero point of the titration and ǻį+ LV WKH
corresponding difference in the proton dimension. The CSP values for each 
residue can then be plotted against residue number to show those regions of the 
protein that are involved in binding the RNA. 
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Figure 4.15: CSP values for each residue of RRM1 on titration with EDEN7. Residues which are in slow 
exchange, for which the values are therefore minimum CSPs rather than exact values, are highlighted in 
red. Gaps are due to prolines, unassigned residues and peaks for which CSPs could not be accurately 
calculated due to signal overlap. 
 
When RRM1 binds to the EDEN7 RNA substrate, the most perturbed residues are 
concentrated in the 18 - 23, 59 - 63 and 93 - 101 regions. While these regions are 
far apart in the protein chain they actually form adjacent VWUDQGVRIWKHȕ-sheet in 
the folded protein, and so represent a single coherent RNA binding patch. This 
binding patch can be more easily visualised by mapping the CSP values for each 
residue onto the structure of the protein. In this case the CSPs were mapped onto 
the relevant part of the CELF1 RRM1 and RRM2 structure produced by Jun et al, 
which is available in the PDB (ID: 2DHS). This map of the binding surface is 
shown in Figure 4.16. 
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Figure 4.16: CSP maps on the structure of RRM1, produced by truncation of Jun et al. ?Ɛ EDZ ƐŽůƵƚŝŽŶ
structure of the first 187 residues of CELF1 from the PDB. RRM2 has been removed by deletion of 
residues 102  ? 187. The CSP values have been mapped onto the structure in red: the brighter the red 
colour, the greater the magnitude of the CSP. Residues which are definitely affected but do not have 
quantified CSP values due to intermediate or slow exchange preventing the peaks from the bound form 
being located are shown in yellow. Residues for which no data can be obtained (i.e. prolines and 
unassigned residues) are shown in black. This image was produced using the molecular graphics package 
Molmol, as were all subsequent CSP maps. 
 
In producing this map, residues with CSP values of less than 0.1 are considered to 
undergo no significant change on binding, and are shown in grey. Residues for 
which no data is available, specifically the prolines and the unassigned residues 
are shown in black. CSP values are displayed as a colour gradient, with bright red 
indicating the most affected residues, and dark red indicating lower CSPs. 
Residues without quantifiable CSPs due to slow exchange preventing location of 
the peak for the bound form are shown in yellow. As slow exchange is associated 
with a large difference in chemical shifts between the free and bound forms these 
residues are presumably the most disrupted on RNA binding, and would show the 
largest CSPs if exact values could be calculated.  
 
From this CSP map, it can be seen that the RNA binding site is across the face of 
WKH ȕ-sheet on the opposite side of the protein WR WKH Į-helices. There are also 
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VRPHVLJQLILFDQWO\SHUWXUEHGUHVLGXHVLQWKHORRSVDWWKHORZHUHGJHRIWKHȕVKHHW
as shown in Figure 4.16, such as Gln22. The most affected residues, such as 
Cys61 and Gly21 OLH LQ WKH FODVVLF 513 UHJLRQV LQ ȕ-sheets 1 and 3. The 
conserved aromatic residues in the RNP regions (Phe19 and Phe63) are also 
affected. This is consistent with them forming stacking interactions with the RNA 
bases, as is commonly seen for RRMs. Some residues near the C-terminus (e.g. 
Asp98) appear to be involved in RNA binding despite being beyond the folded 
region of RRM1. It was not clear whether this was an artefact caused by the 
position at which the protein was truncated, or if some residues beyond the C-
terminus of the structured domain are in fact involved in binding. 
 
It was noted that this titration seemed to reach saturation rather earlier than would 
be expected for simple 1:1 binding, based on the point at which the 15N TROSY 
spectrum ceased to vary significantly between titration points. Very few changes 
in chemical shift were seen after a 0.6: 1 ratio of RNA to protein was reached. 
Examples of the titration curves for some of the most affected residues, such as 
Gly21 and Cys61 are shown in Figure 4.17.  
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Figure 4.17: Chemical shift perturbations at each titration point for a selection of the most affected 
residues for which CSPs can be calculated throughout the titration. The protein concentration was 500 
µM. All reach an apparent plateau before an RNA concentration of 500 µM is reached. 
 
Since the protein concentration in this experiment was 500 µM, in a 1:1 model 
the titration would not be expected to reach saturation before this concentration of 
RNA was reached. A possible explanation for this was that the complex being 
formed did not have a simple 1:1 stoichiometry. If RRM1 is recognising a UGU 
site then the EDEN7 RNA used (UGUUUGU) potentially had two identical 
binding sites. This would permit a 2:1 protein to RNA complex to form, resulting 
in all of the protein being in the bound form after a 0.5:1 ratio of RNA to protein 
was reached.  
 
The titration was repeated with the EDEN3 (UGU) RNA substrate. The protein 
concentration for this titration, and all further titrations with RRM1, was reduced 
to 400 µM.  
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Figure 4.18: Above is a histogram of chemical shift perturbations for the titration of RRM1 with UGU. The 
assignment for the bound peak of Gln22 was unclear, so a minimum CSP estimate to the closest 
unassigned peak has been included for this residue. Below is the CSP map for the titration of RRM1 with 
EDEN3 (the trinucleotide UGU). The protein concentration was 400 µM, and the titration was conducted 
at 298 K. 
 
The UGU RNA substrate was still bound by RRM1, with almost all residues in 
fast exchange in the NMR titration. Only Gln22 still appeared to be in slow 
exchange, and so only has a minimum CSP value. The same residues in the RNP 
regions are disrupted, including the aromatic residues Phe19 and Phe63, which 
can therefore be assumed to be still stacking with two of the three RNA bases. 
The only residues which appeared unaffected in the UGU titration, but showed 
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significant CSPs in the EDEN7 case are Asp98, Glu100 and some of the weakly 
affected residues such as Ile45 LQȕ 
 
Significant CSPs show that RRM1 is still binding to this shorter RNA substrate, 
and the set of affected residues appears to be very similar. The UGU substrate 
was therefore not only binding to RRM1, but occupying the whole of the binding 
site acroVVWKHȕ-sheet as effectively as the longer EDEN7 substrate. From this it 
was concluded that UGU sites are the key component of the EDEN motif, and are 
sufficient for binding of RRM1. It also supported the possibility of two RRM1 
protein molecules binding to EDEN7 (UGUUUGU) with one protein at each 
UGU site.  
 
The titration curves for some of the most affected residues suggest titration had 
not quite reached saturation point at a 1:1 ratio of RNA to protein (see Figure 
4.19). Again this is consistent with the UGU substrate forming a 1:1 complex 
while EDEN7 forms a 2:1 complex with RRM1. 
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Figure 4.19: Titration curves for a selection of residues in the titration of the RNA sequence UGU into 400 
µM RRM1. The curves for Gly21 and Cys61 definitely do not reach a maximum until an RNA 
concentration of 400µM. This is less clear for the other residues shown. 
 
4.2.2 Removal of one UGU site from the EDEN7 RNA Substrate 
 
To confirm the 2:1 complex hypothesis, and hence that RRM1 was recognising 
just a UGU site, a version of the EDEN7 substrate with one of the two UGU sites 
removed was designed (UGUUUAU). UAUU repeats had been previously 
reported in the literature to show at most a low affinity interaction with CELF1, 
so a switch from a UGU to a UAU site would be expected to eliminate, or at least 
greatly reduce binding to the second site.  
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Figure 4.20: At the top is shown a plot of the CSP for each residue on binding to UGUUUAU. Residues 
in slow exchange with minimum CSP estimates are highlighted in red. Below is a CSP map of RRM1 
on titration with UGUUUAU. Exact CSP values are shown in red, with brightness of colour indicating 
the magnitude. Affected residues with only minimum CSP estimates are shown in yellow. A similar 
binding patch is seen as in previous experiments. The protein concentration throughout the titration 
was 400 µM. 
 
The same set of affected residues is seen as for the EDEN7 substrate, consistent 
with RRM1 recognising a simple UGU site in each titration. Gly21, Gln22, 
Val23, Cys61 and Gln93 are all highly affected. Moderate CSPs are seen for 
Asp98 and Ile45, again matching the EDEN7 titration. The titration curves, 
examples of which are shown in Figure 4.21, do seem to reach saturation point at 
a slightly higher RNA to protein ratio than in the EDEN7 case, but it was 
ambiguous whether the stoichiometry of the complex had changed. This RNA 
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substrate was later clarified by mass spectrometry to be primarily forming a 1:1 
complex, for which the data is shown in section 4.5.1.  
 
 
Figure 4.21: Binding curve for the titration of UGUUUAU into 400 µM 15N-labelled RRM1. All curves show 
an increasing CSP up to an RNA: protein ratio of 0.85:1. The curves then appear to plateau, with the 
possible exception of Cys61. 
 
4.2.3 Interactions of RRM2 with Guanine-Rich Elements 
 
There are significant differences in the protein sequences of the three RRMs of 
CELF1, so it could not be assumed that they were all recognising the same site. 
Most of residues with large CSPs from the RRM1 titrations are conserved in 
RRM2, such as WKHWZRSKHQ\ODODQLQHUHVLGXHVLQWKHȕ-sheet, and one of the two 
F\VWHLQH UHVLGXHV LQ ȕ There are some exceptions such as Gln22, which is 
replaced with methionine (Met114) in RRM2 and Gln93, which is replaced with 
valine (Val182). Our initial aim with RRM2 to was to determine whether it was 
recognising a UGU site in the same manner as RRM1, or if it showed a 
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preference for a longer RNA sequence. The same titrations with the RNA 
substrates EDEN7 and UGU were carried out to determine this. 
 
Figure 4.22: Above is shown a histogram of the CSPs for the titration of RRM2 with EDEN7. Values which 
are only minimum estimates, not exact values are highlighted in red. Also shown is the structure of 
RRM2, produced by truncation of Jun et al ? ?ƐƐŽůƵƚŝŽŶƐƚƌƵĐƚƵƌĞŽĨƚ ? ? ? ? with CSP values from the titration 
with EDEN7 mapped onto it. CSP values are shown in red with brightness of colour indicating magnitude 
of the effect. Residues with CSP values of <0.1 shown in grey. Residues for which only minimum CSPs are 
available due to loss of the peaks in slow exchange are shown in yellow. The overall protein 
concentration was 500 µM. 
 
As was the case for RRM1, the classic RNP regions of the RRM are the most 
affected, as well as sRPHRIWKHORRSVDWWKHORZHUHGJHRIWKHȕVKHHWLQFigure 
4.22. The regions 112 - 120, 148 ± 152 and 182 ± 187 contain all those residues 
with CSPs of greater than 0.1. The most perturbed residue in RRM2 is Cys150, 
which is a conserved residue between RRM1 and 2 corresponding to Cys61 in 
RRM1. Cys61 was the most perturbed residue two of the three RRM1 titrations, 
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and the similar pattern of CSPs suggests the two RRMs are binding to the RNA in 
a similar manner. The non-conserved residues Met114 and Val182 are strongly 
affected, and so may be fulfilling the same role as Gln22 and Gln93 in RRM1. 
The C-terminal residue Asp187 (corresponding to Asp98 in RRM1) shows a 
moderate CSP, with a larger CSP seen for the preceding residue Ala186. The 
RRM2 construct was based on the existing t187 construct, resulting in a 
truncation point only two residues from the folded domain. Since this CSP map 
suggested some possible C-terminal involvement in RNA binding, the results 
were later checked with an extended construct (t242) to confirm no critical 
residues had been omitted at the C-terminus (see section 5.6.2). 
 
 
Figure 4.23: Binding curves for the RRM2/EDEN7 titration. Unlike the RRM1/EDEN7 titration this curve 
has clearly not reached a plateau by a 0.6:1 ratio of RNA to protein. The protein concentration was 500 
µM. 
 
There is one clear difference between the titration of RRM2 with the substrate 
UGUUUGU and the equivalent RRM1 titration. This titration had definitely not 
reached saturation point significantly before a 1:1 ratio of RNA to protein was 
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reached, as can be seen from the binding curves in Figure 4.23. This suggests that 
it is not possible to bind two RRM2 proteins simultaneously onto a single EDEN7 
RNA molecule. The binding patch seen on the surface of the protein is not 
sufficiently large for RRM2 to be binding across both UGU sites in the EDEN7 
substrate. Recognition of a fourth nucleotide could however be enough to prevent 
a second protein molecule from binding to the unoccupied UGU site. The 
implication of this was that RRM2 required a UGU(U/G) site rather than being 
able to tolerate a UGU site like RRM1. 
 
This also has implications for the overall EDEN motif recognised by CELF1. In 
sequences such as the EDEN11 GRE there is only a single U between each of the 
UGU sites, just as in EDEN7. If RRM2 is obstructing binding to the adjacent 
UGU site to the one it is bound to, then it seemed unlikely it would be possible to 
bind both RRM1 and RRM2 onto the adjacent UGU(U/G) sites of the EDEN11 
GRE. Since RRM2 did not appear to be forming a 2:1 complex with the EDEN7 
substrate anyway, the titration with the UGUUUAU sequence was not carried 
out. The data for the titration of RRM2 with the shorter UGU substrate is shown 
in Figure 4.24. 
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Figure 4.24: CSP data for the titration of 400 µM RRM2 with the RNA substrate UGU, acquired using a 
Bruker Avance III 600 MHz spectrometer. CSPs of greater than 0.1 ppm are regarded as significant and 
are shown in red, with brightness of colour indicating the magnitude. Residues which only have minimum 
CSP estimates are shown in yellow on the CSP map, and highlighted in red in the histogram. 
 
Only a few residues in RRM2 show significant CSPs on titration with the shorter 
UGU substrate. Cys150 is the most affected residue again, with Gly113, Ala151, 
Val182, Ala186 and Asp187 also above the 0.1 ppm threshold. Met114 is again 
lost on titration, but the bound peak could not be located. Neither of the 
conserved aromatic residues Phe111 and Phe152 are significantly perturbed. 
Overall the binding patch is much smaller than that seen in the UGUUUGU 
titration. 
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4.2.4 RRM3 
 
The original intention was to carry out the EDEN7 and UGU RNA titrations on 
all three RRMs so they could be compared, and an isolated RRM3 construct was 
prepared for this purpose. However before the RNA titrations could be conducted 
Tsuda et al. (2009) published NMR and ITC studies on an isolated RRM3 
construct both unbound and in complex with short UG rich RNA sequences. They 
determined that RRM3 was binding to the sequence UGUGUG with the highest 
affinity, with the core motif being UGU(U/G). The reported binding surface was 
somewhat larger than that seen for RRM1 and RRM2, and involved an N-
terminal extension of the protein. These results implied RRM3 was recognising a 
longer sequence than the UGU site required for RRM1 binding, and possibly 
more than the UGU(U/G) site of RRM2. It would therefore not be expected to 
form a 2:1 complex with EDEN7. The binding affinity for these sites was 
significantly higher than seen for the isolated RRM1 and RRM2 constructs, with 
a reported Kd of 1.9 µM.  
 
Tsuda et al¶V VWXG\ RI 550 DOVR LQYHVWLJDWHG ELQGLQJ other possible RNA 
substrates such as CUG repeat sequences, and adenosine rich elements (AREs) by 
NMR, which showed evidence of low affinity binding. ITC showed the Kd values 
for AREs to be around three orders of magnitude lower than the corresponding 
GREs. They were unable to detect any binding to the CUGCUG substrate by ITC. 
 
4.2.5 Summary of NMR Titrations with GRE Sequences 
 
It can be concluded that RRM1 is capable of binding to just the three nucleotides 
of a UGU site. Multiple copies of RRM1 can bind to UGU sites separated by only 
a single nucleotide, such as those in the UGUU repeating GRE RNA sequence. 
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RRM2 in contrast cannot bind to adjacent UGU sites separated by only a single 
nucleotide, consistent with it requiring a longer sequence such as a UGU(U/G) 
site. While some CSPs are seen on binding of RRM2 to the UGU substrate, their 
magnitude is greatly reduced compared to the corresponding EDEN7 titration, 
again suggesting a fourth nucleotide is required. Tsuda et al¶V GDWD RQ 550
indicates it is recognising at least four nucleotides in a UGU(U/G) site, and 
possibly as many as six (UGUGUG). 
 
4.3 Interactions of CELF1 RRMs with CUG Repeat RNA 
Substrates 
 
CELF1 was originally identified as an RNA binding protein by its ability to bind 
to a (CUG)8 RNA probe. The higher affinity GRE sequences are more likely to be 
representative of the EDEN motif CELF1 recognises in its normal function, but 
the possibility of interactions with CUG repeat sequences is still of interest. In 
DM1 cells extended CUG repeat RNAs accumulate into foci, in which CELF1 is 
not found. It has however been proposed that a soluble fraction of these CUG 
repeat RNAs must also exist and may be interacting with CELF1, contributing to 
the DM1 phenotype. NMR titrations were therefore carried out to determine 
whether each RRM would bind to CUG repeat RNA. Also of interest was 
whether any binding patch found would overlap with that of the GRE substrates, 
resulting in competition between the two RNA substrates.  
 
While these RNAs are usually described as CUG repeats, that does not 
necessarily mean that CELF1 is recognising a CUG site. The closest match to a 
UGU site in a CUG repeating RNA is the sequence UGC. When binding to a 
UGC site the first U and the G could then occupy exactly the same positions as 
when binding a UGU site. The second U would be exchanged for a C, which 
conceivably could occupy a similar part of the binding surface as they are both 
pyrimidines. If however CUG repeat sequences have a different binding patch on 
the protein, the number of nucleotides recognised might be completely different. 
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The RNA sequence CUGCUG was selected for these titrations as it contains a 
single UGC site. 
 
4.3.1 RRM1 
 
 
Figure 4.25: CSP map of RRM1 when titrated with CUGCUG. The protein concentration was 400 µM. 
Over the course of the titration the RNA concentration was raised to 450 µM in 50 µM increments.  
RRM1 showed significant CSPs on titration with CUGCUG, confirming that it 
can bind to this type of RNA substrate. The titration reached an endpoint at 
around a 1:1 ratio of RNA to protein, as expected if a 1:1 complex is forming, and 
was entirely in fast exchange. It was immediately apparent that approximately the 
same regions of the protein were affected as in the titrations with EDEN7 and 
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UGU. Both of the aromatic residues Phe19 and Phe63 still show substantial 
CSPs, suggesting these stacking interactions are conserved between these RNA 
substrates. There are a few additional perturbed UHVLGXHVLQWKHȕDQGȕVWUDQGV
such as Lys95, Ile45 and Asn46 compared to the EDEN7 substrate, suggesting a 
slightly extended RNA binding surface. 
 
Assuming RRM1 is recognising a UGC site, one potential explanation for this 
was that the RNA substrates selected were not the same length. In the EDEN7 
RNA the UGU sites are at the ends of the sequence, while in CUGCUG the UGC 
site is in the centre, with additional nucleotides at both ends. The EDEN7 titration 
was repeated with an extended RNA substrate (EDEN9: UUGUUUGUU), which 
had an equivalent number of nucleotides on either side of the first binding site, 
but this did not show any similar increase in the CSPs for residues such as Lys95. 
A few additional residues from the bound form (in particular Val20 and Gln22) 
could however be located in the bound 1H-15N HSQC. 
 
4.3.2 Comparison of RRM1 Interaction with UGU and UGC Sites 
 
In Figure 4.27 is shown a direct comparison between the CSPs for the CUGCUG 
and EDEN9 titrations. Residues with larger CSPs for CUGCUG are shown in red. 
Residues with larger CSPs for EDEN9 are shown in blue. Brightness of colour 
indicates the magnitude of the difference. Differences in the CSP values of less 
than 0.1 ppm are shown in grey, and treated as background noise. 
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Figure 4.26: Direct comparison of chemical shift perturbations for titration of RRM1 with EDEN9 and with 
CUGCUG. For each residue the CSP for the EDEN9 titration is on the left in blue and the CSP for the 
CUGCUG titration is on the right in red. Some of the residues showing substantial differences between 
the two have been highlighted. 
 
Figure 4.27: Map of the difference in CSPs in RRM1 between EDEN9 and CUGCUG substrates. Residues in 
red are more perturbed on addition of CUGCUG than EDEN9. Residues in blue are more perturbed by 
EDEN9 than CUGCUG. The brighter the colour, the greater the magnitude of the CSP difference. Residues 
in grey have less than a 0.1 difference in CSPs between the two cases. 
 
The absolute magnitudes of the CSPs were in general somewhat larger for the 
EDEN9 substrate (with one clear exception for Lys95). A very similar pattern of 
affected residues is seen for the two RNAs, confirming they are occupying the 
same binding site on the protein, and so would be in competition. In both cases 
the most affected peaks are concentrated in the 19 - 23, 59 - 63 and 98 - 101 
regions of the protein. The main RNP1 and RNP2 regions show significantly 
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larger CSPs when bound to the UGU site, as expected based on the overall 
preferences known for CELF1. The only residue with a dramatically larger CSP 
on binding to CUGCUG is Lys95 DWWKHXSSHUHQGRIWKHȕVWUDQG  
 
Teplova et al. subsequently published a crystal structure of RRM1 in complex 
with a 13 nucleotide RNA substrate (UGUGUGUUGUGUG). Comparison of the 
bound conformation of this RNA with a repeating CUG sequence can help to 
rationalise some of the differences seen in the CSPs. 
 
 
Figure 4.28: Structure of CELF1 RRM1 in complex with a UG rich RNA substrate, determined by Teplova et 
al. (2010) using x-ray crystallography. The position of Lys95 has been highlighted. 
 
Based on this structure the increased disruption to Lys95 on binding to a UGC 
site can be rationalised, as this change would result in the carbonyl group on U3 
closest to this residue being replaced with an NH2 group. 
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4.3.3 Interactions of RRM2 with CUG Repeat RNAs 
 
The comparison between the GRE and CUG repeat sequences was also conducted 
for RRM2. The protein concentration for these titrations was reduced to 400 µM. 
 
Figure 4.29: CSP data for the RRM2/CUGCUG titration. The CSP map shows all values greater than 0.05 in 
red as a colour gradient. The titration curve is consistent with a 1:1 complex. 
 
While the usual RNP regions are still perturbed, the CSP values are in general 
reduced compared to those in the RRM2/EDEN7 titration. The RNP1 region of 
the protein in particular shows significantly reduced CSPs compared to the 
corresponding region in the RRM1/CUGCUG titration. Cys150 is no longer one 
of the most affected residues, which are now to be found at the C-terminus, 
specifically Ala186 and Asp187. Val182 also shows a limited perturbation of 0.1 
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ppm compared to 0.4 ppm in the titration with EDEN7. Met114 is not lost on 
titration as it was in the earlier titrations with substrates containing UGU sites. 
 
While the CUGCUG substrate is still showing some limited interaction, RRM2 
appeared to have more of a preference for UGU(U) sites over UGC(U) sites than 
was seen for RRM1. This difference cannot be accounted for by RRM2 
recognising a fourth nucleotide, as in both titrations the base at position 4 would 
be U. RRM2 must therefore have a lower tolerance for the U to C substitution at 
position 3. 
 
A side by side comparison for all residues is shown in Figure 4.30. Few residues 
in RRM2 show CSPs above the 0.1 ppm significance threshold when titrated with 
CUGCUG, and none are above 0.2 ppm, compared with Val115, Cys150, Ala151, 
Val182 and Ala186 in the titration with EDEN7. Unlike RRM1, there are no 
obvious examples of residues with much larger CSPs in the CUGCUG titration. 
Lys95 is a conserved residue between RRM1 and RRM2, but the corresponding 
Lys184 in RRM2 shows a CSP of less than 0.1 for both RNA substrates.  
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Figure 4.30: A comparison of the CSPs for each residue of RRM2 on titration with the RNA substrates 
EDEN7 (UGUUUGU) in blue and CUGCUG in red. Some of the residues showing significant differences 
have been highlighted. 
 
 
Figure 4.31: Map of the difference in CSPs between the EDEN7 and CUGCUG titrations onto the surface of 
RRM2. Residues in blue show a greater CSP on binding to EDEN7, residues in red show a greater CSP on 
binding to CUGCUG, with brightness of colour indicating the magnitude of the difference. Differences of 
less than 0.1 ppm are regarded as no significant, and the residues are shown in grey. 
From this it can be concluded that UGC(U) sites are quite unfavourable for 
binding of RRM2. There is still some interaction, but the CSPs are greatly 
reduced overall.  
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4.3.4 Summary of Interactions between the CELF1 domains and CUG 
Repeat RNAs 
 
For all three RRMs any interaction with CUG repeat RNA substrates appears to 
occur via the same RNA binding surface as the interaction with GRE sequences. 
These RNAs will therefore be in direct competition for binding, and if CELF1 
does bind to the extended CUG repeat RNAs in DM1 cells it will interfere with 
the normal functions of the protein. It seems probable the RRMs are recognising a 
UGC(U) site in the sequence, as the closest match to the high affinity UGU(U) 
sites. There are noticeable differences between the three RRMs. RRM1 still 
shows quite large CSPs on binding to a UGC site, while RRM2 shows few 
residues above the 0.1 threshold. This suggests RRM1 is relatively tolerant of the 
U to C switch, while RRM2 is only interacting weakly with these sites. RRM3 
was reported by Tsuda et al to have a much lower affinity for CUG repeats, 
suggesting most of the interaction with these substrates reported for CELF1 has 
been occurring via RRM1. 
 
4.4 Interaction of CELF1 RRMs with Adenosine-Rich Elements 
 
4.4.1 RRM1 
 
The third category of RNA substrates reported to show at least some interaction 
with CELF1 was the AREs, particularly those containing UAU sites. The ARE 
equivalent of EDEN7 (UAUUUAU) was investigated. 
125 
 
 
Figure 4.32: CSP values for a titration of 15N RRM1 with ARE7. The protein concentration was 400 µM.  
No residues showed CSP values above the 0.1 threshold. There is possibly some 
very slight disruption to residues such as Gly60 and Val20, but the low CSP 
values suggest this is a very weak non-specific interaction with the RNA. This 
experiment confirmed that this ARE7 sequence is not bound by RRM1. This also 
confirmed that ARE sequences are suitable for use as controls for this domain. 
The G to A substitution in UGUUUAU should therefore have eliminated the 
second binding site in the earlier titration. 
 
4.4.2 RRM2 
 
Since RRM2 was suspected to be recognising a longer section of RNA from the 
GRE titrations, it was decided to use an extended ARE sequence; ARE15 
(UAUUUAUUUAUUUAU) to ensure there were sufficient nucleotides on either 
side of at least one UAU site. 
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Figure 4.33: CSP values for a titration of 15N RRM2with ARE15. The protein concentration was 400 µM. 
Red stars indicate peaks which disappear on titration, but no plausible peak corresponding to the bound 
form appears. These residues are therefore in intermediate exchange, and since none of the visible peaks 
correspond to the bound form it is not possible to calculate either an exact CSP, or estimate a minimum 
value for the CSP. 
 
While the CSP values are substantially lower than for the titration with the 
EDEN7 sequence, in particular for residues such as Cys150 and Val182, there 
does still seem to be some weak/non-specific interaction between the RNA and 
the RNP1 and 2 regions of the protein. The overall intensities are significantly 
higher than those seen for the CUGCUG titration. Residues 186 and 187 are again 
the most affected, though these may have a tendency to be disproportionately 
perturbed as they form the flexible C-terminus. Substantially larger CSP values 
were seen in this titration than for the RRM1/ARE7 combination, where no 
residue showed a CSP of greater than 0.1. From this data it appears that RRM2 
may have a greater tolerance for UAU(U) sites than RRM1. 
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4.5 Determination of Complex Stoichiometry by ESI Mass 
Spectrometry  
 
The NMR data was supplemented using ESI mass spectrometry. This technique is 
useful for confirming the stoichiometry of complexes based on their overall mass. 
The NMR titration curves were ambiguous as to whether the EDEN7 and 
UGUUUAU sequences could form 2:1 complexes with RRM1, so this point was 
clarified by ESI-MS. 
 
4.5.1 RRM1 
All mass spectrometry samples were produced from previously lyophilised and 
desalted protein by carrying out a second desalting step into 50 mM ammonium 
acetate. This was necessary to reduce the salt content to levels tolerated by ESI-
MS. Without this second desalt step only very broad peaks could be observed due 
to a wide range of salt adducts of each species forming. All samples were run as 
native rather than denatured protein so the interactions with RNA could be 
investigated. Data was collected in both positive and negative ion mode since the 
negatively charged phosphate backbone of the RNA could potentially result in an 
overall negative charge on some complexes. 
 
Figure 4.34: ESI mass spectrum of RRM1 only (sample concentration 10 µM). One major species with 
a mass of 12174 Da seen. There are signs of a small population of a dimer, based on small peaks with 
apparent half-integer charge states at 5.5+ and 4.5+.  While there is one report in the literature of 
Xenopus CELF1 forming a dimer, this was also stated only to occur in constructs containing RRM1, 
RRM2 and at least part of the RRM2 ± RRM3 linker. 
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RRM1 has a theoretical mass of 12182 Da, allowing for the additional N-terminal 
residues left after thrombin cleavage of the histidine tag. Mass spectrometry 
showed one major species with a mass of 12174 Da. There were some 
intermediate peaks suggesting a small population of an RRM1 dimer may be 
present (theoretical mass 24364 Da). No evidence of dimerisation of RRM1 was 
observed by NMR or ITC, so this may be an artefact of the protein being in the 
gas phase. 
 
To study the bound complexes RNA was added from a concentrated 5 mM stock 
dissolved in RNase free water to the sample of unbound RRM1 to a concentration 
of 2 µM. On addition of the EDEN9 RNA substrate (UUGUUUGUU), the 
spectrum shown in Figure 4.35 was observed. 
 
Figure 4.35: ESI mass spectrum of a mixture of RRM1 and EDEN9 (UUGUUUGUU), with RRM1 in 
excess. The protein concentration is 10 µM, and the RNA concentration is 2 µM. Two species seen, 
with masses of 12174 Da and 27118 Da. Species A is the unbound protein. Species B is a 2:1 complex of 
the protein and the RNA. No unbound RNA or 1:1 complex could be observed, but given the protein is 
in excess it would be expected that each RNA molecule would bind the largest number of proteins 
possible.  
 
Two species were observed, one with a mass of 12174 Da and a second with a 
mass of 27118 Da.  The first species is unbound protein (which is still in 
considerable excess in this experiment). The second species has a mass which is 
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consistent with a 2:1 protein - RNA complex (theoretical mass 27136 Da). No 1:1 
complex is observed and also no unbound RNA. Since RRM1 is in excess, even 
allowing for the two possible binding sites, it is not surprising that the RNA 
would be saturated to form the 2:1 complex. ITC experiments with RRM1 
binding to a UGU(U) site conducted by our group and Teplova et al. determined a 
Kd of 30 ± 60 µM for this binding event. Under these conditions it would be 
expected that approximately 10% of the protein would be in the form of the 
complex, assuming that the binding of one RRM1 protein to EDEN9 does not 
interfere with the binding of the other. This experiment confirms that RRM1 can 
form a 2:1 complex with RNA substrates such as EDEN7. The experiment was 
then repeated with the EDEN7 knock out sequence UGUUUAU. It was expected 
that this would have only one possible binding site for RRM1, and so no 2:1 
complex would be observed. The results are shown in Figure 4.36. 
 
 
Figure 4.36: ESI mass spectrum of RRM1 + UGUUUAU. The protein concentration is 10 µM and the 
RNA concentration is 2 µM. Two species, with masses of 12177 Da and 14259 Da were seen. One 
significant additional peak with an m/z of 2206 is present, but other charge states from this species 
could not be located. 
 
RRM1 was again in a twofold excess, and the remaining unbound protein is 
visible as a species with an apparent mass of 12177 Da. A 1:1 complex of mass 
14259 Da (theoretical mass 14340 Da) is definitely present with peaks from 
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charge states +5 to +8.  A 2:1 complex would have theoretical mass of 26507 Da. 
One peak with an m/z of 2206 was observed and could not be accounted for by 
the other species, which would be consistent with the +12 charge state of a 2:1 
complex, but other charge states of this species could not be located. The 
relatively large error margins on the mass of the complexes are believed to be due 
to sodium adducts of the RNA. While there may be a small population of the 2:1 
complex present, the majority of the RNA formed a 1:1 complex, which was 
completely absent for the EDEN9 substrate. This is despite the presence of excess 
protein, which should encourage binding multiple proteins to each RNA molecule 
if possible. The switch from a UGU to a UAU site may not have totally 
eliminated the 2:1 complex, but has definitely made it much less favourable than 
the 1:1 complex. 
 
4.5.2 RRM2 
Native ESI mass spectrometry of RRM2 was also carried out, the results of which 
are shown below.  
 
Figure 4.37: ESI mass spectrum of RRM2 only. Protein concentration estimated at 2 µM based on 
mass of lyophilised protein used to produce a concentrated stock which was subsequently diluted. The 
lack of tryptophan and tyrosine residues in this construct results in a negligible absorbance at 280 nm 
preventing this from being confirmed by nanodrop, unlike the other constructs. One species was seen 
with a mass of 9607 Da. 
 
RRM2 has a theoretical mass of 9613 Da (including the remaining N-terminal 
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residues GSHMASM after the removal of the 6-His-tag). A mass of 9607 Da was 
observed by ESI-MS, which is the unbound RRM2. Attempts were made to 
observe the complexes of RRM2 with EDEN9 and CUGCUG in order to confirm 
the stoichiometries, but these were not successful.  
 
 
Figure 4.38: ESI mass spectrum of a mixture of 2 µM RRM2 and 1 µM CUGCUG. Two species were 
seen, of masses 1850 Da and 9607 Da. 
 
Addition of the CUGCUG RNA to a concentration of 1 µM simply results in a 
new series of peaks from the unbound RNA appearing (theoretical mass 1851 
Da). The same results were seen for addition of 1 µM EDEN9. We conducted ITC 
experiments on this system, and similar experiments were also published in 2010 
by Teplova et al. Both sets of experiments showed the Kd for RRM2 binding to a 
UGU(U) site to be ~60 µM. Given this, only a small fraction of the protein 
(~1.5%) would be expected to be in the form of the complex, which may be 
insufficient to observe it. The exact Kd for binding of RRM2 to a CUGCUG 
sequence was not determined, but by NMR this interaction appeared to be of 
lower affinity than RRM2 with UGU(U). The Kd is therefore presumably larger 
than 60 µM, and the proportion of complex correspondingly even smaller, hence 
our inability to observe it in the mass spectrum. 
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4.6 Conclusions 
 
RRM1 has been shown to be capable of binding to a three nucleotide site with the 
sequence UG(U/C). It can therefore bind to both UGU rich sequences such as the 
GRE and to single stranded CUG repeat RNA. Both RNA substrates have been 
confirmed by NMR CSP maps to bind to the same binding surface of the protein. 
The affinity for the UGU site appears to be higher than for UGC, but the 
difference is not as distinct as has been reported for RRM3 or for CELF1 
constructs containing more than one RRM. This suggests RRM1 binds relatively 
promiscuously to RNA sequences, with the overall preference for U/G rich 
sequences being provided by at least one of the other RRMs of CELF1. 
 
The EDEN7 sequence can accommodate two RRM1 proteins, but only one 
RRM2 protein, which suggests RRM2 requires a slightly longer RNA sequence 
for binding, such as UGU(U). The RRM2 titration with the shorter UGU 
substrate showed a greatly reduced binding patch compared to the UGUUUGU 
titration. The difference was not as pronounced in the RRM1 titration, again 
consistent with a fourth nucleotide being of greater importance for RRM2 binding 
than RRM1. Given the reported high affinity interactions with long UG repeat 
sequences RRM2 may tolerate some variation of the nucleotide at position 4 (i.e. 
a UGU(U/G) site). RRM2 appears to have a greater preference for UGU(U) sites 
over UGC(U) sites than was seen for RRM1. RRM2 did however show 
significant CSPs when titrated with UAU sequences (AREs) unlike RRM1. In 
combination the preferences of these two RRMs would account for the overall 
preference of the full length protein for U/G rich sequences which have high 
affinity sites for both RRMs rather than ARE or CUG repeat substrates which are 
unfavourable for at least one of the domains. Teplova et al. subsequently 
published crystal structures of RRM2 in complex with UGUU and UGUG sites 
and RRM1 in complex with a UGUU site51. Their reported structures of both 
domains show similar contacts to the base at position four when binding to the 
UGUU sequence, in the case of RRM1 to residues K17, N46 and F63, and in the 
case of RRM2 to K109, R138 and F152. When RRM2 was bound to a UGUG site 
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they report additional hydrogen bonds between the G4 base and E136. 
Superimposing these structures showed near identical conformations for the first 
three nucleotides, with greater variation seen for the fourth. The authors did 
observe a higher binding affinity by ITC for RRM1 than RRM2, consistent with 
our results, which they attribute to additional hydrogen bonds between the U1 and 
G2 nucleotides and residues Q22 and Q93 of RRM1, which do not have 
counterparts in RRM2 where neither of these residues is conserved. This could 
imply that in RRM1 contacts to the first three nucleotides (UGU) represent a 
greater contribution to the overall binding than in RRM2, diminishing the 
importance of the contacts to the fourth nucleotide for RRM1. 
 
RRM3 has been reported to be capable of recognising up to six nucleotides, 
assisted by an interaction between the RNA and an N-terminal extension of the 
domain. Nothing similar was been seen for these isolated RRM1 or RRM2 
domains, but the possibility of this was investigated later on with longer protein 
constructs. Tsuda et al. identified a core motif of UGU(U/G) for RRM3, similar 
to our predictions for the preferred RRM2 target site.  
 
As all three domains can recognise a variation on a UGU site, these results are 
consistent with the full length protein recognising a sequence of the GRE type.  
The fact that RRM2 cannot bind to adjacent UGU sites that are only separated by 
a single nucleotide does however suggest that UGUU repeating sequences such as 
the EDEN11 GRE may not be suitable for recognition of the full length CELF1 
protein. The importance of the spacing between UGU sites when binding multiple 
CELF1 domains simultaneously was investigated, with the results shown in 
chapter 5.   
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5 Tandem RNA Binding of the two N-terminal 
Domains of CELF1 
 
To be able to predict natural target sequences of CELF1, it was necessary to 
determine not only that each RRM was recognising a UGU or UGU(U/G) site, 
but also what separation was required between the sites to allow the domains to 
bind at the same time. This was investigated using a construct containing the two 
N-terminal domains of CELF1 (RRM1 and RRM2) and the UGU(U) site spacing 
in the proposed EDEN motifs EDEN11 and EDEN15 as a starting point. A series 
of RNA substrates containing two UGU sites with a variable number of 
nucleotides separating them (UGU(U)xUGU)  were then used to determine the 
exact range of spacer lengths tolerated for binding RRMs onto both sites 
simultaneously. 
 
In order to trigger deadenylation and hence translational repression in cells, 
CELF1 must form a high affinity interaction with its target mRNA. The 
interaction of each RRM with its core binding site had been shown to be 
relatively low affinity, particularly for the two N-terminal RRMs. Kd values of 20 
± 60 µM were later reported for each of RRM1 and 2 with a UUGUU substrate, 
significantly lower than the Kd of 1.9 µM reported for RRM3. An important 
question was therefore whether the binding affinity would be enhanced when 
multiple RRMs of CELF1 interact simultaneously with the same RNA molecule. 
If an enhancement of binding affinity was seen then there was also the question of 
whether the lower affinity RNA substrates (the CUG repeat sequences and the 
AREs) would show increased affinity when binding multiple RRMs in tandem, or 
would remain as unfavourable non-specific interactions. 
 
Finally it was important to verify whether any regions of the protein other than 
the three structured RRMs were involved in RNA binding. RRM3 had been found 
by Tsuda et al. (2009) to have a flexible N-terminal extension which could fold 
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back to assist in binding to RNA. Similar N and C-terminal involvement in RNA 
recognition is seen in several structures of RRMs from other proteins42, 173, 174. 
Flexible extensions of some RRMs have also been reported to be indirectly 
involved by the formation of additional structured regions in the presence of the 
RNA, which stabilize the overall structure175, 176, 177. Since the isolated RRM1 and 
RRM2 constructs were truncated within a few residues of the structured regions, 
it was important to check that no similar flexible extensions of these domains had 
been removed. NMR studies to check for involvement of the N-terminus of 
RRM1, the C-terminus of RRM2, and the flexible linker between the two RRMs 
were therefore conducted. 
 
 
5.1.1 Purification of a Construct of the N-terminal domains of CELF1 
 
A construct consisting of the first 187 residues of CELF1 was used in this 
investigation, and has been termed the t187 construct. This consists of both the 
RRM1 and RRM2 domains connected as in the native protein by the short linker 
of residues 102 ± 107, which was not present in either of the isolated RRM 
constructs. The t187 construct was originally produced by Dr Emilie Malaurie 
(University of Nottingham). The mass of this construct is 21.1 kDa, not including 
the N-terminal 6-His tag and the thrombin cleavage site. Test expressions were 
carried out at 30°C and 37°C, which showed the protein was overexpressed, and 
remained soluble at 30°C after a 16 hour induction. The protein was purified 
using the same methods as for the isolated RRM1 and RRM2 constructs, as 
detailed in section 3.7. SDS-PAGE showed the protein to be intact both in the 
cell, and at the IMAC column stage of the purification. 
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Figure 5.1: SDS-PAGE of the IMAC column washes and elution fractions from the first t187 
purification. Low molecular weight markers (Sigma) are shown as a reference in lane 1, with the mass 
of each band shown in Daltons. Lanes 2 and 3 show diluted samples from the cell lysate of an 
uninduced growth, and a growth after a 16 hour induction. The t187 induction band is clearly visible. 
Lanes 4 and 5 show samples from the wash steps from the IMAC column stage. Lanes 6 ± 10 show 2 ml 
elution fractions. The vast majority of the protein is eluted in the first 3 fractions. 
 
The induction band can clearly be seen in lane 3, with a mass of approximately 24 
kDa. A small amount of the protein was eluted by the high salt wash step (lane 4), 
and in later preparations the salt concentration used in this step was reduced from 
2 M to 1 M in order to minimise this. The 1 mM imidazole wash (lane 5) did not 
cause any similar loss of protein. 0.75 M imidazole, 25 mM potassium phosphate, 
50 mM NaCl, pH 7.0 buffer was used to elute the protein from the column. The 
bulk of the protein was eluted in fractions 1 - 3, though trace amounts are still 
visible in fractions 4 and 5. Significant quantities of impurities were still present, 
as can be seen by the additional bands in the SDS-PAGE for fractions 1 - 4, 
which were removed by the subsequent gel filtration step.  
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Figure 5.2: SDS-PAGE of gel filtration fractions from the t187 purification. T187 eluted from the Superdex 
200 gel filtration column between 220 and 250 ml. There are still very faint bands from some impurities 
visible with a slightly lower mass than t187 that was not separated by the gel filtration. 
 
Between the IMAC column stage shown in Figure 5.1 and the gel filtration stage 
shown above in Figure 5.2 the 6-His tag was removed with thrombin using the 
protocol in section 3.8. The tagged protein has a mass of 24911 Da, compared to 
21719 Da after removal of the tag. The thrombin does not cleave immediately 
before the first residue of CELF1, but leaves the additional residues GSHMAS at 
the N-terminus, hence the slightly higher mass than for residues 1 ± 187 alone. 
Comparison to the reference markers in the SDS-PAGE, and ESI mass 
spectrometry confirmed the tag had been successfully removed. 
 
5.1.2 Comparison of  the Isolated Domains and t187 Spectra 
 
An initial 1D proton spectrum was collected on a Bruker Avance III 600 MHz 
spectrometer at 298K using unlabelled material. Lyophilised protein was 
dissolved in NMR buffer A. The dispersion of signals from the amide protons in 
this initial spectrum showed that the protein was correctly folded, with the 
downfield signals from Met94, Val183 and the Trp27 side chain clearly 
resolvable and matching their proton shifts from the isolated RRMs. As the t187 
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construct has a mass of 21.7 kDa, the TROSY technique was used in all 2D and 
3D NMR experiments to compensate for the faster relaxation rate compared to 
the isolated domains. High resolution 15N TROSY spectra with well dispersed 
peaks could still be collected despite the larger size of the protein compared to the 
isolated RRMs, and is shown in Figure 5.3. 
 
Figure 5.3: 15N TROSY of t187, collected on a 500 µM sample using a Bruker Avance III 600 MHz 
spectrometer at 298 K. The sample was prepared by dissolving lyophilised protein in 25 mM potassium 
phosphate, 50 mM NaCl, 10% D2O (v/v) pH 7.0 buffer. 
 
In Figure 5.4 the 15N TROSY spectrum of the t187 protein has been overlaid with 
those of RRM 1 in red and RRM2 in green. 
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Figure 5.4: Overlaid 15N TROSY spectra of t187 in blue, RRM1 in red and RRM2 in green. Virtually all the 
RRM1 and 2 peaks match to peaks in the t187 spectrum, confirming the chemical shifts of the residues 
have not been significantly perturbed by splitting the protein into two fragments. A small number of 
peaks are only seen in the t187 spectrum and are due to the linker region (102 - 107) which is not present 
in either of the smaller constructs. 
 
The vast majority of peaks from the two isolated domain constructs overlay very 
closely with the corresponding peaks from the t187 construct. It can be concluded 
that the removal of RRM2 therefore has no effect on the environment and hence 
the chemical shifts of the residues in RRM1, and vice versa. This confirms that 
despite the short linker between them, the two domains of the protein are free to 
move fairly independently of each other, at least when not bound to RNA. This 
also aided assignment of the t187 spectrum, since in most cases assignments 
could be transferred directly from the spectra of the isolated RRMs. 
 
A few residues do show very substantial changes in chemical shift, for example 
Lys101 (the RRM1 C-terminal residue), Arg108 and Lys109 (the RRM2 N-
terminal residues), but since the environment of these residues changes from 
being in the middle of the protein sequence to being at the terminal regions this 
140 
 
was not surprising. In order to assign these residues, and those in the linker which 
were not present in either the RRM1 or RRM2 constructs, 3D heteronuclear 
NMR data was collected on the t187 construct. 
 
5.1.3 Assignment of the 15N TROSY Spectrum 
 
NMR data on the first 187 residues of human CELF1 had previously been 
collected (Jun et al, 2004), but there are still enough variations in chemical shifts 
compared to Xenopus CELF1 that assignments in the more crowded regions 
could not simply be transferred. There were also some missing assignments, such 
as the downfield peaks at >10 ppm which are not seen in Jun et al.¶V human 
CELF1 NMR spectrum, possibly due to the collection of data over a spectral 
width range that was too narrow. For assignment purposes t187 was both 13C and 
15N labelled by growing in M9 minimal media with appropriately labelled carbon 
and nitrogen sources. The purification yield was reduced to 13 mg/l, comparable 
to the yields of the isolated RRMs. HNCACB, HN(CO)CACB, HNCO, 
HN(CA)CO and HCCH TOCSY spectra were collected, allowing assignment of 
the linker region. Those assignments transferred from the spectra of the isolated 
RRMs were also verified using this 3D heteronuclear NMR data. All non-proline 
residues were assigned except for Met1, Asp12 and Ser178.  
 
5.2 Interactions of the N-terminal Domains of CELF1 with 
Tandem UGU Sites in Guanine Rich Elements 
 
By titrating an RNA substrate into 15N labelled t187 protein, and collecting 15N 
TROSY NMR spectra, it was possible to tell whether each of the domains was 
interacting with the RNA. If CSPs were seen in both RRMs, it would indicate 
they were both binding to the RNA, and so that the RNA substrate contained 
UGU sites with suitable spacing for CELF1 recognition. In contrast if CSPs were 
only seen in one, then the separation between the UGU sites was not suitable for 
tandem binding of the domains. 
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The EDEN11 GRE and EDEN15 consensus sequences reported by Vlasova et al. 
(2008) and Graindorge et al. (2008) respectively were proposed to be capable of 
forming a high affinity interaction with wild type CELF1, and so would be 
expected to be capable of binding both domains of the t187 construct in tandem. 
These sequences are shown in  
Table 5-1, and contain up to four UGU sites in the case of EDEN15. By removing 
one UGU site at a time it was possible to deduce which of the possible UGU sites 
were involved in binding to these sequences, and so the spacing between them. 
With this as a starting point a series of RNAs with shorter and longer spacers 
between UGU sites were systematically investigated to find the exact range of 
spacer lengths that would permit both the N-terminal domains of CELF1 to bind 
in tandem. These RNAs were of the form UGU(U)xUGU, where x is varied to 
alter the spacer length. The range of RNAs of this type used in this study is also 
listed in  
Table 5-1. 
RNA Sequence 
EDEN15 GRE UGUUUGUUUGUUUGU 
EDEN11 GRE UGUUUGUUUGU 
EDEN7 UGUUUGU 
EDEN2U UGUUUUGU 
EDEN3U UGUUUUUGU 
EDEN4U UGUUUUUUGU 
EDEN5U UGUUUUUUUGU 
EDEN6U UGUUUUUUUUGU 
EDEN7U UGUUUUUUUUUGU 
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Table 5-1: This lists the RNA substrates used in determining the UGU site spacing requirements for 
binding the N-terminal domains of CELF1 simultaneously. The positions of all UGU sites in the sequences 
have been underlined. 
 
5.2.1 Interaction of the N-terminal Domains of CELF1 with the EDEN15 
GRE. 
 
In this titration, and all subsequent titrations with this protein construct, a 400 µM 
15N labelled t187 sample was prepared in 600 µl of NMR buffer A. The RNA 
concentration was raised in 50 µM increments by addition of 6 µl aliquots from a 
5 mM stock dissolved in RNase free water. A 15N TROSY spectrum was collected 
at each titration point on a 600 MHz Bruker Avance III spectrometer at 298K. 
Titrations were terminated once no variation could be seen between two 
successive spectra. In all cases this occurred shortly after a 1:1 ratio of RNA to 
protein was reached. 
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Figure 5.5: Graph of the CSP for each residue at the endpoint of the t187/EDEN15 titration. Also shown is 
a CSP map of the affected residues, with red indicating the most affected residues and yellow indicating 
residues with estimated minimum CSPs. The protein concentration was 400 µM, and the titration was 
continued until no further variation in the spectrum was seen between titration points. 
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A mixture of residues in fast and slow exchange is seen. As was the case in the 
titrations with the isolated RRMs it was not always possible to locate the signals 
from the bound form for certain residues. This was due to a combination of signal 
overlap in crowded regions of the spectrum, and certain residues which did not 
appear to show a signal in the bound form (e.g. Met114).  
 
Chemical shift perturbations are seen in both RRMs, confirming that the EDEN15 
GRE is binding both the N-terminal domains of CELF1 in tandem. In RRM1 the 
affected residues are a similar set to those seen in the earlier RRM1/UGU 
WLWUDWLRQ 7KH ȕ DQG ȕ VWUDQGV VKRZ VHYHUDO VWURQJO\ DIIHFWHG UHVLGXHV LQ 
particular Val20, Gly21, Gln22, Cys61 and Cys62. Of the two conserved 
aromatic residues on the ȕ-sheet Phe19 shows a significant CSP of just over 0.2. 
However Phe63 has a negligible CSP of less than 0.05 contrasting with one of 
>0.1 in the RRM1/UGU WLWUDWLRQ,Qȕ2 there are significant CSPs for Ile45 and to 
a lesser extent Val47, suggesting an extended RNA binding surface across this 
SDUW RI WKH ȕ-VKHHW ,Q ȕ RQO\ *OQ VKRZV D &63 DERYH WKH  WKUHVKROG
Asp98, which was an affected residue in slow exchange in the RRM1/EDEN7 
titration, has a negligible CSP and does not appear to be involved in binding. 
NeitKHURIWKHĮ-helices contain any affected residues. 
 
,Q 550 &63V DUH DJDLQ FRQFHQWUDWHG LQ WKH ȕ DQG ȕ VWUDQGV LQ SDUWLFXODU
Gly113, Met114, Val115, Cys150 and Ala151. As with RRM1 only one of the 
WZR FRQVHUYHG DURPDWLF UHVLGXHV RQ WKH ȕ-sheet (Phe152) shows a significant 
&63 3KH LQ FRQWUDVW KDV D &63 RI  ,Q ȕ 9Dl182 is very strongly 
perturbed, as was the case LQWKHLVRODWHG550FRQVWUXFW7KHĮ-helices do not 
have any affected residues, and there is also little disruption to the ȕ strand. 
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5.2.2 Interaction of the N-terminal Domains of CELF1 with the EDEN11 
GRE. 
 
Figure 5.6: Graph of chemical shift perturbation for each residue at the endpoint of the t187/EDEN11 
titration. A large number of residues in this titration appear to be in intermediate exchange, and so the 
peak from the bound form remains broadened out. This prevents minimum CSP estimation for many 
residues  ? estimates have been included for residues such as Gln22 where a plausible peak is present in 
the bound spectrum. These residues are shown in yellow in the CSP map.  
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The RNA sequence was shortened by one UGU(U) site to UGUUUGUUUGU, 
which corresponds to the EDEN11 GRE. The results of this titration are shown in 
Figure 5.6. Again there is a mixture of residues in fast and slow exchange. 
Significant CSPs are seen in both RRMs, confirming this RNA substrate is 
binding both domains in tandem. The set of affected residues is generally the 
same as was seen for the EDEN15 GRE with few exceptions. The most 
noticeable difference is that Asp98 is now affected, though overlap of this peak in 
the bound form prevents accurate quantification of the CSP.  
 
 
5.2.3 Interaction of the N-terminal Domains of CELF1 with the EDEN7 
GRE. 
 
The RNA was shortened by a further UGU(U) site to UGUUUGU (EDEN7). 
Unlike the previous titrations, where the affected signals were predominantly in 
fast exchange, this experiment appeared to show an intermediate exchange 
situation for most of the normally affected residues. In intermediate exchange the 
rate constant k is approximately equal to the difference in chemical shifts between 
the free and bound forms (įȞ)178. This results in extremely broad signals at a 
population weighted average of the chemical shifts. In this case the signals for 
WKRVH UHVLGXHV ZLWK ODUJH įȞ UDSLGO\ EURDGHQ RXW EXW DUH QRW UHFRYHUHG
suggesting the intermediate exchange situation is broadening the peaks to an 
extent where they are not observable above the background noise. The lack of 
peaks specific to the bound form prevented direct CSP determination, or 
minimum CSP estimation based on the closest unknown peak.  
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Figure 5.7: Overlaid 15N TROSY spectra of t187 unbound (shown in blue) and after titration to a 1:1 ratio 
with EDEN7 (UGUUUGU  ? shown in red). Few peaks are seen to move in fast exchange over the course of 
the titration, and none of those in fast exchange show CSPs of >0.1. A number of peaks are however lost, 
and therefore these residues must have a greater change in environment, resulting in an intermediate 
exchange situation. This permits the most affected region of the RNA binding surface to be identified, but 
without bound peaks no CSPs can be estimated.  
 
The binding patch, and hence which domains were bound to the RNA could be 
identified based on which peaks from the free form were lost during the titration. 
This is shown in Figure 5.8. 
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Figure 5.8: Map of the residues affected on titration with EDEN7 (UGUUUGU), plotted onto the NMR 
solution structure of RRM1 and 2 determined by Jun et al. Residues for which the peaks are lost on 
titration are shown in yellow. Residues with no data are show in black. Since CSPs could not be 
quantified for the lost peaks there is no magnitude information in this figure, only an indication whether 
the peak for each residue is lost or not. 
 
With a single exception (Met114) all of the affected residues are in RRM1. The 
RRM1 residues affected are generally the same as those in the earlier titrations. 
Val20, Gly21, Gln22, Cys61 and Cys62 are all lost over the course of the 
titration. Both of the conserved aromatic residues (Phe19 and Phe63) are also 
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affected. ,Q ȕ $VS DQG *OQ DUH ORVW ,Q ȕ $VQ DQG $UJ DUH ORVW LQ
FRQWUDVWZLWK,OHDQG9DOLQWKHHDUOLHUWLWUDWLRQV7KHUHLVQRHIIHFWRQWKHĮ-
helices. 
 
5.2.4 Systematic Investigation of Spacing Requirements for Tandem 
Binding of the N-terminal domains of CELF1 
 
The shortest GRE sequence to show tandem binding of the two N-terminal 
domains of CELF1 (the EDEN11 GRE) had a separation between the UGU sites 
of five nucleotides. RNAs with spacer lengths from 1 to 7 nucleotides were 
investigated by NMR in order to refine the exact spacing requirements between 
UGU sites for tandem binding. The NMR titrations were again carried out using a 
400 µM protein sample in NMR buffer A, and raising the RNA concentration in 
50 µM increments. All titrations were extended to a 1.5:1 ratio of RNA to protein 
to confirm that the sample was fully bound. 
 
Virtually identical CSPs were observed for the residues in RRM1 for all spacer 
lengths from 2 - 7, while a greater range of effects were seen for residues in 
RRM2. In the RNA binding patch acrosVWKHȕ-sheet Val20, Gly21, Gln22, Val23, 
Cys61, Cys62 and Gln93 show large CSPs for spacer lengths 2 - 7. A spacer 
length of 1 is equivalent to the earlier EDEN7 titration, where the signals for all 
of these residues are lost, but are not recovered. In RRM2 Ile112, Gly113, 
Met114, Val115, Cys150, Ala151 and Val182 show comparable CSPs to the 
titration with the EDEN11 GRE for spacer lengths of 2 ± 5 inclusive. Cys150 and 
Val182 are consistently the most affected residues with CSPs of around 0.4 ppm 
in each titration. With a single nucleotide spacer only the Met114 signal is lost 
from RRM2. There are some slight perturbation of Cys150 and Val182, but in 
both cases it is only around 0.05 ppm, and is below the significance threshold. 
For spacers of length 6 and 7 significant CSPs were seen for all of the normally 
affected residues in RRM2, but were consistently reduced to around 50 ± 60% of 
the magnitude of those seen for the 2 ± 5 nucleotide spacers. 
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Figure 5.9 focuses on the peaks from the residues Cys61 and Cys150, which are 
in RRM1 and RRM2 respectively and show the greatest chemical shift 
perturbation in most of these titrations. Similar results are seen for the other 
affected residues, but the differences are most pronounced for these residues due 
to the larger absolute values of the CSPs. 
 
Figure 5.9: Overlaid 15N TROSY spectra for t187 unbound, and in the presence of a saturating amount of 
each of the seven RNA sequences EDEN1U  ? EDEN7U. The RNA sequences are of the form UGU(U)xUGU, 
with x = 1  ? 7. This is a close up of a region of the spectra containing the signals from residue Cys61 in 
RRM1 and Cys62 in RRM2.   
 
5.2.5 Interaction of the N-terminal Domains of CELF1 with GRE 
Sequences 
 
Both the EDEN15 and EDEN11 GREs were found to be capable of binding the 
two N-terminal domains of CELF1 in tandem, consistent with these substrates 
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being targets for wild type CELF1. There are multiple possible UGU sites in 
these sequences (four in EDEN15 and three in EDEN11), some of which are 
expected to be redundant. The two domains could therefore be bound to sites with 
either one or five nucleotides separating them in the EDEN11 case. In the 
EDEN15 case one, five or nine nucleotide spacer lengths are possible depending 
which sites are being occupied by the two domains. 
 
The EDEN7 (UGUUUGU) data clarifies how these two domains are recognising 
GRE sequences. In this titration all of the normally affected residues in RRM1, 
such as Gly21, Gln22, Cys61 and Gln93 are lost, showing that the RRM1 RNA 
binding surface is being fully occupied. In contrast Met114 is the only residue 
affected in RRM2, indicating that this domain is not binding to the RNA in the 
usual manner. This shows that this sequence, and hence a separation of one 
nucleotide between UGU sites, is not suitable for binding of the two N-terminal 
domains in tandem. 
 
In the previous chapter this RNA sequence (UGUUUGU) was found to be 
capable of binding two copies of RRM1 simultaneously. It was not however 
capable of binding two copies of RRM2. It was speculated that RRM2 was 
recognising a slightly larger site of UGU(U/G) rather than the UGU site 
recognised by RRM1. If this is the case there would still be sites for both RRMs 
in this sequence, but with no separation between them, which could result in an 
unfavourable steric clash between the domains. Another possibility is that both 
domains might be able to fit onto the RNA when separated, but the short linker 
between them is not sufficiently flexible to allow the RRMs to adopt a suitable 
conformation relative to each other in order to bind simultaneously. The length of 
this linker may therefore play a role in regulating ELQGLQJ WR &(/)¶V 51$
targets by determining the separation between UGU sites that can permit tandem 
interaction with these domains. The EDEN7 RNA substrate is known to bind 
each of RRM1 and RRM2 in isolation. As they cannot bind at the same time 
when connected in the t187 construct, this titration behaves essentially as a 
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competition experiment. All but one of the affected residues are in RRM1, so it 
can also be concluded that RRM1 has a higher affinity for UGU(U) sites than 
RRM2. 
 
The EDEN7 titration data shows unambiguously that the N-terminal domains 
cannot bind to sites with only a single nucleotide separating them. This eliminates 
one of the possible arrangements of the domains for binding to the EDEN11 
GRE. The only remaining possible arrangement is for the two domains to bind to 
the outer two UGU sites, leaving the central site unoccupied. These sites are 
separated by five nucleotides. The longer EDEN15 GRE also has UGU sites with 
a five nucleotide separation, which the N-terminal domains of CELF1 could be 
recognising in the same manner. There was also still the possibility of binding to 
the outer two UGU sites in EDEN15, which would be a nine nucleotide 
separation.  
 
The data from the GRE sequences had confirmed that a five nucleotide spacer 
between UGU sites was sufficient for tandem binding of RRM1 and RRM2, 
while a single nucleotide was insufficient. From this alone it was not possible to 
tell whether the separation had to be exactly five, or if a range of spacer lengths 
could be tolerated. The NMR data collected on the range of RNAs with spacer 
lengths from 2 ± 7 nucleotides clarified this. For all spacer lengths the residues in 
RRM1 showed almost identical chemical shifts in the bound form. This is as 
expected, since the UGUUUGU titration showed that RRM1 is bound 
preferentially if the domains cannot bind in tandem. RRM2 however shows a 
larger range of effects. 
 
With spacer lengths of 2 ± 5 nucleotides the residues in RRM2 show very similar 
chemical shifts in the bound form to those in the EDEN11 GRE titration. This 
confirms that all of these spacer lengths (from UGUUUUGU to 
UGUUUUUUUGU) can permit tandem binding of these two domains. The RNA 
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with the 5 nucleotide spacer also confirms that the central UGU site in the 
EDEN11 GRE is not playing any role in binding these two domains, since 
altering this G to a U has had no significant effect on the bound spectrum. 
 
The longer 6 and 7 nucleotide spacers show a noticeable reduction in CSPs for 
the normally affected residues in RRM2. This was highlighted in Figure 5.9 for 
the highly perturbed residue Cys150, and a similar decline in CSP is seen for 
residues such as Ile112, Ala150 and Val182. In general they are reduced to 50 - 
60% of the CSPs seen for the 2 ± 5 nucleotide spacers. These CSPs are still above 
the 0.1 significance threshold for these residues, so tandem binding of RRM1 and 
RRM2 has not been completely eliminated as it appeared to be in the case of the 
single nucleotide spacer. The upper limit on the spacer length is therefore not as 
sharply defined as the lower limit. It does however appear that spacing of greater 
than 5 nucleotides between UGU sites is not optimal for tandem binding. It 
therefore seems likely that in the EDEN15 GRE the domains are binding to two 
of the UGU sites separated by five nucleotides, rather than the outer two sites 
which are separated by nine. 
 
5.3 Enhanced Affinity when Binding Multiple Domains of 
CELF1 in Tandem 
 
Our second aim was to determine whether tandem interaction of the two N-
terminal domains results in enhanced binding affinity compared to their 
interactions in isolation. RRM1 had previously been determined by ITC to bind to 
substrates with UGU sites with a Kd of approximately 30 µM. RRM2 was found 
to have a slightly lower affinity for UGU sites of around 45 µM. ITC data was 
collected for titrations of the t187 construct with a UGU substrate, and with the 
series of RNA sequences with spacer lengths of 1 ± 7 nucleotides between UGU 
sites. The UGU substrate would result in the domains binding separately, while 
spacer lengths of 2 ± 5 nucleotides would permit tandem binding, based on the 
NMR data previously shown. Each titration was run with 25 µM RNA in the cell. 
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250 µM protein was injected from the syringe in thirty 10 µl aliquots, while 
stirring at a constant rate. 
 
 
Figure 5.10: ITC trace for titration of 250 µM t187 protein into 25 µM RNA (UGU). The curve has been 
fitted using the MicroCal Origin 7.0 software package. 
 
The Kd value for this interaction was calculated as 64.5 ± 2 µM, consistent with 
ITC data for the titration of UGU with the isolated domains. The stoichiometry is 
approximately 0.5 consistent with the two N-terminal domains of CELF1 binding 
separate UGU molecules. 
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Figure 5.11: ITC binding curves for the X = 1, 2, 4 and 6 examples of the UGUUxUGU sequence. A) 
EDEN1U, previously called EDEN7, shows a biphasic titration curve distinct from all the others. No 
satisfactory fit to this curve could be obtained using the multiple site or sequential site binding models in 
the Origin 7.0 package. B) EDEN2U, showing a single phase curve, fitted to a one site model. C) EDEN4U, 
again showing only a single binding event, and fitted to a one site model. D) EDEN6U which, while it 
shows a single phase curve, the shallower gradient indicates a substantially lower binding affinity for the 
interaction. Data was also collected on the X = 3, 5 and 7 sequences. 
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In Figure 5.11 a) is shown the ITC trace for titration of the t187 construct into 
UGUUUGU (the substrate with the single nucleotide spacer). This shows a 
biphasic curve distinct from the single phase curves of the other RNAs 
investigated. Attempts were made to fit this to the multiple binding site and 
sequential binding site models in Origin 7.0, but no satisfactory fit could be 
obtained. In Figure 5.11 b) and c) are shown the ITC traces and fitted binding 
curves for the 2 and 4 nucleotide spacers. These fit to models with Kd values of 
0.43 ± 0.08 µM and 0.37 ± 0.07 µM respectively. In contrast the trace for the 6 
nucleotide spacer (Figure 5.11 d) shows a significantly lower affinity interaction, 
with a Kd around an order of magnitude larger at 3.4 ± 0.3 µM.  
 
Binding affinities, stoichiometries and other calculated thermodynamic 
parameters for all RNA sequences investigated by ITC are shown below. 
 
RNA Sequence Kd (µM) N ǻ+ 
(kcal/mol) 
ǻ6 
(cal/K/mol) 
UGU UGU 64.5 ± 2.0 0.94 -17.3 -41.0 
EDEN2U UGUUUUGU 0.47 ± 0.06 1.27 -17.0 -28.0 
EDEN3U UGUUUUUGU 1.60 ± 0.30 1.80 -20.1 -42.6 
EDEN4U UGUUUUUUGU 0.37 ± 0.06 1.35 -23.8 -50.5 
EDEN5U UGUUUUUUUGU 3.86 ± 0.79 0.99 -50.4 -144 
EDEN6U UGUUUUUUUUGU 3.38 ± 0.28 1.05 -45.5 -128 
EDEN7U UGUUUUUUUUUGU 3.50 ± 0.72 1.39 -39.4 -107 
 
Table 5-2: ITC results for all spacer lengths, and also the titration of t187 into the UGU RNA substrate. 
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5.3.1 Dependence of Binding Affinity on the Separation between UGU 
Sites 
 
The titration with the RNA substrate UGU showed a Kd of 64 µM, comparable to 
those seen for RRM1 and RRM2 binding in isolation. Since the RNA is only 
three nucleotides each domain must be binding to a separate RNA molecule, so 
there is no tandem binding to increase affinity. The RNA with the single 
nucleotide spacer (UGUUUGU) also does not permit tandem binding, as 
previously shown in the NMR data. Interpretation of these results was however 
complicated by the ITC trace showing two distinct binding events, with different 
affinities. This RNA substrate has previously been shown to be capable of 
binding two RRM1 proteins simultaneously, one to each UGU site. Two binding 
events are occurring and, since RRM2 is known not to be interacting from the 
NMR data, these must be two separate t187 proteins binding via their RRM1 
domains. At low protein concentrations t187 binds to one UGU site of an RNA 
molecule via RRM1, but the spacer length does not permit RRM2 to bind in 
tandem, leaving the second UGU site vacant. When the protein concentration is 
increased until the protein is in excess this vacant UGU site can be occupied by 
the RRM1 domain of a second t187 protein, hence the second binding event seen 
in the ITC trace. A diagram of this complex is shown in Figure 5.12. The 
difference in binding affinity indicates that the two events are not equivalent and 
suggests negative cooperativity, possibly due to steric difficulties in binding the 
second protein onto the short RNA sequence. This may also imply that the bound 
conformation of the second RRM1 to bind may not be identical to that of the first 
RRM1. The presence of more than one bound conformation of RRM1 would 
result in broadening of the signals in the NMR, contributing to the lack of clear 
signals from the bound form. 
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Figure 5.12: This shows a possible 2:1 complex of t187 with the EDEN7 RNA substrate, which would 
account for the two binding events observed by ITC. 
 
The RNAs with spacer lengths of 2 ± 7 nucleotides all show simple sigmoidal 
curves, consistent with the two domains binding in tandem to form a 1:1 
complex. The binding affinity is significantly enhanced for all of these compared 
to the RRMs binding in isolation. The lowest Kd values are seen for the 2 and 4 
nucleotide spacers, both at around 0.4 µM. This is more than a 100-fold 
improvement in affinity compared to the protein binding two unconnected UGU 
sites. The 6 and 7 nucleotide spacers are, as seen in the NMR data, less 
favourable but with Kd values of around 3 µM they still show more than a 10 fold 
improvement in binding affinity. This is consistent with RRM2 still interacting to 
some extent, permitting some degree of tandem binding. The five nucleotide 
spacer showed a Kd value of 3.86 µM, indicating somewhat weaker binding than 
the 2 ± 4 nucleotide spacers. This suggests that the five nucleotide spacing 
between occupied UGU sites in the EDEN11 and EDEN15 GREs may still be 
slightly larger than is optimal for tandem binding. 
 
Based on these results, the optimal sequence for tandem binding of the N-
terminal domains of CELF1 appears to be UGU(U)xUGU where X is 2 - 4 
inclusive. X = 1 results in almost complete loss of binding to RRM2. X  5 
results in some loss of binding affinity, possibly due to binding becoming less 
entropically favourable as the spacer length increases. This upper limit is not as 
sharply defined as the lower limit, and it is possible that an RNA sequence with a 
longer spacer containing secondary structure to hold the UGU sites in close 
proximity might also show comparably favourable binding to the 2 - 4 spacers. 
This data clearly demonstrates that tandem interaction of the two domains leads 
to a significant enhancement in binding affinity. This is consistent with CELF1 
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forming a high affinity complex with its target mRNAs by recognition of an 
EDEN motif that extends across all three RRMs. 
 
A model of the complex of the two N-terminal domains with the shortest of the 
optimal RNA substrates (UGUUUUGU) was constructed based on the available 
crystal structures of the isolated domains. Teplova et al. had published structures 
of RRM1 in complex with the UGU sites of a 12 nucleotide RNA 
(GUUGUUUUGUUU). The unit cell contains two RNA molecules each with two 
RRM1 proteins, one bound to each UGU site. They also published a structure of a 
construct of both RRM1 and RRM2 (residues 14 ± 187) in complex with this 
sequence, but with only RRM2 in contact with the RNA. In order to construct this 
model the RNA in the RRM1 structure was truncated to the sequence UUGU, 
leaving a single RRM1 protein bound to the UGU site. The residues of this 
RRM1 were then superimposed onto the RRM1 region of the structure containing 
both domains, minimising RMSD for the protein. The RNA molecule bound to 
RRM2 in this structure was truncated to the core UGUU sequence in contact with 
the protein. This resulted in a structure of the two N-terminal domains, each 
bound to a four nucleotide section of RNA in the same manner as in the crystal 
structure. 
 
The RNA fragments UGUU (bound to RRM2) and UUGU (bound to RRM1) 
were then connected to form the RNA UGUUUUGU, determined experimentally 
to be the shortest sequence capable of binding the domains in tandem. Due to the 
orientation of the two domains in Teplova et al¶V VWUXFWXUH this required the 
introduction of an implausibly long bond connecting the two RNA fragments in 
this initial structure. The complex was placed in a truncated octahedron of 
TIP3PBOX water, with sodium ions to achieve an overall neutral charge. Energy 
minimisation was conducted in Amber with an initial restraint mask applied to the 
protein and RNA. The force constant of this restraint mask was reduced to zero 
over several stages (100, 50, 25, 10, 5, 2, 1), allowing the domains and RNA to 
shift until the bond where the two RNA fragments were connected had been 
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reduced to a normal length. Molecular dynamics simulations were then run in 
Amber, using the parameters in section 3.22, with a final step at 300 K with no 
restraint mask for 1 ns. The resulting model is shown in Figure 5.13. 
 
Figure 5.13: Model of the N-terminal domains of CELF1 in complex with the RNA substrate UGUUUUGU. 
The protein is shown in green as a ribbon diagram with the amino acid side chains of key residues in the 
binding surface shown as lines. The RNA is shown in light blue. 
 
This is the shortest RNA sequence capable of binding both domains in tandem. 
Bases 1 ±  RI WKH 51$ IRUP FRQWDFWV ZLWK WKH ȕ-sheet and some of the loop 
regions of RRM2. U3 is forming a stacking interaction with Phe111, and U4 is 
forming a similar interaction with Phe152. U5 is relatively distant from the 
protein surface, with only the side chain of His90 in close proximity. U6, G7 and 
8 LQWHUDFW ZLWK WKH ȕ-sheet of RRM1. U8 forms a stacking interaction with 
Phe19. Phe63 does not stack with any of the RNA bases, though it is also quite 
close to the U8 base.  
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5.4 Determining the Stoichiometry of Complexes with GRE 
Substrates by Mass Spectrometry 
 
The titration of t187 into UGUUUGU highlighted the potential for the formation 
of complexes with stoichiometries other than 1:1 when multiple UGU sites are 
present in an RNA substrate. The EDEN15 and EDEN11 GREs both have 
unoccupied UGU sites even after the N-terminal domains are bound in tandem. 
The masses of the complexes of t187 with these RNA substrates were therefore 
measured by ESI-MS to check for the presence of higher stoichiometries. As for 
the isolated domains, purified protein was put through a second desalting step 
into 25 mM ammonium acetate to further reduce the salt concentration, and hence 
the presence of salt adducts. 
 
Figure 5.14: ESI mass spectrum of t187. The protein concentration is 5 µM. One species is seen with a 
mass of 21702 Da. 
 
The t187 construct, including the additional N-terminal residues left after removal 
of the 6-His-tag, has a theoretical mass of 21719 Da. The mass spectrum, shown 
in Figure 5.14, measures WKHSURWHLQ¶VPDVVto be 21702 Da.  
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Figure 5.15: ESI mass spectrum of t187 + EDEN11. Both the protein and RNA concentrations are 5 µM. 
Three species were seen, of masses 21702 Da, 25134 Da and 3449 Da, corresponding to unbound t187, 
1:1 complex and unbound EDEN11 respectively. 
 
RNA was added from a 5 mM stock in RNase free water until a 1:1 ratio of RNA 
to protein was reached. On addition of the EDEN11 GRE substrate a complex 
with a mass of 25134 Da was observed, which is a close match to the 25142 Da 
theoretical mass of a 1:1 complex. A small amount of unbound RNA is 
observable. Comparable amounts of unbound protein and 1:1 complex are 
present. ITC of this protein construct binding to the similar RNA sequence 
UGUUUUUUUGU observed a Kd of 3.86 µM. Under these conditions just over 
40% of the protein would be expected to be in the form of the complex, which is 
consistent with mass spectrometry results. 
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Figure 5.16: ESI mass spectrum of t187 + EDEN15. Both the protein and RNA concentrations were 5 µM. 
Two species were seen, of masses 26386 Da and 4683 Da, corresponding to a 1:1 complex of t187 and 
EDEN15 and unbound RNA respectively. 
 
Figure 5.16 shows the ESI mass spectrum after the addition of the EDEN15 GRE 
substrate. The 1:1 complex is visible. Its theoretical mass is 26405 Da, compared 
to an observed mass of 26389 Da. Unbound RNA is also visible, with a mass of 
4683 Da. No free protein was observed at a 1:1 protein to RNA ratio. We were 
unable to fit a curve to the biphasic ITC trace for binding of this protein construct 
to EDEN15, preventing an accurate Kd for either of the binding events being 
determined. The fact the vast majority of the protein appears to be in the form of 
the 1:1 complex under these conditions does however suggest significantly tighter 
binding than in the EDEN11 case, where a mixture of unbound protein and 
complex was seen.  
 
No 2:1 complex is observed. The biphasic ITC trace observed for this system 
does suggest it is possible for a second protein molecule to bind to this RNA. If 
however the second protein molecule can only bind via one of its two domains, 
the binding affinity will be far lower than for the first protein molecule binding. 
RRM1 binds to a UGU site in isolation with a Kd of ~30 µM, and it is possible 
that negative cooperativity will further reduce the binding affinity. The proportion 
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of the protein in the 2:1 complex may simply be too small to be observed. 
 
In conclusion both the EDEN11 and EDEN15 GREs were confirmed to form high 
affinity 1:1 complexes with t187, with the longer EDEN15 GRE appearing to be 
significantly more favourable than EDEN11. We were not able to observe any 2:1 
complex but given the affinity for the second binding event would be expected to 
be much lower than for the first, and potentially even lower than for the isolated 
domains binding, this does not exclude the possibility 2:1 complex formation.  
 
5.5 Investigation of Binding Affinity Enhancement in Tandem 
binding to UGC and UAU Sites 
In the previous chapter UGC sites were found to be bound by the RRMs of 
CELF1, though with a somewhat reduced affinity in the case of RRM1, and only 
very weakly with RRM2. UAU sites conversely were found to show moderate 
CSPs for RRM2, but showed no significant interaction with RRM1. An important 
question was whether a longer RNA with multiple UGC or UAU sites could bind 
the domains in tandem, with an enhancement in binding affinity similar to that 
seen for UGU sites. This was particularly of interest for UGC sites, due to their 
presence in the extended CUG repeat RNAs in DM1 cells. NMR and ITC data 
was therefore collected on RNA sequences containing multiple UGC and UAU 
sites. The sequences CUG15 and ARE15, shown below in Table 5-3 were 
selected, as they were of comparable size to the EDEN15 GRE, and had at least 
two sites with spacing consistent with tandem binding. 
RNA Sequence 
CUG15 CUGCUGCUGCUGCUG 
ARE15 UAUUUAUUUAUUUAU 
Table 5-3: RNA sequences used to check for enhanced binding affinity when the N-terminal domains of 
CELF1 bind to tandem UGC and UAU sites. 
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5.5.1 Tandem Binding to UGC Sites 
 
Figure 5.17: CSPs at the endpoint of the t187/CUG15 titration. The brightness of the red colour indicates 
the magnitude of the CSPs, with the bright red in the RNP regions of RRM1 indicating relatively large 
CSPs, while the darker red in RRM2 shows residues only just above the 0.1 significance threshold. 
Residues in yellow have only estimated CSPs, which are shown in red in the histogram. The protein 
concentration was 400 µM throughout, and the RNA concentration was raised in 50 µM increments up to 
a 1.5: 1 excess of RNA. The titration was run at 298 K, in NMR buffer A. 
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RRM1 shows CSPs across most RIWKHȕ-sheet residues, with some of comparable 
PDJQLWXGH WR WKRVH LQ WKH('(1 WLWUDWLRQ ,Q ȕ3KH*O\ DQG9DO DOO
VKRZ&63VRIJUHDWHUWKDQ,Qȕ,OHDQG$VQVKRZVLPLODU&63VDVGR
/\VDQG&\VLQȕ,Qȕ/\VVKRZVDODUJH&SP of >0.25, contrasting with 
<0.05 in the EDEN15 titration. RRM2 however shows very limited CSPs. In 
particular the 110 - 115 and 149 - 155 regions, which showed the largest CSPs on 
binding to UGU sites, have no residues in fast exchange with CSPs of magnitudes 
above 0.1. The peaks for Phe111 and Met114 are still lost on titration. Val182 
shows a CSP of just over 0.1, compared to 0.4 for binding to UGU sites. In this 
region Ala186 also has a CSP just over the significance threshold. As with the 
other t187 titrations, a mixture of residues in fast and slow exchange is seen. The 
ITC trace had an unusual shape, as shown in Figure 5.18, which was unlike any of 
those seen for the titrations with UGU substrates. 
 
 
Figure 5.18: ITC curve for a titration of 500 µM t187 protein into 25 µM CUG15 at 298K. All samples were 
dissolved in RNase free water and degassed. 
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A plausible fit to the curve could not be produced using any of the available 
binding models in Origin 7.0, preventing any thermodynamic parameters from 
being calculated. From the NMR data it appears that RRM1 is binding to the 
UGC site with comparable affinity to the UGU site. However RRM2 still shows 
only very weak CSPs, suggesting that even when the domains bind in tandem the 
overall affinity for sequences with UGC sites is not significantly enhanced. 
 
A complication in this titration is the issue of RNA secondary structure. Long 
CUG repeating sequences such as those found in DM1 cells have been shown to 
form hairpin structures. These consist of a stem of C ± G Watson-Crick base 
pairs, separated by U ± U mismatches. Atomic force microscopy by Michalowski 
et al (1999) showed that CELF1 could not bind to this double stranded stem. 
Binding could only occur to short single stranded sections of the RNA at the ends 
of the hairpin. The possibility of similar hairpin structures in the relatively short 
CUG repeat sequences used in these experiments had to be considered. The 
mFOLD RNA secondary structure prediction webservice179 predicted no 
secondary structure for the short CUGCUG sequence, or any of the sequences 
with UGU or UAU sites. It did however predict that CUG15 would form a short 
hairpin structure with two C-G base pairs ǻ* -1.0 kcal/mol). 
 
This could account for the unusual shape of the ITC trace. The endothermic 
section at the start of this titration, which was not seen for any other RNA 
substrate, could be caused by the breaking apart of the RNA hairpin. Since 
CELF1 has been confirmed to only bind to single stranded CUG repeat sequences 
by AFM, and the NMR shows that it is binding to CUG15, any secondary 
structure in the RNA must be breaking down. CUG15 is still a relatively short 
sequence compared to the extended CUG RNAs present in DM1 cells which can 
run to thousands of repeats. While this ITC experiment does suggest CELF1 is 
capable of breaking apart at least a short section of RNA hairpin in order to bind, 
it may not be able to do this except at the ends of the RNA hairpins in DM1 cells. 
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5.5.2 Tandem Binding to Adenosine Rich Elements 
 
Figure 5.19: CSPs at the endpoint of the t187/ARE15 titration. This titration was largely in fast exchange, 
and shows residues in both RRMs above the 0.1 significance threshold. The titration was carried out on a 
400 µM protein sample in NMR buffer A at 298 K. The RNA concentration was raised in 50 µM increments 
until no further variation in the spectrum was seen. Residues lost on titration are shown in yellow on the 
CSP map, and minimum CSP estimates are highlighted in red in the histogram. 
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Significant CSPs of up to 0.4 ppm were seen, comparable to those in the EDEN15 
titration, were seen in both domains. ,Q 550 ȕ DQG ȕ ERWK VKRZ VWURQJO\ 
affected residues, such as Gly21, Val23 and Gly60. The conserved aromatic 
UHVLGXHV 3KH DQG 3KH DUH QRW SHUWXUEHG Ǻ DQG ȕ VKRZ UHODWLYHO\ ORZ
&63VWKRXJK+LVLQWKHORRSFRQQHFWLQJĮDQGȕKDVDKLJK&63RIDOPRVW
0.3 ppm. In RRM2 most of the eIIHFWVDUHLQȕ LQSDUWLFXODU,OH7KHRWKHU
SDUWVRIWKHȕ-VKHHWDUHOHVVDIIHFWHGWKRXJK3KHLQȕLVORVWRQWLWUDWLRQ 
 
 
Figure 5.20: ITC curve for a titration of 500 µM t187 into 25 µM ARE15. Binding is occurring, with multiple 
events as can be seen from the shape of the curve. It was not possible to achieve a good fit to this data 
using any of the binding models in the Origin 7.0 software package. 
 
A titration of t187 protein into the ARE15 RNA substrate showed a curve, 
indicating that binding was occurring. While not as pronounced as in the titration 
with EDEN7, there are clearly at least two phases to the binding curve, indicating 
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at least two binding events are occurring. The multi-site binding model did not 
produce a plausible fit. 
 
From the NMR data it can be concluded that the N-terminal domains of CELF1 
are binding in tandem to two sites in the ARE15 substrate, as there are substantial 
CSPs across both domains. This contrasts with the isolated domain results. RRM2 
did show moderate CSPs with an ARE substrate, but RRM1 showed no 
significant CSPs at all when titrated with ARE7 (UAUUUAU). This suggests that 
binding the two domains in tandem has enhanced the affinity of the N-terminal 
domains of CELF1 for UAU sites. From the ITC it does not appear to be forming 
a simple 1:1 complex with ARE15. Possibly the two redundant UAU sites permit 
a second t187 protein to bind when in large excess. 
 
Based on the ITC data the substrate ARE15 does not appear to form a high 
affinity 1:1 complex like EDEN15 does, so AREs can still be considered as 
relatively low affinity targets.  There is enough of an interaction however that 
they may not be a good choice as control sequences, particularly when multiple 
domains of CELF1 can bind simultaneously to improve the binding affinity. 
 
 
5.6 Investigating the Involvement of Unstructured Regions 
Flanking RRM1 and RRM2 in RNA Binding 
 
In 2009 Tsuda et al published a structure of RRM3 in complex with the RNA 
substrate UGUGUG. One notable feature of this structure was that a flexible 
section at the N-terminus of the protein was folded EDFN DFURVV WKH ȕ-sheet, 
making additional contacts with the RNA and enhancing binding affinity. It was 
therefore important to investigate if any similar regions flanking the structured 
RRM1 and RRM2 domains were involved in RNA binding. This was particularly 
important to determine for the C-terminus of RRM2, since the t187 construct cut 
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the protein only one residue after the end of the structured domain. If any 
unstructured region was involved in the wild type, it would be truncated in the 
t187 construct, potentially altering the RNA target or binding affinity. Also the 
unstructured N-terminus of RRM1 and the linker between RRM1 and RRM2 
were investigated. This was accomplished using a combination of 15N 
heteronuclear NOE experiments, and an extended protein construct (t242). 
 
 
5.6.1 Evidence for Conformational Flexibility from 15N Heteronuclear 
NOEs 
 
By measuring the 1H - 15N heteronuclear NOE it is possible to measure the 
flexibility of each residue in the protein180. Heteronuclear NOEs are sensitive to 
motion on a timescale of 10-8 ± 10-12 seconds, which is a typical range for internal 
protein dynamics181. Heteronuclear NOEs are generally highest in rigid areas of 
the protein, with a theoretical maximum value of 0.82.182 Some values higher 
than 0.82 are seen in practice due to the margin of error in measuring signal 
intensities. Values from 0 ± 0.6 generally indicate relatively dynamic regions of 
the protein. Completely unstructured regions can produce negative values. 15N 
heteronuclear NOE experiments have the disadvantage of low sensitivity 
compared to an ordinary 1H-15N HSQC experiment, and so require long 
acquisition times which can present a problem with unstable samples. They also 
require accurate measurement of the intensity of each peak in the spectrum. As a 
result heteronuclear NOEs cannot be accurately calculated for any overlapping 
peaks. 
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Figure 5.21: The upper graph shows the 15N heteronuclear NOEs seen for each residue in the unbound 
t187 protein. The lower graph shows the same protein after the addition of an excess of the EDEN4U RNA 
substrate (known to be an optimal target to form a 1:1 complex with t187). Data was collected on an 800 
MHz NMR spectrometer with cryoprobe, with 40 scans at a resolution of 2048 x 128 points for each of 
the two interleaved experiments comprising the 15N heteronuclear NOE experiment. 
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In the folded domains of t187 NOEs are typically 0.7 or greater, indicating slow 
isotropic tumbling consistent with a compact, rigid structure. An exception is the 
loop connecting ȕ-sheets 2 and 3 of RRM1 where the NOEs are significantly 
lower, indicating faster internal motion and suggesting this loop is somewhat 
more dynamic than the rest of the domain. This is consistent with the greater 
range of conformations seen for this loop compared to the rest of the domain in 
the available crystal structures of RRM151, and the NMR structural ensemble of 
the N-terminal domains previously reported by Jun et al48. The N-terminus of the 
construct also shows very low, and some negative NOEs, indicating unstructured 
protein. Residues 98 - 105 show relatively low heteronuclear NOEs, consistent 
with the linker between RRM1 and 2 being fairly dynamic. 
 
The experiment for t187 in complex with the EDEN4U substrate showed a similar 
overall pattern of NOEs, showing that it is not becoming significantly more rigid 
on binding to RNA. 7KHUHODWLYHO\IOH[LEOHORRSEHWZHHQWKHȕDQGȕVWUDQGVRI
RRM1 is also remaining flexible when bound to the RNA, as is the N-terminus. 
The N-terminus possibly shows a slight increase in the NOE for residues 2 ± 5, 
but still remains quite dynamic compared to the structured domains. 
 
From this data it can be concluded from this that there is no involvement of the 
flexible N-terminus of RRM1 in binding the RNA, unlike that seen for RRM3. If 
it were, it would be expected to become significantly less dynamic when bound to 
RNA. Similarly the short linker between RRM1 and RRM2 appears to remain 
dynamic even when the domains bind in tandem, consistent with a lack of any N-
terminal involvement in RRM2 binding. 
 
5.6.2 Investigation of Involvement of the RRM2 C-Terminus Using an 
Extended CELF1 Construct 
 
It had been suggested in the literature that not only the first two domains, but also 
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some additional residues from the unstructured region between RRM2 and 3 are 
required for high affinity binding of RNA103, 54. The t187 construct was however 
capable of binding RNA with affinities in the low µM to high nM range even 
without this region. We examined the effects of this proposed extension of RRM2 
using a construct of the first 242 residues of CELF1 (t242). The t242 construct 
was originally produced by Dr. Emilie Malaurie (University of Nottingham), but 
due to lower yields from purifications and poor solubility, work was focused on 
the shorter t187 construct. It contains an additional 55 residues from the linker 
region between RRM2 and 3, which are believed to be completely unstructured. 
The purification was carried out using the same protocol as for t187 construct. 
 
Figure 5.22: SDS PAGE of 15N labelled t242 purification. The protein mass is consistent with t242, and 
there is no sign of truncation of the flexible C-terminal tail. From left to right the lanes show: 1) Standard 
molecular weight markers (Sigma), 2) The supernatant after the protein has bound to the His-Pur column, 
containing the non-binding proteins. 3) Proteins eluted by the 2 M NaCl wash. 4) Proteins eluted by the 1 
mM imidazole wash. 6)  ? 10). The first 5 fractions of elution buffer containing 0.75 M imidazole. The 
elution fraction volume was 2 ml. 
 
From SDS-PAGE the increased size of the protein can be seen. It runs slightly 
above the 29 kDa marker, consistent with its theoretical mass of 30475 (including 
the 6-His-tag). The purification yield was severely reduced, to 2.5 mg/l when 
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grown in minimal media. The protein solubility was also reduced, to 
approximately 100 µM in the phosphate NMR buffer A. Increasing the salt 
concentration to 200 mM only marginally increased the protein solubility, and 
substantially reduced the quality of the resulting NMR spectrum, so buffer A was 
still used for collection of all NMR data on the t242 construct. The NMR data 
was collected using the TROSY technique on a Bruker Avance III 600 MHz 
spectrometer with a TXI probe at 298K. 
 
Figure 5.23: 15N TROSY of t242, collected on a Bruker Avance III 600 MHz spectrometer, shown in blue. 
15N TROSY of t187 overlaid in red for comparison. 55 additional peaks would be expected in the t242 
spectrum. Most of the additional peaks in the t242 spectrum are however tightly clustered in the 7.5 - 
8.5ppm proton region and are difficult to resolve. This indicates they are in an unstructured region of the 
protein, which is consistent with the available information on the structure of CELF1. 
 
Given the difficulty of resolving the heavily overlapped peaks from the 
unstructured 188 - 242 region and the poor signal/noise ratio, it was decided not 
to attempt assigning these, but instead to repeat the earlier titrations with a GRE 
sequence and the CUG15 sequence to check for any differences in the CSPs of 
the structured domains between the two constructs. The low protein concentration 
also prevented the acquisition of 3D heteronuclear NMR data, which would be 
necessary for assignment of a protein of this size. 
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Due to the limited solubility of t242, a very low sample concentration (~100 µM) 
had to be used for all NMR experiments. The number of scans taken at each 
titration point was increased to compensate. The RNA concentration was raised in 
25 µM increments until an excess of RNA was present.  
 
A larger than normal percentage of the peaks do not have quantifiable CSPs, 
since their low initial intensities results in them being more easily lost over the 
course of the titration. Also some peaks which are normally resolvable in the t187 
are obscured by the cluster of peaks from the unstructured C-terminal extension 
of the protein. The binding patch can still be identified from those residues for 
which the signals from the free form disappear over the course of the titration. 
 
Figure 5.24: Graph of CSP values for titration of t242 with CUG15. Red asterisks indicate residues that are 
resolvable in the initial spectrum, but lost on titration. No values are shown for residues 187  ? 242 as 
these were not assigned. Minimum values for the CSPs of residues lost on titration have not been 
estimated, since there are insufficient visible peaks in the bound form to account for all residues. If the 
bound peak is not visible, as opposed to merely unassigned, the distance to the nearest unassigned peak 
could still be a large overestimate of the CSP. 
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Figure 5.25: Map of CSP values onto the first 187 residues of t242. The additional 45 residues at the C-
terminus are assumed to be unstructured, and there is no CSP data available for them. The affected 
residues are mostly in RRM1, as was expected based on the t187 data. 
 
As with t187, most of the residues perturbed on titration with the CUG15 RNA 
are localized to RRM1, with only limited effects in RRM2. Cys61 is the most 
perturbed residue for which a CSP could be calculated. Both Phe19 and Phe63 are 
ORVW RQ WLWUDWLRQ DV DUH UHVLGXHV LQ DOO IRXU VWUDQGV RI WKH ȕ-sheet. The CSP for 
Lys95, could not be quantified as the peak from the bound form was obscured by 
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some of those from the unstructured region. Since the peak from the free form 
was lost Lys95 is definitely affected, consistent with the earlier titrations. In 
RRM2 the peaks from a few residues are lost, such as Phe111, Ala151 and 
Val182. Cys150 is not significantly affected, again consistent with the 
corresponding titration with the t187 construct. A repeat of the EDEN15 titration 
with t242 also matched the results for t187. 
 
In conclusion, these experiments determined that there is no significant difference 
in the RNA binding properties of the t187 and t242 constructs, suggesting little 
involvement of the unstructured region immediately after RRM2. Since the 
spectrum of the unbound t242 matches very closely to that of the unbound t187 
complex it can be concluded that there is no dimerisation occurring due to the 
additional residues from the RRM2 ± RRM3 linker. If these residues did result in 
dimerisation, it would be expected that there would be significant changes in 
chemical shift for the residues in the dimerisation interface. While the protein 
concentration in these experiments was relatively low at 100 µM, if a 
physiologically relevant dimerisation event is occurring then at least some 
population of the dimer should be visible in these spectra. No variation in the 
t187 spectrum was seen for concentrations ranging from 10 µM to 1 mM.  
 
These results confirmed that the C-terminus of RRM2 is not involved in binding 
to RNA. This in conjunction with the earlier 15N heteronuclear NOE data shows 
that no critical regions for RNA binding have been omitted from the t187 and 
isolated domain constructs. The behaviour of these proteins is therefore 
representative of the behaviour of the domains of wild type CELF1. 
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5.7 Summary of Cooperative Binding by the N-terminal 
Domains of CELF1 to RNA targets 
 
The data presented in this chapter shows that tandem binding of multiple CELF1 
domains to RNAs with more than one UGU site greatly increases the overall 
affinity of the interaction. Kd values are reduced from tens of micromolar for the 
domains binding in isolation to less than one micromolar for optimal RNA 
targets. This increase in affinity is most pronounced for cooperative binding of 
UGU sites. There does appear to be some increase in affinity for UAU sites when 
the domains bind in tandem, but not to the same extent as was seen for UGU 
sites. UGC sites do not appear to show any significant increase in affinity. As for 
the isolated domains most of the interaction with CUG repeat RNA substrates is 
occurring via RRM1, with minimal perturbation of residues in RRM2. 
 
We have shown that the separation between UGU sites is critical in determining 
whether a given RNA sequence can bind both domains in tandem. For optimal 
binding an absolute minimum of 2 nucleotides between UGU sites is required. 
The upper limit is not as well defined, with a gradual decline in binding affinity 
seen for spacers of 5 or more nucleotides. Even with a seven nucleotide spacer 
there was still a tenfold increase in binding affinity compared to the isolated 
domains. The optimal target sequence of the N-terminal domains of CELF1 was 
therefore concluded to be UGU(U)xUGU with x between 2 and 4, which were 
found to have a Kd of around 400 nM.  
 
The 15N heteronuclear NOE data shows that even when bound to an optimal RNA 
target, there remain some intrinsic dynamics in the linker region that facilitates 
binding to RNAs with a range of spacer lengths. This in combination with the 
data collected on the extended t242 construct showed no involvement of the N- or 
C-terminal unstructured regions in RNA binding, contrasting with the N-terminal 
extension involvement reported for RRM3. 
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Both the EDEN11 GRE and EDEN15 sequences have been demonstrated to form 
high affinity complexes with the two N-terminal domains of CELF1, consistent 
ZLWKWKHPEHLQJ³('(1´PRWLIVWargeted by the full length CELF1 protein. Both 
sequences have unoccupied UGU sites, which could potentially be bound by the 
third RRM, increasing the affinity even further.  
 
Figure 5.26: Possible arrangements of full length CELF1 on a repeating UGUU RNA substrate such as 
EDEN15 or EDEN11. Red arrows indicate possible locations of the binding site for RRM3 on the RNA 
strand. Since RRM1 and RRM2 have been shown to occupy the outer two UGU sites of EDEN11, there is 
potentially an unoccupied site between the domains. If this site cannot be bound by RRM3, then an 
additional UGU site must be added to the sequence ƚŽǁĂƌĚƐĞŝƚŚĞƌƚŚĞ  ? ?Žƌ  ? ?ĞŶĚŽĨƚŚĞZEƐƚƌĂŶĚ ? 
The length and flexibility of the RRM2  ? RRM3 linker meant that any of these positions initially appeared 
to be plausible. This was further investigated in chapter 6. 
 
For the EDEN11 GRE to be binding all three RRMs, RRM3 would have to 
occupy the central UGU site between RRM1 and RRM2, as shown by the central 
arrow in Figure 5.26. If this site is too hindered for RRM3 to bind then a longer 
RNA with an additional UGU site (such as the EDEN15 GRE) would be required. 
The length of the RRM2 ± RRM3 linker is sufficient that it seems possible RRM3 
FRXOGELQGHLWKHUWRZDUGVWKH¶HQGRUWRWKH¶HQGRIWKHRWKHUWZRGRPDLQV 
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6 Optimal RNA Targets of Full Length CELF1 
 
6.1 Introduction 
 
Wild type full length CELF1 is known to form a high affinity interaction with an 
RNA motif IRXQG LQ WKH¶875RI WKHP51$VWKDW WKHSURWHLQUHJXODWHV7KLV
KDGEHHQWHUPHGWKH³('(1PRWLI´EXWWKHVHTXHQFHRUUDQJHRIsequences that 
could be recognised by CELF1 was not well defined. Some mRNAs, such as c-
mos, c-MXQ DQG 71)Į KDYH EHHQ VKRZQ HPSLULFDOO\ WR EH ERXQG E\ &(/)
triggering deadenylation, but it is not clear which regions of these sequences are 
being recognised. Without knowing the exact criteria for an EDEN motif, it is not 
possible to predict whether any given mRNA is regulated by CELF1. 
 
Full length CELF1 consists of three RRMs. The two N-terminal domains were 
investigated by NMR and ITC in the previous chapters. X-ray crystallography 
data on these domains was also collected by Teplova et al. (2010). The C-
terminal RRM3 was investigated in isolation by Tsuda et al. (2009). However no 
data had been collected on the full length CELF1 protein containing all three 
domains, so it was not known how they worked together in order to bind a 
complete EDEN motif. 
 
Some consensus sequences which constitute possible EDEN motifs have been 
discussed previously. Vlasova et al. suggested the EDEN11 GRE 
(UGUUUGUUUGU) and Graindorge et al. the longer EDEN15 
(UGUUUGUUUGUUUGU) sequence. Rattenbacher et al. (2010) later suggested 
a long UG repeating sequence as a possible EDEN motif, while Masuda et al. 
(2012) suggested UGUUUGU (the EDEN7 sequence previously investigated). 
While all of these sequences were shown to be capable of binding to CELF1, it 
was not known if they were interacting with all three RRMs simultaneously, or 
sufficient to trigger deadenylation. These sequences could therefore be only 
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partial EDEN motifs, interacting with a subset of the CELF1 RRMs. The target 
identified by Masuda et al. (UGUUUGU) was already known to be incapable of 
interacting with both N-terminal RRMs simultaneously from work in the previous 
chapter. The question was therefore whether the longer EDEN11 GRE and 
EDEN15 sequences were complete, or merely partial targets for full length 
CELF1. 
 
Previous in vitro studies of CELF1 had all used constructs of one or two RRMs 
rather than the full length protein. Our initial aim was therefore to devise a 
purification protocol for the complete CELF1 protein. Using this we would then 
determine by NMR and ITC whether the reported EDEN11 and/or EDEN15 GRE 
consensus sequences do in fact represent high affinity ³('(1PRWLIV´WDUJHWHGE\
CELF1. If these sequences were not complete EDEN motifs, we then aimed to 
design high affinity RNA sequences capable of binding all three RRMs based on 
our data on preferences of the smaller constructs. From this we would refine the 
overall criteria for an EDEN motif, and use these to explain how CELF1 is 
recognising known mRNA targets such as c-jun, c-PRVDQG71)Į 
 
6.2 Purification of Wild Type CELF1 
 
To study how all three RRMs of CELF1 interact, it was necessary to develop a 
purification protocol for the full length protein. This proved problematic due to 
the protein undergoing rapid proteolysis in the linker region between RRM2 and 
RRM3. The DNA for the full 489 residue CELF1 protein in a pET28b(+) vector 
(supplied by Dr. Emilie Malaurie, University of Nottingham) was transformed 
into XL1 Blue, and then BL21 (DE3) cells. Initial test growths showed some 
solubility issues. At 37°C the protein expressed, but rapidly became insoluble, as 
can be seen in the SDS-PAGE gel in Figure 6.1. 
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Figure 6.1: 20% SDS-PAGE of the test growth of full length wild type CELF1 at 37°C. At each time point the 
total fraction containing both soluble and insoluble proteins is shown in lane T, while the soluble fraction 
is shown in lane S. An expression band at the expected mass (~53kDa) is seen, but the percentage in the 
soluble fraction declines over time. No band is visible in the soluble fraction after 16 hours, and only a 
small fraction of the protein is in solution after 4 hours. 
 
The decline in solubility over time indicates insoluble inclusion bodies are 
forming. The protein was mostly in the insoluble fraction 4 hours after induction, 
and completely in the insoluble fraction after this. The same problem was seen in 
test growths at 30°C and 25°C. To improve solubility it proved necessary to both 
reduce the induction temperature (to 20°C), and keep the induction period short at 
4 hours. This resulted in soluble protein, as shown in Figure 6.2, but a very low 
overall yield of approximately 1 mg/l of growth. 
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Figure 6.2: 20% SDS-PAGE from a short induction, low temperature test expression. The protein 
expression was induced with 1 ml of IPTG for 4 hours at 20°C to prevent formation of insoluble inclusion 
bodies. The CELF1 expression band is visible, and the majority of the protein seems to be in the soluble 
fraction. At this stage the protein is intact. Fragmentation of the RRM2 - RRM3 linker does not occur until 
after the cells are lysed. 
 
While less protein was expressed in total, more of it is in the soluble fraction than 
after 4 hours at 30°C. These durations and temperatures were therefore used for 
large scale growths. Cell lysis and the IMAC column stage of the purification 
were initially carried out using the same basic protocol as for the t187 construct. 
A Roche EDTA free protease inhibitor cocktail was added to the resuspended 
cells prior to sonication. The time allowed for binding to the cobalt resin was 
restricted to one hour in order to minimise the time available for proteases to 
break down the protein. Samples from each stage of the purification were 
analysed by SDS-PAGE to check the condition of the eluted protein. The 
resulting gel is shown in Figure 6.3. 
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Figure 6.3: 20% SDS-PAGE of the IMAC column washes and elution fractions from a purification of 
unlabelled wild type CELF1. The wash step consisted of 25 ml of buffer A + 10 mM imidazole. The 
 “unbound ? ůĂŶĞ is a diluted sample of the cell lysate drained from the IMAC column. The presence of 
multiple bands in the elution fractions indicate that the full length CELF1 has largely fragmented by this 
stage of the purification. 
 
While a small amount of intact CELF1 was visible as the uppermost band on the 
gel (with a mass of approximately 53 kDa), the vast majority of the protein had 
been fragmented. The presence of multiple strong bands with masses of 24 - 36 
kDa indicates that all these fragmentation sites are in the linker between RRM2 
and RRM3. The protease inhibitor cocktail evidently was not effective in 
preventing proteolysis of the full length CELF1 protein. The elution fractions 
were combined and loaded onto a Superdex 200 gel filtration in an attempt to 
separate the remaining intact protein from the truncated forms. The thrombin 
cleave step was omitted. The trace of 280 nm absorbance showed multiple broad 
peaks. Analysis of the fractions by SDS-PAGE is shown in Figure 6.4. 
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Figure 6.4: SDS-PAGE of the protein containing gel filtration fractions 22  ? 30 from a purification of wild 
type CELF1 using a Superdex 200 column. Lanes are labelled with the elution fraction number (40 x 10 ml 
fractions were collected). The protein has continued to degrade since the drip column stage, and has now 
mostly been truncated to a stable fragment of between 24 and 29 kDa. 
 
The void volume for this gel filtration column is 120 ml. No protein bands were 
observed in elution fractions from 130 ± 210 ml.  The vast majority of the 
material seen on this gel has a molecular mass of between 24 and 29 kDa, 
consistent with protein fragments slightly longer than the t242 construct. It 
appears the protein continued to break down during the gel filtration stage, until it 
reached the longest stable fragment. Analysis by ESI mass-spectrometry showed 
multiple species, even after an additional desalting step into ammonium acetate. 
Only a rough approximation of the exact mass of the longest stable fragment 
could be calculated. 
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Figure 6.5: ESI mass spectrum of the degradation products of full length wild type CELF1. The total 
protein concentration was approximately 2 µM. The major species has a mass of approximately 24799 
Da. There is an additional minor species with a mass of approximately 21730 Da. 
 
The major species appears to have a mass of approximately 24800, which does 
not match precisely to a fragmentation product of CELF1. The break site, 
assuming this is the N-terminal fragment, would be at around Leu217 or Thr218, 
though the observed mass does not match precisely to either. This is closer to the 
N-terminus than expected, given that the t242 construct appeared stable when 
analysed by SDS-PAGE. The C-terminal fragment could not be detected, but may 
have been removed at the gel filtration stage. 
 
The earlier gels from the IMAC column stage of the purification also suggest that 
the fragmentation is occurring in several places in the linker region from the 
number of bands present. If only a small number of protease sites were present 
then they could have been removed by point mutation. However the number of 
protease sites required to give the range of species seen in the elution fractions 
and the difficulties of precisely locating them made this approach impractical. 
The main band of ~25 kDa after gel filtration is merely the longest stable 
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fragment, consisting of approximately the first 220 residues, and by this point in 
the purification the vast majority of the protein was fully degraded. 
 
CELF1 is expressed intact, and remains so as long as it is in the cell, as can be 
seen by SDS-PAGE if all proteins are denatured immediately after cell lysis. 
Diluting the cell lysate immediately after sonication slowed the fragmentation 
process to some extent, but did not prevent it completely. It was found that lysing 
the cells under denaturing conditions (in the presence of 8 M urea) prevented 
fragmentation of CELF1, presumably due to denaturation of the proteases 
responsible as well. This also had the advantage of solubilising the insoluble 
fraction of the protein, allowing a longer induction time to be used resulting in an 
improved overall yield. A purification based on denaturing CELF1 at the cell lysis 
stage, and refolding it after the gel filtration step was attempted, but the peak 
dispersion in the 1D proton NMR spectra indicated that the protein was not 
correctly refolded. None of the normal dispersed peaks from the domains could 
be observed, and all signals were in a narrow band suggestive of random coil. 
 
Reducing the concentration of urea in the lysis buffer to 4 M still prevented most 
of the fragmentation problems. Based on fluorescence experiments with varying 
concentrations of denaturant CELF1 should still be mostly folded under these 
conditions. Small amounts of intact material (1 - 2 mg per litre of M9 minimal 
media) were produced by this method, and confirmed to be folded based on the 
peak dispersion in the NMR spectra. The 15N TROSY spectrum of this material is 
shown in Figure 6.6. 
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Figure 6.6: 15N TROSY of full length wild type CELF1. This spectrum was collected on a 100 µM protein 
sample in 50 mM potassium phosphate, 200 mM NaCl, 10% (v/v) D2O pH 7.0 NMR buffer, using an 800 
MHz Bruker Avance III spectrometer with a QCI cryoprobe at 298 K. Due to the low signal to noise ratio 
360 scans were required to obtain this quality of spectrum. The lengthy acquisition time and poor sample 
stability made it impractical to run titrations similar to those carried out on t187 and the isolated RRMs 
using this sample. 
 
Peaks with chemical shifts closely matching those of the residues of the isolated 
RRM1, RRM2 and RRM3 constructs can be seen. There are also a large number 
of peaks from the flexible RRM2 ± RRM3 linker visible between 7.5 and 8.5 ppm 
in the proton dimension. Solubility remained a serious problem, as the protein 
could not be concentrated above ~125 µM without a significant concentration of 
urea present. The protein was also insoluble in the 50 mM salt buffers used in 
previous experiments, requiring a 200 mM salt concentration in the NMR buffer 
resulting in a reduction in signal to noise ratio. The long acquisition times 
required made it difficult to carry out NMR titrations similar to those used to 
identify the preferred t187 RNA substrate. 
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6.2.1 Production of a Stable Construct Containing all three Domains 
 
To bypass the solubility and stability issues encountered with wild type CELF1 it 
was decided to produce a construct in which a large section of the RRM2 - RRM3 
linker was removed. This would remove the many fragmentation sites in this 
region, and was also expected to improve the solubility of the protein.  
 
The first designed construct consisted of t242 fused to residues 385 - 489 based 
on Tsuda et al's RRM3 construct which was reported to be stable, and the t242 
construct which appeared to remain intact during the purification (see section 
5.6.2). While fragmentation of the protein was greatly reduced, the solubility for 
this new construct remained low, with a maximum concentration of ~125 µM in 
the 50 mM potassium phosphate, 200 mM NaCl buffer. The construct was 
therefore further shortened to residues 1 - 214 fused to 385 - 489 on the basis that 
t242 had been previously observed to have solubility issues, while RRM3 did not.  
 
This shortened construct proved to be both stable and soluble to protein 
concentrations of at least 500 µM in buffer A. Purification yields were improved 
to ~15 mg/l when grown in LB and 8 - 9 mg in M9 minimal media. The 
interaction of all three RRMs to bind long RNAs could be studied by NMR and 
ITC using this new construct, which was termed RRM123. With around 30 
residues of flexible protein remaining between RRM2 and RRM3, the domains 
were still free to adopt any orientation relative to each other.  
 
6.2.2 Production of Deletion Mutants Using a Single Step PCR  
 
These constructs were produced using a one-step PCR deletion method as 
outlined by Qi et al. (2008), from the wild type CELF1 DNA, as specified in 
section 3.15.6. In this method the primers are designed so that the PCR amplifies 
the entire plasmid except for the section to be deleted. The primers consist of two 
sections; a short overlapping section with a low annealing temperature and a 
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longer non-overlapping section which will anneal to the template DNA at a 
temperature at least 5 K higher166. 
 
The PCR is run for 18 cycles at a temperature where the non-overlapping sections 
of the primer will anneal, but the overlapping sections will not. This amplifies the 
entire plasmid except the section to be deleted, and leaves complementary ³VWLFN\
HQGV´7KH WHPSHUDWXUH LV WKHQ UHGXFHGVR WKDW WKHVHHQGVDQQHDO WRHDFKRWKHU
reforming the plasmid into a circle, as shown below in Figure 6.7. This is 
followed by a final elongation step of 30 minutes. 
 
Figure 6.7: Above is shown the design of primers in this one step deletion method. In the initial higher 
temperature stage of the PCR the non-overlapping regions of the primers anneal, amplifying the entire 
plasmid except for the region to be deleted. The complementary sections of the primers anneal at the 
lower temperature. 
As before the sequence of the resulting construct was verified by DNA 
sequencing. However the success of the deletion process could also be rapidly 
checked using an agarose gel. As the deleted section is relatively large, being in 
excess of 500 bases for each of these constructs, the difference in size between 
the template DNA and the PCR product is clearly visible after a successful 
reaction. 
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Figure 6.8:  DNA gel showing the change in plasmid size in a successful deletion PCR. In the left hand lane 
is a 2-log DNA ladder (New England Biolabs) as a reference. In lane 2 is the template DNA, in this case the 
plasmid containing full length CELF1 in a pET28b vector with a total size of 6500 bp. In lane 3 is the PCR 
product from the reaction to produce the RRM123 construct. In lane 4 is the PCR product from a reaction 
to produce the RRM3 construct. The difference in size between these two PCR products and the template 
DNA is clear. 
 
The plasmid DNA was transformed into XL1 Blue cells. The DNA was extracted 
from an overnight cell culture and sequenced to confirm the intended section had 
been deleted, after which it was transformed into BL21 (DE3) cells for 
expression. 
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6.3 Expression and Purification of RRM123 
 
The expression and IMAC column stages of the purification used the same 
protocols as for the t187 construct. RRM123 was found to remain soluble in a 16 
hour expression at 30°C, unlike the full length CELF1 protein. 
 
Figure 6.9: SDS-PAGE of the washes and elution fractions from the IMAC column stage of the RRM123 
purification. The vast majority of the protein is now intact, and is of the expected molecular weight (38 
kDa). The presence of low intensity bands at approximately 25 suggests a small amount of fragmentation 
is still occurring, but not to the same extent as seen in Figure 6.3 for the wild type CELF1. 
 
The eluted protein was purified using a Superdex 200 gel filtration column, which 
separated out the lower molecular weight fragments of RRM123 as well as any 
other impurities. Those fractions containing protein were identified by their 
absorbance at 280 nm, and analysed by SDS-PAGE. The results of this are shown 
in Figure 6.10. 
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Figure 6.10: SDS-PAGE of gel filtration fractions. RRM123 is remaining intact and in solution throughout 
the gel filtration stage of the purification, although it does appear spread across an unusually large range 
of fractions. 
 
The mass of the protein was determined by mass spectrometry to be 38348 ± 7 
Da. RRM123 has a theoretical mass of 36026 Da, but this protein still has the N-
terminal 6-His tag attached, giving a theoretical overall mass of 38348 Da. A 
much larger range of charge states is seen for this construct than for t187, as can 
be seen in Figure 6.11. This can be attributed to the unstructured linker region in 
RRM123, and the presence of the complete N-terminal His-tag. Denatured 
proteins tend to show a very large charge envelope due to the greater ability of the 
unstructured peptide chain to pick up additional charges, and this is presumably 
the case for the long unstructured regions in the larger CELF1 constructs. 
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Figure 6.11: ESI mass spectrum of RRM123, under native conditions. The protein concentration was 5 µM. 
A single species with a mass of 38348 Da is seen, consistent with the His-tagged RRM123 protein. Charge 
states ranging from +9 to +40 are seen. This large range compared to the other constructs is presumably 
due to both the remaining unstructured section of the RRM2  ? RRM3 linker and the 6-His tag. 
 
6.3.1 NMR Characterisation of RRM123 
 
15N labelled material was produced, and an initial 15N TROSY spectrum was 
collected on a Bruker Avance III 600 MHz spectrometer. While it required higher 
scans and resolution than previous experiments with t187, a spectrum in which 
peaks from all three RRMs could be clearly resolved was acquired. A higher 
resolution spectrum was later collected at 800 MHz which is shown in Figure 
6.12. 
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Figure 6.12: 15N TROSY spectrum of the RRM123 construct. This was collected on a 250 µM sample in 25 
mM potassium phosphate, 100 mM NaCl, 10% v/v D2O pH 7.0 NMR buffer. Data was collected on a 
Bruker Avance III 800 MHz spectrometer with QCI cryoprobe at 298 K. 
 
The quality of the spectrum is surprisingly good given this is a relatively large 
protein with a mass of 38 kDa. This is likely2 to be due to the favourable internal 
dynamics in the protein. Since the three structured RRMs are separated by 
flexible linkers and move fairly independently the relaxation rates are likely to be 
closer to those of a 12 kDa RRM than a 38 kDa globular protein. The linewidths 
of the peaks are therefore still quite narrow, allowing clear resolution of most 
peaks despite the spectrum being relatively crowded with signals from more than 
300 residues. 
 
Combining the spectra of the three separate RRMs gives a very good match to the 
RRM123 spectrum. There are still some additional peaks from the remaining 
section of the RRM2 - RRM3 linker, and these are clustered in a narrow band 
between 7.5 and 8.5 ppm, indicative of unstructured protein. RRM3 can therefore 
be concluded not to interact with the other RRMs or the flexible linker since the 
chemical shifts of its residues in the RRM123 spectrum are not significantly 
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different from those in the spectrum of the isolated domain. The RRM1 and 
RRM2 chemical shifts as expected match those in the t187 construct, with the 
exception of Ala186 and Asp187. 
 
The increased sample solubility and improved signal to noise ratio from the lower 
salt concentration meant that adequate resolution of the peaks of all three RRMs 
required only 32 scans at a resolution of 2048 x 128 points. This meant that 
acquisition times were short enough that RNA titrations could be conducted 
easily using this construct. 
 
Assignment of the peaks from all three RRMs was carried out by analogy to the 
smaller constructs. No assignment of the peaks from the RRM2 ± RRM3 linker 
was attempted. This protein does give surprisingly high quality NMR spectra, and 
so it should be possible to collect 3D heteronuclear data. The unstructured nature 
of this linker would make the assignment strategy used so far problematic, but 
alternative assignment strategies for intrinsically disordered regions of proteins 
could be used. While the peaks from the side chain &ĮDQG&ȕVKLIWV show very 
limited dispersion in intrinsically disordered regions, greater dispersion is seen 
for the 15N and 13&¶ VKLIWV $OWHUQDWLYH +$-detect 3D experiments such as 
H(CA)NCO and H(CA)CON can be used to establish backbone connectivities 
from these nuclei183. Further dispersion of peaks could be achieved by the use of 
4D or 5D NMR experiments, with non-uniform sampling methods to reduce the 
acquisition time required184, 185, 186. 
 
6.3.2 15N Heteronuclear NOE 
 
To characterise the relative flexibility of different sections of the protein 15N 
heteronuclear NOE data was collected on an 800 MHz spectrometer with 
cryoprobe. 168 scans were accumulated at a resolution of 2048 x 256 points. 
Experiments with and without the NOE were interleaved to minimise artefacts 
from any changes in the spectrum over time. 
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Figure 6.13: 15N Heteronuclear NOE plotted against residue number. It can be seen that the three RRMs 
are highly structured, with the exception of some loop regions. Smaller NOEs are seen for the residues in 
the flexible regions between the domains, though assignments are not available for most of the RRM2 to 
RRM3 linker. 
 
RRM1 and 2 show similar 15N heteronuclear NOE values to the t187 construct. A 
few residues show NOE values of greater than 1, which is probably due to the 
relatively large margin of error in measuring the intensity of some of the weaker 
signals. Both domains are quite rigid, with the exception of the N-terminus, the 
linker around residues 100 - 107 and the loop from residues 52 - 57 which are 
moderately flexible. No assignments are available for most of the RRM2 to 
RRM3 linker. RRM3 is quite rigid, though there is a noticeable drop in the 
heteronuclear NOE for the N-terminal extension and the C-terminus of the 
protein. There is a slight decrease around residue 270, again due to a relatively 
flexible loop between two VWUDQGVRIWKHȕ-sheet. These loops do not appear to be 
involved in RNA recognition, based on NMR chemical shift perturbations and the 
available x-ray crystal structures. 
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These flexible linkers allow significant interdomain dynamics, which may 
contribute to the high quality NMR spectra that can be collected for this 
construct. The overall structure of the RRM123 construct (and presumably also 
the 53 kDa wild type CELF1) can be summarised as WKUHH³EHDGVRQD VWULQJ´
The domains are free to move relatively independently with the result that their 
relaxation rates are closer to those of than isolated domains than for the average 
38 kDa protein. This effect was observed for the RRM1 and RRM2 domains by 
Teplova et al. They reported rotational correlation times of 10.2 ns and 9.7 ns for 
RRM1 and RRM2 respectively, when connected as a construct of residues 14 ± 
187 of CELF1187. These are both lower than the ~12 ns time which would be 
expected for a globular protein of the same mass188, 189. Teplova et al. also noted a 
substantial increase in the rotational correlation times for both domains when 
bound in tandem to an RNA substrate, to 14.6 ns and 12.0 ns for RRM1 and 
RRM2 respectively. This was attributed to restriction of the relative motion of the 
domains by the RNA, though the significant difference seen for the two domains 
indicates the resulting structure is not completely rigid51. 
 
6.4 Interactions of RRM123 with the EDEN11 GRE 
 
With the aim of identifying RNA sequences which could bind all three RRMs 
simultaneously, NMR titrations were carried out on 15N-labelled RRM123, using 
an 800 MHz NMR spectrometer. The EDEN11 GRE (UGUUUGUUUGU) was 
considered as a possible candidate, containing three UGU sites. This RNA was 
titrated into a 250 µM sample of 15N-labelled RRM123.  
 
Chemical shift perturbations were observed for residues on the binding surfaces 
of all three RRMs, with generally the same set of affected residues as were seen 
with the isolated domains. Gly21, Cys61 and Gln93 from RRM1 and Gly113, 
Cys150 and Val182 from RRM2 all show large CSPs. From RRM3 residues such 
as Cys446 and Gly448 are strongly perturbed, matching data reported by Tsuda et 
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al. for the binding of RRM3 to UGUGUG in isolation. This confirmed that all of 
the RRMs could recognise a UGU(U) site in the EDEN11 GRE. However the 
titration did not reach an endpoint until a 2:1 excess of RNA had been reached. At 
a 1:1 ratio the peaks were very broad, with far too few resolvable signals to 
account for all of the residues. This suggests the midpoint of a titration in 
intermediate exchange on the NMR timescale. The peaks from the perturbed 
residues are therefore extremely broad, and not observable in the spectra from the 
intermediate titration points. Since each of the smaller constructs generally 
reached saturation at about a 1:1 RNA to protein ratio this indicated that the 
EDEN11 GRE is not forming a tight 1:1 complex, but instead one with a higher 
stoichiometry, which would not be expected if the EDEN11 GRE represented a 
complete EDEN motif capable of binding all three domains of CELF1. 
 
The fully bound spectrum at a 2:1 excess of RNA is a close match to a 
combination of the bound spectra of each of the three RRMs in isolation, and is 
shown in Figure 6.14. 
 
Figure 6.14: The 15N TROSY of the unbound RRM123 is shown in blue. Overlaid in red is the spectrum of 
RRM123 after the addition of a 2:1 excess of the EDEN11 GRE RNA (UGUUUGUUUGU). Both spectra were 
collected on a Bruker Avance III 800 MHz spectrometer with a cryoprobe. The protein concentration was 
250 µM. 32 scans were collected at a temperature of 298K. 
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Figure 6.15: A possible 2:1 complex of RRM123 with the EDEN11 GRE, consistent with the NMR data. 
 
The data suggest that the protein is binding two RNA molecules, one via RRM3, 
and the other by the tandem interaction of RRM1 and RRM2, as shown in Figure 
6.15. If the binding affinity of RRM3 to the RNA is of comparable strength to the 
tandem binding of N-terminal domains to the RNA (as would be predicted based 
on the ITC results for t187, and the reported RRM3 ITC data from Tsuda et al. 
2009) then at a 1:1 ratio a mixture of bound species would be present. Multiple 
species in intermediate exchange would account for the poor signal to noise seen 
across the residues in the binding interfaces of all three RRMs. Another 
possibility was that all three RRMs were binding onto a single RNA molecule, 
but with more than one conformation. For example, it might be possible to 
arrange the RRMs in a different order IURPWKH¶WR¶HQGRIWKH51$VXEVWUDWH
if the linkers between domains are sufficiently flexible. While this would account 
for a broadening of the line widths, it would not account for the apparent 2:1 
stoichiometry observed for this titration. 
 
 As a control experiment a titration with the EDEN4U RNA substrate 
(UGUUUUUUGU) was carried out under the same conditions. Since this 
sequence contains only two UGU sites, and was known to be an optimal target for 
the tandem binding of RRM1 and RRM2, it is definitely not capable of binding 
all three RRMs simultaneously. This control titration showed almost identical 
results to the EDEN11 GRE case, supporting the hypothesis of EDEN11 forming 
a 2:1 complex. Again, the signals were broad and poorly resolved at a 1:1 ratio, 
with a recovery of spectrum quality at around a 2:1 excess of RNA. 
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6.4.1 ITC of the EDEN11 GRE Binding to RRM123 
 
The EDEN11 GRE was tested for formation of a 1:1 complex, again using 
EDEN4U as a control, with the results shown in Figure 6.16. 
 
 
Figure 6.16: Binding curves for ITC of 125 µM EDEN11 GRE (UGUUUGUUUGU) and EDEN4U 
(UGUUUUUUGU) RNA substrates into 12.5 µM RRM123. Red lines show the best fitting match to a one-
site binding model. Neither titration reaches full saturation at the endpoint (a 2.5:1 excess of RNA). 
 
The EDEN11 GRE and EDEN4U RNA substrates give very similar binding 
curves on titration into RRM123. In both cases the titration fails to reach an 
endpoint until more than a 2:1 excess of RNA is present. Kd values of around 2 
µM are seen for both sequences, which is comparable to that seen in the t187 ITC 
data. This is all consistent with the model of two EDEN11 molecules binding to 
each protein, with the two binding events having comparable Kd values. This 
confirms that RRM3 cannot occupy the central UGU site of an EDEN11 RNA 
molecule that has already bound to RRM1 and RRM2. This is consistent with the 
conclusion in the previous chapter that t187 is binding to the two terminal UGU 
sites of EDEN11, leaving the central UGU site sterically inaccessible.  
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From the Kd values of ~3 µM determined in earlier experiments for t187 binding 
to EDEN5U, and 1.9 µM reported for RRM3 by Tsuda et al, it seems likely that 
the two binding events in this titration do in fact have quite similar Kd values, 
making them competitive. This would account for unresolved binding events 
observed in the EDEN4U and EDEN11 ITC experiments, contrasting with the 
biphasic scheme seen for RRM1/EDEN7 where the Kd values for the two binding 
events are substantially different.  
 
The NMR and ITC data enable us to conclude that the EDEN11 GRE is only a 
partial binding motif for CELF1. Its inability to bind all three RRMs 
simultaneously is likely to be due to steric effects between RRM3 and the other 
domains, as RRM3 would have to bind to the central UGU site. The crystal 
structure by Tsuda et al. suggests RRM3 is capable of forming contacts with up to 
six RNA bases, and so it was not surprising that it might require a greater spacing 
between binding sites than the other two RRMs. 
 
6.5 CELF1 Recognition of the EDEN15 GRE 
 
The ITC and NMR data collected on the shorter EDEN11 GRE showed 
unambiguously that it cannot bind all three RRMs simultaneously, and so does 
not represent a complete EDEN motif. Although the EDEN11 GRE has been 
presented as a consensus sequence in the recent literature, the analysis by 
Graindorge et al. in 2008 originally suggested a fourth UGU site might be 
conserved, giving the longer GRE sequence EDEN15 as a possible complete 
EDEN motif.  
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RNA Sequence 
EDEN11 UGUUUGUUUGU 
EDEN15 UGUUUGUUUGUUUGU 
(UGUC)4 UGUCUGUCUGUCUGU 
GU15 GUGUGUGUGUGUGUG 
 
The RNA substrate (UGUC)4 was investigated by ITC. This has four potential 
UGUX sites, with the same spacing as the EDEN15 GRE. The binding curve 
showed both a higher affinity than the EDEN11 GRE (Kd = 0.53 µM), and 
stoichiometry consistent with a 1:1 complex (n = 0.84). A 15 nucleotide GU 
repeat RNA substrate, similar to that suggested by Rattenbacher et al. (2010) was 
also investigated and found to give similar results as shown in Figure 6.17.  
 
 
Figure 6.17: ITC Binding curves for the RNA substrates GU15 and (UGUC)4. In red are shown the best fits 
to a 1: 1 binding model that could be obtained. Data processing carried out using MicroCal Origin 7.0. 
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From the ITC data it appears that both GU15 and (UGUC)4 form a 1:1 complex 
with RRM123. Since EDEN15 has the same spacing between UGU sites as the 
(UGUC)4 sequence, it could be concluded that the EDEN15 GRE will form a 
high affinity 1:1 complex with RRM123, and so appears to represent a complete 
EDEN motif. The binding affinities, while higher than for the EDEN11 GRE with 
RRM123 are still not much improved compared to those seen for tandem binding 
of the N-terminal domains. This suggests that while EDEN15 and similar 
sequences are capable of binding all three RRMs, the spacing between UGU sites 
may not be optimal. 
 
In GU15 the separation between the UGU sites is 1 and 3 nucleotides, while in 
(UGUC)4 it is 1 and 5 nucleotides. In both cases binding all three RRMs onto a 
single RNA molecule requires two of the RRMs to be occupying UGU sites with 
only a single nucleotide separating them, as illustrated in Figure 6.18. Since this 
was known not to be possible for the two N-terminal domains, it seemed to imply 
that RRM2 and RRM3 could tolerate this tight spacing between UGU sites. This 
was surprising, given that both of these domains were predicted to recognise 
UGUX sites and so would be expected to require more space than RRM1. 
 
 
Figure 6.18: Possible arrangements of the three domains of CELF1 on the proposed EDEN motifs EDEN15 
and GU15. In both cases two of the domains must occupy UGU sites separated by a single nucleotide, 
which is known not to be possible for the N-terminal domains RRM1 and 2. 
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6.6 Design of a High Affinity EDEN Motif 
 
For optimal binding it was expected that RRM3 would need a greater spacing 
between the third UGU(U) site and the other two. Since the minimum spacing 
requirement for t187 had been determined it was possible to return to the known 
natural targets of CELF1, and examine the spacing between suitable sites for t187 
and the next nearest UGU site. Based on these it was concluded that a spacing of 
2 ± 4 nucleotides between UGU sites was relatively common in the known 
natural targets. 
 
c-fos:  UGUUCAUUGUAAUGUU 
TNFĮ:  UGUUCCCAUGU««««UGU 
c-jun:  UGUUUGGGUAUCCUGCCCAGUGUUGUUUGU« 
c-mos:  UAUAUGUAUGUGUUGUUUUAUGUGUGUGUGUGUGCU 
 
This spacing was consistent with the c-mos and c-fos targets. It could also 
account for binding to c-jun if secondary structure in the spacing region could 
bring distant UGU sites together. This involvement of secondary structure 
appeared to be the only way WRDFFRXQWIRUELQGLQJWR71)ĮLQZKLFKWKHWKLUG
UGU site is separated by more than 30 nucleotides. Based on this observation the 
RNA substrate EDEN-2U/4U (UGUUUUGUUUUUUGU) was designed. RRM1 
and 2 could potentially bind across either spacer with high affinity. RRM3 could 
be allowed up to four nucleotides between its site and the adjacent site, which 
was expected to improve the binding affinity compared to EDEN15 and similar 
RNA substrates. Also designed was a variant that used an RNA hairpin to bring 
two of the UGU sites into close proximity: EDEN-2U/HL 
(UGUUUUGUUCCCGAGGACGGGUUGU). These two RNAs were 
investigated by NMR and ITC to determine if they formed a 1:1 complex, and if 
the binding affinity was improved compared to the EDEN15 GRE. 
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6.6.1 NMR Studies of the EDEN-2U/4U Complex with RRM123 
 
The initial titration of EDEN-2U/4U into 15N-labelled RRM123 showed large 
CSPs for residues across the RNA binding surfaces of all three RRMs (see Figure 
6.19). 
 
Figure 6.19: Chemical shift perturbations at a 1:1 ratio of EDEN2U/4U RNA to RRM123 protein. The 
brightness of the red colour indicates the magnitude of the perturbation. CSPs of less than 0.1 are 
ĂƐƐƵŵĞĚƚŽďĞďĂĐŬŐƌŽƵŶĚŶŽŝƐĞ ?ĂŶĚĂƌĞƐŚŽǁŶŝŶŐƌĞǇ ?ĨĨĞĐƚƐĂƌĞƐĞĞŶĂĐƌŽƐƐƚŚĞɴ-sheet surface of all 
three RRMs. Residues where the signal from the free form is rapidly lost, but no bound signal can be 
located are shown in yellow. Due to the presence of residues in intermediate exchange, where the peaks 
from the bound form are too broad to observe, minimum CSP estimates cannot be made in this situation.  
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With this RNA substrate there were some noticeable differences in the binding 
characteristics compared to earlier titrations. The signal to noise ratio remained 
poor throughout the titration, and was not recovered even at large excesses of 
RNA (3:1), unlike in the EDEN11 GRE and EDEN4U titrations. A 15N TROSY 
spectrum with a greatly increased number of scans (720) was collected on a 
sample with a 1:1 ratio of RNA to protein, which showed only peaks 
corresponding to the bound spectrum for all three RRMs (shown in Figure 6.20). 
This can be seen most clearly for residues with large CSPs, such as Cys61, 
Cys150 and Gly478. The glycine and cysteine regions of the spectrum have been 
expanded and compared to the corresponding regions from the EDEN11 GRE 
titration in Figure 6.21. 
 
Figure 6.20: Complete 15N TROSY at a 1:1 ratio of RRM123 and EDEN2U/4U, illustrating the decrease in 
spectrum quality compared to the free form, and the 2:1 complex with EDEN11 GRE. Peaks 
corresponding to the bound form of all three RRMs are visible. No peaks specific to the free form can be 
seen. This spectrum was acquired with 720 scans on a Bruker Avance III 800 MHz spectrometer with QCI 
cryoprobe at 298K. 
 
Cys61 and Cys150 both show large CSPs, matching those seen for the titration of 
t187 with EDEN4U. In the glycine region of the spectrum from RRM1 Gly21, 
Gly60 and Cys62 also show significant CSPs. From RRM2 Gly113, Gly149 and 
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to a lesser extent Gln172 can be seen to move. RRM3 shows major CSPs for 
Gly416, Cys446 and Gly448, which match the observations reported for binding 
of RRM3 to a UGU site. The chemical shifts in the bound spectra for the 2:1 
complex of EDEN11 with RRM123 and the 1:1 complex of EDEN-2U/4U with 
RRM123 are almost identical. 
 
Figure 6.21: Expanded view of two regions of the 15N TROSY spectrum, showing the residues most 
affected on binding to RNA. The spectrum of the unbound RRM123 is shown in blue. Overlaid in maroon 
is the spectrum at a 1:1 ratio with the EDEN11 RNA substrate, where very few peaks are visible. In green 
is the spectrum at a 1:1 ratio with the EDEN-2U/4U substrate, where peaks from the bound form are 
clearly visible. In red is the spectrum for a 2:1 ratio of EDEN11 to RRM123, where the peaks from the 
bound form have appeared. 
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No peaks specific to the free form could be observed in the EDEN-2U/4U case so 
it appears that the protein is fully bound at a ratio of 1:1. However the bound 
complex is showing a reduced signal to noise ratio and much broader linewidths 
compared to the end point of the EDEN11 titration. The poor signal to noise ratio 
cannot be attributed to intermediate exchange in this case. The peaks at a 1:1 
ratio, while broad, match the bound chemical shifts of the isolated RRMs, and so 
are not at a population weighted average of the free and bound forms. The signal 
intensity is also not recovered for large excesses of RNA, which would be 
expected in the case of intermediate exchange. 
 
The reduced spectrum quality could be due to the formation of a bound complex 
which is less dynamic and slower tumbling than the free protein. The high quality 
of the NMR spectra collected from unbound RRM123 samples has been 
attributed to the interdomain dynamics and resulting short rotational correlation 
times for the protein. If the dynamics of the protein change on binding, for 
example if it becomes more rigid and compact as all of the RRMs bind onto a 
single RNA molecule, this effect will be lost. The correlation times for RRM1 and 
RRM2 reported by Teplova et al. suggest this is occurring when the N-terminal 
domains bind in tandem51. It is therefore possible that a similar restriction is 
placed on the motion of RRM3 when all three domains are bound simultaneously 
to a single RNA molecule. Relaxation rates will become faster, resulting in more 
rapid loss of magnetisation and hence a poorer signal to noise ratio in the NMR 
spectrum. In contrast the signal to noise ratio was recovered in the EDEN11 GRE 
titration as RRM3 remained free to move relative to RRM1 and RRM2 due to 
binding a separate RNA molecule. Therefore the data for the complex of 
RRM123 with EDEN-2U/4U is consistent with a slow tumbling 1:1 complex with 
all three domains bound simultaneously. 
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6.6.2 Size Exclusion Chromatography 
 
If the loss of signal is due to the protein becoming more compact on binding all 
three RRMs to a single RNA molecule, it would be expected that size exclusion 
chromatography (SEC) could confirm this. The rate at which the protein complex 
moves through the gel matrix is dependent not only on the mass, but also the 
shape of the protein. A more globular complex would be expected to elute 
significantly later than the unbound protein. 
 
SEC however showed only a minimal difference between the free and bound 
RRM123. The bound complex eluted around 0.5 ml earlier than the unbound 
complex, as shown in Figure 6.22. It is possible this is due to the opposing 
influences of an increase in mass on binding to the RNA and the formation of a 
more compact protein complex. However the RRM123/EDEN11 complex was 
used as a control, and also showed little difference in the elution volume. This 
should have a higher mass than the RRM123/EDEN-2U/4U complex, and is not 
expected to be more compact than the free protein. From these results it was 
inconclusive whether the loss of signal in the NMR spectrum was due to a more 
compact bound form of the protein. 
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Figure 6.22: 280 nm absorption traces for size exclusion chromatography on an analytical Superdex 
GF200 column. The protein/RNA complexes are remaining intact when travelling through the column, as 
is clear from the increased 280 nm absorbance of the complexes compared to an equal concentration of 
the RRM123 protein. The maximum point of each peak has been marked with a vertical line in the same 
colour. 
 
Ion mobility mass spectrometry to measure the cross-sectional area of the protein 
complex is another potential method to confirm this. In this technique the ions 
produced by ESI travel through a tube with an applied electric current. A carrier 
buffer gas flows in the opposite direction, impeding the motion of the ions. 
Depending on the size and shape of the ions, they have different collision cross 
sections for the buffer gas molecules to collide with. The ions therefore travel at 
different speeds to the detector depending on their collision cross sections. 
Unfortunately ESI-MS of the complex resulted in very broad signals and poor 
quality spectra, preventing a comparison to the unbound RRM123 being made. 
This is probably due to an increase in salt adducts due to the longer RNAs 
compared to those used in mass spectrometry of the isolated RRMs and the t187 
construct. 
 
 
213 
 
6.6.3 RRM123 Binding to an RNA Substrate Containing a Hairpin Loop 
 
The EDEN-2U/HL substrate (UGUUUUGUUCCCGAGGACGGGUUGU) was 
designed to test the hypothesis that secondary structure in the RNA could bring 
distant UGU sites together resulting in a higher overall binding affinity. This 
RNA contains a hairpin between the expected t187 and RRM3 sites with a 
predicted stability of -5.2 kcal/mol, as shown in Figure 6.23179. The RNA was 
confirmed to form a hairpin in solution using 1D proton NMR, which identified 
imino peaks in the 12 - 14 ppm region of the spectrum. 
 
 
Figure 6.23: Secondary structure of the EDEN-2U/HL RNA substrate, as predicted by the RNA Institute 
mFOLD web service179. 
 
Hydrogen bonding between RNA bases results in distinctive chemical shifts 
downfield of the other RNA signals. With four C-*EDVHSDLUVIRUPLQJWKH³VWHP´
of the hairpin, it would be expected to see four signals in this region if the hairpin 
is present. In the 1D proton NMR of the RNA three signals were observed, at 
shifts of 13.33, 12.65 and 12.18 ppm. The signal at 12.18 ppm is significantly 
more intense than the other two, and so may be caused by two protons with very 
similar shifts. This confirms that at least three of the C-G base pairs and hence the 
RNA hairpin is forming in solution. 
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Figure 6.24: 1D proton NMR of the endpoint of the titration of 15N labelled RRM123 with EDEN2U/HL. 
The imine peaks at the far left of the spectrum are clear indicators of the presence of RNA secondary 
structure. Theoretically there should be one peak for each of the four C  ? G base pairs in the hairpin. Only 
three clearly resolved peaks can be seen, but the more intense peak at 12.18 ppm may be due to two 
peaks with very similar proton chemical shifts. 
 
As with the EDEN-2U/4U substrate, CSPs are seen across the RNA binding 
surfaces of all three RRMs. The same loss of spectrum quality is seen, and again 
is not recovered with a large excess of RNA. The 1:1 high affinity complex is 
therefore still forming, despite the insertion of the RNA hairpin between two of 
the UGU sites. The imino peaks from the RNA hairpin are present at the end of 
the titration, confirming that CELF1 is capable of binding across the base of the 
hairpin without breaking it apart. This is consistent with the AFM data reported 
by Michalowski et al. which showed CELF1 only binding to the single stranded 
ends of long CUG repeat hairpins and not to the stems. 
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6.6.4 ITC of RRM123 Binding to EDEN-2U/4U and EDEN-2U/HL 
 
The EDEN-2U/4U and EDEN-2U/HL substrates which were identified as 
forming high affinity 1:1 complexes by NMR were also examined by ITC, with 
the results shown in Figure 6.25. 
 
Figure 6.25: Binding curves from the titration of 125 µM EDEN-2U/4U (UGUUUUGUUUUUUGU) and 
EDEN-2U/HL (UGUUUUGUUCCCGAGGACGGGUUGU) into 12.5µM RRM123. Red lines show the curves 
from the one site binding model the data is fitted to. The first data point has been removed from each 
data set because the volume of the first aliquot is generally inaccurate. 
 
The EDEN-2U/4U substrate did produce a simple 1:1 curve when titrated into 
RRM123. Fitting to a one site binding model gave an n value of 0.85, showing a 
clear contrast with the n values of 1.45 and 1.64 observed for the EDEN11 and 
EDEN4U substrates. The Kd was calculated as 110 nM, which is the highest 
affinity so far observed by ITC for any combination of the CELF1 constructs and 
RNA substrates. 
 
The EDEN-2U/HL RNA showed a similar binding curve, with a somewhat lower 
affinity (Kd = 550 nM). While the presence of a hairpin in the spacer may be 
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having a slight negative effect on the binding affinity, the stoichiometry appears 
to be the same as seen for EDEN-2U/4U (n = 0.83), which is consistent with the 
NMR data. Unlike the earlier ITC experiments with CUG repeat hairpins, there 
were no signs of the hairpin breaking apart on binding, which would have been 
expected to introduce a second endothermic event similar to that seen for the 
earlier t187/CUG15 titration, altering the overall shape of the ITC trace. This is 
consistent with the 1D proton NMR of the bound complex showing peaks in the 
11 ± 13 ppm region from Watson-Crick base pair hydrogen bonding in the stem of 
the hairpin.  
 
ITC data was also collected for the EDEN-2U/4U and EDEN-2U/HL sequences 
as a reverse titration with the RNA in the cell and the RRM123 protein in the 
syringe. This was to examine how the protein behaved in the presence of large 
excesses of RNA, and to clarify whether the poor signal to noise in the NMR 
spectra at large excesses of RNA was due to multiple species forming. 
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Figure 6.26: ITC curve for a titration of 250 µM RRM123 into 25 µM EDEN-2U/4U. 30 x 10 µl aliquots were 
injected at 5 minute intervals.  
 
Both EDEN-2U/4U and EDEN-2U/HL showed an unusual shape to the start of 
the ITC curve, i.e. where there was a large excess of RNA present. The difference 
in the ITC traces for titrating protein into RNA compared to titrating RNA into 
protein can be rationalised. If this protein construct forms a high affinity complex 
with all three RRMs bound to this RNA sequence, then in a situation with a large 
excess of protein it would be expected that only simple 1:1 binding would be 
seen. Once a protein binds to the RNA substrate via one RRM, the chelate effect 
should strongly favour binding of the other two RRMs onto the same RNA 
molecule if there are suitable sites for them. This is the case for the RNA into 
protein titrations. In contrast if the RNA is in very large excess then the formation 
of complexes with two or possibly three RNA molecules per protein becomes 
more favourable. The formation and later dissociation of these complexes as the 
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protein to RNA ratio increases could account for the anomalous shape of the 
curve in the protein into RNA titrations for molar ratios of 0 to ~0.6 protein to 
RNA. Once the protein concentration increases, formation of the 1:1 complex 
becomes more favourable, resulting in the second part of the curve which shows 
similar Kd and enthalpy changes to those seen in the RNA into protein titration. 
 
6.6.5 Comparison of ITC Data shows Two Distinct Binding Schemes 
 
Since the titrations with the EDEN11, EDEN4U, EDEN-2U/4U and EDEN-
2U/HL substrates were run under exactly the same conditions they could be 
compared directly by overlaying the ITC binding curves. This overlay is shown in 
Figure 6.27 and clearly shows that these four titrations can be divided into two 
distinct binding schemes, one indicative of 1:1 stoichiometry and one suggesting 
a higher stoichiometry. 
 
 
Figure 6.27: Comparison of the ITC traces for RRM123 on titration with EDEN4U, EDEN11, EDEN2U/4U 
and EDEN2U/HL. In all cases 125 µM RNA was titrated into 12.5 µM RRM123, in 30 x 10 µl aliquots. 
 
Where RRM123 can bind all three RRMs simultaneously to the RNA (in the 
EDEN-2U/4U and EDEN-2U/HL cases) the titration reaches saturation point 
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earlier, and there is a larger enthalpy change. When all the domains cannot bind 
simultaneously (in the EDEN11 and EDEN4U cases) the titration does not reach 
saturation until more than a 2:1 excess of RNA is present. This suggests that at a 
1:1 ratio a mixture of species is present, with some proteins bound to the RNA via 
their N-terminal domains and some bound via the RRM3 domain, as shown in 
Figure 6.28. The binding affinities for these events are believed to be similar, 
accounting for the lack of resolvable binding events in the ITC trace. At a 2:1 
excess all proteins can bind to two RNA molecules. In contrast in the scheme 
where all three RRMs can bind simultaneously the higher affinity 1:1 complex is 
not affected by addition of further RNA. 
 
 
Figure 6.28: This diagram shows the species present in each of the two binding schemes at a 1:1 and 2:1 
ratio of RNA to protein. 
 
6.7 Refining the Criteria for an EDEN Motif 
 
The spacer lengths of 2 and 4 nucleotides were originally selected based on a 
combination of known mRNA targets of CELF1, and the spacing requirements 
seen for the two N-terminal domains. Once these were known to permit the 
formation of a high affinity 1:1 complex it was necessary to investigate the 
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minimum and maximum spacer lengths tolerated as was done for the t187 
construct, in order to determine the overall criteria for an EDEN motif. In 
addition, since the two spacers are not necessarily the same length, it was 
important to determine if CELF1 showed any SUHIHUHQFHLQ WKH¶ WR¶RUGHU of 
them. 
 
6.7.1 EDEN4U/2U 
 
The closest matching section to the EDEN-2U/4U RNA substrate from the 
naturally occurring mRNAs is a sequence from the c-fos ARE. 
 
c-fos ARE 14-30: UGUUCAUUGUAAUGUU 
EDEN-2U/4U: UGUUUUGUUUUUUGU 
 
There are differences, as some of the U spacers have been replaced with A and C 
bases, and the 2U/4U spacers have been reversed. However this still seemed a 
likely candidate to form a 1:1 complex with RRM123. Since it is possible that the 
RRMs have a preference for a specific 5¶ ± 3¶ RUGHU RQ WKH 51$ VWUDQG WKH
arrangement of the spacer lengths may be relevant. The ITC experiment with the 
RNA EDEN-4U/2U (UGUUUUUUGUUUUGU) was used to check for any 
difference in binding affinity. 
 
Reversing the spacers did result in some loss of binding affinity (the Kd was 
increased from 110 nM to 980 nM), but still permitted a 1:1 complex to form. It is 
not clear whether the change in binding from EDEN-2U/4U involves reversing 
WKH¶ WR¶DUUDQJHPHQWRI WKH550VRQ WKH51$ ,WFRXOGVLPSO\EH WKHFDVH
WKDW550DQG550DUH VWLOOERXQGDW WKH¶ HQGRI the RNA, across the 4U 
spacer, while the 2U spacer is still sufficient for RRM3 WRELQGDWWKH¶HQG7KH
results of the EDEN15 titrations suggested that RRM3 can tolerate even a one 
nucleotide spacer. It therefore seems likely that RRM3 can bind across the 2U 
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spacer as well as the 4U spacer. If RRM3 and the neighbouring RRM begin to 
clash when binding to UGU sites with only two uracils separating them, it could 
account for the reduction in binding affinity seen. Since this arrangement of 
spacers is tolerated it confirms that the section of the c-fos mRNA tentatively 
suggested by Moraes et al. in 2006 is a high affinity EDEN motif capable of fully 
binding CELF1. 
 
6.7.2 Involvement of RNA Secondary Structure in CELF1 Binding 
 
C-jun was reported by Paillard et al. (2002) to bind to both Xenopus and human 
&(/) DQG WULJJHU UDSLG GHDGHQ\ODWLRQ ZKHQ SUHVHQW LQ WKH ¶ 875 RI DQ
mRNA190. Vlasova et al. reported a shorter version of the c-jun sequence which 
could also trigger deadenylation. Since the EDEN11 GRE has been shown to be 
insufficient this RNA does not contain a set of UGU sites with suitable spacing 
for CELF1 binding when considered only as a linear sequence. 7KH 71)Į
sequence reported by Moraes et al. is another example, which has no instances of 
three UGU sites within 40 nucleotides of each other. The experiments with 
EDEN-2U/HL however showed that secondary structure could also create a high 
affinity CELF1 site by bringing distant UGU sites together. Similar secondary 
structure in the C-MXQ DQG 71)Į VHTXHQFHV SURYLGH DQ H[SODQDWLRQ IRU WKHLU
binding of CELF1. The secondary structures of the relevant regions of these two 
RNA, as predicted by the mFOLD web service, are shown in Figure 6.29.  
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Figure 6.29: Left is shown the C-jun section shown by Vlasova et al to be capable of binding CELF1. Right 
ŝƐƐŚŽǁŶƉĂƌƚŽĨƚŚĞdE&ɲ substrate reported by Moraes et al. In each case the UGU sites which appear to 
be in the most favourable arrangement for binding CELF1 have been highlighted. RNA secondary 
structure predictions were made by the mFOLD web service179. 
 
The c-jun RNA shows two clear double stranded regions. One is from bases 17 ± 
31, which forms a hairpin held together primarily by three Watson-Crick C-G 
base pairs, similar to the hairpin in the EDEN-2U/HL sequence. The second 
double stranded region is between bases 1 ± 11 and 44 ± 53, mostly composed of 
U ±A base pairs. This leaves a single stranded region between them, which 
contains five of the possible UGU sites in close proximity. The three highlighted 
UGU sites are essentially equivalent to the EDEN-2U/4U high affinity substrate, 
with a hairpin inserted into the 2U spacer. This seems the most probable site for 
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binding of all three RRMs of CELF1. 
 
71)Į LVSUHGLFWHG WR IRUPDQH[WHQGHGKDLUSLQPRWLI IRUPHG ODUJHO\E\8 ± A 
base pairing in the AUUUA repeating region. As shown, this does bring three 
UGU sites into relatively close proximity. They are however predicted to be in 
double stranded regions of the RNA, which has been shown to prevent CELF1 
binding in the long CUG repeat hairpins found in DM1 cells. The CELF1 
interaction with UGU sites is of higher affinity, and there are more mismatched 
U-G and U-U bases in this hairpin than in the CUG repeat case. It is possible that 
some of this double stranded region can break apart in order to bind CELF1 (as 
was seen in the t187/CUG15 titration). 
 
This also provides a possible explanation for the reported dependence of 
deadenylation efficiency on the presence of an AU rich element, in this case an 
AUUUA repeat. It can be hypothesised that deadenylation is more efficient when 
the AU rich elements are present because they form secondary structures that 
bring UGU sites into more favourable configurations for CELF1 binding, rather 
than  any direct binding of CELF1 to the AU rich elements themselves. 
 
6.7.3 Determination of the Minimal Binding Sequence for CELF1 
 
If the earlier hypotheses about the spacing tolerances of each of the RRMs are 
correct then the RNA substrate EDEN-2U/1U (UGUUUUGUUUGU) would be 
expected to be the minimum sequence capable of binding all three RRMs. It 
would therefore represent the smallest possible EDEN motif, and confirm the 
minimum requirements for binding. ITC was carried out on this substrate, with 
the results shown in Figure 6.30. 
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Figure 6.30: ITC binding curve for the titration of 125 µM EDEN-2U/1U into 12.5 µM RRM123. 
 
The EDEN-2U/1U substrate seems to fall somewhere between the binding 
scenarios seen for the EDEN11 GRE and EDEN-2U/4U cases. The Kd indicates a 
higher affinity than the EDEN11 GRE, but more than a 10 fold reduction in 
affinity compared to the EDEN-2U/4U substrate. The n value is 1.19, roughly 
halfway between those of the EDEN11 GRE and EDEN-2U/4U RNAs. This RNA 
sequence was also investigated by NMR, which showed bound peaks for all three 
domains of CELF1 at a 1:1 ratio of protein to RNA, with the characteristic loss of 
signal to noise ratio, which suggests it probably is forming a 1:1 complex. As for 
EDEN-2U/4U, the spectrum quality was not recovered on addition of excess 
RNA. This RNA substrate therefore does represent a complete EDEN motif, but 
the short spacers between the UGU sites appear to be sufficiently unfavourable 
that there is only a marginal increase in affinity compared to binding of the N-
terminal domains to the EDEN11 GRE. 
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6.7.4 Investigation of a Two Domain Construct of RRM2 and RRM3 
 
As both the EDEN15 GRE and EDEN-2U/1U can bind all three RRMs, at least to 
some extent, then it was conceivable that RRM2 and RRM3 could bind 
simultaneously to the EDEN7 (UGUUUGU) sequence which previously failed to 
bind both RRMs of t187. To investigate this possibility a construct containing 
only the RRM2 and RRM3 domains was required. A construct retaining the wild 
type 200 residue linker between these two domains as expected had all of the 
same issues with solubility and stability as the full length wild type CELF1. For 
direct comparison with the RRM123 construct a version with the shortened 
RRM2 ± RRM3 linker was needed. 
 
Both the wild type and deletion mutant versions were produced using the same 
method of single step PCR deletion to remove the codons for residues 1 - 107 of 
CELF1 from the construct. The only difference in the PCR protocol was whether 
full length CELF1 or the RRM123 construct DNA was used as the template. The 
growth, expression and purification protocols were the same as for the RRM123 
complex. The solubility and stability of the protein were found to be similar to 
RRM123, allowing NMR and ITC data to be collected. 
 
The 15N TROSY spectrum of this construct was well resolved, and is shown in 
Figure 6.31. As expected the spectrum essentially a composite of the RRM2 and 
RRM3 spectra, with some additional peaks from the unstructured linker. 
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Figure 6.31: 15N TROSY spectrum of a 250 µM sample of the RRM23 construct, collected on an 800 MHz 
spectrometer with cryoprobe at 298K. 
 
This new construct was used to determine whether RRM2 and RRM3 could bind 
to UGU sites separated by only a single nucleotide, using a similar approach to 
that described for the t187 construct. The EDEN7 RNA substrate was titrated into 
15N-labelled RRM23. 
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Figure 6.32: The 15N TROSY spectrum of unbound RRM23 is shown in blue. Overlaid in red is the 15N 
TROSY at the midpoint of the titration with EDEN7. As the titration is in slow exchange sharp peaks from 
both the free and bound form are clearly visible. CSPs are only seen for residues in RRM3. No effects are 
seen for any residues in RRM2. Some significantly perturbed residues in RRM3, and some residues that 
are normally perturbed on binding in RRM2 have been highlighted. 
 
As shown in Figure 6.32, CSPs were only seen in RRM3, indicating that only this 
domain was binding to the EDEN7 substrate. The titration was entirely in slow 
exchange and peaks from both the free and bound forms of RRM3 can be clearly 
seen at the midpoint of the titration. No significant CSPs were seen for any 
residues in RRM2. When RRM2 and RRM3 are in competition RRM3 is bound 
preferentially. This is as expected since the ITC data showed that RRM3 had a 
significantly stronger binding affinity for UGU sites than RRM2, with a Kd that 
was at least an order of magnitude lower. 
 
This was corroborated by ITC of RRM23 into EDEN7, which showed only a 
single binding event with a Kd of 0.52 ± 0.12 µM, consistent with only RRM3 
binding (Figure 6.33). Due to the large difference in the affinities of the two 
domains, there would be expected to be a strong preference for binding of RRM3. 
No effects were seen for residues in RRM2 until after a 1:1 ratio of RNA to 
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protein was reached. It is unclear if this is due to an inability to bind the domains 
in tandem to the UGUUUGU substrate, or simply the 100 fold difference in 
binding affinities between the domains. 
 
 
Figure 6.33: ITC curve for a titration of 125 µM RRM3 into 12.5 µM EDEN7. A single binding event is seen, 
indicating formation of a 1:1 complex.  
 
These observations had failed to produce any evidence of tandem binding of 
RRM2 and RRM3 to UGU sites separated by only a single nucleotide. A 
remaining possibility in sequences such as EDEN-2U/1U was that RRM1 and 
RRM3 were occupying the UGU sites on either side of the single nucleotide 
spacer, leaving the RRMs arranged in the order RRM2 ± RRM1 ± RRM3 from 
WKH¶WR¶HQGRIWKH51$VXEVWUDWH Whether this was a viable arrangement of 
the domains was initially investigated by molecular modelling, and then 
investigated in solution by NMR using a paramagnetic relaxation enhancement 
technique as detailed in the next chapter. 
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6.7.5 Summary of ITC Data for all RNA Substrates 
 
All calculated thermodynamic parameters for each RNA substrate on titration into 
RRM123 are summarised in the table below. 
 
RNA Kd (PM) N 
(sites) 
ȴ, ?ŬĐĂůŵŽů-1) ȴ^ ?ĐĂů<-
1mol-1) 
UGUUUGUUUGU (GRE) 2.2 ± 0.3 1.45 -53.7 ± 1.4 -154.0 
UGUUUUUUGU (EDEN-4U) 2.1 ± 0.4 1.64 -54.4 ± 1.7 -157.0 
UGUAUGUGUUGUUUUAUGU 
(EDEN19) 
0.33 ± 
0.07 
0.79 -111.4 ± 3.1 -344.0 
UGUUUUGUUUUUUGU (EDEN-
2U/4U) 
0.11 ± 
0.02 
0.85 -51.8 ± 1.0 -142.0 
UGUUUUUUGUUUUGU (EDEN-
4U/2U) 
0.98 ± 
0.12 
0.67 -35.7 ± 1.0 -92.3 
UGUUUUGUUCCCGAGGACGGGUUG
U (EDEN2U/HL) 
0.55 ± 
0.08 
0.83 -69.0 ± 1.6 -203.0 
GUGUGUGUGUGUGUGUG (GU15) 0.66 ± 
0.08 
0.74 -46.3 ± 1.2 -127.0 
UGUCUGUCUGUCUGUC (UGUC)4 0.53 ± 
0.07 
0.84 -56.9 ± 1.1 -162.0 
UGUUUUGUUUGU (EDEN-2U/1U) 1.49 ± 
0.23 
1.19 -64.7 ± 2.9 -190.0 
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6.8 Conclusions 
 
Wild type CELF1 was found to be a difficult protein to investigate by most 
biophysical techniques due to its poor solubility and the low yield of the 
purification method. We did however succeed in producing the much more 
soluble and stable RRM123 construct allowing the behaviour of all three domains 
of CELF1 together to be investigated by NMR and ITC.  
 
Using RRM123 we have shown that the EDEN11 GRE is not capable of forming 
a high affinity 1:1 complex with CELF1, and so only represents a partial EDEN 
motif. While it does contain three UGU sites the spacing between them is 
unsuitable for simultaneous binding of all three domains. The longer EDEN15 
RNA substrate does however appear to be capable of binding all three RRMs and 
so is a complete EDEN motif. However the ITC results suggest the spacing is not 
optimal, as little enhancement of affinity was seen compared to binding of the N-
terminal domains only. Based on the spacing requirements of the N-terminal 
domains deduced in the previous chapter, and the known natural mRNA targets 
of CELF1 we have designed the RNA substrate EDEN-2U/4U, which was found 
to be a complete EDEN motif with the highest binding affinity so far observed 
(Kd = 110 nM). 
 
We have refined the criteria for the EDEN motif to UGU(x)UGU(y)UGU where 
x = 2 ± 4 and y = 1 ± 5 result in a 1:1 complex. There is a 5-fold difference in Kd 
for y = 5 vs. y = 4, and a 10-fold difference for y = 1 vs. y = 4. The combination x 
= 2, y = 4 results in the highest affinity interaction measured so far. However we 
have also shown using the RNA EDEN-2U/HL that much longer spacers can bind 
with comparable affinity if RNA secondary structure can bring distant UGU sites 
into close proximity. We have identified both c-jun DQG71)Į as possible natural 
examples of this. All other mRNAs previously demonstrated to trigger 
deadenylation by binding CELF1 contain sequences consistent with our EDEN 
motif criteria without the need for secondary structure involvement. 
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7 Characterisation of a Complex of CELF1 with a 
High Affinity EDEN Motif 
 
We originally aimed to characterise the structure of the complex of CELF1 with a 
high affinity EDEN motif using either NMR or x-ray crystallography. 
Unfortunately the decrease in signal to noise ratio seen in the NMR spectra when 
the complex formed prevented the collection of sufficiently high quality NOE and 
RDC data to gather restraints for an NMR solution structure. Attempts were also 
made to co-crystallise RRM123 with high affinity RNA substrates in order to 
obtain a structure by x-ray crystallography, but no diffraction quality crystals 
were produced.  
 
A different approach of modelling the structure of the complex, starting from the 
available structures of the isolated domains was therefore chosen. In constructing 
this model the main uncertainty to be resolved was the arrangement of the three 
structured domains on the three UGU(U) sites of a high affinity RNA substrate. 
There was also the question of whether there was a single preferred bound 
conformation, or if the inherent flexibility of the linkers between the domains 
would permit a range of conformations in solution. The range of possible RNA 
binding modes in multi-RRM systems has been previously found to present 
problems, particularly for x-ray crystallography. For example when the tandem 
interaction of RRM1 and RRM2 of U2AF65 with an RNA substrate was 
investigated by both NMR and x-ray crystallography, the resulting structures 
differed significantly191, 192, 193. The potential for multi-RRM systems to have 
several possible binding modes, depending on the exact target RNA and the 
presence of any secondary structure therefore had to be considered. 
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7.1 Arrangement of the Domains on the RNA Substrate 
 
A key question in constructing the model was the relative arrangement of the 
three domains when bound onto a single RNA molecule. The data in the previous 
chapter showed that substrates such as EDEN-2U/4U could bind all three 
domains, one to each of its three UGU sites, but did not indicate which domain 
was occupying which site. There are several possible ways of arranging the 
domains on the three UGU sites, but steric considerations allowed some 
possibilities to be eliminated. In the available crystal structures the RNA substrate 
LVFRQVLVWHQWO\SRVLWLRQHGZLWKWKH¶HQG towards WKHȕVLGHRIthe ȕ-sheet and 
WKH¶ HQGRQ WKHȕ VLGH IRU DOO three RRMs of CELF1. This alignment of the 
51$ DFURVV WKH ȕ-sheet is common for RRMs in general43. The short linker 
between the N-terminal domains RRM1 and RRM2 of CELF1 imposes 
significant steric constraints on binding, and in order for each domain to bind in 
the same way as they do in isolation they must be arranged in the order RRM2 ± 
550IURP¶WR¶DORQJWKH51$This arrangement is shown in Figure 7.1. 
 
Figure 7.1: Model of the N-terminal domains RRM1 and RRM2 in complex with the RNA substrate 
UGUUUUUUUGU. This was produced by constructing the RNA sequence UUUUU in XLEAP, and 
superimposing the two terminal nucleotides with U4 and U5 of the t187/EDEN2U model shown earlier. 
The model was then minimised, and underwent a molecular dynamics run according to the protocol in 
section 3.22. The domains are in the order RRM2  ? ZZD ?ĨƌŽŵƚŚĞ  ? ?ƚŽ  ? ?ĞŶĚŽĨƚŚĞZE ?dŚĞ ůŝŶŬĞƌ
between the domains is not sufficiently long to allow the domains to adopt the other arrangement. 
Energy minimization and molecular dynamics were carried out in Amber. This image was produced using 
Pymol. 
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While there are no available structures in the protein databank showing tandem 
binding of any combination of the CELF1 domains onto a single RNA molecule, 
there are some structures of other multi-RRM systems available in the literature. 
Structural data is available for some examples of proteins containing two RRMs 
separated by a comparably short linker to CELF1, such as Sx138, PABP194 and 
Hrp144. Each of these proteins is capable of binding in tandem to an RNA 
substrate of between 7 and 10 nucleotides. Restricted by an interdomain linker of 
less than 10 residues in each case, these proteins have consistently been found to 
ELQG ZLWK 550 DW WKH ¶ HQG RI WKH 51$ DQG 550 WRZDUGV WKH ¶ HQG
(numbering the RRMs from the N-terminus of each protein). These proteins 
displayed considerable cooperativity between the RRMs, with them acting in 
WDQGHPWRIRUPDQH[WHQGHGȕ-sheet surface to recognise longer RNA sequences. 
While the CELF1 RRMs appear to be rather more independent, the short linker 
still forces 550WREHSRVLWLRQHGWRWKH¶HQGRIWKH51$UHODWLYHWR550 
 
The location of RRM3 remained uncertain. With the restriction that RRM2 must 
be WRZDUGVWKH¶HQGUHODWLYHWR550WKHUHZHUHWKUHHSRVVLEOHDUUDngements of 
the domains on the EDEN-2U/4U substrate, as shown in Figure 7.2. 
 
 
Figure 7.2 PWŽƐƐŝďůĞĂƌƌĂŶŐĞŵĞŶƚƐŽĨƚŚĞƚŚƌĞĞĚŽŵĂŝŶƐŽĨ>& ?ĨƌŽŵ ? ?ƚŽ  ? ?ǁŚĞŶďŽƵnd to the RNA 
substrate EDEN-2U/4U. 
 
The earlier investigation of the N-terminal domains in the t187 construct showed 
a significant decrease in binding affinity for UGU sites separated by more than 4 
nucleotides. The 2 ± 3 ± 1 arrangement forces RRM1 and RRM2 to occupy sites 
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which are 9 nucleotides apart, which is therefore likely to be unfavourable. Based 
on this observation and the known inability of RRM3 to occupy to the central site 
of the EDEN11 GRE (UGUUUGUUUGU) it seemed unlikely that the 2 ± 3 ± 1 
arrangement would be preferred.  
 
This left the 3 ± 2 ± 1 and 2 ± 1 ± 3 arrangements as possibilities. In the RRM123 
construct the linker between RRM2 and RRM3 consists of around 30 residues, 
which is sufficient to make either arrangement sterically plausible. In wild type 
CELF1 this linker is far longer at around 200 residues, allowing RRM3 even 
more freedom to move independently, again making either arrangement possible. 
In order to determine whether one of these arrangements is preferred, and if so 
which, a technique was required that could connect one of the domains to a 
specific UGU site. Paramagnetic relaxation enhancement was used for this 
purpose. 
 
7.2 Modelling RRM123 in Complex with a High Affinity RNA 
Substrate 
 
Models of the RRM123 construct bound to the EDEN-2U/4U and EDEN-2U/HL 
RNA sequences were constructed, as an initial check to ensure that no steric 
clashes or implausible strains on the interdomain linkers were present. These 
were constructed based on the available crystal and NMR structures in the Protein 
Data Bank produced by Teplova et al. and Tsuda et al. Since none of these 
structures had more than one of the RRMs bound to a single RNA substrate, it 
was necessary to splice the isolated structures together to produce the overall 
model of RRM123.  
 
The model of RRM1 and RRM2 in complex with the RNA sequence 
UGUUUUGU (a two nucleotide spacer), shown earlier in Figure 5.13, was used 
as the N-terminal fragment of the protein. The structure of RRM3 in complex 
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with the RNA sequence UGUGUG produced by Tsuda et al. was used as the C-
terminal fragment. Since no structural data existed for the RRM2 ± RRM3 linker 
region a section of the RRM123 protein consisting of residues 186 - 216 was 
constructed in the program XLEAP, and then energy minimised in AMBER. This 
linker was then attached to the N-terminal fragment by superimposing residues 
186 and 187 of the linker onto their counterparts in RRM2 of the N-terminal 
fragment (minimising RMSD). The C-terminal fragment was similarly attached 
by superimposing residues 215 and 216 of the RRM3 structure onto the 
corresponding residues in the RRM2 - RRM3 linker. This resulted in a complete 
RRM123 protein with two separate RNA fragments, one bound to the N-terminal 
domains and one to RRM3. 
 
This model was energy minimised, and underwent molecular dynamics 
simulations in AMBER for 1 ns at 300 K. To produce the complete RNA the 
fragment bound to RRM3 was truncated to the UGU site. A section of RNA 
consisting of the sequence UUUUUU was constructed in XLEAP, energy 
minimised in AMBER, and attached to the RRM3 fragment by superposition of 
WKH¶XUDFLOZLWKWKH¶XUDFLORIWKH8*8VLWH7KH¶XUDFLORIWKLV51$VSDFHU
ZDV WKHQ VXSHULPSRVHG RQWR WKH ¶ 8 RI WKH 8*8888*8 IUDJPHQW ZKLch 
necessitated the introduction of implausibly long bonds into the RNA backbone 
to make this connection. This structure, corresponding to RRM123 in complex 
with EDEN-2U/4U with the domains arranged in the order 2 ± 1 ± 3, was energy 
minimised with a restraint mask applied to the RNA, which was gradually 
reduced until all bonds had relaxed to normal lengths. The structure was then 
subjected to molecular dynamics simulations in AMBER for 2 ns.  
 
A model of the same complex, but with the RRMs in the order 3 ± 2 ± 1 was also 
constructed by a similar method. The spacing in the RNA sequence 
UGUUUUGU, bound to the N-terminal fragment was expanded from 2U to 4U 
E\ VXSHULPSRVLQJ WKH ¶ DQG ¶ QXFOHRWLGHV RI D FRQVWUXFWHG 8888 VHTXHQFH
onto U4 and U5. This structure was then minimised and used as the starting point 
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for a molecular dynamics run as described in section 3.22. The RRM2 ± RRM3 
linker and the third domain were added by the same method as in the 2 ± 1 ± 3 
model. Another constructed section of RNA, with the sequence UUUU was then 
XVHG WR FRQQHFW WKH ¶ HQG RI WKH 550 ERXQG 8*8 VLWH WR WKH ¶ HQG RI WKH
UGUUUUUUGU sequence bound by the N-terminal domains. This starting 
structure then underwent energy minimisation and a molecular dynamics run, 
with a final 2 ns step at 300 K with no restraint applied to the protein or RNA. 
Both arrangements of the domains appeared sterically plausible, and the RNA 
remained bound throughout the molecular dynamics run. The model with the 2 ± 
1 ± 3 arrangement is shown in Figure 7.3. 
 
Models of RRM123 in complex with the EDEN-2U/HL RNA sequence were also 
constructed. The RNA hairpin (consisting of the sequence 
UCCCGAGGACGGGU folded to form hydrogen bonds between the bases in 
LWDOLFVZDVFRQVWUXFWHGLQ;/($3DQGHQHUJ\PLQLPLVHG7KH¶DQG¶XUDFLOV
were then superimposed onto U9 and U12 respectively of EDEN-2U/4U in the 
complex of this RNA sequence with RRM123. U10 and U11 of the EDEN-
2U/4U sequence were then deleting, leaving an overall RNA sequence matching 
EDEN-2U/HL. The model then underwent energy minimisation and a 2 ns 
molecular dynamics simulation. The structure appeared sterically plausible with 
either the 3 ± 2 ± 1 or 2 ± 1 ± 3 arrangement of the domains, and in both cases the 
RNA hairpin remained intact throughout the molecular dynamics run. The model 
with the 2 ± 1 ± 3 arrangement is shown in Figure 7.4. 
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Figure 7.3: Model of RRM123 in complex with the EDEN-2U/4U substrate. The RRMs are in the 2  ? 1  ? 3 
ĂƌƌĂŶŐĞŵĞŶƚĨƌŽŵƚŚĞ ? ?ƚŽ ? ?ĞŶĚŽĨƚŚĞZEƐƚƌĂŶĚ ? 
 
 
Figure 7.4: A model of the EDEN-2U/HL RNA substrate bound to the RRM123 protein. Modelling was 
carried out using Amber for energy minimization followed by molecular dynamics simulations as 
specified in section 3.22. 
 
238 
 
From the molecular modelling it was evident that there was still considerable 
flexibility in the structure from the RNA and interdomain linkers. This permits 
the domains to either form a compact structure, or a range of more extended 
structures. 
 
7.3 Paramagnetic Relaxation Enhancement 
 
When a paramagnetic centre is present in a protein the relaxation rates of 
surrounding nuclei are greatly increased, resulting in attenuation of their signals 
in NMR spectra. By observing which residues contain affected nuclei, the 
position of the paramagnetic centre within the structure can be determined195. 
Some proteins contain endogenous paramagnetic centres such as Fe3+, or metal 
ions which can be substituted for a paramagnetic lanthanide ion196, 197. In addition 
to using existing metal ions in proteins it is also possible to add paramagnetic 
tags, containing either a lanthanide ion, or a stable radical such as a nitroxide 
group198, 199. These are usually attached by a coupling reaction to a cysteine 
residue, either endogenous or introduced by point mutation. These tags can also 
be attached to ligands200, 201 and nucleic acids202, 203. 
 
The PRE effect has a much longer range than NOEs, of up to 25 Å. This is a 
sufficiently long distance that the effect could potentially extend between the 
domains of CELF1, allowing interdomain restraints to be generated. This 
technique would also distinguish between the 3 ± 2 ± 1 and 2 ± 1 ± 3 
arrangements. If the tag were attached to one of the protein domains then 
measurement of the signal attenuation in the 15N TROSY spectrum for residues in 
each of the other two domains would show which domain was closest to the 
paramagnetic tag, and hence the overall arrangement. Alternatively the 
paramagnetic tag could be attached to the RNA, close to one of the UGU sites. 
The residues in the domain binding to that UGU site would then be expected 
show the greatest signal attenuation in the 15N TROSY spectrum. 
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The paramagnetic tag selected for these experiments was MTSL (S-(2,2,5,5-
tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate) supplied 
by Toronto Research Chemicals Inc. MTSL consists of a stable nitroxide group 
attached to a sulfinic acid (CH3SO2) leaving group. This is normally reacted to 
form a disulphide link to a specific cysteine residue in the protein, but it can also 
be coupled to other sulphur containing groups. Since the RRM123 construct 
contains seven cysteine residues attaching the spin label to a specific cysteine 
would require a minimum of six point mutations. In addition some of these 
cysteines (specifically Cys61, Cys62 and Cys150) are located in the key RNP 
UHJLRQVRIWKHSURWHLQ¶VELQGLQJVXUIDFHVDQGIRUPK\GURJHQ bonds to the RNA in 
the reported crystal structures of the isolated domains. RNA binding would 
almost certainly be interfered with if the tag was attached to one of these residues. 
Altering these residues to, for example, serine or alanine would however 
potentially disrupt the normal RNA binding properties of the protein. Attaching 
the spin label to a specific site on the RNA was a more attractive option, as RNA 
sequences with modified bases at specific sites were commercially available from 
Dharmacon. MTSL can be coupled to a 4-thio-uridine base, as shown in Figure 
7.5. 
 
Figure 7.5: On the left is the structure of the 4-thio-uridine modified RNA base. In the centre is the 
structure of the MTSL, showing the unpaired electron of the nitroxide group which acts as the spin label. 
On the right is shown the structure of the modified RNA base after the coupling reaction with the MTSL. 
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With the tag attached to a modified base at one end of the RNA strand it would 
attenuate the signals of the nearby residues in the 1H-15N HSQC spectrum, 
unambiguously showing which domain was binding closest to that end. 
 
7.3.1 Paramagnetic Relaxation Enhancement in RRM1 on binding to 
MTSL Labelled UGUU 
 
As an initial proof of concept the RNA tetramer U*GUU, where the 5' uridine 
had been replaced with 4-thiouridine was used. A 3x molar excess of MTSL was 
added to the RNA, and allowed to react in darkness at room temperature for two 
hours. This was then loaded onto a HiTrap desalting column and eluted into 
RNAse free MilliQ H2O to remove unreacted MTSL. The eluted RNA was then 
frozen using liquid nitrogen, and lyophilised, again in darkness. 
 
Titration of this MTSL-tagged RNA into a 15N labelled RRM1 sample resulted in 
attenuation of a large percentage of the amide signals in the spectrum. Those in ȕ-
strands 1 and 3 were most affected, with signals from residues such as 19 ± 23 
and 60 - 62 lost completely by the time a 1:1 ratio of RNA to protein was 
reached. 
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Figure 7.6: In blue is the 1H-15N HSQC of the unbound RRM1 construct. Overlaid in maroon is the 
spectrum at a 1:1 ratio of MTSL coupled U*GUU to protein, and in red the spectrum at a 2:1 ratio. Very 
few peaks specific to the bound form can be seen.  
 
Once the titration had reached saturation point 5 molar equivalents of a buffered 
sodium ascorbate solution was added to the NMR sample, and allowed to react 
for 15 hours. This was to reduce the sample, leaving no unpaired electrons and so 
removing all paramagnetic relaxation enhancement effects. The magnitude of the 
PRE could then be calculated as the ratio Ipara/Idia, where Ipara is the signal 
intensity for a given residue in the presence of the spin label and Idia is the signal 
intensity after reduction of the spin label.  
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Figure 7.7: Graph of the ratio Ipara/Idia for the titration of RRM1 with U*GUU. Residues for which the 
signals are completely obliterated have been highlighted in red to distinguish them from the prolines and 
overlapped residues which have no data. 
 
The most affected residues are 19 ± 23, 47 ± 51, 59 ± 64, 81 and 93 ± 95, the 
signals of which are all completely obliterated. These include most of the residues 
LQWKHȕ-sheet, and almost all of those residues previously seen to be involved in 
RNA binding to this domain. Strong signal attenuation is also seen for the C-
terminal residues, and for residues such as Ser52 and Gln53 in the loop 
FRQQHFWLQJȕDQGȕSome attenuation of signal (around a 20 ± 40% decrease in 
intensity) is seen even for the relatively unaffected regions of the protein. These 
are residues 2 ± 7, 35 ± 44 and 65 ± 79, which make up the N-WHUPLQXVDQGWKHĮ-
helices of the protein. When the values for each residue are mapped onto the 
surface of the protein, a coherent patch of attenuated signals can be seen. 
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Figure 7.8: The largest paramagnetic enhancement effects are shown in red (residues where Ipara/Idia < 
0.3). Moderate effects (0.3 < Ipara/Idia < 0.5) are shown in orange. Less affected residues are shown in grey 
(Ipara/Idia > 0.5). The RNA substrate is also shown, with the position of the modified base with the MTSL 
tag highlighted in red. 
 
Figure 7.8 shows the most affected area of the protein in red, and the approximate 
position of the spin label based on the crystal structures. The most affected region 
covers a rather larger area of the protein surface than was generally seen in the 
CSP maps. The MTSL tag is attached to the ¶51$EDVHYLDDGLVXOSKLGHERQG
which allows it some range of movement relative to the RNA. This may allow the 
spin label some freedom of movement even when the RNA remains fixed in the 
binding site. There are additional affected residues above and to the left of the 
binding patch (visible in orange in Figure 7.8) which are greatly attenuated but 
not lost completely may be due to this. They are outside the normal RNA binding 
surface seen on CSP maps, but are plausibly within the range of motion of the 
MTSL tag. 
 
There is a general loss of signal intensity of 20 - 40% over virtually all of the 
remaining surface area of the protein, including those residues in the Į-helices on 
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the opposite face of the protein from the RNA. This can be attributed to the long 
range of the PRE effect (up to 25 Å) encompassing almost the entirety of RRM1. 
 
7.3.2 PRE on labelling of the EDEN-2U/4U substrate with MTSL 
 
The MTSL coupling method was used to attach a spin label to the EDEN-2U/4U 
sequence. As it is a rather bulky group, the MTSL tag was coupled to an 
additional 4-thio-uridine DW WKH ¶ HQG RI WKH 51$ UDWKHU WKDQ WR RQH RI WKH
existing uridines in the EDEN-2U/4U substrate to ensure it did not interfere with 
binding of the protein to the 8*8 VLWH DW WKH ¶ HQG RI WKH RNA. The RNA 
VHTXHQFHZDVWKHUHIRUH¶-U*UGUUUUGUUUUUUGU-¶ 
 
After completion of the titration the sample was treated with 5 molar equivalents 
of buffered sodium ascorbate for 16 hours. Comparison of the 15N TROSY 
spectrum after this with the bound spectrum from the RRM123 titration with 
unlabelled EDEN-2U/4U showed the spin label had been at best partially 
reduced. In particular the peaks for several residues in RRM2 were still of very 
low intensity compared to the conventional titration. 10 additional molar 
equivalents of buffered sodium ascorbate were therefore added and the sample 
was allowed to react at room temperature for an additional 24 hours. This 
achieved a greater recovery of signal intensity. It is unclear why the spin label 
was more difficult to reduce in this case compared to the RRM1/U*GUU 
titration. Possibly it had packed against the surface of the protein via some form 
of hydrophobic interaction with the MTSL group, making the nitroxide spin label 
harder to access. 
 
The ratio of Ipara/Idia was again calculated for each residue to quantify the PRE 
effect. The signal to noise ratio for the bound complex was poor even without the 
attenuation from the spin label, resulting in relatively large margins of error 
compared to the previous titration. There were also far more overlapping peaks in 
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this spectrum, for which it was not possible to accurately measure the signal 
intensity for each residue. The ratio is shown below in Figure 7.9 for all residues 
where it could be calculated. 
 
Figure 7.9: Graph of the PRE effects seen on the RRM123 construct on addition of MTSL labelled EDEN-
2U/4U (U*-UGUUUUGUUUUUUGU). Values greater than 1 are seen for some residues due to the large 
margin of error. Moderate PRE effects (ratio = 0.4  ? 0.8) are seen for some residues in all three domains. 
A noticeable cluster of strongly affected residues (ratio < 0.4) is seen in RRM2, and has been highlighted, 
though there are a few other strongly affected residues in the other domains. 
 
The MTSL spin label is expected to have some freedom of movement due to both 
the disulphide link attaching it to the RNA base, and the fact the 4-thiouracil is an 
DGGLWLRQ WR WKH ¶ HQG RI WKH 51$ and so does not interact directly with the 
protein. This accounts for the observation of PRE effects across a relatively large 
number of residues. While there is some attenuation of signals across all three 
domains, most of the strongly affected residues are concentrated in RRM2, as is 
shown in Figure 7.10. From this it can be concluded that CELF1 is preferentially 
binding with RRM2 at the 5¶HQGRIWKLV51$VHTXHQFHThis indicates that the 2 
± 1 ± DUUDQJHPHQWRIWKHGRPDLQVIURP¶WR¶LVPRVWIDYRXUDEOHQRWWKH± 2 
± 1 arrangement. 
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Figure 7.10: A model of RRM123 with PRE effects shown, in complex with the RNA substrate 
U*UGUUUUGUUUUUUGU. Details of the model construction are explained in section 7.2. Large 
paramagnetic enhancement effects are shown in red (residues where Ipara/Idia < 0.3). Moderate effects 
(0.3 < Ipara/Idia < 0.5) are shown in orange. Less affected residues are shown in grey (Ipara/Idia > 0.5), as are 
any with no data such as the unassigned RRM2  ? RRM3 linker. The RNA substrate is also shown, with the 
position of the modified base with the MTSL tag highlighted in red. 
 
It seems likely that the signals in RRM2 that are almost completely obliterated 
are due to PRE from the directly bound RNA, while the much more widespread 
partial attenuation of signals may be due to non-specific intermolecular 
interactions, and represent the exposed surface of the protein. The most affected 
residues are shown in Figure 7.10 with those losing >70% of signal intensity 
shown in red, and those with 50 - 70% loss shown in orange. 
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With a single exception (Met18) the most affected residues are in RRM2, and 
JHQHUDOO\ DUH LQ WKH ȕ-sheet and loop regions of the domain. There is also a 
concentration of moderately affected residues in this domain, with a few 
additional residues in RRM1 and RRM3 with 50 ± 70% loss of signal intensity. 
 
7.4 Small Angle X-ray Scattering 
 
The loss of NMR spectrum quality on formation of a high affinity 1:1 complex 
was attributed to the protein becoming more globular and rigid on binding. Small 
angle X-ray scattering (SAXS) was used as a complementary technique to help 
investigate whether the complex was more rigid and compact than the unbound 
protein. SAXS data was collected for the RRM123 construct both unbound, and 
in complex with the high affinity EDEN-2U/4U substrate. Data for the 
protein/RNA complex was collected at two concentrations ± 1 mg/ml and 5 
mg/ml to check for any aggregation effects. Collection of the SAXS data was 
carried out by Dr. Chan Li (School of Pharmacy, University of Nottingham). We 
analysed the data to calculate Kratky and Guinier plots in the ATSAS software 
package. Advice during this analysis was provided by Dr. Katherine Carr (School 
of Pharmacy, University of Nottingham). Calculation of the 3D envelope was 
carried out by Dr. Jonas Emsley (School of Pharmacy, University of 
Nottingham). 
 
7.4.1 Guinier Plots 
 
The radius of gyration (Rg) of the protein and the complex can be calculated from 
a Guinier plot of the SAXS data. By comparing Rg values for the free RRM123 
protein and the complex, it would possible to tell if the overall protein geometry 
was changing. If a more compact complex was forming, it would be expected to 
have a lower radius of gyration. The Guinier plots for the unbound protein, the 
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complex at low concentration, and the complex at high concentration are shown 
in Figure 7.11. 
 
 
Figure 7.11: Left is the Guinier plot for the unbound CELF1. Centre is the plot for the RRM123/EDEN-
2U/4U complex at low concentration (1 mg/ml) and right is the plot for the complex at higher 
concentration (5 mg/ml). Calculated Rg for the unbound protein was 2.72 nm, Rg for the complex was 
calculated as 2.69 nm from the low concentration plot and 2.94 nm at high concentration. Plots were 
produced using the ATSAS software package. 
 
There is a slight deviation from linearity in the plot for the complex at high 
concentration, suggesting some aggregation is occurring in this sample. This is 
likely to be the reason for the slightly higher Rg seen for the complex at this 
concentration. At 1 mg/ml the Guinier plot is linear, and the calculated Rg should 
therefore be more accurate. Rg values of 27.2 Å for the unbound protein, and 26.9 
Å for the complex were calculated. This difference in the radius of gyration for 
the free and bound RRM123 is negligible. This is somewhat surprising if the 
domains are forming into a more compact arrangement on binding, but is 
consistent with the earlier size exclusion chromatography data, which showed 
very little change for RRM123 on binding to the RNA. 
 
7.4.2 Kratky Plots 
 
Earlier in Error! Reference source not found. were shown examples of the Kratky 
plots for globular proteins, disordered proteins, and a protein with both structured 
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and disordered regions. If the complex of RRM123 with EDEN-2U/4U is more 
compact and rigid than the free RRM123 protein the Kratky plots, shown below 
in Figure 7.12, would be expected to show a significant difference. 
 
 
Figure 7.12: Kratky plots for unbound RRM123 (left) and the complex of RRM123 with EDEN-2U/4U 
(right). 
 
Both the free protein and the complex show considerable flexibility, with a long 
increasing tail for high values of q. The complex shows a rather more clearly 
defined peak than the free protein, suggesting some population of a more compact 
form when bound to RNA. The Kratky plot does still show flexibility in the 
bound form though, so there may also be a range of more elongated 
conformations in solution. 
 
7.4.3 Predicted Envelope 
 
SAXS can be used to predict a low resolution 3D envelope of the particles in 
solution. Based on the data from the high concentration sample of the bound 
complex a 3D envelope was calculated by Dr. Jonas Emsley (School of 
Pharmacy, University of Nottingham), which is shown in Figure 7.13.  
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Figure 7.13: Autoenvelope calculated from the SAXS data for the RRM123/EDEN-2U/4U complex. 
Envelope calculated by Dr. Jonas Emsley (School of Pharmacy, University of Nottingham). 
 
It is not immediately obvious how the three domains of CELF1 would occupy 
this volume. As shown in Figure 7.14 the envelope is large enough to 
accommodate a relatively linear arrangement of the domains, but this leaves a 
significant amount of unaccounted for volume in the envelope. Similarly a more 
compact form of CELF1 will fit reasonably well into the roughly triangular 
section to the left hand side in Figure 7.13, but again leaves D ³WDLO´ RI
unaccounted for volume to the right. It is possible that in solution there are a 
range of conformations between these two extremes, resulting in a calculated 
SAXS envelope which is not representative of any individual conformation. 
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Figure 7.14: Possible arrangements of the domains within the SAXS envelope. A) shows a relatively 
compact arrangement of the three domains. B) shows a more extended model. In both cases the 
envelope is large enough to accommodate all three domains, but there are significant volumes 
unaccounted for.  
 
 
 
252 
 
7.5 Refining the Model 
 
The initial model was refined using distance restraints based on the paramagnetic 
relaxation enhancement experiments. Due to the potential issues with 
intermolecular PRE effects, only those from the most affected residues (Ipara/Idia < 
0.5) were used, though this left relatively few restraints between the tag and 
residues outside RRM2. Molecular dynamics simulations starting from either an 
³H[WHQGHG´RU³FRPSDFW´DUUDQJHPHQWRI WKHGRPDLQVUHVXOWHG LQDYHU\VLPLODU
final model.  
 
Figure 7.15: Refined model of RRM123 in complex with the EDEN-2U/4U RNA substrate, produced using 
restraints based on the most affected residues in the PRE experiment. Restraints were approximated as 
an upper limit of 24.5 Å between those residues where Ipara/Idia < 0.3 and the paramagnetic centre, and 29 
Å for residues where 0.3 < Ipara/Idia < 0.5. 
 
The model could be refined further by repeating the experiment with the spin 
ODEHODWGLIIHUHQWSRVLWLRQVLQWKH51$IRUH[DPSOHDWWKH¶HQGDQd at a position 
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close to the middle UGU site. This would provide corroborating information on 
the ¶ WR ¶ arrangement of the three RRMs and increase the number of long 
range distance restraints which could be used in molecular dynamics simulations. 
 
7.6 Conclusions 
 
We were not able to produce an NMR solution structure of the complex, but we 
were able to construct a model based on the structural data from the isolated 
domains supplemented by PRE and SAXS data. The intrinsic flexibility of the 
RRM2 ± RRM3 linker sequence can be seen in the Kratky plots from the SAXS 
data, and is conserved in the bound state. This suggests that conformational 
flexibility, together with the long range distance dependence of the PRE effect 
may account for the attenuation of signals observed in all three domains. The 
ODUJHVW HIIHFWV DSSHDU WRSODFH WKH¶076/ ODEHO LQ FORVHSUR[LPLW\ WR 550
which uniquely defines the alignment of all three domains on the RNA substrate. 
From this it appears that CELF1 forms a relatively compact complex with high 
affinity RNA substrates such as EDEN-2U/4U, with the RRMs preferentially 
arranged in the order 2 ± 1 ± IURPWKH¶WR¶HQGRIWKH51$7KHSRVVLELOLW\
of a minor population in solution with a different domain arrangement, or a more 
extended conformation cannot be excluded. 
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8 CELF1 Phosphorylation and Interactions with 
Poly(A) Ribonuclease 
 
8.1 Phosphorylation 
 
CELF1 has been previously identified as a phosphoprotein, with multiple possible 
phosphorylation sites for different kinases11. In DM1 cells it has been shown that 
CELF1 is hyperphosphorylated by protein kinase C, resulting in an extended 
protein half-life105. So far the only phosphorylation sites to have been investigated 
and observed to have an effect on the properties of CELF1 are Ser28 in RRM1 
and Ser302 in the RRM2 ± RRM3 linker (cyclinD3/cdk4). Both of these have 
been reporWHG WR LQFUHDVH &(/)¶V affinity for RNA in general and possibly to 
influence the preferred RNA target sequence106, 109. The Ser302 phosphorylation 
has also been reported to promote association with an initiation factor (eIF2), 
which would impact the translation of the target mRNAs204. 
 
Other potential phosphorylation sites have been predicted for three other 
phosphatases. GSK3 at Thr277, Thr281, Ser285, Ser292 and Ser300. PKC delta 
at Thr163, Ser268 and Ser383. Finally Akt kinase has been predicted to also be 
capable of phosphorylation at Ser28. Most of these sites are in a serine and 
threonine rich region in the middle of the flexible linker between RRM2 and 
RRM3. The only sites in structured regions are Ser28 in RRM1 and Thr163 in 
RRM2. It is worth noting that Thr163 is not conserved between human and 
Xenopus CELF1, being replaced with methionine in Xenopus. Given human and 
Xenopus CELF1 have been shown to be functionally interchangeable it seems 
unlikely this residue plays any key role. Work by Salisbury et al. in 2008 was 
unable to confirm any activity by GSK3 or PKC delta on CELF1, but did show 
phosphorylation by Akt1 in vitro. Akt1 has also been noted to be upregulated in 
DM1 cells109. 
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Salisbury et al. also reported increased affinity for the cyclin D1 mRNA sequence 
when CELF1 is phosphorylated. This sequence bears very little resemblance to 
any of the other sequences known to be targets of CELF1, with very few uracils, 
no UGU sites and only a single UGC site. It has been proposed that 
phosphorylation of CELF1 at Ser28 may VHUYHDVD³VZLWFK´FDSDEOHRI changing 
the RNA target of the protein from U/G rich sequences to C/G rich sequences, 
enabling the reported interaction with cyclin D1 RNA. Ser28 does not show a 
significant CSP when binding to any of the NMR substrates investigated earlier 
in this study, and did not show any contacts with the RNA substrate UUGUU in 
the crystal structure. 
 
Cyclin D1: 5'-
CCCAGCCAGGACCCACAGCCCUCCCCAGCUGCCCAGGAAGAGCCCCA
GCC-3' 
 
This sequence is clearly distinct from the U/G rich sequences capable of forming 
high affinity complexes with CELF1. To examine this potential range of 
additional RNA targets, a phosphomimetic mutant of CELF1: S28D was 
produced by site directed mutagenesis. This mutation was used in the original 
paper, and serine to aspartate mutations have been shown in many cases to mimic 
phosphorylation205, 206. Mutants of the RRM1, t187 and RRM123 constructs were 
also produced. The purification methods used for the S28D mutants were 
identical to those for the wild type.  
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Figure 8.1: From left to right are shown structures of a) serine, b) phosphoserine from post translational 
modification, c) aspartic acid, used as a mimic for phosphoserine in the original study, and in this 
investigation. Glutamic acid can also be used as a phosphomimetic mutant. 
 
15N labelling the protein and collecting a 15N TROSY showed moderate 
disruption to the spectrum, localised to those residues near the point mutation. 
 
Figure 8.2: The 15N TROSY of the RRM1 S28D phosphomimetic mutant is shown in red, overlaid on the 
spectrum of wild type protein in blue. The signals for residue 28, and other strongly perturbed residues, 
are highlighted. The spectrum is generally very similar to that of the wild type RRM1, suggesting this 
phosphorylation is not drastically altering the fold of the protein. Data was collected on a Bruker Avance 
III 800 MHz spectrometer at 298 K. 
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Most residues could be assigned by analogy to the wild type protein. There were 
however several residues with large enough chemical shift changes between the 
wild type and S28D mutant to render assignments ambiguous (specifically for 
residues 30, 32, 33, and 34, in addition to residue 28 itself). Assignment of these 
residues was carried out using HNCACB and HN(CO)CACB spectra collected on 
a 250 µM doubly labelled sample on an 800 MHz spectrometer with QCI 
cryoprobe. 
 
Figure 8.3: Structure of RRM1 with Ser28 shown using a ball and stick depiction. Those residues which 
show significant changes to their chemical shifts when Ser28 is mutated to aspartic acid are highlighted in 
red, with brightness of colour indicating the magnitude of the perturbation. The most affected residues 
ĐŽŶƐŝƐƚŽĨƚŚĞĨŝƌƐƚŚĂůĨŽĨɲ-ŚĞůŝǆ ? ?ĂŶĚƚŽĂůĞƐƐĞƌĞǆƚĞŶƚĂĨĞǁƌĞƐŝĚƵĞƐŝŶɴ-strand 2, which is packed 
against it. 
 
In the wild type protein the side chain of Ser28 extends out into solution at the 
start of the first alpha helix. In the S28D mutant, there is disruption of the 
chemical shifts for all residues in the first two turns of this helix, with the 
exception of Glu31. There are minor shifts for Ile45, Val47 and Arg49 as well. 
The side chains of these residues extend from the underside of ȕ2, pointing 
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towards the disrupted residues in Į-helix 1. There are negligible CSPs for Trp27 
and Ser26, despite their close proximity to the mutation site. 
 
From the changes in the NMR spectrum on mutation it appears that 
phosphorylation at this position does not greatly alter the overall fold of the 
protein. The effects are confined to the Į-helix, which has not previously been 
VHHQ WR EH LQYROYHG LQ ELQGLQJ DQG WR D OHVVHU H[WHQW WKH ȕ VWUDQG 7KLV was 
consistently the least affected strand RIWKHȕ-sheet in the titrations shown earlier, 
so again it would be surprising if this had a significant impact on the normal 
binding mode of the domain. 
 
S28D mutants were also produced of the t187, RRM123 and full length CELF1 
proteins with the assistance of Zoe Le Gray-Wise. The binding affinity of the 
S28D mutants relative to the wild type constructs was investigated by ITC, NMR 
and fluorescence methods. It was expected that the S28D mutant would show an 
increase in affinity for CUG repeating sequences, and/or a reduction in affinity 
for the sequences containing UGU sites. Comparison of the ITC data for wild 
type vs. S28D did not however show any significant difference on binding to the 
sequence UGUUUAU, as shown in Figure 8.4. 
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Figure 8.4: Comparison of ITC traces for the titration of RRM1 wild type and the S28D mutant with the 
RNA substrate UGUUUAU. This phosphomimetic mutation is not resulting in any loss of binding affinity 
to the normal UGU site. 
 
In practice no significant differences in binding affinity (or stoichiometry) were 
seen for the S28D mutant binding to UGUGUG, EDEN11 or EDEN-2U/4U. To 
within the margin of error of these techniques the results were the same as for the 
wild type CELF1 constructs. The S28D mutant in fact showed a somewhat 
reduced affinity for CUG based sequences, with no detectable binding seen by 
ITC. NMR showed greatly reduced CSPs on binding to CUGCUG, and the 
titration required a much larger excess of RNA in order to reach an endpoint. 
Based on this it could be concluded that phosphorylation at Ser28 does not serve 
as any kind of regulatory switch between UGU and CUG targets of CELF1. The 
cyclin D1 mRNA from could perhaps be being recognised via some other motif, 
such as GCGC.  
 
This leaves the possibility that phosphorylation may play a role in regulating the 
stability of CELF1, and its ability to interact with other proteins. The multiple 
sites in the serine rich region of the RRM2 to RRM3 linker are the most likely 
residues for this. The limited impact of Ser28 phosphorylation and the lack of 
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predicted phosphorylation sites in the other structured regions of the protein 
indicate that it does not regulate RNA recognition though. 
 
 
8.2 Dimerisation of CELF1 
 
Bonnet-Corven et al. (2002) reported dimerisation of Xenopus CELF1 using a 
yeast two hybrid assay54. Biophysical techniques have not shown any sign of 
dimer formation except possibly in the ESI-MS of RRM1. No dimer population 
was seen for the t187 or RRM123 constructs, despite the fact the RRM123 
construct still incorporates the section of the linker proposed to be involved in 
dimerisation103. The elution point by gel filtration of all CELF1 constructs is 
consistent with a monomeric species. ITC of concentrated wild type CELF1 into 
buffer showed no significant enthalpy change. If a dimer was present then this 
dilution titration would be expected to show a dissociation curve. 
 
There are signs of a small dimer population in some of the mass spectra, in 
particular the unbound RRM1 construct. This appears as a smaller set of peaks 
with m/z values that imply half-integer values of z. Since this is not possible, it 
indicates a second species consisting of a dimer. The NMR data shows no change 
in the spectrum of any of the CELF1 constructs on dilution from 400 µM to 20 
µM. No change is seen on dilution for the high affinity RRM123/EDEN2U4U 
complex either. As the ITC and NMR do not show any evidence of dimerisation 
and the fraction of this species seen in the mass spectrum is very small it is 
possible this is an artefact of the experiment being in the gas phase. There were 
also no signs of dimerisation in the spectrum for the t187 or RRM123 constructs. 
Wild type CELF1 did not give clear enough mass spectrometry data for accurate 
determination of its mass, or to detect the presence of any low population species. 
The NMR spectrum of full length CELF1 was essentially the same as that of 
RRM123 for the structured region, so it seems unlikely that any dimerisation 
interface could exist in the RRMs. The spectrum did not show any changes on 
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dilution, so again there is no evidence of dimerisation of CELF1 by NMR. 
 
8.3 Poly(A) Ribonuclease 
 
In 2006 Moraes et al. reported a protein - protein interaction between CELF1 and 
poly(A) ribonuclease (PARN)56. 3$51 LV D ¶-exoribonuclease, which 
specifically degrades poly(A) tails207, 208, 209. This presents a possible mechanism 
for CELF1 binding increasing deadenylation rates, as the protein could be directly 
recruiting PARN to the target mRNA substrate. This interaction was observed in 
the absence of RNA so it must occur between the proteins, and not simply be a 
case of the two proteins binding to the same RNA molecule. It was later shown 
that the presence of CELF1 affected patterns of mRNA deadenylation by 
PARN13. No structural information indicating which regions of these two proteins 
are involved in the interaction has been reported. 
 
Poly(A) ribonuclease is a 72.8 kDa protein containing three structured domains; a 
310 residue exoribonuclease domain, a 75 residue R3H domain, and an 80 residue 
RNA recognition motif210. The R3H domain is inserted into a long flexible loop 
in the middle of the protein sequence of the nuclease domain. The RRM is 
separated from the other domains by an unstructured region, and there are an 
additional 120 residues of flexible protein forming the C-terminal end of the 
protein. A 54 kDa fragment of the protein has been found to be sufficient to 
specifically degrade poly(A) tails211. 
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Figure 8.5: Domain layout of PARN. The R3H domain is inserted into an extended loop in the middle of 
the exoribonuclease domain. 
 
PARN is believed to form a homodimer via the exoribonuclease domain211. 
Dimerisation of a construct of residues 443 - 560 has also been reported, and 
speculated to be mediated by a zipper motif in the C-terminal region212. Crystal 
structures of all three structured domains are available (PDB IDs: 1UG8, 1WHV 
and 2A1R), however no structure in which all three domains are visible 
simultaneously has yet been reported. Structural data is also available for the 
nuclease domain in complex with a poly(A) sequence213 and for the RRM in 
FRPSOH[ZLWKWKH¶P51$FDSVWUXFWXUH112. The RRM has also been implicated 
in interactions with the poly(A) tail214, 215. The largest complex which has been 
directly observed consisted of residues 1 - 510 of PARN in complex with RNA, 
but the R3H domain appeared unstructured in this crystal. In 2009 Wu et al. 
produced a possible model of the complete homodimeric protein in complex with 
ERWKWKH¶FDSDQGWKHSRO\$WDLORIDQPRNA based on a combination of the 
different crystal structures, which is shown in Error! Reference source not 
found.111.  
 
The reported dimerisation via the C-terminal zipper motif is however inconsistent 
with this model. While the C-terminus of the protein is not visible in the available 
crystal structures due to its flexibility, the model by Wu et al. would have these 
regions at opposite ends of the protein dimer. There is no indication of how 
CELF1 might interact with this complex 
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The R3H domain has been suggested to play a role in stabilizing the RRM, and 
hence the rest of the protein and the model does suggest a possible contact surface 
between these domains216. In the model the R3H domain of each monomer is 
paired up with the RRM of the other monomer unit. PARN has been previously 
noted to truncate in the region of the RRM to give the p54 isoform, and removal 
of the R3H domain encourages this breakdown. PARN is also stabilised by the 
presence of Mg2+ ions, and requires them for catalytic activity217. 
 
8.4 Aims 
 
Our initial aim was to express and purify poly (A) ribonuclease and determine 
whether it possible to acquire high resolution NMR data on this system. If NMR 
spectra of sufficient quality could be collected, we then aimed to observe the 
reported CELF1/PARN interaction using 15N TROSY spectra, and so determine 
which regions of the proteins were involved. This would enable us to determine if 
a ternary complex of CELF1, PARN and an EDEN motif could form, and so 
whether the proposed mechanism of PARN recruitment by CELF1 was plausible. 
As a complex of CELF1 with the PARN dimer would have a mass of around 200 
kDa, this system is an ambitious target for NMR.  
 
8.5 Expression and Purification of Poly(A) Ribonuclease 
 
Expression plasmids of human and Xenopus PARN cloned into the pET33 vector 
were supplied by Dr. Cornelia de Moor (University of Nottingham). The 
expression and purification protocols were based on the methods reported by 
Nilsson et al. (2006), which had been shown to produce catalytically active 
PARN110 and so was expected to give intact and correctly folded protein. 
 
Poly(A) ribonuclease was overexpressed successfully, though a significant 
fraction of the material was insoluble after a 16 hour induction at 30°C. Reducing 
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the induction temperature to 20°C resulted in almost all of the protein remaining 
in the soluble fraction. The intact protein was visible as a band just above the 66 
kDa marker. There were also signs of truncation of the protein resulting in a 
significant band on the SDS-PAGE at approximately 55 kDa. Similar truncation 
products were seen in the purification by Nilsson et al, and were attributed to 
degradation of the unstructured C-terminus of PARN.  Unlike CELF1, PARN did 
not appear to degrade further after the IMAC column stage, allowing the intact 
fraction of the protein to be separated from the truncation products. 
 
 
Figure 8.6: SDS-PAGE of the elution fractions from the IMAC column stage of the purification of poly(A) 
ribonuclease. Two strong bands are visible, one at more than 66 kDa, corresponding to the intact protein, 
and one just below, corresponding to a truncation product. 
 
Gel filtration was found to be ineffective in separating the intact and truncated 
protein, as both eluted between 160 and 170 ml from a Superdex GF200 column. 
An ion exchange method similar to that used by Nilsson et al. was attempted, 
which succeeded in separating some of the truncation products. 
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Figure 8.7: SDS-PAGE of samples from the ion exchange stage of the poly(A) ribonuclease purification. 
Lane 2 shows the proteins loaded onto the anion exchange column, lane 3 shows the proteins which 
were not bound. The remaining lanes show the proteins eluted by a 50 mM to 2 M NaCl gradient.  
 
Some separation was achieved, though the truncation products were not 
completely removed. In the original purification by Nilsson et al these could not 
be completely eliminated either, though the resulting material was found to be 
catalytically active. The protein at this point was in a high salt buffer containing 
10% (v/v) glycerol, which was not ideal for NMR, and prevented the protein from 
being lyophilised. The protein was therefore desalted into MilliQ water using a 
HiTrap desalting column. 
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Figure 8.8: SDS-PAGE of the elution fractions from the desalt column. Fraction 2 contained intact protein 
only. Fraction 3 contained a greater quantity of intact protein, but also contained visible bands from the 
remaining truncation products. 
 
Fraction 2 was lyophilised, and yielded 3 - 4 mg of pure protein per litre when 
grown in M9 minimal media. Fraction 3 was found to contain residual glycerol, 
and so could not be lyophilised, but additional material could be recovered by 
repetition of the desalting step. 
 
8.6 NMR Studies of Poly(A) Ribonuclease 
 
Since the protein has a mass of 72.8 kDa and was believed to form a homodimer, 
it seemed likely that rapid relaxation rates would result in a poor signal to noise 
ratio in the NMR spectrum, and that the protein would therefore be difficult to 
examine even using the TROSY method. 15N labelled material was purified and a 
TROSY spectrum was collected. With 720 scans acquired on a Bruker Avance III 
800 MHz spectrometer some well dispersed peaks were resolvable, as shown in 
Figure 8.9.  
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Figure 8.9: 15N TROSY of full length PARN deadenylase. 720 scans were accumulated on an 800 MHz 
spectrometer with QCI cryoprobe. The protein was dissolved in 25 mM potassium phosphate, 200 mM 
NaCl, 10% (v/v) D2O pH 7.0 buffer. The temperature was 298 K.  
 
A large number of the peaks are heavily overlapped in a band with 1H chemical 
shifts of between 7.5 and 8.5 ppm, consistent with unstructured protein. These 
presumably originate from the unstructured C-terminal region of the protein, and 
the long flexible sections flanking the R3H domain. There are around 120 well 
dispersed peaks, which are believed to be from structured regions of the protein. 
Based on the relative sizes of the domains in PARN it seems likely these are from 
the smaller RRM and R3H domains. The number of dispersed peaks is too large 
to be accounted for by just one of these domains, so it appears both the RRM and 
R3H domains are being observed. The larger exoribonuclease domain, while 
structured, should undergo much more rapid relaxation resulting in weaker 
signals in the NMR spectrum, accounting for the lack of signals seen for this 
domain.   
 
NMR data for an isolated construct of the RRM (residues 430 - 516) was 
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published by Nagata et al. in 2008. The published 1H-15N HSQC does not 
however match very closely to any subset of the well dispersed peaks in the 
spectrum of full length PARN. A possible explanation for this is that the RRM has 
been reported to be stabilized by interaction with the R3H domain. In the model 
by Wu et al. of the dimeric form the RRM domain of one protein subunit has 
contacts with the R3H domain of the other, consistent with this stabilisation. 
These contacts will not be present for the isolated RRM, which will exist as a 
simple monomeric protein accounting for the significant differences in the 15N 
TROSY spectrum. 
 
8.7 Interactions of CELF1 with Poly(A) Ribonuclease 
 
An excess of unlabelled wild type CELF1 was added to a 15N labelled PARN 
sample. The resulting 15N TROSY spectrum is shown in Figure 8.10, overlaid on 
the spectrum of unbound PARN. 
 
Figure 8.10: Spectrum of unbound 15N labelled PARN shown in blue. Overlaid in red is 15N PARN after the 
addition of an excess of unlabelled full length wild type CELF1. Acquisition was carried out on an 800 MHz 
spectrometer with QCI cryoprobe. Both spectra were collected with 720 scans at 298 K, with a resolution 
of 2048 x 128 points. 
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The poorly dispersed peaks from the unstructured region showed minimal 
perturbation on addition of CELF1. There were however some significant 
changes to the chemical shifts of some of the well dispersed peaks, presumed to 
be from the RRM and R3H domains. Without assignments it is not possible to 
unambiguously match up signals for the same residue bound and unbound and so 
calculate exact CSPs. However the distance between signals lost, and the closest 
signals that appear on addition of PARN allows a lower boundary for the CSPs to 
be set. It appears that several residues display CSPs of at least 0.4 ppm, indicating 
a significant change in environment. It can therefore be concluded that PARN and 
CELF1 do interact. As the most affected residues lie in the dispersed region of the 
spectrum it can be hypothesized that the interaction between these two proteins is 
mediated by the RRM or perhaps the R3H domain of PARN deadenylase. 
 
The tryptophan side chains of PARN may provide some additional evidence as to 
which domain is interacting with CELF1. PARN contains six tryptophan residues, 
two of which are in the RRM. One tryptophan is located in the R3H domain, and 
the remaining three are in the unstructured C-terminal region. In the 15N TROSY 
of PARN, a tight cluster of six peaks with chemical shifts characteristic of 
tryptophan side chains is visible. 
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Figure 8.11: Tryptophan side chain region of the PARN 15N TROSY spectrum. Unbound PARN is shown in 
blue. The spectrum after the addition of a saturating amount of unlabelled wild type CELF1 is overlaid in 
red. Six clear peaks can be seen in the unbound spectrum, of which two move significantly on binding. 
The remaining four, one of which is clearly the C-terminal tryptophan, are not affected. 
 
Two of these peaks are perturbed by addition of unlabelled wild type CELF1, 
while the other four remain completely unaffected. As the only section of the 
protein with two tryptophan residues in close proximity is the RRM, this would 
seem to suggest this domain is mediating the PARN/CELF1 interaction. 
 
There are some RRMs which are known to mediate protein ± protein interactions. 
One subgroup of RRMs is known as U2AF homology motifs (UHM), and interact 
ZLWKRWKHUSURWHLQVYLDWKHĮ-helices on the opposite face from the normal RNA 
binding surface218, 219, 220. In some cases RRMs may bind both proteins and RNA 
simultaneously, as has been reported for PTB RRM2221. Another subgroup of 
RRMs is capable of forming protein ± SURWHLQLQWHUDFWLRQVYLDWKHȕ-sheet surface, 
though this generally prevents RNA binding222, 223, 224. The PARN RRM has both 
a non-VWDQGDUGVWUXFWXUHZLWKDWKLUGĮ-helix at the C-terminus, and a novel RNA 
binding site. The C-WHUPLQDOĮ-KHOL[EORFNVDFFHVVWRPRVWRIWKHȕ-sheet surface, 
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even in the presence of its target RNA (the m7GpppG cap structure). The RNA is 
instead bound by the loop regions, in particular a key tryptophan residue at the C-
WHUPLQDOHQGRIȕ112, 33, 34.  
 
One possibility considered was that the interaction was between the PARN RRM 
and one of the three RRMs of CELF1, perhaps via the opposite face to the RNA 
binding surface in the case of the CELF1 domain. To investigate this possibility 
the NMR experiment was run again with the labelling scheme reversed so the 
effects on the residues in CELF1 could be observed. An excess of unlabelled 
PARN deadenylase was added to 15N labelled wild type CELF1, resulting in the 
15N TROSY spectra shown in Figure 8.12.  
 
Figure 8.12: 15N TROSY of unbound wild type CELF1 shown in blue. Overlaid in red is the 15N TROSY after 
addition of unlabelled full length PARN.  There are only very minor perturbations seen to the signals from 
the structured RRMs.  A much greater disruption is seen for some signals from the unstructured RRM2-
RRM3 linker, suggesting that PARN may be recognising some part of this sequence. Some degradation 
products of CELF1 are visible in the bound spectrum. 
 
The addition of unlabelled PARN deadenylase had very little effect on the peaks 
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from any of the three RRMs of CELF1. There was some disruption to peaks in 
the unstructured region of CELF1, but without assignments the exact residues 
involved could not be determined. This indicates that the RRMs of CELF1 are not 
involved in any interaction with PARN. The remaining possibility is that the 
interaction is between the RRM and/or R3H domain of PARN and a peptide 
sequence in the long linker between RRM2 and RRM3. This is consistent with 
the disruption seen for the residues from the unstructured region of CELF1. It 
also implies that the interaction with PARN should not interfere with the normal 
RNA binding interactions of CELF1, and so a ternary complex could be formed. 
 
If a section of the RRM2 - RRM3 linker is recognised by PARN it would be 
expected to be conserved across the different species where CELF1 and PARN 
homologs exist. Unfortunately this linker, while somewhat less conserved than 
the structured domains of CELF1, still has a high degree of sequence identity 
across species such as human, mouse, chicken, Xenopus and zebrafish. There are 
many conserved sections which could potentially be a binding motif for PARN. In 
Figure 8.13 is shown a sequence comparison of this region of the protein. 
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Figure 8.13: Sequence alignment of the RRM2  ? RRM3 linker region of CELF1 for the species human, 
mouse, Xenopus, chicken and zebrafish. There is still a high degree of sequence conservation even in the 
unstructured regions of CELF1, so no obvious binding site for poly(A) ribonuclease is evident. 
 
An alternative approach would be to compare the linker region of CELF1 with 
other proteins which are already known to interact with PARN, and look for a 
conserved sequence. Zinc-finger antiviral protein (ZAP) has been reported to 
recruit PARN to degrade the poly(A) tails of viral mRNAs, and so may have a 
similar binding site to CELF1225. There has been one point mutation in the RRM2 
± RRM3 linker of human CELF1 which has been reported to prevent 
deadenylation in vivo, but not to interfere with RNA binding (G331D)23. 
Mutations disrupting the region of CELF1 recognised by PARN would be 
expected to have this effect, so it is possible that Gly331 is within the PARN 
binding site. However Gly331 is also one of the least conserved residues between 
the CELF1 homologs, replaced with asparagine in Xenopus and serine in 
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zebrafish. 
 
If PARN is remaining as a dimer when it binds CELF1, the resulting complex 
would have a mass of around 200 kDa. It would be very surprising to see any 
clear peaks in the NMR for a system of this size. It is possible that the PARN 
dimer is disrupted by binding to CELF1, which would result in a 
monomer/CELF1 complex with a total mass of approximately 135 kDa. Given 
the NMR spectra of the complex are of at least the same quality as those of the 
free protein, it seems likely that the complex is not drastically larger than the 
PARN dimer. 
 
8.7.1 Isolation of the PARN RRM 
 
An initial attempt was made to confirm the regions of PARN involved in CELF1 
binding by breaking the protein into isolated domains. The RRM was the simplest 
domain to isolate, using the one-step deletion PCR method to remove the codons 
for residues 1 ± 430 from the full length protein plasmid. This construct retained 
the long unstructured C-terminus of the protein, which has been predicted to form 
D³]LSSHU´PRWLIGLPHU 
 
Expression and purification of this construct was carried out using the same 
protocols as for the full length protein. The solubility was considerably higher 
than for the full length protein, though SDS-PAGE did still show some C-
terminal degradation of the protein after the IMAC column stage of the 
purification. 
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Figure 8.14: 15N TROSY spectrum of the 431  ? 631 construct of PARN deadenylase. Both well dispersed 
peaks from the structured RRM and heavily overlapped peaks from the unstructured C-terminus of the 
protein are visible. The unstructured peaks generally are a close match to a subset of those in the 
spectrum of the full length protein. The structured peaks do not match any of those in the full length 
protein, but do match the data in Nagata et al ? ?Ɛ ? ? ? ?ƉĂƉĞƌ ? 
 
The 15N TROSY of this protein showed around 80 well dispersed peaks, 
consistent with the structured RRM domain. There are also clusters of intense 
peaks from the unstructured region. The signals from the unstructured region 
closely match a subset of the signals in the spectrum of the full length protein. 
The signals from the RRM however do not match the chemical shifts of any 
subset of the peaks in the spectrum of the full length protein. This can be 
attributed to a change from dimer to monomer in going from full length protein to 
the 431 ± 631 construct. The well dispersed peaks are a reasonable match to the 
NMR data published by Nagata et al. in 2008, which was from a smaller 
monomeric construct, lacking the C-terminal region.  
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Addition of a saturating amount of wild type CELF1 had no apparent effect on 
the spectrum. From this it can be concluded that the RRM on its own is 
insufficient to bind to CELF1. Contacts with an R3H domain in the dimeric form 
of PARN may be required to form the binding site for CELF1, and/or stabilise the 
RRM. Since the domains are not functioning independently the approach of 
investigating each domain in isolation which was successful for CELF1, may not 
suitable for locating the CELF1 binding site on PARN. 
 
8.7.2 Supplementary Biophysical Techniques 
 
Preliminary investigations of the CELF1/PARN interaction were also conducted 
using ITC and ESI-MS. Mass spectrometry of PARN was not successful. Some 
very broad signals were present, possibly indicating a range of species with 
different numbers of bound sodium ions. The SDS-PAGE analysis carried out 
during the purification suggested that the truncation products were not completely 
removed, which may also be contributing to the broad peaks seen in the mass 
spectrum 
 
ITC experiments were conducted, titrating wild type CELF1 from the syringe into 
a dilute solution of PARN in the cell. The syringe and cell concentrations were 
reduced to 125 µM and 12.5 µM respectively due to the limited solubility of both 
wild type CELF1 and PARN. Titration of CELF1 into PARN showed a 
pronounced endothermic curve, shown in Figure 8.15, similar to that seen for 
dissociation of a dimer, though it could not be fitted to a simple dissociation 
model. Control experiments titrating CELF1 into buffer, and buffer into PARN 
showed no significant enthalpy change in either case, confirming that the curve 
seen was from direct interaction of the two proteins rather than simply the effect 
of diluting either protein. 
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Figure 8.15: ITC traces collected for: A) Titration of 125 µM wild type CELF1 into 12.5 µM PARN. B) Control 
titration of 125 µM CELF1 into buffer. C) Control titration of buffer into 12.5 µM PARN. No satisfactory fit 
to the CELF1/PARN binding curve could be achieved using any of the binding models in Origin 7.0. 
 
The curve suggests an entropically driven process, and could perhaps be due to 
the dissociation of the PARN dimer when binding to CELF1. Repeating the ITC 
experiment with the RRM123 construct showed no significant interaction, 
consistent with the requirement of some part of the linker between RRM2 and 
RRM3 of CELF1. It can also be concluded that the sequence recognised by 
PARN is not in the 188 ± 214 or >385 regions which are retained in the RRM123 
construct. A series of constructs incorporating different sections of the RRM2 ± 
RRM3 linker could be used to narrow down the region involved in the interaction 
with PARN. 
 
8.8 Conclusions 
 
We have shown that despite its size at 72.8 kDa, and existence in solution as a 
146 kDa homodimer, poly(A) ribonuclease can be investigated by NMR. Peaks 
from at least the RRM and R3H domains are clearly resolvable in the 15N TROSY 
spectrum of the wild type protein. The interaction with CELF1 can therefore be 
investigated using this technique. The preliminary data collected on the isolated 
RRM does however show that the domains are not functioning independently. 
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The approach of studying each domain in isolation which proved effective for 
CELF1 may not be as successful for PARN. 
 
The initial NMR and ITC data does support the hypothesis of a direct interaction 
between these two proteins. This interaction appears to be mediated by some part 
of the flexibOHVHFWLRQEHWZHHQ550DQGWKH³GLYHUJHQWGRPDLQ´RI&(/)
It is less clear which regions of PARN form the binding interface, though the 
NMR spectra do suggest that the RRM and/or the R3H domains are involved. The 
lack of interaction with the RRM123 construct seen by ITC shows that residues 
188 ± 214 of CELF1 do not include a binding site for PARN. The section of the 
CELF1 RRM2 ± RRM3 linker recognised by PARN could be identified by 
producing a series of CELF1 constructs containing only a short section of this 
linker, and observing by ITC and NMR whether an interaction occurred with each 
one. Since the interaction with the EDEN motif and PARN appear to be mediated 
by completely separate regions of CELF1, this preliminary data is consistent with 
the formation of a ternary complex, and hence CELF1 triggering deadenylation 
by recruitment of PARN to the target mRNA. 
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9 Conclusions 
 
Our first aim was to determine the minimum RNA sequence that would permit 
binding by each of the isolated domains. Using NMR and ITC we showed that 
RRM1 can bind to the three nucleotide RNA substrate UGU with a Kd of around 
60 µM. This indicates only a slightly lower binding affinity than Teplova et al. 
later observed for a UUGUU substrate. The CSP map also showed little 
difference in the set of affected residues between the UGU and UGUUUGU 
substrates. From this it could be concluded that a UGU site is sufficient for 
RRM1 to bind, with the addition of a fourth nucleotide providing only a slight 
increase in binding affinity. This was corroborated by the observation that RRM1 
will form a 2:1 complex with the UGUUUGU substrate, which was detected by 
ESI-MS. In contrast RRM2 showed a significantly smaller RNA binding patch in 
the CSP map when binding to a UGU substrate compared to UGUUUGU. It was 
also unable to form a 2:1 complex with the UGUUUGU substrate, unlike RRM1. 
We could therefore conclude that RRM2 requires a fourth nucleotide for high 
affinity binding, and hence needs a UGU(U/G) site. 
 
For the lower affinity substrates RRM1 still showed significant CSPs on titration 
with a CUG repeat RNA, but not with an ARE. It was therefore concluded to be 
capable of recognising either a UGU or UGC site. RRM2 showed very limited 
interactions with a CUG substrate, but significant CSPs were seen on titration 
with an ARE. This suggests that the domain can tolerate a UAU(U/G) site as well 
as a UGU(U/G) site. Together these observations can account for the overall 
binding preferences seen for CELF1. Both can recognise sites in a UGU(U/G) 
repeating sequence, resulting in a high affinity complex. For CUG and ARE 
substrates only one of the two domains has a high affinity site, resulting in a low 
affinity interaction for the overall complex. 
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Our second aim was to determine the sequence requirements for tandem binding 
of the two N-terminal domains of CELF1. We demonstrated by NMR and ITC 
that for a sequence of the form UGU(U)x(UGU) spacer lengths of x = 2 ± 4 are 
optimal for tandem binding. ITC shows a substantial enhancement of the binding 
affinity from ~60 µM to ~0.4 µM when the domains can bind in tandem. X = 1 
does not permit binding of both domains simultaneously, and in this situation 
RRM1 is bound preferentially. The upper limit was not as sharply defined, with 
spacer lengths of 5 nucleotides or more showing a reduction in binding affinity 
with Kd values of ~3 µM. This indicates the interaction is still of significantly 
higher affinity than for the domains binding in isolation, and the bound NMR 
spectrum for x = 5 matched that of the 2 ± 4 nucleotide spacers. CSP maps did 
however show reduced perturbations in RRM2 for x = 6 and 7. We demonstrated 
that the EDEN11 GRE and EDEN15 consensus sequences will bind the N-
terminal domains of CELF1 in tandem, to two of the UGU sites which are 
separated by 5 nucleotides. 
 
An extended CUG repeat substrate still showed little interaction with RRM2 by 
NMR. An extended ARE however showed significant CSPs in both domains, 
unlike the isolated RRM1 construct, suggesting some enhancement of affinity 
when the domains bind in tandem to ARE substrates as well. RRM3 has been 
previously reported to have only very weak interactions with CUGCUG repeats. 
It can be concluded that any interaction of wild type CELF1 with single stranded 
CUG repeat RNA will be of very low affinity, and will be outcompeted by the 
preferred U/G rich sequences. We also confirmed that there is no RRM1 or 
RRM2 equivalent of the RRM3 N-terminal involvement in RNA binding. 15N 
heteronuclear NOE experiments showed that the RRM1 N-terminus and the 
interdomain linker between RRM1 and RRM2 remain dynamic even when both 
domains are bound to RNA. A construct with 50 additional residues at the C-
terminus of RRM2 also showed no differences in RNA binding properties to the 
t187 construct. This confirms that the isolated domain and t187 constructs are not 
omitting any functional extensions of these domains, and so should behave in the 
same manner as in wild type CELF1. 
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Our third aim was to characterise the full EDEN motif capable of binding all 
three domains of CELF1 simultaneously. We were able to devise a purification to 
produce small amounts (~ 1-2 mg/l) RIZLOGW\SH&(/)EXWWKHSURWHLQ¶V poor 
solubility and vulnerability to proteolysis severely limited the data that could be 
collected using it. We therefore produced the RRM123 construct, in which 
residues 215 - 384 of CELF1 have been deleted, which was found to be stable, 
soluble, and allowed the acquisition of high quality NMR spectra. Using this 
construct we demonstrated that the EDEN11 GRE proposed as an EDEN motif by 
Vlasova et al. is not in fact capable of binding all three domains simultaneously. 
It can be concluded that neither the EDEN11 GRE, or the 11 nucleotide UG 
repeat proposed by Rattenbacher et al. represent complete EDEN motifs. The 
EDEN15 sequence proposed by Graindorge et al. did appear to permit the 
formation of a 1:1 complex with all three domains bound and so probably is a 
functional EDEN motif, but the affinity was not significantly enhanced compared 
to binding of just the N-terminal domains. It was therefore concluded that the 
while the spacing in this sequence can be tolerated by CELF1, it is not optimal. 
 
We designed the sequence EDEN-2U/4U (UGUUUUGUUUUUUGU) which 
formed the highest affinity 1:1 complex so far observed, with a Kd of 110 nM. We 
concluded that sequences of the form UGU(U)xUGU(U)yUGU, with  x = 2 ± 5 
and y = 1 ± 4 permitted a 1:1 complex with all three domains of CELF1 bound 
simultaneously, and therefore represented functional EDEN motifs. The shortest 
sequence for which formation of a 1:1 complex was observed was EDEN-2U/1U 
(UGUUUUGUUUGU), though more than a 10-fold reduction in binding affinity 
was seen compared to EDEN-2U/4U. This is the minimum sequence capable of 
binding all three RRMs simultaneously. We also demonstrated that secondary 
structure in the RNA substrate can play an important role in forming a high 
affinity target for CELF1. The sequence EDEN-2U/HL still formed a 1:1 
complex with comparable affinity to the EDEN15 sequence despite the 14 
nucleotide spacer between two of the UGU sites. This was because the spacer was 
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capable of forming an RNA hairpin, which was confirmed to be present by NMR, 
bringing the UGU sites into close proximity and making the binding of CELF1 
more favourable.  
 
The fourth aim was to rationalise those RNA sequences which have been 
empirically demonstrated to be EDEN motifs by their ability to trigger 
deadenylation. All of the sequences shown to be EDEN motifs by Moraes et al, 
Vlasova et al. and Rattenbacher et al. contain at least one set of UGU sites 
FRPSO\LQJZLWKRXUFULWHULDIRUWKHIRUPDWLRQRIDFRPSOH[H[FHSW71)ĮDQG
c-jun. Both of these sequences are however predicted to contain secondary 
structure which will bring distant UGU sites into close proximity, which can 
therefore account for &(/)ELQGLQJ,QWHUHVWLQJO\LQWKH71)ĮFDVHWKLV LVGXH
to the formation of a hairpin from the repeating AUUUA region of the RNA, 
which may account for the observation that this motif increases deadenylation 
efficiency when present. 
 
The fifth aim was to characterise the structure of the high affinity 1:1 complex 
between CELF1 and an EDEN motif. We were however unable to produce an 
NMR or crystal structure of the complex. A substantial loss in NMR spectrum 
quality was seen when all three domains bound simultaneously to a single RNA 
molecule, which prevented acquisition of sufficient quality NOE restraints and 
RDC data to determine a structure. Attempts to co-crystallise the protein and 
RNA were unsuccessful preventing determination of the structure by x-ray 
crystallography. We were however able to produce a model of the complex based 
on the existing crystal structures of the isolated domains, supplemented by PRE 
and SAXS data. The PRE data showed a significant preference for arranging the 
domains in the order 2 ± 1 ± IURPWKH¶WR¶HQGRIWKH51$VHTXHQFH.UDWN\
plots suggest the complex is slightly more globular than the unbound RRM123 
protein. This may indicate a loss of internal dynamics in the protein, which could 
account for the reduction in the quality of the NMR spectra. 
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The sixth aim was to investigate whether phosphorylation at Ser28 could act as a 
³VZLWFK´FKDQJLQJ&(/)¶VSUHIHUUHG51$WDUJHWIURP8*ULFKHOHPHQWVWR&*
rich sequences. We produced and expressed phosphomimetic S28D mutants of all 
of our constructs of CELF1 which contained this residue. The disruption to the 
fold of the domain appeared very limited ZLWK RQO\ VL[ UHVLGXHV LQ Į-helix 1 
showing large CSPs when compared to the wild type. No significant difference in 
binding affinity was seen for U/G rich sequences between the wild type and the 
S28D mutant. No enhancement of binding affinity was seen for the S28D mutant 
when binding to a CUG repeat sequence. It is possible that recognition of some 
element other than the CG sites of the cyclin D1 RNA reported by Salisbury et al. 
is being enhanced, but we found no evidence to support this idea of a 
phosphorylation switch. 
 
Our final aim was to determine whether it was possible to acquire high resolution 
NMR data on poly(A) ribonuclease, and its key regulatory complex with CELF1 
reported by Moraes et al. We expressed and purified the full 631 residue poly (A) 
ribonuclease, though the protein was found to be prone to proteolysis of the 
unstructured C-terminal region. We were able to acquire the first 15N TROSY 
spectrum of the complete protein (a 146 kDa dimer). Around 140 dispersed peaks 
could be clearly resolved which are believed to be from the smaller RRM and 
R3H domains, with the signals from the larger nuclease domain being lost due to 
rapid relaxation. This demonstrates that NMR can be used to study the behaviour 
of these domains even as part of the full length protein. 
 
We observed significant CSPs for some of the well dispersed peaks in the PARN 
spectrum on addition of unlabelled wild type CELF1, confirming a direct 
interaction between these two proteins. This interaction is likely to involve the 
RRM and/or the R3H domains of PARN. Reversing the labels showed no CSPs 
in the three RRMs of wild type CELF1 on addition of unlabelled PARN, but did 
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appear to show some disruption to the poorly dispersed signals from the long 
linker between RRM2 and RRM3. If PARN is interacting with this region of 
CELF1 it is unlikely to interfere with the normal binding of &(/)¶V550VWR
the EDEN motif. This is consistent with CELF1 binding to both the EDEN motif 
and PARN simultaneously, and so the mechanism of CELF1 recruiting PARN to 
its mRNA targets in order to trigger deadenylation. 
 
9.1 Future Work 
 
The structure of the high affinity complex between CELF1 and an EDEN motif 
could be refined by additional paramagnetic relaxation enhancement experiments. 
If several titrations were conducted with the spin label placed at a different 
position in each RQH VXFK DV DW WKH ¶ HQG RI WKH 51$ DQG HLWKHU VLGH RI WKH
central UGU site) a far greater number of distance restraints could be generated 
and a more accurate model could be produced. 
 
Control experiments with the wild type CELF1 have shown no appreciable 
difference between its RNA binding preferences and those of the RRM123 
construct. A further control experiment could be to replace the RRM2 to RRM3 
linker with a more stable sequence oIFRPSDUDEOH OHQJWK7KLV³GXPP\´ OLQNHU
would allow the same freedom of movement of the RRMs relative to each other, 
while bypassing the stability and solubility issues which have hindered the 
collection of data on the wild type protein. In particular it would allow SAXS 
data to be collected, which the low solubility of the wild type protein prevented. 
A longer linker between RRM2 and RRM3 would be expected to be more visible 
in the envelope, making the orientation of the protein domains much clearer.
  
While the S28D phosphomimetic mutant did not show any change in the binding 
preferences for U/G rich sequences and CUG repeats, there remains the 
possibility of increased affinity for some other motif present in the cyclin D1 
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mRNA. Systematic NMR titrations of CELF1 with short sections of the cyclin D1 
RNA could locate any elements other than the single UGC site that are being 
recognised. Even if Ser28 proves not to have any important role in the function of 
CELF1, there are a number of other possible phosphorylation sites to be 
investigated. Most of these are within the unstructured RRM2 ± RRM3 linker, 
and so could have a role in regulating the interaction with poly(A) ribonuclease. 
Phosphomimetic mutations could be produced at these sites, and any impact on 
the binding of PARN observed by ITC and NMR. 
 
The exact region of CELF1 recognised by PARN could be determined by 
systematically testing short sections of the RRM2 ± RRM3 linker for binding 
using NMR and ITC. These could either be isolated peptide sequences, or as 
deletion constructs of CELF1 produced by the same methods as RRM123. 
Locating the binding surface of PARN is more difficult due to the interaction 
between the domains. It might be possible to collect 3D heteronuclear NMR 
spectra of sufficient quality to assign the dispersed peaks in the 15N TROSY of 
the full length protein, and so determine the exact residues involved. An 
alternative approach would be to investigate whether in combination the PARN 
RRM and R3H domains can interact with CELF1. A construct with these 
domains, but not the large nuclease domain, would be expected to result in a 
substantial improvement in the NMR spectrum quality, and so the ease of 
assigning the spectrum. 
 
The ability of CELF1 to bridge the end of an RNA hairpin, demonstrated using 
the RNA substrate EDEN-2U/HL presents a possible mechanism for its function 
as an alternative splicing regulator. By binding RRM1 and RRM2 in tandem to a 
partial EDEN motif on one side of an exon, and binding RRM3 to a UGU(U/G) 
site on the other side, it could encourage skipping of the exon. This is consistent 
with recently published results by Masuda et al. (2012), which reported that 
CELF1 binding sites are concentrated in intronic regions flanking alternative 
exons. In their study they were however treating the sequence UGUUUGU as a 
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CELF1 binding site, which we have shown in this thesis to be incapable of 
binding multiple CELF1 domains simultaneously. CELF1 would therefore need 
multiple copies of this RNA sequence for high affinity binding, which could be 
located on either side of the exon. 
 
&(/)SUHVHQWVDSRVVLEOHGUXJWDUJHWDV LI LWV³JDLQRIIXQFWLRQ´LQ'0FHOOV
could be reversed then normal alternative splicing patterns should be restored and 
the DM1 phenotype mitigated. The recent publication by Masuda et al. (2012) 
also suggests that one of the mRNAs bound by CELF1, and hence translationally 
repressed, is the MBNL1 mRNA. Down-regulation of CELF1 should therefore 
result in upregulation of MBNL1, counterbalancing its sequestration by CUG 
repeat RNAs in DM1 cells. With the understanding of requirements for high 
affinity binding of CELF1 gained in this study it may be possible to design a 
ligand capable of binding with higher affinity than the natural substrates, and so 
sequestering CELF1. This would involve further studies to produce high affinity 
ligands, working from templates such as EDEN-2U/4U and possibly 
incorporating modified RNA bases.  
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11 Appendix 
 
11.1 Primers 
 
Construct Primer Sequence 
RRM1 GCC GAC AGT GAA AAG TAA AAT GCT GTG GAA G 
C TTC CAC AGC ATT TTA CTT TTC ACT GTC GGC 
RRM2 CGTT GCT AGC ATG CGA AAG CTA TTT ATC GGA ATG G 
CGTT AAG CTT TCA GTC TGC GAA CTT TAC CAC TAT TGG  
RRM3 GA CAA AAG*GCT AGC CAT ATG GCT GCC GCG 
CAT ATG GCT AGC*CTT TTG TCA CAA CAG GGT TTG 
RRM123 G TGA CAA AAG*CCA CAT TGA GGC TGC ATT GAG CTG 
C TCA ATG TGG*CTT TTG TCA CAA CAG GGT TTG GGG GC 
S28D GGT CAG GTT CCT CGA AGC TGG GAC GAG AAA GAG CTA 
AG 
CT TAG CTC TTT CTC GTC CCA GCT TCG AGG AAC CTG 
ACC 
RRM23 C ATT ATT*GCT AGC CAT ATG GCT GCC GCG 
CAT ATG GCT AGC*AAT AAT GCT GTG GAA GAC CGA AAG 
 
* - Indicates position of the deletion site in the primers used for one-step deletion 
methods. 
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11.2 NMR Assignments 
 
11.2.1 RRM1 Wild Type Assignment 
 
Number Residue 
HN Chemical 
Shift NH Chemical Shift 
1 Met1 - - 
2 Asn2 8.27 119.89 
3 Gly3 8.22 110.02 
4 Thr4 7.90 114.20 
5 Met5 8.24 122.68 
6 Asp6 8.08 122.02 
7 His7 7.67 116.12 
8 Pro8 - - 
9 Asp9 8.51 120.30 
10 His10 7.83 118.35 
11 Pro11 - - 
12 Asp12 - - 
13 Pro13 - - 
14 Asp14 7.97 114.98 
15 Ser15 7.34 114.46 
16 Ile16 7.83 121.89 
17 Lys17 8.59 129.52 
18 Met18 8.67 127.86 
19 Phe19 9.60 125.36 
20 Val20 8.19 129.28 
21 Gly21 9.06 112.78 
22 Gln22 8.07 110.05 
23 Val23 7.09 115.91 
24 Pro24 - - 
25 Arg25 9.02 123.39 
26 Ser26 7.63 109.29 
314 
 
27 Trp27 10.16 129.80 
 Trp27(E) 7.45 123.75 
28 Ser28 9.23 121.80 
29 Glu29 9.85 120.49 
30 Lys30 7.90 120.06 
31 Glu31 7.97 120.12 
32 Leu32 7.54 118.80 
33 Arg33 8.59 121.93 
34 Glu34 7.23 117.20 
35 Leu35 7.07 118.88 
36 Phe36 8.30 114.83 
37 Glu37 8.96 118.85 
38 Gln38 7.01 117.19 
39 Tyr39 7.90 117.16 
40 Gly40 7.30 106.89 
41 Ala41 7.94 119.35 
42 Val42 9.47 127.28 
43 Tyr43 8.21 129.94 
44 Glu44 7.34 117.84 
45 Ile45 8.44 126.49 
46 Asn46 8.80 125.77 
47 Val47 8.90 127.59 
48 Leu48 7.79 130.62 
49 Arg49 8.36 121.74 
50 Asp50 8.89 121.30 
51 Arg51 8.66 124.92 
52 Ser52 8.59 117.08 
53 Gln53 6.87 120.25 
54 Asn54 8.26 118.54 
55 Pro55 - - 
56 Pro56 - - 
57 Gln57 7.38 122.28 
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58 Ser58 8.03 115.88 
59 Lys59 8.88 125.26 
60 Gly60 9.47 110.79 
61 Cys61 7.08 111.43 
62 Cys62 8.86 114.59 
63 Phe63 8.43 115.82 
64 Ile64 9.18 121.40 
65 Thr65 8.66 125.91 
66 Phe66 9.76 130.29 
67 Tyr67 8.09 119.33 
68 Thr68 8.26 104.76 
69 Arg69 9.67 126.83 
70 Lys70 8.42 117.76 
71 Ala71 7.52 121.12 
72 Ala72 6.54 118.42 
73 Leu73 7.77 116.47 
74 Glu74 8.20 122.48 
75 Ala75 8.14 123.54 
76 Gln76 8.02 118.13 
77 Asn77 8.07 115.22 
78 Ala78 7.62 119.99 
79 Leu79 7.78 114.09 
80 His80 8.50 120.17 
81 Asn81 9.02 122.28 
82 Met82 7.93 116.65 
83 Lys83 7.27 121.48 
84 Val84 8.52 128.49 
85 Leu85 8.91 130.93 
86 Pro86 - - 
87 Gly87 8.32 112.12 
88 Met88 7.61 118.36 
89 His89 8.10 122.06 
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90 His90 7.39 119.29 
91 Pro91 - - 
92 Ile92 8.30 120.28 
93 Gln93 7.24 125.58 
94 Met94 11.69 130.12 
95 Lys95 8.82 123.85 
96 Pro96 - - 
97 Ala97 8.86 127.53 
98 Asp98 8.58 120.45 
99 Ser99 8.06 115.97 
100 Glu100 8.36 124.17 
101 Lys101 7.68 126.98 
 
11.2.2 RRM1 S28D Assignment 
 
Number Residue HN Chemical Shift NH Chemical Shift 
1 Met1 - - 
2 Asn2 8.27 119.91 
3 Gly3 8.22 109.99 
4 Thr4 7.92 114.14 
5 Met5 8.23 122.63 
6 Asp6 8.08 122.03 
7 His7 7.67 116.18 
8 Pro8 - - 
9 Asp9 8.51 120.22 
10 His10 7.83 118.52 
11 Pro11 - - 
12 Asp12 - - 
13 Pro13 - - 
14 Asp14 7.97 114.88 
15 Ser15 7.34 114.37 
16 Ile16 7.83 121.81 
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17 Lys17 8.58 129.47 
18 Met18 8.66 127.71 
19 Phe19 9.60 125.34 
20 Val20 8.20 129.30 
21 Gly21 9.06 112.64 
22 Gln22 8.05 110.11 
23 Val23 7.12 115.77 
24 Pro24 - - 
25 Arg25 9.02 123.36 
26 Ser26 7.60 109.15 
27 Trp27 10.12 129.62 
 Trp27(E) 7.42 123.83 
28 Asp28 8.94 126.87 
29 Glu29 9.86 122.09 
30 Lys30 8.31 118.76 
31 Glu31 7.96 120.12 
32 Leu32 7.76 119.32 
33 Arg33 8.89 121.70 
34 Glu34 7.26 117.51 
35 Leu35 7.04 118.62 
36 Phe36 8.34 114.63 
37 Glu37 9.02 118.65 
38 Gln38 7.00 117.04 
39 Tyr39 7.89 117.17 
40 Gly40 7.30 106.82 
41 Ala41 7.95 119.30 
42 Val42 9.51 127.17 
43 Tyr43 8.21 130.06 
44 Glu44 7.31 117.72 
45 Ile45 8.51 126.89 
46 Asn46 8.81 125.75 
47 Val47 8.96 127.88 
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48 Leu48 7.78 130.50 
49 Arg49 8.38 121.28 
50 Asp50 8.91 121.28 
51 Arg51 8.70 124.79 
52 Ser52 8.58 116.95 
53 Gln53 6.88 120.22 
54 Asn54 8.25 118.47 
55 Pro55 - - 
56 Pro56 - - 
57 Gln57 7.40 122.46 
58 Ser58 8.03 115.88 
59 Lys59 8.86 125.10 
60 Gly60 9.51 110.94 
61 Cys61 7.10 111.48 
62 Cys62 8.85 114.44 
63 Phe63 8.44 115.57 
64 Ile64 9.20 121.18 
65 Thr65 8.64 125.82 
66 Phe66 9.76 130.18 
67 Tyr67 8.09 119.21 
68 Thr68 8.26 104.72 
69 Arg69 9.66 126.72 
70 Lys70 8.42 117.60 
71 Ala71 7.52 121.07 
72 Ala72 6.53 118.35 
73 Leu73 7.76 116.34 
74 Glu74 8.20 122.44 
75 Ala75 8.13 123.45 
76 Gln76 8.02 118.05 
77 Asn77 8.09 115.27 
78 Ala78 7.62 119.90 
79 Leu79 7.78 114.04 
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80 His80 8.49 120.04 
81 Asn81 9.03 122.21 
82 Met82 7.94 116.61 
83 Lys83 7.26 121.42 
84 Val84 8.52 128.37 
85 Leu85 8.93 130.90 
86 Pro86 - - 
87 Gly87 8.32 112.08 
88 Met88 7.61 118.29 
89 His89 8.10 122.03 
90 His90 7.41 118.93 
91 Pro91 - - 
92 Ile92 8.30 120.35 
93 Gln93 7.29 125.61 
94 Met94 11.68 129.92 
95 Lys95 8.83 123.85 
96 Pro96 - - 
97 Ala97 8.85 127.36 
98 Asp98 8.51 120.22 
99 Ser99 8.04 116.00 
100 Glu100 8.35 123.95 
101 Lys101 7.69 127.07 
    
    
    
11.2.3 RRM2 Assignment    
    
    
Number Residue HN Chemical Shift NH Chemical Shift 
108 Arg108 7.98 114.72 
109 Lys109 7.46 121.78 
110 Leu110 9.51 126.92 
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111 Phe111 9.25 123.34 
112 Ile112 8.14 128.04 
113 Gly113 9.25 112.16 
114 Met114 8.25 114.18 
115 Val115 7.26 111.30 
116 Ser116 7.04 117.51 
117 Lys117 8.98 127.78 
118 Asn118 7.99 114.23 
119 Cys119 7.05 117.68 
120 Asn120 9.34 123.23 
121 Glu121 9.40 120.25 
122 Asn122 8.20 118.07 
123 Asp123 7.88 121.67 
124 Ile124 7.48 119.92 
125 Arg125 8.60 121.42 
126 Ala126 7.88 121.30 
127 Met127 7.40 115.75 
128 Phe128 7.66 112.71 
129 Ser129 8.47 120.76 
130 Pro130 - - 
131 Phe131 7.20 112.49 
132 Gly132 7.51 104.46 
133 Gln133 7.59 120.35 
134 Ile134 8.45 127.47 
135 Glu135 8.78 129.54 
136 Glu136 7.10 116.69 
137 Cys137 8.74 126.46 
138 Arg138 8.62 126.54 
139 Ile139 8.66 125.34 
140 Leu140 8.17 129.67 
141 Arg141 8.34 123.16 
142 Gly142 8.34 108.43 
143 Pro143 - - 
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144 Asp144 7.80 115.85 
145 Gly145 8.16 108.21 
146 Met146 7.77 120.80 
147 Ser147 8.74 117.21 
148 Arg148 9.04 125.08 
149 Gly149 9.45 110.44 
150 Cys150 6.91 111.11 
151 Ala151 8.93 122.37 
152 Phe152 8.52 114.78 
153 Val153 8.46 121.08 
154 Thr154 8.62 123.92 
155 Phe155 8.34 126.95 
156 The156 8.40 112.16 
157 Thr157 7.56 108.68 
158 Arg158 9.05 123.34 
159 Ser159 8.41 115.88 
160 Met160 7.21 121.76 
161 Ala161 6.57 119.53 
162 Gln162 8.41 115.55 
163 Met163 7.66 120.21 
164 Ala164 7.57 123.43 
165 Ile165 7.60 118.38 
166 Lys166 7.46 117.82 
167 Ser167 7.46 110.52 
168 Met168 7.87 115.61 
169 His169 8.09 120.32 
170 Gln170 8.45 121.61 
171 Ala171 7.75 120.36 
172 Gln172 7.07 110.75 
173 Thr173 8.54 119.31 
174 Met174 9.72 128.23 
175 Glu175 8.44 121.92 
176 Gly176 8.69 114.34 
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177 Cys177 7.79 119.11 
178 Ser178 - - 
179 Ser179 7.33 117.03 
180 Pro180 - - 
181 Ile181 7.96 118.29 
182 Val182 8.07 127.84 
183 Val183 10.98 129.69 
184 Lys184 8.64 122.00 
185 Phe185 8.21 120.11 
186 Ala186 8.66 125.13 
187 Asp187 7.94 125.92 
    
 
11.2.4 RRM3 Assignment  
  
Number Residue HN Chemical Shift NH Chemical Shift 
390 Gly390 8.50 110.75 
391 Leu391 8.04 122.22 
392 Gly392 8.28 110.18 
393 Ala393 8.09 122.80 
394 Ala394 - - 
395 Gly395 - - 
396 Ser396 7.75 116.25 
397 Gln397 8.21 121.56 
398 Lys398 7.98 123.90 
399 Glu399 8.27 123.75 
400 Gly400 8.93 110.90 
401 Pro401 - - 
402 Glu402 8.21 119.96 
403 Gly403 8.35 113.21 
404 Ala404 8.16 120.49 
405 Asn405 7.26 115.95  
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406 Leu406 9.15 124.22 
407 Phe407 8.93 119.35 
408 Ile408 8.37 122.39 
409 Tyr409 9.25 123.82 
410 His410 8.43 112.81 
411 Leu411 7.35 115.03 
412 Pro412 - - 
413 Gln413 8.91 126.21 
414 Glu414 8.95 115.23 
415 Phe415 7.44 123.33 
416 Gly416 9.40 114.88 
417 Asp417 8.48 120.87 
418 Gln418 8.70 118.36 
419 Asp419 6.90 119.79 
420 Leu420 7.52 120.87 
421 Leu421 7.57 119.92 
422 Gln422 7.81 116.41 
423 Met423 7.35 116.47 
424 Phe424 7.45 113.61 
425 Met425 8.45 128.29 
426 Pro426 - - 
427 Phe427 6.43 110.65 
428 Gly428 7.50 106.59 
429 Asn429 8.84 117.95 
430 Val430 8.18 128.72 
431 Val431 8.79 130.28 
432 Ser432 7.08 114.01 
433 Ser433 7.60 116.22 
434 Lys434 8.40 125.39 
435 Val435 8.43 125.68 
436 Phe436 8.09 127.79 
437 Ile437 8.13 121.93 
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438 Asp438 8.55 127.07 
439 Lys439 8.74 128.05 
440 Gln440 8.51 117.86 
441 Thr441 7.63 107.81 
442 Asn442 8.32 117.66 
443 Leu443 7.48 118.57 
444 Ser444 8.59 115.96 
445 Lys445 9.12 126.03 
446 Cys446 10.02 113.78 
447 Phe447 7.54 115.76 
448 Gly448 9.11 108.50 
449 Phe449 8.64 120.68 
450 Val450 7.65 124.26 
451 Ser451 8.18 119.96 
452 Tyr452 8.25 121.67 
453 Asp453 7.73 114.18 
454 Asn454 7.07 114.67 
455 Pro455 - - 
456 Val456 7.91 121.99 
457 Ser457 7.72 118.61 
458 Ala458 6.19 120.78 
459 Gln459 7.57 116.71 
460 Ala460 7.68 123.73 
461 Ala461 7.69 122.44 
462 Ile462 7.91 119.25 
463 Gln463 7.69 117.52 
464 Ser464 7.39 111.41 
465 Met465 8.17 114.91 
466 Asn466 8.23 119.43 
467 Gly467 8.83 118.76 
468 Phe468 7.78 123.99 
469 Gln469 7.88 129.25 
325 
 
470 Ile470 8.32 126.95 
471 Gly471 8.80 118.33 
472 Met472 8.79 123.74 
473 Lys473 7.70 120.26 
474 Arg474 7.98 120.18 
475 Leu475 8.92 123.33 
476 Lys476 7.91 124.23 
477 Val477 8.61 127.49 
478 Gln478 8.97 124.04 
479 Leu479 8.57 123.28 
480 Lys480 8.20 124.81 
481 Arg481 - - 
482 Ser482 - - 
483 Lys483 - - 
484 Asn484 - - 
485 Asp485 7.96 121.63 
486 Ser486 8.03 116.32 
487 Lys487 7.95 124.34 
488 Pro488 - - 
489 Tyr489 7.30 124.49 
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